National Survey of Substance Abuse Treatment Services (N-SSATS): 2020

Data on Substance Abuse Treatment Facilities

ACKNOWLEDGMENTS

This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS). Work was performed under Contract No. HHSS283201600001C. The Contracting Officer's Representative (COR) at SAMHSA/CBHSO was Nichele Waller.

SAMHSA complies with applicable federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. SAMHSA cumple con las leyes federales de derechos civiles aplicables y no discrimina por motivos de raza, color, nacionalidad, edad, discapacidad o sexo.

PUBLIC DOMAIN NOTICE

All material appearing in this report is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, U.S. Department of Health and Human Services.

RECOMMENDED CITATION

Substance Abuse and Mental Health Services Administration, *National Survey of Substance Abuse Treatment Services (N-SSATS): 2020. Data on Substance Abuse Treatment Facilities.* Rockville, MD: Substance Abuse and Mental Health Services Administration, 2021.

ELECTRONIC ACCESS AND COPIES OF PUBLICATION

This publication may be downloaded at https://www.samhsa.gov/data/.

ORIGINATING OFFICE

Center for Behavioral Health Statistics and Quality
Substance Abuse and Mental Health Services Administration
5600 Fishers Lane, Room 15SEH03
Rockville, Maryland 20857

June 2021

TABLE OF CONTENTS

List of Tables	V
List of Figures	XV
Highlights	1
Chapter 1. Description of the National Survey of Substance Abuse T	
Services (N-SSATS)	
Data Collection Procedures for the 2020 N-SSATS	
Facility Selection for the 2020 N-SSATS Report	
Survey Response Mode	
Data Considerations and Limitations	
Organization of the Report	
Terminology	11
Chapter 2. Trends in Facility Characteristics	13
Number of Facilities	13
Facility Operation	13
Type of Care Offered	14
Facilities That Use MAT	15
Chapter 3. Trends in Client Characteristics	17
Number of Clients	17
Facility Operation	17
Type of Care Received	18
Clients Receiving MAT	19
Substance Abuse Problem Treated	19
Clients Under the Age of 18 Years in Treatment	20
Chapter 4. Facility Characteristics and Services	21
Facility Operation and Type of Care	21
Substance Abuse Treatment	
Facility Size	22
Facility Capacity and Utilization Rates	24
Services Provided	25
Clinical/Therapeutic Approaches	28
MAT for Opioid Use Disorder	
Treatment of Alcohol Use Disorder	29
Programs or Groups for Specific Client Types	29

TABLE OF CONTENTS (CONTINUED)

Treatment Services in Sign Language for the Deaf and Hard-of-Hearing and	20
in Languages Other Than English	
Detoxification Services	
Client Outreach	
Facility Licensing, Certification, or Accreditation	
Federally Qualified Health Centers	
Payment Options Facility Funding	
Facilities Using MAT	
Facility Smoking Policy	
Suicide Prevention-Related Services in Veterans Affairs Facilities	
Chapter 5. Client Characteristics	35
Facility Operation and Type of Care	35
Clients in Federally Qualified Health Centers	
Clients at High Risk of Suicide at VA Facilities	
Substance Abuse Treatment	
Clients Under the Age of 18 Years in Treatment	36
Clients Receiving MAT for OUD	37
Clients Receiving MAT for Alcohol Use Disorder	38
Chapter 6. State Data	39
Survey Response	39
Trends	39
Clients in Treatment per 100,000 Population Aged 18 Years and Older	40
Tables	43
Appendix A. N-SSATS Background	253
Survey History	253
N-SSATS in the Context of the Behavioral Health Services Information	
System (BHSIS)	253
Survey Coverage	254
Changes in Survey Content	256
Appendix B. 2020 N-SSATS Questionnaire	261
Appendix C. Item Response for 2020 N-SSATS	285
Appendix D. List of Contributors	297

LIST OF TABLES

	SATS)	
1.1	N-SSATS facilities, by status and mode of response: 2020	9
Trend	ls in Facility Characteristics	
2.1	Facility turnover: Number and column percent distribution, 2010–2020	44
2.2	Facility operation: Number and column percent distribution, 2010–2020	45
2.3	All facilities and facilities with opioid treatment programs (OTPs), by type of care offered: Number and column percent, 2010–2020	46
2.4	Medication-assisted opioid therapy provided at facilities with OTPs and non-OTP facilities: Number and column percent, 2010–2020	47
Trend	ls in Client Characteristics	
3.1	Clients in treatment, by facility operation: Number and column percent distribution, 2011–2020	48
3.2	Clients in treatment, by type of care received, and clients receiving buprenorphine, naltrexone, or methadone: Number and column percent distribution, 2011–2020	49
3.3	Clients in treatment, by substance abuse problem and diagnosed co- occurring mental and substance use disorders: Number and column percent distribution, 2011–2020	50
3.4	Clients under the age of 18 years in treatment, by type of care received, and clients under the age of 18 years in treatment in facilities offering special programs or groups for adolescents: Number and column percent distribution, 2011–2020	51
Facili	ity Characteristics and Services	
4.1a	Type of care offered, by facility operation: Number, 2020	52
4.1b	Type of care offered, by facility operation: Row percent, 2020	53
4.2	Type of substance abuse problem treated and treatment of clients with diagnosed co-occurring mental and substance use disorders, by facility operation: Number and row percent, March 31, 2020	54
4.3	Facility size, by type of care offered and facility operation at facilities with opioid treatment programs (OTPs): Median number of clients per facility, March 31, 2020	55

4.4	Facility size, by type of care offered and facility operation at facilities without opioid treatment programs (non-OTPs): Median number of clients per facility, March 31, 2020	56
4.5a	Facility size in terms of number of clients in outpatient treatment, by facility operation: Number and row percent distribution, March 31, 2020	57
4.5b	Facility size in terms of number of clients in residential (non-hospital) treatment, by facility operation: Number and row percent distribution, March 31, 2020	58
4.5c	Facility size in terms of number of clients in hospital inpatient treatment, by facility operation: Number and row percent distribution, March 31, 2020	59
4.6	Facility capacity and utilization of residential (non-hospital) care, by facility operation: Number, utilization rate, and row percent distribution, March 31, 2020	60
4.7	Facility capacity and utilization of hospital inpatient care, by facility operation: Number, utilization rate, and row percent distribution, March 31, 2020	61
4.8a	Services provided, by facility operation: Number and column percent, 2020	62
4.8b	Services provided, by facility type: Number and column percent, 2020	65
4.9a	Services provided, by type of care: Number, 2020	68
4.9b	Services provided, by type of care: Column percent, 2020	71
4.10	Clinical/therapeutic approaches used frequently, by facility type: Number and column percent, 2020	74
4.11a	Provision of MAT for opioid use disorder, by type of care: Number, 2020	75
4.11b	Provision of MAT for opioid use disorder, by type of care: Column percent, 2020	76
4.12	Treatment of alcohol use disorder, by facility operation: Number and column percent, 2020	77
4.13a	Provision of MAT for alcohol use disorder, by type of care: Number, 2020	78
4.13b	Provision of MAT for alcohol use disorder, by type of care: Column percent, 2020	79

4.14a	Facilities offering special programs or groups for specific client types, by facility operation: Number, 2020	80
4.14b	Facilities offering special programs or groups for specific client types, by facility operation: Row percent, 2020	82
4.15a	Facilities offering substance use treatment services in sign language for the deaf and hard-of-hearing and in languages other than English, by facility operation: Number, 2020	84
4.15b	Facilities offering substance use treatment services in sign language for the deaf and hard-of-hearing and in languages other than English, by facility operation: Row percent distribution, 2020.	85
4.16	Facilities detoxifying clients, by substance and facility operation: Number and row percent, 2020	86
4.17	Facilities with client outreach, by facility operation: Number and percent, 2020	87
4.18a	Facility licensing, certification, or accreditation, by facility operation: Number, 2020	88
4.18b	Facility licensing, certification, or accreditation, by facility operation: Row percent, 2020	89
4.19a	Facility licensing, certification, or accreditation, by type of care offered: Number, 2020	90
4.19b	Facility licensing, certification, or accreditation, by type of care offered: Row percent, 2020	91
4.20	Federally Qualified Health Centers providing substance use treatment, by type of care offered: Number and percent, 2020	92
4.21a	Types of payments accepted, by facility operation: Number, 2020	93
4.21b	Types of payments accepted, by facility operation: Row percent, 2020	94
4.22	Facility funding, by facility operation: Number and percent, 2020	95
4.23a	Medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by facility operation: Number, 2020	96

4.23b	Medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by facility operation: Column percent distribution, 2020	97
4.24a	Type of care offered in facilities with opioid treatment programs (OTPs), by facility operation: Number, 2020	98
4.24b	Type of care offered in facilities with opioid treatment programs (OTPs), by facility operation: Row percent, 2020	99
4.25a	Facility licensing, certification, or accreditation of facilities with opioid treatment programs (OTPs), by type of care offered: Number, 2020	100
4.25b	Facility licensing, certification, or accreditation of facilities with opioid treatment programs (OTPs), by type of care offered: Row percent, 2020	101
4.26	Facility smoking policy, by facility operation: Number and row percent distribution, 2020	102
4.27	Suicide prevention-related services provided by Veterans Affairs (VA) facilities: Number and percent, 2020	103
Client	Characteristics	
5.1a	Clients in treatment, by type of care received and facility operation: Number, March 31, 2020	105
5.1b	Clients in treatment, by type of care received and facility operation: Row percent distribution, March 31, 2020	106
5.1c	Clients in treatment, by type of care received and facility operation: Column percent distribution, March 31, 2020	107
5.2	Clients in treatment and clients receiving buprenorphine, naltrexone, or methadone at Federally Qualified Health Centers providing substance use treatment: Number and percent, March 31, 2020	108
5.3	Clients in treatment at Veterans Affairs facilities identified as being at high suicide risk, by type of care: Number and column percent distribution, March 31, 2020	109
5.4	Clients in treatment, according to substance abuse problem and diagnosed co-occurring mental and substance use disorders, by facility operation: Number and row percent distribution, March 31, 2020	110

5.5	facility operation: Number and row percent distribution, March 31, 2020	111
5.6a	Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by facility operation: Number, March 31, 2020	112
5.6b	Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by facility operation: Column percent distribution, March 31, 2020	113
5.7	Clients receiving medications for alcohol use disorder, by type of care received: Number and row percent distribution, March 31, 2020	114
State	Data	
6.1	N-SSATS facilities, by status, response rate, mode of response, and state or jurisdiction: Number and row percent, 2020	115
6.2a	Facilities and clients in treatment, by state or jurisdiction: Number, 2011–2020	117
6.2b	Facilities and clients in treatment, by state or jurisdiction: Column percent distribution, 2011–2020	119
6.3a	Clients under the age of 18 years in treatment, and clients under the age of 18 years in facilities offering special programs or groups for adolescents, by state or jurisdiction: Number, 2011–2020	121
6.3b	Clients under the age of 18 years in treatment, and clients under the age of 18 years in facilities offering special programs or groups for adolescents, by state or jurisdiction: Percent, 2011–2020	123
6.4a	Facility operation, by state or jurisdiction: Number, 2020	125
6.4b	Facility operation, by state or jurisdiction: Row percent distribution, 2020	127
6.5a	Type of care offered, by state or jurisdiction: Number, 2020	129
6.5b	Type of care offered, by state or jurisdiction: Row percent, 2020	131
6.6a	Type of assessment and pre-treatment services offered by facilities, by state or jurisdiction: Number, 2020	133
6.6b	Type of assessment and pre-treatment services offered by facilities, by state or jurisdiction: Row percent, 2020	135

6.7a	Type of testing offered by facilities, by state or jurisdiction: Number, 2020	137
6.7b	Type of testing offered by facilities, by state or jurisdiction: Row percent, 2020	139
6.8	Type of medical services offered by facilities, by state or jurisdiction: Number and row percent, 2020	141
6.9	Type of transitional services offered by facilities, by state or jurisdiction: Number and row percent, 2020	143
6.10a	Type of recovery support services offered by facilities, by state or jurisdiction: Number, 2020	145
6.10b	Type of recovery support services offered by facilities, by state or jurisdiction: Row percent, 2020	147
6.11a	Type of education and counseling services offered by facilities, by state or jurisdiction: Number, 2020	149
6.11b	Type of education and counseling services offered by facilities, by state or jurisdiction: Row percent, 2020	151
6.12a	Type of pharmacotherapies offered by facilities, by state or jurisdiction: Number, 2020	153
6.12b	Type of pharmacotherapies offered by facilities, by state or jurisdiction: Row percent, 2020	157
6.13a	Type of ancillary services offered by facilities, by state or jurisdiction: Number, 2020	161
6.13b	Type of ancillary services offered by facilities, by state or jurisdiction: Row percent, 2020	163
6.14	Type of other services offered by facilities, by state or jurisdiction: Number and row percent, 2020	165
6.15	Type of client substance abuse problem treated and treatment of clients with diagnosed co-occurring mental and substance use disorders, by state or jurisdiction: Number and row percent, 2020	167
6.16	Facility size, by type of care offered and state or jurisdiction at facilities with opioid treatment programs (OTPs): Median number of clients per facility, March 31, 2020	169

6.17	Facility size, by type of care offered and state or jurisdiction at facilities without opioid treatment programs (non-OTPs): Median number of clients per facility, March 31, 2020	171
6.18a	Facility size in terms of number of clients in outpatient treatment, by state or jurisdiction: Number and row percent distribution, March 31, 2020	173
6.18b	Facility size in terms of number of clients in residential (non-hospital) treatment, by state or jurisdiction: Number and row percent distribution, March 31, 2020	175
6.18c	Facility size in terms of number of clients in hospital inpatient treatment, by state or jurisdiction: Number and row percent distribution, March 31, 2020	177
6.19	Facility capacity and utilization of residential (non-hospital) and hospital inpatient care, by state or jurisdiction: Number and utilization rate, March 31, 2020	179
6.20a	Clinical/therapeutic approaches used frequently, by state or jurisdiction: Number, 2020	181
6.20b	Clinical/therapeutic approaches used frequently, by state or jurisdiction: Row percent, 2020	183
6.21a	Facilities offering special programs or groups for specific client types, by state or jurisdiction: Number, 2020	185
6.21b	Facilities offering special programs or groups for specific client types, by state or jurisdiction: Row percent, 2020	189
6.22a	Facilities offering substance use treatment services in sign language for the deaf and hard-of-hearing and in languages other than English, by state or jurisdiction: Number, 2020	193
6.22b	Facilities offering substance use treatment services in sign language for the deaf and hard-of-hearing and in languages other than English, by state or jurisdiction: Row percent distribution, 2020	195
6.23	Facilities detoxifying clients, by substance and state or jurisdiction: Number and row percent, 2020	197
6.24	Facilities with client outreach, by state or jurisdiction: Number and percent, 2020.	199

6.25a	Facility licensing, certification, or accreditation, by state or jurisdiction: Number, 2020	200
6.25b	Facility licensing, certification, or accreditation, by state or jurisdiction: Row percent, 2020	202
6.26	Federally Qualified Health Centers providing substance use treatment, by state or jurisdiction: Number and percent, 2020	204
6.27	Clients in treatment at Federally Qualified Health Centers providing substance use treatment, by state or jurisdiction: Number and percent, March 31, 2020	206
6.28a	Types of payments accepted by facility, by state or jurisdiction: Number, 2020	208
6.28b	Types of payments accepted by facility, by state or jurisdiction: Row percent, 2020	210
6.29	Facility funding, by state or jurisdiction: Number and percent, 2020	212
6.30a	Medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and other facilities, by state or jurisdiction: Number, 2020 (continued)	213
6.30b	Medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and other facilities, by state or jurisdiction: Column percent distribution, 2020	215
6.31a	Type of care offered in facilities with opioid treatment programs (OTPs), by state or jurisdiction: Number, 2020	217
6.31b	Type of care offered in facilities with opioid treatment programs (OTPs), by state or jurisdiction: Row percent, 2020	219
6.32a	Facility licensing, certification, or accreditation of facilities with opioid treatment programs (OTPs), by state or jurisdiction: Number, 2020	221
6.32b	Facility licensing, certification, or accreditation of facilities with opioid treatment programs (OTPs), by state or jurisdiction: Row percent, 2020	223
6.33	Facility smoking policy, by state or jurisdiction: Number and row percent distribution, 2020	225
6.34a	Clients in treatment, according to facility operation, by state or jurisdiction: Number, March 31, 2020	227

6.34b	Clients in treatment, according to facility operation, by state or jurisdiction: Row percent distribution, March 31, 2020	229
6.35a	Clients in treatment, according to type of care received, by state or jurisdiction: Number, March 31, 2020	231
6.35b	Clients in treatment, according to type of care received, by state or jurisdiction: Row percent distribution, March 31, 2020	233
6.36	Clients in outpatient treatment at Federally Qualified Health Centers providing substance use treatment, by type of care received and state or jurisdiction: Number and row percent distribution, March 31, 2020	235
6.37	Clients in treatment, according to substance abuse problem and diagnosed co-occurring mental and substance use disorders, by state or jurisdiction: Number and row percent distribution, March 31, 2020	237
6.38a	Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by state or jurisdiction: Number, March 31, 2020	239
6.38b	Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and other facilities, by state or jurisdiction: Column percent distribution, March 31, 2020	241
6.39a	Clients under the age of 18 years in treatment, according to facility operation, by state or jurisdiction: Number, March 31, 2020	243
6.39b	Clients under the age of 18 years in treatment, according to facility operation, by state or jurisdiction: Row percent distribution, March 31, 2020	245
6.40	Clients under the age of 18 years in treatment, according to type of care received, by state or jurisdiction: Number and row percent distribution, March 31, 2020	247
6.41	Clients in treatment aged 18 years and older, according to substance abuse problem, by state or jurisdiction: Number and clients per 100, 000 population aged 18 years and older, March 31, 2020	249
6.42	Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs), by state or jurisdiction: Clients per 100, 000 population, March 31, 2020	251

App	endix A	
A1	Survey contents: 1998–2020.	259
App	endix C	
C1	Item response rates, by question number and description: 2020	286

LIST OF FIGURES

Description of the National Survey of Substance Abuse Treatment Services (N-SSATS)					
1	Survey response mode: Percent, 2006–2020	10			
Trends	s in Facility Characteristics				
2	Facility operation: Percent, 2010–2020	14			
3	Facilities by type of care offered and facilities with opioid treatment programs: Percent, 2010–2020	.15			
Trends	s in Client Characteristics				
4	Clients in treatment, by facility operation: Number (thousands), 2011–2020.	.17			
5	Clients in treatment, by type of care received: Percent, 2011–2020	18			
Facilit	y Characteristics and Services				
6	Residential (non-hospital) and hospital inpatient utilization rates: March 31, 2020	.24			
State I	Data				
7	Clients in treatment per 100,000 population aged 18 years and older: March 31, 2020	.41			
8	Clients in treatment per 100,000 population aged 18 years and older: March 31, 2011	.41			



HIGHLIGHTS

This report presents results from the 2020 National Survey of Substance Abuse Treatment Services (N-SSATS), an annual census of facilities providing substance abuse treatment. Conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 states, the District of Columbia, and other jurisdictions. It is important to note that values in charts, narrative lists, and percentage distributions are calculated using actual raw numbers and rounded for presentation in this report; calculations using rounded values may produce different results.

- The N-SSATS facility response rate in 2020 was 90 percent. The response rates in 31 states and jurisdictions equaled or surpassed the overall rate [Tables 1.1 and 6.1].
- A total of 16,394 facilities completed the survey. The 16,066 facilities included in this report had a one-day census of 1,090,357 clients enrolled in substance abuse treatment on March 31, 2020 [Tables 1.1 and 3.1].¹
- Among those 18 years and older, there were 390 clients in treatment per 100,000 population on March 31, 2020. The ratio was highest for clients in treatment for drug abuse only (214 per 100,000 population), followed by both alcohol and drug abuse (122 per 100,000 population), and alcohol abuse only (54 per 100,000 population) [Table 6.41].

Trends in Facility and Client Characteristics 2010–2020

- The number of substance abuse treatment facilities increased between 2010 and 2020. The number of surveyed facilities eligible for inclusion in the 2020 N-SSATS report was 20 percent larger in 2020 (16,066) than in 2010 (13,339) [Table 2.1]. The number of clients in treatment on the survey reference date increased from 1,224,127 in 2011 to 1,460,706 in 2019, but fell to 1,090,357 in 2020 [Table 3.1].
- The types of entities responsible for operating facilities—private non-profit organizations, private for-profit organizations, or governments—had some notable changes between 2010 and 2020.² Facilities operated by private non-profit organizations decreased from 58 percent of all facilities in 2010 to 50 percent of facilities in 2020. Facilities operated by private for-profit organizations increased from 30 percent in 2010 to 41 percent in 2020 [Table 2.2 and Figure 2].
- The proportions of facilities that offered outpatient, residential [non-hospital], and hospital inpatient care were stable between 2010 and 2020, with the exception of facilities that offered outpatient methadone/buprenorphine maintenance or naltrexone treatment, the proportion of which increased from 9 percent of facilities in 2010 to 36 percent of facilities in 2020 [Table 2.3].

Facilities excluded from the report included 158 non-treatment halfway houses, 62 solo practices not approved by their state agency for inclusion, and 29 facilities that treated incarcerated clients only.

Data for the federal agencies specified in the survey (the Department of Veterans Affairs, the Department of Defense, the Indian Health Service, and other unspecified federal agencies) are detailed in the tables.

- The proportion of facilities with opioid treatment programs (OTPs) certified by SAMHSA for the provision of medication-assisted treatment (MAT) with methadone and/or buprenorphine increased from 9 percent in 2010 to 11 percent in 2020 [Table 2.4].
- Between 2011 and 2020, the proportions of clients in treatment for the major types of care—outpatient, residential (non-hospital), and hospital inpatient—shifted. Clients in outpatient treatment increased from 90 to 94 percent while clients in residential (non-hospital) treatment declined from 9 to 5 percent. The proportion of clients in inpatient hospital treatment ranged between 1 percent and 2 percent from 2011 to 2020 [Table 3.2 and Figure 5].
- The proportion of all clients who were receiving methadone increased from 25 percent in 2011 to 29 percent in 2020 [Table 3.2].
- The proportion of all clients who were receiving buprenorphine increased from 3 percent in 2011 to 16 percent 2020 [Table 3.2].
- The proportions of clients in treatment for the three broad categories of substance abuse problems—both alcohol and drug abuse, drug abuse only, and alcohol abuse only—changed between 2011 and 2020. The proportion of clients in treatment for both drug and alcohol abuse decreased from 44 to 31 percent of all clients. Clients in treatment for drug abuse only increased from 38 to 52 percent, and clients in treatment for alcohol abuse only decreased from 18 to 13 percent [Table 3.3].
- The number of clients under the age of 18 years declined from 82,532 in 2011 to 39,271 in 2020. The proportion of clients under the age of 18 years in treatment in each type of care (outpatient, residential [non-hospital], or hospital inpatient) differed slightly from the proportion overall. The proportion of clients under the age of 18 years in outpatient treatment increased from 87 percent in 2011 to 91 percent in 2020; the proportion of clients under the age of 18 years in residential (non-hospital) treatment decreased from 12 percent in 2011 to 8 percent in 2020; the proportion of clients under the age of 18 years in hospital inpatient treatment remained steady at 1 percent over this time [Tables 3.4 and 3.2].

Facility Operation—March 31, 2020

- Private non-profit organizations operated 50 percent of all facilities and treated 46 percent of all clients [Tables 2.2 and 3.1].
- Private for-profit organizations operated 41 percent of all facilities and treated 45 percent of all clients [Tables 2.2 and 3.1].
- Local, county, or community governments operated 4 percent of all facilities and treated 4 percent of all clients [Tables 2.2 and 3.1].
- State governments operated 2 percent of all facilities and treated 2 percent of all clients [Tables 2.2 and 3.1].
- The federal government operated 2 percent of all facilities and treated 3 percent of all clients [Tables 2.2 and 3.1].

• Tribal governments operated 2 percent of all facilities and treated 1 percent of all clients [Tables 2.2 and 3.1].

Type of Care—March 31, 2020

- Outpatient treatment was offered by 82 percent of all facilities and was received by 94 percent of all clients in treatment [Tables 4.1b and 5.1b].
- Residential (non-hospital) treatment was offered by 24 percent of all facilities and was received by 5 percent of all clients in treatment [Tables 4.1b and 5.1b].
- Hospital inpatient care was offered by 5 percent of all facilities and was received by 1 percent of all clients in treatment [Tables 4.1b and 5.1b].

Diagnosed Co-occurring Mental and Substance Use Disorders—March 31, 2020

Among clients in treatment, 57 percent were diagnosed with co-occurring mental and substance use disorders. In facilities operated by the Department of Defense, less than half of clients in treatment were diagnosed with co-occurring substance use and mental disorders (46 percent); however, facilities operated by the Department of Veterans Affairs reported the highest proportion of clients in treatment with diagnosed co-occurring substance use and mental disorders—77 percent—the highest among all types of facility operation [Table 5.4].

Facility Size and Utilization Rates—March 31, 2020

- Facilities with OTPs had a median of 260 clients. Outpatient facilities with OTPs had a median of 280 clients, while residential (non-hospital) facilities with OTPs had a median of 31 clients. Hospital inpatient facilities with OTPs had a median of 23 clients [Table 4.3].
- The median number of outpatient clients for OTPs that offered methadone or buprenorphine maintenance or naltrexone treatment varied by facility operation. For outpatient facilities with OTPs operated by private non-profit organizations, the median was 280 clients; at outpatient facilities with OTPs operated by private for-profit organizations, the median was 277 clients; for local, county, and community government-operated outpatient facilities with OTPs, the median was 240 clients; for state government-operated outpatient facilities with OTPs, the median was 173 clients; for federally operated outpatient facilities with OTPs, the median was 114 clients; and for tribal government-operated outpatient facilities with OTPs, the median was 131 clients [Table 4.3].
- Facilities without OTPs (non-OTPs) reported a median of 31 clients. Outpatient facilities had a median of 39 clients, while residential (non-hospital) facilities had a median of 16 clients, and hospital inpatient facilities had a median of 10 clients [Table 4.4].
- The median number of outpatient clients for non-OTP facilities that offered methadone/buprenorphine maintenance or naltrexone treatment varied by facility operation. Among all non-OTP facilities that offered outpatient methadone/buprenorphine maintenance or naltrexone treatment, there was a median of 25 clients; for private non-profit facilities, the median was 20 clients; for private for-profit facilities, the median was 40 clients; for local, county, or community government-operated facilities, the median was 15 clients; for state government-operated

- facilities, the median was 22 clients; for federal government-operated facilities, the median was 24 clients; and for tribal government-operated facilities, the median was 28 clients [Table 4.4].
- Of all residential (non-hospital) beds designated for substance abuse treatment, 79 percent were in use. Of all hospital inpatient beds designated for substance abuse treatment, 79 percent were in use [Tables 4.6 and 4.7].

Medication-Assisted Opioid Treatment—March 31, 2020

- OTPs were available in 1,754 facilities (11 percent of all facilities) in 2020 [Table 2.4].
- Private for-profit organizations operated 62 percent of facilities with OTPs [Table 4.23b].
- Of clients who were in OTPs that dispensed methadone, 62 percent were in facilities operated by private for-profit organizations [Table 5.6b].

CHAPTER 1

DESCRIPTION OF THE NATIONAL SURVEY OF SUBSTANCE ABUSE TREATMENT SERVICES (N-SSATS)

The 2020 National Survey of Substance Abuse Treatment Services (N-SSATS) was conducted between March and December 2020, with a reference date of March 31, 2020. It is the 43rd in a series of national surveys begun in the 1970s. The surveys were designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 states, the District of Columbia, and other jurisdictions. The Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services, plans and directs the N-SSATS. This report presents tabular information and highlights from the 2020 N-SSATS. It is important to note that percentages in charts, narrative lists, and percentage distributions in tables may not add to 100 percent due to rounding.

N-SSATS is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment.⁴ (Additional information on N-SSATS, its history, and changes in the survey and survey universe over time is provided in Appendix A.) N-SSATS provides a mechanism for quantifying the dynamic characteristics and composition of the U.S. substance abuse treatment delivery system. N-SSATS collects multipurpose data that can be used to:

- assist SAMHSA and state and local governments in assessing the nature and extent of services
 provided in state-supported and other substance abuse treatment facilities and in forecasting
 substance abuse treatment resource requirements;
- update SAMHSA's Inventory of Behavioral Health Services (I-BHS), which includes all known drug and alcohol abuse treatment facilities, both public and private (see Appendix A);
- analyze substance abuse treatment services trends and conduct comparative analyses for the nation, regions, and states;
- generate the National Directory of Drug and Alcohol Abuse Treatment Facilities, a compendium
 of facilities approved by state substance abuse agencies for the provision of substance abuse
 treatment; and
- update the information in SAMHSA's Behavioral Health Treatment Services Locator, a searchable database of facilities that provide treatment. The Treatment Services Locator is available on the Internet at: https://findtreatment.samhsa.gov

The jurisdictions include the territory of Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, the Commonwealth of Puerto Rico, and the Virgin Islands of the United States.

⁴ In this report, entities responding to N-SSATS are referred to as "facilities." As discussed later in the report, a "facility" may be a program-level, clinic-level, or multi-site respondent.

Data Collection Procedures for the 2020 N-SSATS

Field period and reference date

The survey reference date for the 2020 N-SSATS was March 31, 2020. The field period was from March 31, 2020, through December 14, 2020.

Survey universe

The 2020 N-SSATS facility universe totaled 19,926 facilities, including all 18,434 active treatment facilities on SAMHSA's I-BHS at a point five weeks before the survey reference date and 1,492 facilities that were added by state substance abuse agencies or otherwise discovered during the data collection period.

Content

The 2020 N-SSATS questionnaire contained 37 numbered questions (see Appendix B for the paper version of the questionnaire). Topics included:

- facility identification information;
- operating entity;
- primary focus;
- type of care provided, i.e.
 - outpatient treatment services (regular outpatient treatment, intensive outpatient treatment, day treatment or partial hospitalization, detoxification, methadone/buprenorphine maintenance or naltrexone treatment),
 - o residential (non-hospital) treatment services (long-term—more than 30 days, short-term—30 days or fewer, detoxification), and
 - hospital inpatient treatment services (inpatient treatment, inpatient detoxification);
- services offered (assessment and pre-treatment services, medical services, recovery support services, education and counseling services, pharmacotherapies, testing, transitional services, ancillary services, and other services);
- clinical/therapeutic approaches;
- special programs or groups provided for specific client types;
- provision of treatment services in sign language and/or in languages other than English;
- detoxification from alcohol, benzodiazepines, opioids, cocaine, methamphetamines, or other drugs, and routine use of medication during detoxification;
- client outreach (outreach to persons in the community who may need treatment);
- licensure, certification, or accreditation agencies or organizations;

- payment options accepted, including use of a sliding fee scale and/or treatment at no charge or minimal payment;
- receipt of government funding;
- smoking policy;
- manner in which opioid use disorder is treated, the operation of an opioid treatment program (OTP) certified by SAMHSA offering maintenance and/or detoxification, and medications used;
- number of clients in treatment on March 31, 2020 (total clients; clients by type of treatment; total clients under the age of 18 years; and clients who were receiving methadone, buprenorphine, or naltrexone);
- percentage of clients in treatment on March 31, 2020, for abuse of both alcohol and drugs, alcohol abuse only, and drug abuse only;
- percentage of clients in treatment on March 31, 2020, with diagnosed co-occurring mental and substance use disorders;
- number of beds designated for residential (non-hospital) and hospital inpatient substance abuse treatment on March 31, 2020;
- whether the facility is a Federally Qualified Health Center (FQHC);
- manner in which alcohol use disorder is treated and medications used;
- number of clients in treatment on March 31, 2020, who received medication for alcohol use disorder, medications used, and the type of care provided; and
- for Veterans Affairs (VA) facilities, suicide prevention-related services offered, suicide prevention interventions used, standardized suicide screening and evaluation tools used or made available, the number of clients identified for high risk of suicide, and the types of care provided to such clients.

Data collection

There were three modes of data collection employed: a secure web-based questionnaire, a paper questionnaire sent by mail, and a telephone interview. About four weeks before the survey reference date of March 31, 2020, letters were mailed to all facilities to announce the survey. The letters also served to update records with new address information received from the U.S. Postal Service. During the last week of March 2020, a data collection packet (including the SAMHSA cover letter, state-specific letter of endorsement, state profile, information on completing the survey on the web, and a sheet of frequently asked questions) was mailed to each facility. To ease the burden on respondents, many of the data items that typically do not change from year to year were prefilled in the web-based questionnaire for those facilities that had completed the 2019 survey. Respondents could also request a paper questionnaire be sent to them.

During the data collection phase, contract personnel were available to answer facilities' questions concerning the survey. Support for facilities completing the questionnaire on the web was also available by e-mail. About four weeks after the initial data collection packet mailing, thank you/

reminder letters were sent to all facilities. Approximately eight weeks after the initial packet mailing, a second packet was sent to newly added facilities. About three weeks after the second packet mailing, non-respondents received a reminder telephone call. A third packet containing a hard copy questionnaire was mailed about eight weeks after the second packet mailing. Those facilities that had not completed the survey by July 13, 2020, received reminder calls and were asked to complete the survey by computer-assisted telephone interview (CATI).

Quality assurance

The web questionnaire was programmed to be self-editing; that is, respondents were prompted to complete missing responses and to confirm or correct inconsistent responses.

All mail questionnaires were reviewed manually for consistency and for missing data. Calls were made to facilities to resolve unclear responses and to obtain missing data. After data entry, automated quality assurance reviews were conducted. The reviews incorporated the rules used in manual editing, plus consistency checks and checks for data outliers not readily identified by manual review.

Item non-response was minimized through editing and extensive follow-up. The item response rate for the 2020 N-SSATS averaged more than 99 percent across 322 separate items. Appendix C details item response rates and imputation procedures.

Facility status and response rate

Table 1.1 presents a summary of response rate information. There were 19,926 facilities in the survey universe. Of these facilities, 1,742 facilities (9 percent) were found to be ineligible for the survey because they had closed or did not provide substance abuse treatment or detoxification. Of the remaining 18,184 facilities, 16,394 facilities (90 percent) completed the survey and 16,066 (88 percent) were included in this report.

Table 1.1. N-SSATS facilities, by status and mode of response: 2020

	Number	Percent
Total facilities in universe	19,926	100.0
Closed/ineligible	1,742	8.7
Eligible	18,184	91.3
Total eligible	18,184	100.0
Non-respondents	1,790	9.8
Respondents	16,394	90.2
Excluded from report ¹	249	1.4
Roll-ups ²	79	0.4
Included in report	16,066	88.4
Mode of response	16,066	100.0
Internet	15,301	95.2
Telephone	656	4.1
Mail	109	0.7

¹ Facilities excluded from the report included 158 non-treatment halfway houses, 62 solo practices not approved by the state agency for inclusion, and 29 facilities that treated incarcerated clients only.

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Facility Selection for the 2020 N-SSATS Report

Table 1.1. The N-SSATS questionnaire is deliberately sent to some facilities that are excluded from this report, as explained below. For this cycle, 249 of the 16,394 questionnaire respondents provided information but were deemed out of the scope of this report and excluded from the analyses presented here. The excluded facilities and reasons for exclusion fell into three categories:

- 158 facilities were halfway houses that did not provide substance abuse treatment. These
 facilities were included in the survey so that they could be listed in the Directory and SAMHSA's
 Behavioral Health Treatment Services Locator.
- 62 facilities were solo practitioners. I-BHS and N-SSATS are designed to include facilities
 rather than individuals. Solo practitioners are listed and surveyed only if a state substance abuse
 agency explicitly requests that they be included in the survey. The excluded solo practitioners
 were not identified for inclusion by a state substance abuse agency.
- 29 facilities were jails, prisons, or other organizations that treated incarcerated clients exclusively.

In addition to the facilities that were excluded from the report, there were 79 facilities whose client counts were included in or "rolled into" other facilities' counts and whose facility characteristics were not reported separately. After the exclusion of 249 out-of-scope facilities and the roll-up of 79 facilities, 16,066 eligible respondent facilities remained to be included in the 2020 N-SSATS report.

² Facilities whose client counts were included in or "rolled into" other facilities' counts and whose facility characteristics were not reported separately.

Survey Response Mode

Figure 1. The proportion of facilities using the web survey to respond to N-SSATS has increased steadily since the option was introduced in 2002. The percentage of facilities responding via the web increased from 37 percent in 2006 to 95 percent in 2020. Mail response declined from 41 percent in 2006 to less than 1 percent in 2020. Telephone response, which represents follow-up of facilities that had not responded by mail or web, also declined, from 23 percent in 2006 to 4 percent in 2020.




Figure 1. Survey response mode: Percent, 2006–2020

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2006–2020.

Data Considerations and Limitations

As with any data collection effort, certain procedural considerations and data limitations must be taken into account when interpreting data from the 2020 N-SSATS. Some general issues are listed below; other considerations are detailed in Appendix A. Considerations and limitations of specific data items are discussed where the data are presented.

- N-SSATS attempts to obtain responses from all known treatment facilities, but it is a voluntary survey. There was no adjustment for the 10 percent facility non-response.
- N-SSATS is a point-prevalence survey. It provides information on the substance abuse treatment system and its clients on the reference date. Client counts reported do not represent annual totals. Rather, N-SSATS provides a "snapshot" of substance abuse treatment facilities and clients on an average day.

• Multiple responses were allowed for certain variables (e.g., services provided and specialized programs). Tabulations of these variables include the total number of facilities reporting each response.

Organization of the Report

The balance of this report is organized into the following chapters.

- Chapter 2 presents trends in facility characteristics for 2010 to 2020.
- Chapter 3 presents trends in client characteristics for 2011 to 2020.
- Chapter 4 describes key characteristics of facilities and the programs and services they provided in 2020.
- Chapter 5 describes key characteristics of clients in substance abuse treatment on March 31, 2020.
- Chapter 6 presents state-level detail for many of the tables presented in Chapters 4 and 5.
- Appendix A provides additional information on N-SSATS, its history, and changes in the survey and survey universe over time.
- Appendix B contains the 2020 N-SSATS mail survey questionnaire.
- Appendix C contains information on item response and imputation.

Terminology

The majority of tables in the report are organized by facility operation and type of care. Therefore, it is important to define these terms.

Facility operation indicates the type of entity responsible for the operation of the facility:

- private for-profit
- private non-profit
- government
 - o local, county, or community
 - o state
 - o federal (Department of Veterans Affairs, Department of Defense, Indian Health Service, other)
 - o tribal

Clients in treatment were defined as:

- hospital inpatient or residential (non-hospital) clients who received substance abuse treatment services at the facility on March 31, 2020; and
- outpatient clients who were seen at the facility for a substance abuse treatment or detoxification service at least once during the month of March 2020, and who were still enrolled in treatment on March 31, 2020.

Type of care indicates the services the facility offers:

- outpatient
 - o regular outpatient
 - o intensive outpatient
 - o outpatient day treatment or partial hospitalization
 - o outpatient detoxification
 - o utpatient methadone/buprenorphine maintenance or naltrexone treatment
- residential (non-hospital)
 - o short-term (30 days or less)
 - o long-term (more than 30 days)
 - detoxification
- hospital inpatient
 - o inpatient detoxification
 - o inpatient treatment

CHAPTER 2 TRENDS IN FACILITY CHARACTERISTICS

This chapter presents trends in facility characteristics for 2010 to 2020.

Number of Facilities

Table 2.1. The total number of substance abuse treatment facilities remained stable between 2010 and 2017 but increased from 2017 to 2020. There was considerable turnover from year to year in the individual facilities that responded to the survey: Between 82 and 91 percent of the facilities that responded to a survey had also responded to the previous year's survey. Between 9 and 14 percent of the facilities from year to year closed, were no longer providing substance abuse treatment, or did not respond to the current year's survey.

In 2020, there was a net increase of 105 facilities that responded to the survey and were included in the N-SSATS report, up from 15,961 facilities in 2019. Of the 16,066 facilities that responded to the 2020 survey and were included in this report, 86 percent had also responded to the 2019 survey, and 14 percent were new to the 2020 survey or did not respond in 2019. Of the facilities that responded in 2019, 13 percent had closed, were no longer providing substance abuse treatment, or did not respond in 2020.

Facility Operation

Table 2.2 and Figure 2. The operational structure of the substance abuse treatment system (i.e., the types of entities responsible for operating facilities) had some notable changes between 2010 and 2020.

- Private non-profit organizations operated 58 percent of all facilities in 2010, decreasing to 50 percent in 2020 [Table 2.2 and Figure 2].
- Private for-profit organizations operated 30 percent of facilities in 2010, increasing to 41 percent of facilities in 2020 [Table 2.2 and Figure 2].
- Local, county, or community governments operated 6 percent of facilities in 2010, decreasing to 4 percent in 2020 [Table 2.2 and Figure 2].
- State governments operated 3 percent of facilities in 2010, decreasing to 2 percent in 2020 [Table 2.2 and Figure 2].
- The federal government operated 2 to 3 percent of facilities each year between 2010 and 2020 [Table 2.2 and Figure 2].⁵
- Tribal governments operated 1 to 2 percent of facilities each year between 2010 and 2020 [Table 2.2 and Figure 2].

Data for the federal agencies specified in the survey (the Department of Veterans Affairs, the Department of Defense, the Indian Health Service, and other unspecified federal agencies) are detailed in the tables.




Figure 2. Facility operation: Percent, 2010–2020

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2010–2020.

Type of Care Offered⁶

Table 2.3 and Figure 3. The proportions of facilities that offered outpatient, residential (non-hospital), and hospital inpatient care were stable between 2010 and 2020. OTPs, certified by SAMHSA, provide MAT with methadone, buprenorphine, and naltrexone. Facilities with OTPs can be associated with any type of care. Facilities with OTPs made up 8 to 11 percent of all facilities between 2010 and 2020 [Table 2.4].

- Outpatient treatment was provided by 81 to 83 percent of facilities during this period [Table 2.3].
- Residential (non-hospital) treatment was provided by 24 to 26 percent of facilities in this period [Table 2.3].
- Hospital inpatient treatment was provided by 5 to 6 percent of facilities during this time period [Table 2.3].
- Outpatient treatment was provided by 90 to 95 percent of facilities with OTPs between 2010 and 2020 [Table 2.3].
- Residential (non-hospital) treatment was provided by 7 to 9 percent of facilities with OTPs between 2010 and 2020 [Table 2.3].
- Hospital inpatient treatment was provided by 7 to 10 percent of facilities with OTPs between 2010 and 2020 [Table 2.3].

⁶ Facilities can offer more than one type of care.

100 80 Percent of all facilities 60 Outpatient Residential (non-hospital) Hospital inpatient 40 Opioid treatment program (OTP) 20 2010 2012 2014 2016 2018 2020

Figure 3. Facilities by type of care offered and facilities with opioid treatment programs:

Percent, 2010–2020

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2010–2020.

Facilities That Use MAT

Table 2.4. MAT includes the use of methadone or buprenorphine for the treatment of opioid use disorder (OUD) and the use of naltrexone for relapse prevention in OUD. Methadone for OUD is available only at the OTPs that are certified by SAMHSA's Center for Substance Abuse Treatment.⁷ Buprenorphine may be prescribed by physicians or other authorized medical practitioners (physicians, physician assistants, and nurse practitioners) who have received Drug Addiction Treatment Act of 2000 (DATA 2000) specific training and received a waiver to prescribe the medication for treatment of OUD; some of these authorized medical practitioners are affiliated with facilities (either OTPs or other). All medical practitioners with prescribing privileges can prescribe injectable naltrexone.

- The proportion of OTPs that provided methadone-only treatment decreased from 52 percent of all facilities with OTPs in 2010 to 17 percent of all facilities with OTPs in 2020 [Table 2.4].
- The proportion of OTPs that provided only methadone and buprenorphine treatment decreased from 47 percent of all facilities with OTPs in 2010 to 42 percent in 2020. Between 2012 and 2020, the proportion of facilities with OTPs that offered methadone, buprenorphine, and injectable naltrexone increased from 12 percent in 2012 to 31 percent in 2020; over the same period, the proportion of facilities that offered only buprenorphine and injectable naltrexone increased from less than 1 percent to 6 percent [Table 2.4].8
- The proportion of facilities (either OTP or non-OTP) that provided any buprenorphine services increased from 18 percent of all facilities in 2010 to 44 percent of all facilities in 2020 [Table 2.4].

For more information on CSAT and the certifying process, see https://www.samhsa.gov/medication-assisted-treatment/certification-opioid-treatment-programs.

The question on extended-release injectable naltrexone (for example, Vivitrol®) was first added to the N-SSATS questionnaire in 2011.

increased from 10 percent in 2012 to 37 percent in 2020 [Table 2.4].								

CHAPTER 3 TRENDS IN CLIENT CHARACTERISTICS

This chapter presents trends in client characteristics for 2011 to 2020.

Number of Clients

Table 3.1. The number of clients in treatment on the survey reference date increased from 1,224,127 in 2011 to 1,460,706 in 2019, before falling to 1,090,357 clients in 2020.

Facility Operation

Table 3.1 and Figure 4. Within the categories of facility operation, the proportions of clients in treatment demonstrated some changes between 2011 and 2020.

- Private non-profit facilities treated 53 percent of clients in 2011, decreasing to 46 percent in 2020. (The number of clients in private non-profit facilities increased from 646,904 in 2011 to 726,238 in 2019, before falling to 504,780 clients in 2020 [Table 3.1 and Figure 4].)
- Private for-profit facilities treated 32 percent of clients in 2011, increasing to 45 percent in 2020. (The number of clients in private for-profit facilities from 395,577 in 2011 to 591,442 in 2019, before falling to 485,411 clients in 2020 [Table 3.1 and Figure 4].)




Figure 4. Clients in treatment, by facility operation: Number (thousands), 2011–2020

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2011–2020.

- Local, county, or community government-operated facilities treated 6 percent of clients in 2011, decreasing to 4 percent in 2020. (The number of clients in local government-operated facilities decreased from 73,338 in 2011 to 39,571 clients in 2020 [Table 3.1 and Figure 4].)
- State government-operated facilities treated 3 percent of clients in 2011, decreasing to 2 percent in 2020. (The number of clients in state government-operated facilities decreased from 40,303 in 2011 to 19,601 in 2020 [Table 3.1 and Figure 4].)
- Federal government-operated facilities treated 4 percent of clients in 2011, decreasing to 3 percent in 2020. (The number of clients in federal government-operated facilities decreased by 36 percent from 47,742 in 2011 to 30,589 in 2020 [Table 3.1 and Figure 4].)9
- Tribal government-operated facilities treated 2 percent of clients in 2011, decreasing to 1 percent of clients in 2020. (The number of clients in tribal government-operated facilities decreased from 20,263 in 2011 to 10,405 in 2020 [Table 3.1 and Figure 4].)

Type of Care Received

Table 3.2 and Figure 5. The proportions of clients in treatment for the major types of care—outpatient, residential (non-hospital), and hospital inpatient—were relatively stable between 2011 and 2020.

• Clients in outpatient treatment comprised between 89 and 94 percent of all clients each year. (The number of outpatient clients increased from 1,095,897 in 2011 to 1,355,024 in 2019, before falling to 1,021,185 in 2020 [Table 3.2 and Figure 5].)




Figure 5. Clients in treatment, by type of care received: Percent, 2011–2020

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2011–2020.

Data for the federal agencies specified in the survey (the Department of Veterans Affairs, the Department of Defense, the Indian Health Service, and other unspecified federal agencies) are detailed in the tables.

- Clients in residential (non-hospital) treatment comprised between 5 and 9 percent of all clients each year. (The number of residential [non-hospital] clients decreased from 112,827 in 2011 to 58,952 in 2020 [Table 3.2 and Figure 5].)
- Clients in hospital inpatient treatment comprised between 1 and 2 percent of all clients each year. (The number of hospital inpatient clients decreased from 15,403 in 2011 to 10,220 in 2020 [Table 3.2 and Figure 5].)

Clients Receiving MAT

Table 3.2. Clients who were receiving methadone, buprenorphine, or naltrexone could be in any type of care—outpatient, residential (non-hospital), or hospital inpatient. Clients could receive methadone for OUD only in OTPs certified by SAMHSA to provide MAT with methadone and buprenorphine. However, clients could receive buprenorphine or naltrexone in any type of facility.

- The proportion of all clients who were receiving methadone increased from 25 percent in 2011 to 29 percent in 2020. (The number of clients receiving methadone increased from 306,440 in 2011 to 408,550 in 2019 and then decreased to 311,531 in 2020 [Table 3.2].)
- The proportion of clients who were receiving buprenorphine increased from 3 percent in 2011 to 16 percent in 2020. (The number of clients receiving buprenorphine increased from 32,676 in 2011 to 176,152 in 2020 [Table 3.2].)¹⁰
- The proportion of clients receiving naltrexone increased from less than 1 percent in 2013 to 2 percent in 2020. (The number of clients receiving naltrexone increased from 3,781 in 2013 to 30,394 in 2019, before falling to 21,325 in 2020 [Table 3.2].)¹¹

Substance Abuse Problem Treated

Table 3.3. The proportion of clients in treatment for the three broad categories of substance abuse problems—both alcohol and drug abuse, drug abuse alone, and alcohol abuse alone—demonstrated some changes between 2011 and 2020.

- The percentage of clients in treatment for both drug and alcohol abuse decreased from 44 percent in 2011 to 31 percent in 2020. (The number of clients in treatment for both drug and alcohol abuse decreased from 535,258 in 2011 to 333,526 in 2020 [Table 3.3].)
- The percentage of clients in treatment for drug abuse alone increased from 38 percent in 2011 to 52 percent in 2020. (The number of clients in treatment for drug abuse alone increased from 464,406 in 2011 to 743,828 in 2019 and then decreased to 569,522 in 2020 [Table 3.3].)

Individual physicians, physician assistants, and nurse practitioners can receive special authorization from the U.S. Department of Health and Human Services that allows them to prescribe buprenorphine for the treatment of opioid use disorder. These practitioners may prescribe buprenorphine to patients in an office setting or to patients at substance abuse treatment facilities. Only clients who received buprenorphine through a facility affiliated with an authorized practitioner are included in this report; it does not include clients who received buprenorphine through an independent DATA 2000-waivered practitioner.

In the 2017, 2019, and 2020 surveys, facilities reported client counts of those receiving naltrexone for opioid use disorder. In the 2011, 2013, and 2015 surveys, the reported counts of clients receiving naltrexone were limited to those receiving extended-release injectable naltrexone (Vivitrol®). This report does not include those who received naltrexone through other sources.

- The percentage of all clients in treatment for alcohol abuse alone decreased from 18 percent in 2009 to 13 percent in 2020. (The number of clients in treatment for alcohol abuse alone decreased from 221,632 in 2011 to 146,710 in 2020 [Table 3.3].)
- The percentage of clients in treatment for diagnosed co-occurring mental and substance use disorders increased from 41 percent in 2011 to 49 percent in 2020. (The number of clients in treatment for diagnosed co-occurring mental and substance use disorders increased from 506,162 in 2011 to 702,914 in 2019, before falling to 531,105 in 2020 [Table 3.3].)

Clients Under the Age of 18 Years in Treatment

Table 3.4. The number of clients who were under the age of 18 years declined from 82,532 in 2011 to 39,271 in 2020.

- Of all clients under the age of 18 years, between 87 and 91 percent were in outpatient treatment from 2011 to 2020. (The number of outpatient clients under the age of 18 years decreased from 71,687 in 2011 to 35,612 in 2020 [Table 3.4].)
- Of all clients under the age of 18 years, between 8 and 12 percent were in residential (non-hospital) treatment from 2011 to 2020. (The number of residential [non-hospital] clients under the age of 18 years decreased from 9,738 in 2011 to 3,197 in 2020 [Table 3.4].)
- Of all clients under the age of 18 years, between 1 and 2 percent were in hospital inpatient treatment from 2011 to 2020. (The number of hospital inpatient clients under the age of 18 years decreased from 1,107 in 2011 to 462 in 2020 [Table 3.4].)
- The proportion of clients under the age of 18 years in treatment facilities with special programs or groups for adolescents decreased from 80 percent in 2011 to 71 percent in 2020. (The number of clients under the age of 18 years in treatment facilities with special programs or groups for adolescents decreased from 65,918 in 2011 to 27,944 in 2020 [Table 3.4].)

CHAPTER 4 FACILITY CHARACTERISTICS AND SERVICES

This chapter outlines key characteristics of facilities and programs in 2020.

Facility Operation and Type of Care

Table 2.2. Facilities were asked to designate the type of entity responsible for the operation of the facility.

- Private organizations were the most common type of entity responsible for facility operation, with private non-profit organizations making up the largest share of facilities at 50 percent and private for-profit organizations making up the second largest share of facilities at 41 percent [Table 2.2].
- Government entities were responsible for facility operation in the remaining 10 percent of facilities; local, county, or community governments accounted for 4 percent; state governments made up 2 percent; the federal government comprised another 2 percent; and tribal governments also comprised 2 percent [Table 2.2].¹²

Table 4.1b. Type of care offered consists of three broad categories (outpatient, residential [non-hospital], and hospital inpatient), each with several subcategories. A facility could offer more than one type of care. The proportions of all facilities that offered the different types of care were:¹³

- A majority (82 percent) offered some form of outpatient treatment. Regular outpatient treatment was the most common form of care offered and was offered at 76 percent of facilities. Intensive outpatient treatment was offered at slightly less than half of facilities (45 percent). Outpatient methadone/buprenorphine maintenance or naltrexone treatment was offered at over a third of facilities (36 percent). Outpatient day treatment or partial hospitalization and outpatient detoxification were offered at 14 and 12 percent of facilities, respectively [Table 4.1b].
- Residential (non-hospital) treatment was offered in slightly less than a quarter of facilities (24 percent). Long-term treatment (more than 30 days) was the most common type of residential treatment, with 18 percent of facilities offering this type of service; followed by short-term treatment (30 days or fewer), which was offered in 15 percent of facilities; and residential detoxification, which was offered in 9 percent of facilities [Table 4.1b].
- Hospital inpatient treatment was offered in a significantly smaller percentage of facilities than outpatient and residential (non-hospital) treatment, with only 5 percent of facilities offering hospital inpatient care. Inpatient detoxification was offered in 5 percent of facilities, and inpatient treatment was offered in 4 percent of facilities [Table 4.1b].

Data for the federal agencies specified in the survey (the Department of Veterans Affairs, the Department of Defense, the Indian Health Service, and other unspecified federal agencies) are detailed in the tables.

¹³ Facility percentages sum to more than 100 percent, because a facility could provide more than one type of care.

Approximately three quarters (77 percent) of private non-profit facilities provided outpatient care and about one third (30 percent) provided residential (non-hospital) care. In contrast, 87 percent of private for-profit facilities provided outpatient care, and 18 percent provided residential (non-hospital) care [Table 4.1b].

Substance Abuse Treatment

Table 4.2. Facilities were asked to estimate the proportions of clients in treatment for both alcohol and drug abuse, for alcohol abuse only, and for drug abuse only. They were also asked to estimate the proportion of clients with diagnosed co-occurring mental and substance use disorders. On March 31, 2020:

- About nine of every 10 facilities (87 percent) had clients in treatment for both alcohol and drug abuse, 86 percent had clients in treatment for drug abuse only, and 75 percent had clients in treatment for alcohol abuse only [Table 4.2].
- Most facilities (88 percent) had clients in treatment with diagnosed co-occurring mental and substance use disorders [Table 4.2].

Facility Size

Facilities with OTPs

Table 4.3. Facility size is defined by the number of clients in substance abuse treatment on the survey reference date. Facilities with OTPs reported a median of 260 clients in substance abuse treatment on March 31, 2020.

The median number of clients, by facility operation, ranged from 172 clients in facilities with OTPs operated by state governments to 314 clients in facilities with OTPs operated by tribal governments.

- On March 31, 2020, the median number of clients for facilities with OTPs that offered any outpatient treatment was 280. For facilities that offered outpatient methadone/buprenorphine maintenance or naltrexone treatment, the median was 270 clients. For facilities that offered regular outpatient care, the median number of clients was 55. Facilities with facilities with outpatient day treatment or partial hospitalization, intensive outpatient treatment, and facilities with outpatient detoxification had median client numbers of 20, 13, and five, respectively [Table 4.3].
- Facilities with OTPs that offered any residential (non-hospital) treatment had a median of 31 clients on March 31, 2020. Facilities with OTPs that offered long-term treatment (more than 30 days) reported a median of 30 clients. ¹⁴ Facilities with OTPs that offered short-term treatment (30 days or fewer) had a median of 21 clients. At facilities with OTPs that offered residential detoxification, the median number of clients was 14 [Table 4.3].
- Facilities with OTPs that offered hospital inpatient treatment had a median of 23 clients on March 31, 2020. Facilities with OTPs that offered inpatient treatment reported a median of

The median number of clients for the main categories of type of care (outpatient, residential, and hospital inpatient) can be greater than the median for any of the subcategories, because a facility can provide more than one subcategory of the main types of care. The median for each category or subcategory is computed separately excluding facilities that did not have client counts with respect to that category or subcategory.

19 clients, while facilities with OTPs that offered inpatient detoxification treatment reported a median of 15 clients [Table 4.3].

Facilities without OTPs

Table 4.4. Facility size is defined by the number of clients in substance abuse treatment on the survey reference date. The median number of clients in substance abuse treatment at a facility without an OTP (a non-OTP facility) on March 31, 2020, was 31 clients.

The median number of clients in facilities without an OTP ranged, by facility operation, from 29 clients in tribal government-operated facilities and 29 clients state government-operated facilities to 59 clients in facilities operated by the federal government.

- On March 31, 2020, the median number of clients for facilities without OTPs that offered any outpatient treatment was 39 clients. For non-OTP facilities that offered outpatient methadone/ buprenorphine maintenance or naltrexone treatment, the median was 25 clients. Non-OTP facilities that offered regular outpatient care reported a median of 29 clients; non-OTP facilities with intensive outpatient treatment reported a median of 14 clients; non-OTP facilities with outpatient day treatment or partial hospitalization reported a median of 10 clients; and non-OTP facilities with outpatient detoxification reported a median of five clients [Table 4.4].
- Non-OTP facilities that offered any residential (non-hospital) treatment had a median of 16 clients on March 31, 2020. Non-OTP facilities that offered long-term treatment (more than 30 days), had a median of 15 clients, and non-OTP facilities that offered short-term treatment (30 days or fewer) reported a median of 12 clients. Facilities without OTPs that offered residential detoxification reported a median of five clients [Table 4.4].
- Facilities without OTPs that offered hospital inpatient treatment had a median of 10 clients on March 31, 2020. Facilities without OTPs that offered inpatient treatment reported a median of 10 clients, while facilities without OTPs that offered inpatient detoxification treatment had a median of five clients [Table 4.4].

Tables 4.5a–c. Facilities were sorted into five size groups based on the total number of clients in treatment on March 31, 2020: fewer than 15 clients, 15–29 clients, 30–59 clients, 60–119 clients, and 120 or more clients.

Table 4.5a. Outpatient facilities operated by the federal government reported client counts within the largest size class in greater proportion than outpatient facilities operated by other entities—38 percent of federally operated facilities had 120 or more clients in treatment on March 31, 2020, compared with 28 percent of all outpatient facilities.

Table 4.5b. Residential (non-hospital) facilities operated by tribal governments and by private forprofit organizations reported client counts within the smallest size class in greater proportion than residential (non-hospital) facilities operated by other entities: 85 percent and 60 percent, respectively, had fewer than 15 clients in treatment on March 31, 2020, compared with 49 percent of all residential (non-hospital) facilities.

Table 4.5c. Inpatient facilities operated by the federal government reported client counts within the smallest size class in greater proportion than inpatient facilities operated by other entities—93

percent had fewer than 15 clients in treatment on March 31, 2020, compared with 65 percent of all inpatient facilities.

Facility Capacity and Utilization Rates

Facilities were asked to report the number of residential (non-hospital) and hospital inpatient beds designated for substance abuse treatment. Utilization rates were calculated by dividing the number of residential (non-hospital) or hospital inpatient clients by the number of residential (non-hospital) or hospital inpatient designated beds. Because substance abuse treatment clients may also occupy non-designated beds, utilization rates could be more than 100 percent.

Table 4.6. There were 1,920 facilities that reported having 61,743 residential (non-hospital) beds designated for substance abuse treatment on March 31, 2020. The utilization rate was 79 percent, and ranged from 61 percent in facilities operated by local, county, or community governments to 80 percent in facilities operated by state governments.¹⁵

Table 4.7. There were 322 facilities that reported having 9,690 hospital inpatient beds designated for substance abuse treatment on March 31, 2020. The utilization rate was 79 percent, and ranged




Figure 6. Residential (non-hospital) and hospital inpatient utilization rates:

March 31, 2020

Residential (non-hospital) utilization rates are based on a subset of 1,920 facilities that reported for themselves alone and that reported numbers greater than zero for both designated beds and clients.

from 61 percent in facilities operated by local, county, or community governments to 102 percent in facilities operated by the federal government.¹⁶

Tables 4.6–4.7 and Figure 6 show the distribution of facility-level utilization rates for residential (non-hospital) beds and for hospital inpatient beds. Facilities with hospital inpatient beds (79 percent) had similar overall utilization rates as facilities with residential (non-hospital) beds (79 percent); however, the distribution of utilization rates differed across the two. Of facilities with residential (non-hospital) beds, 21 percent had utilization rates of 50 percent or less, 29 percent had utilization rates between 91 and 100 percent, and 8 percent had utilization rates above 100 percent. Of facilities with hospital inpatient beds, 32 percent had utilization rates of 50 percent or less, 15 percent had utilization rates between 91 and 100 percent, while 16 percent had utilization rates above 100 percent.

Services Provided

Table 4.8a. Facilities were asked about the types of services they provided. Services were grouped into the nine broad categories shown below.

Assessment and pre-treatment services were offered by 99 percent of all facilities [Table 4.8a].

- Screening for substance abuse was provided by 97 percent of all facilities [Table 4.8a].
- Comprehensive substance abuse assessment or diagnosis was provided by 94 percent of all facilities [Table 4.8a].
- Screening for mental disorders was provided by 80 percent of all facilities [Table 4.8a].
- Screening for tobacco use was provided by 76 percent of all facilities [Table 4.8a].
- Outreach to persons in the community who may need treatment was provided by 66 percent of all facilities. By contrast, 85 percent of tribal government-operated facilities offered outreach services [Table 4.8a].
- Comprehensive mental health assessment or diagnosis was provided by 58 percent of all facilities [Table 4.8a].
- Interim services for clients when immediate admission was not possible were provided by 50 percent of all facilities. By contrast, 81 percent of federal government-operated and 80 percent of tribal government-operated facilities offered interim services [Table 4.8a].
- A professional interventionist/educational consultant was provided by 21 percent of all facilities [Table 4.8a].

Testing services were provided by 91 percent of all facilities.

- Drug or alcohol urine screening was provided by 88 percent of all facilities [Table 4.8a].
- Breathalyzer or other blood alcohol testing was provided by 64 percent of all facilities. By contrast, 85 percent of federal government-operated facilities provided breathalyzer or other blood alcohol testing [Table 4.8a].

Hospital inpatient utilization rates are based on a subset of 322 facilities that reported for themselves alone and that reported numbers greater than zero for both designated beds and clients.

- Testing for hepatitis B (HBV), hepatitis C (HCV), HIV, STDs, and TB was provided by between 26 and 42 percent of all facilities [Table 4.8a].
- Drug and alcohol oral fluid testing was provided by 32 percent of all facilities [Table 4.8a].
- Testing for metabolic syndrome was provided by 10 percent of all facilities [Table 4.8a].

Medical services were provided by 12 percent of facilities.

• Vaccination services for hepatitis A (HAV) and hepatitis B (HBV) each were provided by 11 percent of all facilities [Table 4.8a].

Transitional services were provided by 99 percent of all facilities.

- Discharge planning was provided by 96 percent of all facilities [Table 4.8a].
- Aftercare/continuing care was provided by 87 percent of all facilities [Table 4.8a].
- Outcome follow-up after discharge was provided by 70 percent of all facilities [Table 4.8a].
- Naloxone and overdose education were provided by 60 percent of all facilities [Table 4.8a].

Recovery support services were provided by 89 percent of facilities.

- Assistance with obtaining social services was provided by 69 percent of all facilities [Table 4.8a].
- Assistance in locating housing for clients was provided by 64 percent of all facilities [Table 4.8a].
- Mentoring/peer support was provided by 63 percent of all facilities [Table 4.8a].
- Self-help groups were provided by 49 percent of all facilities [Table 4.8a].
- Employment counseling or training for clients was provided by 44 percent of all facilities [Table 4.8a].
- Recovery coach services were provided by 28 percent of all facilities [Table 4.8a].

Education and counseling services were provided by more than 99 percent of all facilities.

- Substance abuse education was provided by 97 percent of all facilities [Table 4.8a].
- Individual counseling was provided by 97 percent of all facilities [Table 4.8a].
- Group counseling was provided by 93 percent of all facilities [Table 4.8a].
- Family counseling was provided by 79 percent of all facilities [Table 4.8a].
- Smoking/tobacco cessation counseling was provided by 62 percent of all facilities [Table 4.8a].
- HIV or AIDS education, counseling, or support was provided by 61 percent of all facilities [Table 4.8a].
- Health education other than HIV/AIDS or hepatitis was provided by 59 percent of all facilities [Table 4.8a].
- Marital/couples counseling was provided by 58 percent of all facilities [Table 4.8a].

- Hepatitis education, counseling, or support was provided by 55 percent of all facilities [Table 4.8a].
- Vocational training or educational support was provided by 18 percent of all facilities [Table 4.8a]. Ancillary services were provided by 97 percent of all facilities.
- Case management services were provided by 83 percent of all facilities [Table 4.8a].
- Social skills development was provided by 74 percent of all facilities [Table 4.8a].
- Mental health services were provided by 71 percent of all facilities [Table 4.8a].
- Transportation assistance to treatment was provided by 48 percent of all facilities [Table 4.8a].
- Domestic violence services were provided by 37 percent of all facilities [Table 4.8a].
- Early intervention for HIV was provided by 23 percent of all facilities [Table 4.8a].
- Acupuncture and child care for clients' children were each provided by 6 percent of all facilities [Table 4.8a].
- Residential beds for clients' children were provided by 2 percent of all facilities [Table 4.8a]. "Other" services were provided by 44 percent of all facilities.¹⁷
- Treatment for other non-substance addiction disorders was provided by 37 percent of all facilities [Table 4.8a].
- Treatment for gambling disorders was provided by 28 percent of all facilities [Table 4.8a].
- Treatment for Internet use disorder was provided by 17 percent of all facilities [Table 4.8a].

At least one pharmacotherapy was provided by 67 percent of all facilities; rates were higher in federal government-operated facilities (89 percent).

- Medications for psychiatric disorders were the most frequently available pharmacotherapies, and were provided in 50 percent of all facilities [Table 4.8a].
- Buprenorphine (with or without naloxone, as sub-dermal implant, or extended-release injectable) was provided by 44 percent of all facilities [Table 4.8a].
- Naltrexone (oral or extended-release injectable) was provided by 37 to 38 percent of all facilities [Table 4.8a].
- Nicotine replacement was provided by 35 percent of all facilities [Table 4.8a].
- Non-nicotine medications for smoking cessation were provided by 29 percent of all facilities [Table 4.8a].
- Clonidine was provided by 29 percent of all facilities [Table 4.8a].
- Acamprosate (Campral®) was provided by 26 percent of all facilities [Table 4.8a].

¹⁷ "Other" services consist of treatment for gambling disorder, Internet use disorder, or any other non-substance use addiction disorder.

- Disulfiram (Antabuse®) and was provided by 25 percent of all facilities [Table 4.8a].
- Medications for hepatitis C and methadone were each provided by 10 percent of all facilities [Table 4.8a].
- Medications for HIV treatment were provided by 9 percent of all facilities [Table 4.8a].
- Lofexidine was provided by 6 percent of all facilities [Table 4.8a].

Clinical/Therapeutic Approaches

Table 4.10. Facilities were asked to indicate if they used any of 15 specific clinical/therapeutic approaches frequently.

- The approaches that facilities most commonly reported using frequently were substance abuse counseling (98 percent), relapse prevention (96 percent), cognitive behavioral therapy (94 percent), and motivational interviewing (93 percent) [Table 4.10].
- A majority of facilities reported frequently using trauma-related counseling (83 percent), brief intervention (82 percent), anger management (79 percent), 12-step facilitation (65 percent), dialectical behavior therapy (61 percent), telemedicine/telehealth therapy (59 percent), and contingency management/motivational incentives (54 percent) [Table 4.10].
- Less than half of facilities reported "frequently" using matrix model (45 percent), rational emotive behavioral therapy (43 percent), and community reinforcement plus vouchers (10 percent) [Table 4.10].

MAT for Opioid Use Disorder

Table 4.11b. Facilities were asked about whether they treated opioid use disorder (OUD) and how MAT was used in the treatment they provided for OUD. In response, facilities reported the following:

- Overall, 90 percent of facilities reported that they treat OUD [Table 4.11b].
- The proportion of facilities which reported that they did not use MAT, nor accept clients using MAT to treat OUD, was 7 percent [Table 4.11b].
- Just over half of all facilities (51 percent) reported that they accepted clients using MAT, but that the medications originated from or were prescribed by another entity. The most common source for medications when they originated from or were prescribed by another entity was a facility with no formal relationship (38 percent) to the respondent [Table 4.11b].
- The proportion of facilities that reported having a federally certified OTP was 11 percent [Table 4.11b].
- The proportion of facilities which reported that they administered naltrexone to treat OUD was 38 percent, and the proportion which reported that they prescribed buprenorphine was 37 percent [Table 4.11b].

Treatment of Alcohol Use Disorder

Tables 4.12 and 4.13b. Facilities were asked whether and how they treat alcohol use disorder (AUD). Overall, 91 percent of facilities treated AUD. The proportion of facilities that reported treating AUD without MAT was 15 percent. Over a third of facilities (39 percent) reported that they administer or prescribe disulfiram, naltrexone, or acamprosate; 51 percent of facilities reported that they treat clients with MAT using medications that originate elsewhere. When clients were treated with medications that originate elsewhere, the most common source was a facility with no formal relationship (41 percent); a business, contractual, or formal referral relationship with a prescribing entity (17 percent); or a prescribing entity in same network (13 percent).

Programs or Groups for Specific Client Types

Table 4.14b. Facilities were asked about the provision of substance use treatment programs or groups specifically tailored for categories of clients. Overall, 84 percent of facilities offered at least one substance use treatment program or group specifically tailored for a category of client. The proportions of facilities that provided specifically tailored substance use treatment programs or groups were:

- Many facilities offered programs or groups for clients in specific demographic groups. Programs for adult women and programs for adult men were provided by 51 percent and 49 percent of facilities, respectively. Programs for young adults, programs for pregnant or postpartum women, programs for seniors or older adults, and programs for adolescents were provided by 32 percent, 26 percent, 25 percent, and 24 percent of facilities, respectively [Table 4.14b].
- Facilities offered programs for clients with a variety of co-occurring conditions. Programs for clients with co-occurring mental and substance use disorders were provided by 55 percent of facilities. Programs for clients with co-occurring pain and substance use were provided by 22 percent of facilities. Programs for clients with HIV or AIDS were provided by 21 percent of facilities [Table 4.14b].
- Some facilities offered programs for clients who have experienced trauma. Programs for clients who have experienced trauma were provided by 45 percent of facilities. Programs for clients who have experienced sexual abuse were provided by 30 percent of facilities. Programs for clients who have experienced intimate partner violence or domestic violence were provided by 30 percent of facilities [Table 4.14b].
- Some facilities offered specifically tailored programs or groups for current or former members of the military or their families. Programs for veterans were provided by 23 percent of facilities. Programs for members of military families were provided by 15 percent of facilities, and programs for active duty military were provided by 14 percent of facilities [Table 4.14b].
- Specifically tailored programs or groups for criminal justice clients (other than DUI/DWI)¹⁸ were provided by 38 percent of facilities, and programs for clients arrested for DUI or DWI were provided by 23 percent of facilities [Table 4.14b].
- Specifically tailored programs or groups for lesbian, gay, bisexual, transgender, or queer/questioning (LGBTQ) clients were provided by 24 percent of facilities [Table 4.14b].

¹⁸ Facilities treating incarcerated persons only were excluded from this report; see Chapter 1.

Treatment Services in Sign Language for the Deaf and Hard-of-Hearing and in Languages Other Than English

Table 4.15b. Facilities were asked about the provision of substance abuse treatment services in sign language for the deaf and hard-of-hearing. They were also asked if treatment was provided in languages other than English, if this treatment was provided by a staff counselor or by an on-call interpreter, and in what languages staff counselors provided treatment.

- Substance abuse treatment services in sign language for the deaf and hard-of-hearing were provided in 36 percent of all facilities. Facilities operated by local, county, or community governments and by state governments most frequently reported that they offer these services (70 and 61 percent, respectively) [Table 4.15b].
- Substance abuse treatment services in languages other than English were provided in 55 percent of all facilities, ranging from 35 percent of tribal government-operated facilities to 82 percent of local, county, or community government-operated facilities [Table 4.15b].
- Of facilities that provided treatment services in languages other than English, 22 percent used only staff counselors who spoke other languages; another 25 percent of facilities used both staff counselors and on-call interpreters [Table 4.15b].
- In facilities where staff counselors provided treatment services in languages other than English, Spanish was the most frequently spoken language (94 percent of those facilities). Treatment services in American Indian/Alaska Native languages were provided by 2 percent of all facilities where staff counselors provided treatment services in languages other than English. A majority of tribal government-operated facilities and most Indian Health Service-operated facilities where staff counselors provided treatment services in languages other than English offered services in American Indian/Alaska Native languages (77 and 50 percent, respectively) [Table 4.15b].

Detoxification Services

Table 4.16. Facilities that provided detoxification services were asked to indicate whether they detoxified clients from specified substances, and whether medication was routinely used during detoxification. The number of facilities that provided any type of substance detoxification services was 3,609 from a total of 16,066 facilities.

Of the 3,609 facilities that offered detoxification, the proportions that offered detoxification from the following specific substances were: 96 percent for opioids, 71 percent for alcohol, 66 percent for benzodiazepines, 61 percent for methamphetamines, 60 percent for cocaine, and 15 percent for other substances. Medications were routinely used during detoxification in 91 percent of the facilities providing detoxification services.

Client Outreach

Table 4.17. Facilities were asked if they provided outreach to persons who may need treatment. Outreach to persons in the community who may need treatment was provided by 66 percent of all facilities and by 85 percent of tribal government-operated facilities.

Facility Licensing, Certification, or Accreditation

Facilities were asked to report licensure, certification, or accreditation by specified agencies or organizations. These included the state substance abuse agency; state mental health department; state department of health; hospital licensing authority; the Joint Commission; CARF; NCQA; COA; HFAP; and other national organizations or federal, state, or local agencies.¹⁹

Table 4.18b. Overall, 94 percent of all facilities reported that they were licensed, certified, or accredited by one or more agencies or organizations.

The proportions of facilities reporting that they were licensed, certified, or accredited by specified agencies or organizations were 77 percent by a state substance abuse agency; 48 percent by a state department of health; 39 percent by a state mental health department; 30 percent by CARF; 23 percent by the Joint Commission; 5 percent by a hospital licensing authority; 4 percent by COA; 2 percent by NCQA; 1 percent by HFAP; and 5 percent by some other national organization or federal, state, or local agency. A further 6 percent of facilities reported that they were not licensed, certified, or accredited to provide substance abuse services by any of the organizations listed.

Table 4.19b. Facility licensing, certification, or accreditation was associated with the type of care offered. State substance abuse agencies licensed, certified, or accredited 78 percent of facilities that offered residential (non-hospital) treatment, 77 percent of facilities that offered outpatient treatment, and 60 percent of facilities that offered hospital inpatient treatment.

State mental health departments licensed, certified, or accredited 42 percent of facilities that offered outpatient treatment, 38 percent of hospital inpatient facilities, and 30 percent of residential (non-hospital) facilities.

Federally Qualified Health Centers

Table 4.20. Facilities were asked to indicate whether they were a Federally Qualified Health Center (FQHC). Of all 16,066 facilities included in the report, 1,592 facilities were Federally Qualified Health Centers. Most FQHCs provided outpatient care (90 percent). Residential (non-hospital) care and inpatient hospital care were provided by a smaller proportion of FQHCs—15 percent and 4 percent, respectively.

Payment Options

Table 4.21b. Facilities were asked to indicate whether they accepted specified types of payment or insurance for substance abuse treatment. They were also asked about the use of a sliding fee scale and if they offered treatment at no charge or minimal payment to clients who could not pay.

- The mostly commonly accepted payment types were cash or self-payment (90 percent), private health insurance (74 percent), and Medicaid (71 percent) [Table 4.21b].
- Nearly half of facilities reported that they accept a state-financed health insurance plan other than Medicaid (49 percent) [Table 4.21b].

¹⁹ CARF: Commission on Accreditation of Rehabilitation Facilities; NCQA: National Committee for Quality Assurance; COA: Council on Accreditation; and HFAP: Healthcare Facilities Accreditation Program.

• A minority of facilities reported that they accept Medicare (42 percent), federal military insurance (39 percent), and IHS/Tribal/Urban funds (12 percent) [Table 4.21b].²⁰

A smaller proportion of facilities operated by tribal governments and the federal government reported that they accept cash or self-payment (43 and 42 percent, respectively) than did facilities operated by any other entity. Facilities operated by private for-profit organizations and by the federal government less frequently reported that they accept Medicaid (56 percent and 39 percent, respectively), or a state-financed health insurance plan other than Medicaid (37 percent and 25 percent, respectively), than facilities operated by any other entity.

A larger proportion of facilities operated by the Indian Health Service reported that they accept ITU (IHS/Tribal/Urban) funds (83 percent) than did facilities operated by any other entity.²⁰

Use of a sliding fee scale was reported by 57 percent of all facilities, ranging from 5 percent of facilities operated by the federal government to 80 percent of facilities operated by local, county, or community governments.

Treatment at no charge or minimal payment for persons who cannot afford to pay was offered by 44 percent of all facilities, ranging from 13 percent of facilities operated by the federal government to 78 percent of facilities operated by tribal governments

Facility Funding

Table 4.22. Facilities were asked if they receive federal, state, or local government funds or grants to support their substance abuse treatment programs.

Overall, 51 percent of facilities reported receiving government funds to support substance use treatment programs. The proportions were highest in facilities operated by local, county, or community governments and by tribal governments (87 and 86 percent, respectively). Of facilities operated by private non-profit organizations, 73 percent reported that they receive public funds, whereas 18 percent of facilities operated by private for-profit organizations reported receiving public funds.

Facilities Using MAT

OTPs are certified by SAMHSA to provide MAT in the treatment of OUD. Currently, methadone and buprenorphine are the only opioid medications approved for the treatment of OUD. Injectable naltrexone is approved for relapse prevention in OUD. Only OTPs may use methadone for the treatment of OUD. Facilities with DATA 2000-waivered practitioners may prescribe buprenorphine. Any authorized personnel (physicians, physician assistants, etc.) may prescribe or administer injectable naltrexone.

Table 4.23a. There were 8,250 facilities that offered any type of MAT, of which 1,754 facilities had OTPs, 7,066 facilities offered buprenorphine for MAT, and 6,016 facilities offered injectable naltrexone for MAT.

Through a contract, tribes can receive the money that the Indian Health Service (IHS) would have used to provide direct health services for tribal members. Tribes can use these funds to provide directly, or through another entity, a broad range of health services. This option was part of P.L. 93-638 and is commonly known as "638 contracting."

- Of the 1,754 facilities with OTPs, 303 facilities provided methadone only; 741 facilities provided methadone and buprenorphine; 545 facilities provided methadone, buprenorphine, and injectable naltrexone; 100 facilities provided buprenorphine and injectable naltrexone; 38 facilities provided methadone and injectable naltrexone; 20 facilities offered buprenorphine only; and 7 facilities provided injectable naltrexone only [Table 4.23a].
- Among non-OTP facilities, there were 4,490 facilities that offered buprenorphine and injectable naltrexone, 1,170 facilities that offered buprenorphine only, and 836 that offered injectable naltrexone only [Table 4.23a].

Table 4.23b. The majority of facilities with OTPs that offered methadone only were operated by private for-profit organizations (67 percent). In contrast, facilities with OTPs operated by private non-profit organizations accounted for the majority of facilities that offered methadone and injectable naltrexone (92 percent).

- Of all facilities that offered buprenorphine, 91 percent were operated by either private for-profit or private non-profit organizations (46 and 45 percent, respectively). Federal government-operated facilities represented 3 percent of all facilities that offered buprenorphine, and local, county, or community government-operated facilities represented another 3 percent [Table 4.23b].
- Of all facilities that offered injectable naltrexone, 89 percent were operated by either private non-profit or private for-profit organizations (49 percent and 41 percent each); 4 percent were operated by the federal government; and 4 percent were operated by local, county, or community governments [Table 4.23b].
- Private for-profit organizations operated 62 percent of facilities with OTPs, and private non-profit organizations operated 31 percent of facilities with OTPs [Table 4.23b].

Table 4.24b. Most facilities with OTPs offered outpatient treatment (91 percent). Of facilities with OTPs, 90 percent offered outpatient methadone/buprenorphine maintenance or injectable naltrexone treatment and 42 percent offered outpatient detoxification.

Tables 4.19b and 4.25b. A larger proportion of facilities with OTPs than all facilities, combined, reported being licensed, certified, or accredited by a state department of health (60 vs. 48 percent), the Joint Commission (28 vs. 23 percent), CARF (66 vs. 30 percent), or a state substance abuse agency (88 vs. 77 percent).

Facility Smoking Policy

Table 4.26. Of the 15,980 facilities that responded to the question about smoking policies, 57 percent permitted smoking in designated outdoor areas, whereas 36 percent of facilities did not permit smoking anywhere outside or within any building.

Suicide Prevention-Related Services in Veterans Affairs Facilities

Table 4.27. Veterans Affairs (VA) facilities were asked what types of suicide prevention-related services they offered.

Among VA facilities, 93 percent provided suicide risk evaluation, 93 percent provided suicide risk screening, and 90 percent provided evidence-based suicide prevention interventions. All VA facilities reported offering suicide prevention-related services.

Chapter 5 Client Characteristics

This chapter describes key characteristics of the 1,090,357 clients in substance abuse treatment on March 31, 2020 [Table 5.1a]. Clients in treatment were defined as: (1) hospital inpatient and residential (non-hospital) clients receiving substance abuse treatment services on March 31, 2020, and (2) outpatient clients who were seen at the facility for substance abuse treatment or detoxification service at least once during the month of March 2020, and who were still enrolled in treatment on March 31, 2020.

Facility Operation and Type of Care

Table 5.1c. Facilities were asked to designate the type of entity responsible for the operation of the facility. On March 31, 2020, 46 percent of all clients were receiving treatment in facilities operated by private non-profit organizations and 45 percent were receiving treatment in facilities operated by private for-profit organizations. The remaining clients were receiving treatment in facilities operated by local, county, or community government (4 percent); the federal government (3 percent); state government (2 percent); or a tribal government (1 percent).

The majority of clients in outpatient methadone/buprenorphine maintenance or naltrexone treatment (62 percent) were in facilities operated by private for-profit organizations.

Table 5.1b. Facilities were asked how many clients in treatment on March 31, 2020, received specified subcategories of type of care within three broad categories.

- On March 31, 2020, 94 percent of clients were receiving outpatient treatment, with 42 percent receiving regular outpatient treatment, 41 percent receiving outpatient methadone/buprenorphine maintenance or naltrexone treatment, 8 percent receiving intensive outpatient treatment, 1 percent receiving outpatient detoxification, and 1 percent receiving outpatient day treatment/partial hospitalization [Table 5.1b].
- On March 31, 2020, 5 percent of clients were receiving residential (non-hospital) treatment, with 3 percent receiving long-term treatment (more than 30 days), 2 percent receiving short-term treatment (30 days or fewer), and less than 1 percent receiving residential detoxification services [Table 5.1b].
- On March 31, 2020, 1 percent of clients were receiving hospital inpatient care, with less than 1 percent receiving hospital inpatient treatment and less than 1 percent receiving hospital inpatient detoxification [Table 5.1b].

Clients in Federally Qualified Health Centers

Table 5.2. FQHCs reported 115,868 clients in treatment on March 31, 2020. FQHC clients were reported in three broad types of care:

- Outpatient treatment accounted for 96 percent of FQHC clients, with 45 percent receiving regular outpatient, 41 percent receiving outpatient methadone/buprenorphine maintenance or naltrexone treatment, 7 percent receiving intensive outpatient treatment, 3 percent receiving outpatient detoxification, and 1 percent receiving outpatient day treatment/partial hospitalization [Table 5.2].
- Residential (non-hospital) treatment accounted for 4 percent of FQHC clients, with 2 percent receiving long-term treatment (more than 30 days), 1 percent receiving short-term treatment (30 days or fewer), and less than 1 percent receiving residential detoxification services [Table 5.2].
- Hospital inpatient treatment accounted for less than 1 percent of FQHC clients [Table 5.2].

Clients at High Risk of Suicide at VA Facilities²¹

Table 5.3. VA facilities were asked about the number of clients in treatment on March 31, 2020, at high risk of suicide. Across all reporting VA facilities, the total number of clients at high risk of suicide in each type of care was as follows: 2,325 clients in outpatient treatment, 187 clients in residential (non-hospital) treatment, and 86 clients in hospital inpatient treatment.

Substance Abuse Treatment

Table 5.4. Facilities were asked to estimate the proportions of clients in treatment on March 31, 2020, by substance abuse problem treated (alcohol abuse only, drug abuse only, or both alcohol and drug abuse).

On March 31, 2020, 54 percent of clients were in treatment for drug abuse only, 32 percent were in treatment for both alcohol and drug abuse, and 14 percent were in treatment for alcohol abuse only.

By facility operation, the largest proportion of clients in treatment for abuse of both alcohol and drugs was in tribal government-operated facilities (49 percent). For abuse of drugs only, the largest proportion of clients was in facilities operated by private for-profit organizations (65 percent); for abuse of alcohol only, the largest proportion was in federal government-operated facilities (35 percent).

Clients Under the Age of 18 Years in Treatment

Table 5.5. Facilities were asked how many clients in treatment on March 31, 2020, were under the age of 18 years.

There were 39,271 clients under the age of 18 years in substance abuse treatment on March 31, 2020, of the total 1,090,357 clients in treatment on that date.

Of the 39,271 clients under the age of 18 years, 35,612 clients (91 percent) were in outpatient treatment, while 3,197 clients (8 percent) were in residential (non-hospital) treatment, and 462 clients (1 percent) were in hospital inpatient treatment.

Data for the federal agencies specified in the survey (the Department of Veterans Affairs, the Department of Defense, the Indian Health Service, and other federal agencies specified by respondents) are detailed in the tables.

Clients Receiving MAT for OUD

Tables 5.6a–b. Facilities were asked how many clients in treatment on March 31, 2020, received MAT for OUD for detoxification or maintenance purposes. MAT includes the use of methadone and buprenorphine for the treatment of OUD, and the use of naltrexone for relapse prevention in OUD. Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of OUD; some of these practitioners are affiliated with facilities (either OTPs or other). All physicians or approved medical personnel with prescribing privileges can prescribe naltrexone.²²

- Of the total 1,090,357 clients in treatment, 347,223 received MAT in OTP facilities [Table 5.6a].
- There were 311,531 clients receiving methadone in OTP facilities. Of the clients receiving methadone, 191,625 clients (62 percent) were provided treatment at facilities with OTPs operated by private for-profit organizations, and 103,707 clients (33 percent) were provided treatment at facilities with OTPs operated by private non-profit organizations [Tables 5.6a–b].
- There were 31,864 clients receiving buprenorphine in facilities with OTPs and 144,288 clients receiving buprenorphine in facilities that did not have OTPs [Table 5.6a].
 - Of the clients receiving buprenorphine in facilities with OTPs, 20,295 clients (64 percent) were provided treatment at facilities with OTPs operated by private for-profit organizations, and 8,565 clients (27 percent) were provided treatment at non-OTP facilities operated by private non-profit organizations [Tables 5.6a–b].
 - Of the clients receiving buprenorphine in non-OTP facilities, 92,745 clients (64 percent) were provided treatment at non-OTP facilities operated by private for-profit organizations, and 42,413 clients (29 percent) were provided treatment at non-OTP facilities operated by private non-profit organizations [Tables 5.6a–b].

There were 3,828 clients receiving naltrexone in facilities with OTPs for OUD and 17,497 clients receiving naltrexone in non-OTP facilities [Table 5.6a].

- Of the clients receiving naltrexone in OTPs, 2,678 clients (70 percent) were provided treatment at facilities with OTPs operated by private for-profit organizations, and 578 clients (15 percent) were provided treatment at facilities with OTPs operated by private non-profit organizations [Tables 5.6a–b].
- Of the clients receiving naltrexone in non-OTP facilities, 8,439 clients (48 percent) were provided treatment at non-OTP facilities operated by private non-profit organizations, and 6,985 clients (40 percent) were provided treatment at non-OTP facilities operated by private for-profit organizations [Tables 5.6a–b].

Only clients who received buprenorphine through a facility affiliated with an authorized practitioner are included in this report; it does not include clients who received buprenorphine through an independent DATA 2000-waivered practitioner. This report also does not include clients who received naltrexone through other sources.

Clients Receiving MAT for Alcohol Use Disorder

Table 5.7. Facilities that offered MAT for alcohol use disorder were asked how many clients in treatment on March 31, 2020, received disulfiram (Antabuse®), naltrexone, or acamprosate for alcohol use disorder. By type of care, the total numbers of clients on March 31, 2020, that received each medication were as follows:

- Among clients who received outpatient treatment, 3,365 clients received disulfiram (Antabuse®), 17,475 clients received naltrexone, and 3,343 clients received acamprosate (Campral®) [Table 5.7].
- Among clients who received residential (non-hospital) treatment, 216 clients received disulfiram (Antabuse®), 1,861 clients received naltrexone, and 541 clients received acamprosate (Campral®) [Table 5.7].
- For clients who received hospital inpatient treatment, 229 clients received disulfiram (Antabuse®), 714 clients received naltrexone, and 258 clients received acamprosate (Campral®) [Table 5.7].

CHAPTER 6 STATE DATA

This chapter breaks down data presented in earlier chapters by state or jurisdiction. The Chapter 6 tables correspond thematically to many of the tables presented in Chapters 4 and 5. Note that facilities operated by federal agencies are included in the states in which the facilities are located, although these facilities may have clients from other states.

Table 6.1 details the 2020 N-SSATS response rate.

Tables 6.2a–6.3b present data on facilities and clients in treatment by state or jurisdiction for 2011 to 2020.

Tables 6.4a through 6.33 present facility data for 2020.

Tables 6.34a through 6.42 present client data for 2020.

Tables 6.41 and 6.42 present the number of clients aged 18 years or older in treatment—according to substance abuse problem and receipt of medication-assisted opioid treatment, respectively—per 100,000 population, by state or jurisdiction for 2020.

Survey Response

Table 6.1. The overall response rate for the survey was 90 percent. Response rates in 31 states or jurisdictions equaled or surpassed the overall rate.

Trends

Tables 6.2a–b. California and New York had the largest numbers of both facilities and clients in treatment for every odd year from 2011 through 2019 and in 2020.²³ On March 31, 2020, California had 11 percent of all facilities and 6 percent of all clients, and New York had 6 percent of all facilities and 7 percent of all clients.

In terms of total numbers of facilities in every odd year from 2011 through 2019 and in 2020, Illinois and Florida ranked either third or fourth. North Carolina, Pennsylvania, Texas, and Washington have also consistently ranked within the top 10.

In terms of total numbers of clients in every odd year from 2011 through 2019 and in 2020, New York, Pennsylvania, Florida, Illinois, and Massachusetts have consistently ranked within the top 10.

From 2013 through 2019, the full N-SSATS questionnaire alternated with an abbreviated version, fielded in even-numbered years, that did not collect client counts. In 2020, the full N-SSATS questionnaire, with client counts, was fielded. Therefore, this report draws only on client counts collected in odd-numbered years from 2011 through 2019 and in 2020.

Clients in Treatment per 100,000 Population Aged 18 Years and Older

Table 6.41 and Figures 7–8. Among those 18 years and older, there were 390 clients in treatment per 100,000 population on March 31, 2020. The ratio was highest for clients in treatment for drug abuse only (214 per 100,000 population), followed by both alcohol and drug abuse (122 per 100,000 population), and alcohol abuse only (54 per 100,000 population). Figure 7 maps each state or jurisdiction's ratio of clients in treatment per 100,000 population by quartile in 2020. There are between 12 and 13 states in each quartile. Figure 8 maps the ratios of clients in treatment per 100,000 population for each state or jurisdiction by quartile in 2011. It has been included in this section for comparison.

March 31, 2020 WA МТ ND OR MN SD WY IΑ ΝE NV UT СО KS МО ΚY ΤN OK ΑZ NM AR AL MS ΤX ٥٥ PR ____ 110–273 274-394 395-680 681 or more

Figure 7. Clients in treatment per 100,000 population aged 18 years and older:

SOURCES: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020. Population: U.S. Census Bureau, Population Estimates Program, SC-EST2020-18+POP-RES: "Estimates of the Total Resident Population and Resident Population Age 18 Years and Older for the United States, Regions, States, the District of Columbia, and Puerto Rico: July 1, 2020"; U.S. Census Bureau, International Programs, International Data Base. Last Updated: December 2020.




Figure 8. Clients in treatment per 100,000 population aged 18 years and older: March 31, 2011

SOURCES: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2011. Population: U.S. Census Bureau, Population Estimates, State population dataset – SCPRC-EST2011-18+POP-RES: "Estimates of the Total Resident Population and Resident Population Age 18 Years and Older for the United States, States, and Puerto Rico: July 1, 2011"; U.S. Census Bureau, International Programs, International Data Base, Last Updated: December 2020.

TABLES

Table 2.1. Facility turnover: Number and column percent distribution, 2010–2020

_					Nui	mber of facil	ities				
Facility status	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total	13,339	13,720	14,311	14,148	14,152	13,873	14,399	13,585	14,809	15,961	16,066
Responded to both current and prior year's surveys	11,882	11,943	12,230	12,711	12,643	12,564	12,500	12,400	12,334	13,107	13,878
New in survey year or non-respondents in previous year	1,457	1,777	2,081	1,437	1,509	1,309	1,899	1,185	2,475	2,854	2,188
Closed/non-respondents since previous survey year	1,631	1,396	1,490	1,600	1,505	1,588	1,373	1,999	1,251	1,702	2,083
				C	Column perc	ent distributi	on of facilitie	s			
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Responded to both current and prior year's surveys	89.1	87.0	85.5	89.8	89.3	90.6	86.8	91.3	83.3	82.1	86.4
New in survey year or non-respondents in previous year	10.9	13.0	14.5	10.2	10.7	9.4	13.2	8.7	16.7	17.9	13.6
Closed/non-respondents since previous survey year	12.1	10.5	10.9	11.2	10.6	11.2	9.9	13.9	9.2	11.5	13.1

NOTES: Survey reference dates were: March 31 for 2010–2011, 2014–2017, and 2020; March 30 for 2012 and 2018; and March 29 for 2013 and 2019. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time. Percentages may not sum to 100 percent because of rounding.

Table 2.2. Facility operation: Number and column percent distribution, 2010–2020

			Number o	f facilities				Column	percent dis	tribution of fa	acilities	
Facility operation	2010	2012	2014	2016	2018	2020	2010	2012	2014	2016	2018	2020
Total	13,339	14,311	14,152	14,399	14,809	16,066	100.0	100.0	100.0	100.0	100.0	100.0
Facility operation												
Private non-profit	7,683	8,054	7,817	7,662	7,642	8,004	57.6	56.3	55.2	53.2	51.6	49.8
Private for-profit	3,985	4,450	4,664	5,101	5,584	6,535	29.9	31.1	33.0	35.4	37.7	40.7
Local, county, or community govt.	751	758	713	706	690	670	5.6	5.3	5.0	4.9	4.7	4.2
State government	380	363	344	340	304	285	2.8	2.5	2.4	2.4	2.1	1.8
Federal government	348	364	337	332	327	323	2.6	2.5	2.4	2.3	2.2	2.0
Dept. of Veterans Affairs	218	215	211	211	219	228	1.6	1.5	1.5	1.5	1.5	1.4
Dept. of Defense	91	89	85	87	76	57	0.7	0.6	0.6	0.6	0.5	0.4
Indian Health Service	36	50	32	31	23	29	0.3	0.3	0.2	0.2	0.2	0.2
Other	3	10	9	3	9	9	*	0.1	0.1	*	0.1	0.1
Tribal government	192	322	277	258	262	249	1.4	2.3	2.0	1.8	1.8	1.5

^{*} Less than 0.05 percent.

NOTES: Survey reference dates were March 31 for 2010, 2014, 2016 and 2020; March 30 for 2012 and 2018. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time. Percentages may not sum to 100 percent because of rounding.

Table 2.3. All facilities and facilities with opioid treatment programs (OTPs), by type of care offered: Number and column percent, 2010–2020

Type of care offered and facilities			Number of	facilities¹				C	Column percei	nt of facilities	1	
with opioid treatment programs	2010	2012	2014	2016	2018	2020	2010	2012	2014	2016	2018	2020
Total	13,339	14,311	14,152	14,399	14,809	16,066						
Type of care offered												
Outpatient	10,753	11,650	11,618	11,836	12,243	13,161	80.6	81.4	82.1	82.2	82.7	81.9
Regular	9,914	10,858	10,826	11,036	11,394	12,249	74.3	75.9	76.5	76.6	76.9	76.2
Intensive	5,990	6,427	6,409	6,553	6,868	7,243	44.9	44.9	45.3	45.5	46.4	45.1
Detoxification	1,227	1,367	1,422	1,361	1,505	1,869	9.2	9.6	10.0	9.5	10.2	11.6
Day treatment/partial hospitalization	1,678	1,762	1,759	1,890	2,051	2,277	12.6	12.3	12.4	13.1	13.8	14.2
Methadone/buprenorphine maintenance or												
naltrexone treatment	1,137	1,316	2,498	3,079	4,087	5,829	8.5	9.2	17.7	21.4	27.6	36.3
Residential (non-hospital)	3,452	3,566	3,473	3,469	3,500	3,825	25.9	24.9	24.5	24.1	23.6	23.8
Detoxification	893	894	914	954	1,140	1,412	6.7	6.2	6.5	6.6	7.7	8.8
Short-term treatment (30 days or fewer)	1,691	1,804	1,785	1,816	2,039	2,427	12.7	12.6	12.6	12.6	13.8	15.1
Long-term treatment (more than 30 days)	2,801	2,932	2,845	2,814	2,770	2,972	21.0	20.5	20.1	19.5	18.7	18.5
Hospital inpatient	748	780	762	751	785	861	5.6	5.5	5.4	5.2	5.3	5.4
Detoxification	666	686	664	661	721	784	5.0	4.8	4.7	4.6	4.9	4.9
Treatment	548	578	550	550	588	658	4.1	4.0	3.9	3.8	4.0	4.1
Facilities with opioid treatment programs ²												
Total	1,166	1,167	1,312	1,308	1,519	1,754						
Outpatient	1,083	1,109	1,184	1,215	1,411	1,602	92.9	95.0	90.2	92.9	92.9	91.3
Regular	724	813	905	915	1,090	1,291	62.1	69.7	69.0	70.0	71.8	73.6
Intensive	295	310	354	332	431	517	25.3	26.6	27.0	25.4	28.5	29.5
Detoxification	568	597	604	542	661	734	48.7	51.2	46.0	41.4	43.5	41.8
Day treatment/partial hospitalization	80	73	83	64	97	106	6.9	6.3	6.3	4.9	6.4	6.0
Methadone/buprenorphine maintenance or												
naltrexone treatment	1,043	1,079	1,145	1,187	1,360	1,570	89.5	92.5	87.3	90.7	89.5	89.5
Residential (non-hospital)	93	81	112	93	132	165	8.0	6.9	8.5	7.1	8.7	9.4
Detoxification	48	36	57	56	84	100	4.1	3.1	4.3	4.3	5.5	5.7
Short-term treatment (30 days or fewer)	68	63	82	73	96	129	5.8	5.4	6.3	5.6	6.3	7.4
Long-term treatment (more than 30 days)	51	50	61	44	76	87	4.4	4.3	4.6	3.4	5.0	5.0
Hospital inpatient	99	85	125	98	121	134	8.5	7.3	9.5	7.5	8.0	7.6
Detoxification	93	82	111	87	116	125	8.0	7.0	8.5	6.7	7.6	7.1
Treatment	75	66	92	69	89	96	6.4	5.7	7.0	5.3	5.9	5.5

Numbers of facilities sum to more than the total and percentages sum to more than 100 percent, because a facility could provide more than one type of care.

² Only those facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration are included.

NOTES: Survey reference dates were March 31 for 2010, 2014, 2016 and 2020; March 30 for 2012 and 2018. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time. Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 2.4. Medication-assisted opioid therapy provided at facilities with OTPs and non-OTP facilities: Number and column percent, 2010–2020

Facilities with opioid treatment				Number c	f facilities				С	olumn perce	nt of facilitie	s	
programs and other facilities	20	010	2012	2014	2016	2018	2020	2010	2012	2014	2016	2018	2020
Te	otal 13,	,339	14,311	14,152	14,399	14,809	16,066						
Any MAT type ¹	3,	,054	3,905	4,366	5,300	6,259	8,250	22.9	27.3	30.9	36.8	42.3	51.4
Total OTPs	1,	,166	1,167	1,312	1,308	1,519	1,754	8.7	8.2	9.3	9.1	10.3	10.9
Total buprenorphine ²	2,	,451	2,930	3,280	3,890	4,951	7,066	18.4	20.5	23.2	27.0	33.4	44.0
Total injectable naltrexone		n/a	1,438	1,935	3,028	4,178	6,016	n/a	10.0	13.7	21.0	28.2	37.4
Facilities with opioid treatment programs	1,	,166	1,167	1,312	1,308	1,519	1,754						
Any MAT type ¹	1,	,166	1,167	1,312	1,308	1,519	1,754	100.0	100.0	100.0	100.0	100.0	100.0
Methadone only		603	550	523	485	383	303	51.7	47.1	39.9	37.1	25.2	17.3
Methadone and buprenorphine ²		546	453	498	482	597	741	46.8	38.8	38.0	36.9	39.3	42.2
Methadone, buprenorphine ² , and injectable													
naltrexone		n/a	143	227	284	428	545	n/a	12.3	17.3	21.7	28.2	31.1
Methadone and injectable naltrexone		n/a	7	25	32	39	38	n/a	0.6	1.9	2.4	2.6	2.2
Buprenorphine ² and injectable naltrexone		n/a	6	23	19	50	100	n/a	0.5	1.8	1.5	3.3	5.7
Buprenorphine ² only		17	8	16	4	20	20	1.5	0.7	1.2	0.3	1.3	1.1
Injectable naltrexone only		n/a			2	2	7	n/a			0.2	0.1	0.4
Total buprenorphine	2,	,451	2,930	3,280	3,890	4,951	7,066						
OTPs providing buprenorphine ²		563	610	764	789	1,095	1,406	23.0	20.8	23.3	20.3	22.1	19.9
Non-OTP facilities providing buprenorphine ²	1,	,888,	2,320	2,516	3,101	3,856	5,660	77.0	79.2	76.7	79.7	77.9	80.1
Total injectable naltrexone		n/a	1,438	1,935	3,028	4,178	6,016						
OTPs providing injectable naltrexone		n/a	156	275	337	519	690	n/a	10.8	14.2	11.1	12.4	11.5
Non-OTP facilities providing buprenorphine ² and													
injectable naltrexone		n/a	864	1,122	1,800	2,775	4,490	n/a	60.1	58.0	59.4	66.4	74.6
Non-OTP facilities providing injectable naltrexone													
only		n/a	418	538	891	884	836	n/a	29.1	27.8	29.4	21.2	13.9

^{- -} Quantity is zero; n/a Not applicable.

NOTES: Survey reference dates were March 31 for 2010, 2014, 2016 and 2020; March 30 for 2012 and 2018. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time. Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility. Percentages may not sum to 100 percent because of rounding.

Injectable naltrexone = extended-release injectable naltrexone; MAT = medication assisted treatment.

¹ Any MAT type for all facilities providing medication-assisted opioid therapy includes all facilities providing buprenorphine or injectable naltrexone and OTP facilities providing methadone, buprenorphine, or injectable naltrexone.

² Buprenorphine includes buprenorphine with and without naloxone, buprenorphine sub-dermal implant, and extended-release injectable buprenorphine.

Table 3.1. Clients in treatment, by facility operation: Number and column percent distribution, 2011–2020

			Number	of clients				Colum	n percent di	stribution of	clients	
Facility operation	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Total	1,224,127	1,249,629	1,305,647	1,356,015	1,460,706	1,090,357	100.0	100.0	100.0	100.0	100.0	100.0
Facility operation												
Private non-profit	646,904	638,858	670,593	658,896	726,238	504,780	52.8	51.1	51.4	48.6	49.7	46.3
Private for-profit	395,577	430,362	475,531	550,992	591,442	485,411	32.3	34.4	36.4	40.6	40.5	44.5
Local, county, or community govt.	73,338	72,949	67,060	66,577	59,708	39,571	6.0	5.8	5.1	4.9	4.1	3.6
State government	40,303	35,812	30,675	28,529	27,081	19,601	3.3	2.9	2.3	2.1	1.9	1.8
Federal government	47,742	53,695	46,721	34,435	41,848	30,589	3.9	4.3	3.6	2.5	2.9	2.8
Dept. of Veterans Affairs	37,321	44,180	39,501	29,619	36,951	26,825	3.0	3.5	3.0	2.2	2.5	2.5
Dept. of Defense	8,487	6,685	5,774	3,618	2,065	2,278	0.7	0.5	0.4	0.3	0.1	0.2
Indian Health Service	1,838	1,368	1,218	1,103	842	502	0.2	0.1	0.1	0.1	0.1	*
Other	96	1,462	228	95	1,990	984	*	0.1	*	*	0.1	0.1
Tribal government	20,263	17,953	15,067	16,586	14,389	10,405	1.7	1.4	1.2	1.2	1.0	1.0

^{*} Less than 0.05 percent.

NOTES: Survey reference dates were March 31 for 2011, 2015, 2017 and 2020; March 29 for 2013 and 2019. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time. Percentages may not sum to 100 percent because of rounding.

Table 3.2. Clients in treatment, by type of care received, and clients receiving buprenorphine, naltrexone, or methadone:

Number and column percent distribution, 2011–2020

Type of care received and clients receiving			Number o	of clients				Colum	n percent dis	stribution of	clients	
buprenorphine, naltrexone, or methadone	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Total	1,224,127	1,249,629	1,305,647	1,356,015	1,460,706	1,090,357	100.0	100.0	100.0	100.0	100.0	100.0
Type of care received												
Outpatient	1,095,897	1,127,235	1,161,456	1,238,654	1,355,024	1,021,185	89.5	90.2	89.0	91.3	92.8	93.7
Regular	617,715	603,315	604,819	599,290	642,554	459,157	50.5	48.3	46.3	44.2	44.0	42.1
Intensive	141,964	147,162	128,536	133,850	130,343	83,073	11.6	11.8	9.8	9.9	8.9	7.6
Detoxification	13,450	13,839	14,457	11,839	21,460	13,445	1.1	1.1	1.1	0.9	1.5	1.2
Day treatment/partial hospitalization	23,338	22,828	23,138	23,310	19,973	14,112	1.9	1.8	1.8	1.7	1.4	1.3
Methadone/buprenorphine maintenance												
or naltrexone treatment	299,430	340,091	390,506	470,365	540,694	451,398	24.5	27.2	29.9	34.7	37.0	41.4
Residential (non-hospital)	112,827	107,727	119,900	99,881	91,592	58,952	9.2	8.6	9.2	7.4	6.3	5.4
Detoxification	9,326	10,244	13,748	10,938	8,629	5,377	0.8	0.8	1.1	0.8	0.6	0.5
Short-term treatment (30 days or fewer)	29,164	27,184	36,651	32,156	33,698	20,440	2.4	2.2	2.8	2.4	2.3	1.9
Long-term treatment (more than 30 days)	74,337	70,299	69,501	56,787	49,265	33,135	6.1	5.6	5.3	4.2	3.4	3.0
Hospital inpatient	15,403	14,667	24,291	17,480	14,090	10,220	1.3	1.2	1.9	1.3	1.0	0.9
Detoxification	6,179	5,768	12,394	7,551	6,258	4,776	0.5	0.5	0.9	0.6	0.4	0.4
Treatment	9,224	8,899	11,897	9,929	7,832	5,444	0.8	0.7	0.9	0.7	0.5	0.5
Clients receiving buprenorphine or naltrexone												
Clients receiving buprenorphine	32,676	48,148	75,724	112,223	168,428	176,152	2.7	3.9	5.8	8.3	11.5	16.2
Clients receiving naltrexone	n/a	3,781	7,035	23,065	30,394	21,325	n/a	0.3	0.5	1.7	2.1	2.0
Clients receiving methadone (OTP facilities only)												
Clients receiving methadone	306,440	330,308	356,843	382,867	408,550	311,531	25.0	26.4	27.3	28.2	28.0	28.6

n/a Not applicable.

NOTES: Survey reference dates were: March 31 for 2011, 2015, 2017, and 2020; and March 29 for 2013 and 2019. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time. Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 3.3. Clients in treatment, by substance abuse problem and diagnosed co-occurring mental and substance use disorders:

Number and column percent distribution, 2011–2020

Substance abuse problem and diagnosed co-occurring mental and			Number	of clients				Colum	n percent dis	stribution of	clients	
substance use disorders	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Total ¹	1,224,127	1,249,629	1,305,647	1,356,015	1,460,706	1,090,357	100.0	100.0	100.0	100.0	100.0	100.0
Substance abuse problem												
Clients with both alcohol and drug												
abuse	535,258	534,078	520,866	500,948	476,065	333,526	43.7	42.7	39.9	36.9	32.6	30.6
Clients with drug abuse only	464,406	491,903	531,963	642,713	743,828	569,522	37.9	39.4	40.7	47.4	50.9	52.2
Clients with alcohol abuse only	221,632	216,856	200,187	211,460	205,402	146,710	18.1	17.4	15.3	15.6	14.1	13.4
Diagnosed co-occurring mental and						•						
substance use disorders	506,162	563,071	614,789	683,810	702,914	531,105	41.3	45.1	47.1	50.4	48.1	48.7

¹ Totals include clients in facilities that did not respond to the substance abuse problem question (in 2011, 2,832 clients reported by 188 facilities; in 2013, 6,792 clients reported by 257 facilities; in 2015, 725 clients reported by 235 facilities; in 2017, 894 clients reported by 279 facilities; in 2019, 35,412 clients reported by 522 facilities; and in 2020, 40,599 clients reported by 632 facilities).

NOTES: Survey reference dates were: March 31 for 2011, 2015, 2017, and 2020; and March 29 for 2013 and 2019. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time. Numbers may not sum to totals and percentages may not sum to 100 percent because of rounding.

Table 3.4. Clients under the age of 18 years in treatment, by type of care received, and clients under the age of 18 years in treatment in facilities offering special programs or groups for adolescents: Number and column percent distribution, 2011–2020

Type of care received and clients under the age of 18 years in facilities with special programs or groups for		Number o	f clients und	er the age o	f 18 years¹				•	stribution of e of 18 year		
adolescents	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
	82,532	78,156	72,977	62,862	59,854	39,271	100.0	100.0	100.0	100.0	100.0	100.0
Type of care received												
Outpatient	71,687	69,184	63,493	55,613	53,636	35,612	86.9	88.5	87.0	88.5	89.6	90.7
Residential (non-hospital)	9,738	8,071	7,807	6,539	5,468	3,197	11.8	10.3	10.7	10.4	9.1	8.1
Hospital inpatient	1,107	901	1,677	710	750	462	1.3	1.2	2.3	1.1	1.3	1.2
Clients under the age of 18 years in facilities												
with special programs or groups for												
adolescents	65,918	65,276	54,650	46,253	43,996	27,944	79.9	83.5	74.9	73.6	73.5	71.2

¹ The total number of clients excludes the clients in the facilities that did not respond to the question about clients under the age of 18 years (in 2011, 1,417 total clients reported by nine facilities; in 2013, 2,520 clients reported by 19 facilities; in 2015, 41 clients reported by one facility; and in 2017, 62 clients reported by two facilities; in 2019, 4,684 total clients reported by 37 facilities; and in 2020, zero total clients reported by zero facilities).

NOTES: Survey reference dates were: March 31 for 2011, 2015, 2017, and 2020; and March 29 for 2013 and 2019. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time. Percentages may not sum to 100 percent because of rounding.

Table 4.1a. Type of care offered, by facility operation: Number, 2020

							Type of care o	offered						
					Outpatier	nt				Residentia non-hospita				spital atient
Facility operation	Total¹	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
Total	16,066	13,161	12,249	7,243	2,277	1,869	5,829	3,825	2,427	2,972	1,412	861	658	784
Facility operation														
Private non-profit	8,004	6,134	5,839	3,498	848	608	2,531	2,374	1,260	1,936	611	348	255	312
Private for-profit Local, county, or	6,535	5,685	5,102	3,068	1,304	1,067	2,682	1,154	994	829	701	366	306	344
community govt.	670	604	588	295	42	34	237	78	42	50	37	35	24	30
State government	285	198	186	96	26	25	77	88	43	57	23	39	32	25
Federal government	323	310	307	168	41	122	233	99	76	72	37	71	41	71
Dept. of Veterans Affairs	228	220	218	141	34	113	208	88	70	64	35	68	38	68
Dept. of Defense	57	56	56	16	6	5	11	3	2	1	1	2	2	2
Indian Health Service	29	26	26	9		2	8	8	4	7	1			
Other	9	8	7	2	1	2	6					1	1	1
Tribal government	249	230	227	118	16	13	69	32	12	28	3	2		2

⁻⁻ Quantity is zero.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

¹ Numbers of facilities sum to more than the total column, because a facility could provide more than one type of care.

Table 4.1b. Type of care offered, by facility operation: Row percent, 2020

							Type of	care offered						
					Outpatien	nt				Residential (non-hospital)				pital tient
Facility operation	Number of facilities¹	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long-term	Detox	Any hospital inpatient	Treat- ment	Detox
Total	16,066	81.9	76.2	45.1	14.2	11.6	36.3	23.8	15.1	18.5	8.8	5.4	4.1	4.9
Facility operation														
Private non-profit	8,004	76.6	73.0	43.7	10.6	7.6	31.6	29.7	15.7	24.2	7.6	4.3	3.2	3.9
Private for-profit	6,535	87.0	78.1	46.9	20.0	16.3	41.0	17.7	15.2	12.7	10.7	5.6	4.7	5.3
Local, county, or														
community govt.	670	90.1	87.8	44.0	6.3	5.1	35.4	11.6	6.3	7.5	5.5	5.2	3.6	4.5
State government	285	69.5	65.3	33.7	9.1	8.8	27.0	30.9	15.1	20.0	8.1	13.7	11.2	8.8
Federal government	323	96.0	95.0	52.0	12.7	37.8	72.1	30.7	23.5	22.3	11.5	22.0	12.7	22.0
Dept. of Veterans Affairs	228	96.5	95.6	61.8	14.9	49.6	91.2	38.6	30.7	28.1	15.4	29.8	16.7	29.8
Dept. of Defense	57	98.2	98.2	28.1	10.5	8.8	19.3	5.3	3.5	1.8	1.8	3.5	3.5	3.5
Indian Health Service	29	89.7	89.7	31.0		6.9	27.6	27.6	13.8	24.1	3.4			
Other	9	88.9	77.8	22.2	11.1	22.2	66.7					11.1	11.1	11.1
Tribal government	249	92.4	91.2	47.4	6.4	5.2	27.7	12.9	4.8	11.2	1.2	0.8		8.0

⁻⁻ Quantity is zero.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

¹ Percentages sum to more than 100 percent, because a facility could provide more than one type of care.

Table 4.2. Type of substance abuse problem treated and treatment of clients with diagnosed co-occurring mental and substance use disorders, by facility operation: Number and row percent, March 31, 2020

		Ν	lumber of faci	lities ^{1,2}			Row perc	ent of facilities	1
_		Client sul	bstance abuse	e problem	Treats clients	Client su	bstance abuse	e problem	Treats clients
Facility operation	Total²	Treats clients with both alcohol and drug abuse	Treats clients with drug abuse only	Treats clients with alcohol abuse only	with diagnosed co-occurring mental and substance use disorders	Treats clients with both alcohol and drug abuse	Treats clients with drug abuse only	Treats clients with alcohol abuse only	with diagnosed co-occurring mental and substance use disorders
Total	8,474	7,389	7,276	6,310	7,467	87.2	85.9	74.5	88.1
Facility operation									
Private non-profit	4,107	3,802	3,597	3,266	3,724	92.6	87.6	79.5	90.7
Private for-profit	3,552	2,832	2,985	2,369	2,991	79.7	84.0	66.7	84.2
Local, county, or community govt.	337	320	299	278	306	95.0	88.7	82.5	90.8
State government	158	143	135	115	147	90.5	85.4	72.8	93.0
Federal government	176	156	150	165	167	88.6	85.2	93.8	94.9
Dept. of Veterans Affairs	129	123	122	120	126	95.3	94.6	93.0	97.7
Dept. of Defense	29	18	12	29	23	62.1	41.4	100.0	79.3
Indian Health Service	13	12	11	12	13	92.3	84.6	92.3	100.0
Other	5	3	5	4	5	60.0	100.0	80.0	100.0
Tribal government	144	136	110	117	132	94.4	76.4	81.3	91.7

¹ Number of facilities sums to more than the total column, and percentages sum to more than 100 percent, because a facility could treat more than one type of client substance abuse problem.

² Of 16,066 facilities, 7,592 facilities (47 percent) did not respond to the questions on client substance abuse problem and diagnosed co-occurring mental and substance abuse disorders; percentages are based on the remaining 8,474 facilities.

Table 4.3. Facility size, by type of care offered and facility operation at facilities with opioid treatment programs (OTPs):

Median number of clients per facility, March 31, 2020

-							Type of	care offere	ed					
					Outpatie	nt				Residentia non-hospit			Hospital ii	npatient
Facility operation	All	Total out-			Day treatment or partial hospitali-		Methadone/ buprenorphine maintenance or naltrexone	Total residen-	Short-	Long-	,	Total hospital		•
	facilities1	patient	Regular	Intensive	zation	Detox	treatment	tial	term	term	Detox	inpatient	Treatment	Detox
Total	260	280	55	13	20	5	270	31	21	30	14	23	19	15
Facility operation														
Private non-profit	263	321	45	15	12	4	280	36	24	30	14	18	16	17
Private for-profit	260	274	50	11	23	6	277	37	30	72	20	36	42	20
Local, county, or community										5				
govt.	250	258	103	27	23	6	240	7	5	3		16	14	18
State government	172	234	85	24	18		173	27	21		10	26	15	11
Federal government	305	294	256	28		4	114	8	8	19		7	5	9
Dept. of Veterans Affairs	305	294	256	28		4	114	8	8	19		7	5	9
Dept. of Defense	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Indian Health Service	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Tribal government	314	314	206	48	‡		131							

⁻⁻ Quantity is zero; ‡ No facilities in this category.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

¹ Of 1,754 OTP facilities, 657 facilities (37 percent) whose client counts were reported by another facility were not asked to respond to these questions. Of the remaining 1,097 OTP facilities, 37 facilities (3 percent) that included client counts for other facilities were excluded from tabulations for this table, and thus, tabulations are based on 1,060 OTP facilities that reported client counts for their facility alone.

Table 4.4. Facility size, by type of care offered and facility operation at facilities without opioid treatment programs (non-OTPs):

Median number of clients per facility, March 31, 2020

		Type of care offered												
		Outpatient						Residential (non-hospital)				Hospital inpatient		
Facility operation	All facilities¹	Total out-	Regular Intensive		Day treat- ment or partial hospitali- zation Detox		Methadone/ buprenorphine maintenance or naltrexone treatment	Total residential	Short- term	Long- term	Detox	Total hospital inpatient	Treatment	Detox
Total	31	39	29	14	10	5	25	16	12	15	5	10	10	5
Facility operation														
Private non-profit	32	43	34	15	10	5	20	17	13	15	5	9	10	4
Private for-profit	30	33	20	12	10	6	40	12	9	10	4	15	16	7
Local, county, or community govt.	39	48	44	12	8	5	15	17	8	17	6	7	7	2
State government	29	51	35	20	7	7	22	17	21	15	9	11	15	9
Federal government	59	60	40	15	17	3	24	17	10	17	5	6	8	2
Dept. of Veterans Affairs	91	95	50	15	9	5	25	20	10	18	8	6	7	2
Dept. of Defense	20	18	12	11	35	2	15	12	13	6	1	13	12	2
Indian Health Service	31	32	31			3	5	7	9	5				
Other	29	29	56	18			23							
Tribal government	29	31	23	14	5	5	28	12	14	7	5	4	3	3

⁻⁻ Quantity is zero.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

¹ Of 14,312 non-OTP facilities, 6,307 facilities (44 percent) whose client counts were reported by another facility were not asked to respond to these questions. Of the remaining 8,005 non-OTP facilities, 516 facilities (6 percent) that included client counts for other facilities were excluded from tabulations for this table, tabulations are based on 7,489 facilities that reported client counts for their facility alone.

Table 4.5a. Facility size in terms of number of clients in outpatient treatment, by facility operation: Number and row percent distribution, March 31, 2020

			Number	of facilities				Row	percent dist	ribution of fa	acilities	
Facility operation	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more
Total	8,624	2,134	1,344	1,449	1,305	2,392	100.0	24.7	15.6	16.8	15.1	27.7
Facility operation												
Private non-profit	4,007	982	594	736	655	1,040	100.0	24.5	14.8	18.4	16.3	26.0
Private for-profit	3,754	951	631	565	487	1,120	100.0	25.3	16.8	15.1	13.0	29.8
Local, county, or community govt.	394	76	65	72	83	98	100.0	19.3	16.5	18.3	21.1	24.9
State government	119	26	13	22	22	36	100.0	21.8	10.9	18.5	18.5	30.3
Federal government	197	44	16	30	32	75	100.0	22.3	8.1	15.2	16.2	38.1
Dept. of Veterans Affairs	148	23	11	20	23	71	100.0	15.5	7.4	13.5	15.5	48.0
Dept. of Defense	30	15	2	5	6	2	100.0	50.0	6.7	16.7	20.0	6.7
Indian Health Service	14	5	1	5	3		100.0	35.7	7.1	35.7	21.4	
Other	5	1	2			2	100.0	20.0	40.0			40.0
Tribal government	153	55	25	24	26	23	100.0	35.9	16.3	15.7	17.0	15.0

⁻⁻ Quantity is zero.

Table 4.5b. Facility size in terms of number of clients in residential (non-hospital) treatment, by facility operation:

Number and row percent distribution, March 31, 2020

			Number	of facilities				Row	percent dist	tribution of fa	cilities	
Facility operation	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more
Total	2,512	1,239	699	372	158	44	100.0	49.3	27.8	14.8	6.3	1.8
Facility operation												
Private non-profit	1,533	666	487	250	99	31	100.0	43.4	31.8	16.3	6.5	2.0
Private for-profit	790	476	158	93	52	11	100.0	60.3	20.0	11.8	6.6	1.4
Local, county, or community govt.	51	25	16	6	4		100.0	49.0	31.4	11.8	7.8	
State government	58	25	20	10	2	1	100.0	43.1	34.5	17.2	3.4	1.7
Federal government	60	30	16	12	1	1	100.0	50.0	26.7	20.0	1.7	1.7
Dept. of Veterans Affairs	53	24	15	12	1	1	100.0	45.3	28.3	22.6	1.9	1.9
Dept. of Defense	3	3					100.0	100.0				
Indian Health Service	4	3	1				100.0	75.0	25.0			
Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Tribal government	20	17	2	1			100.0	85.0	10.0	5.0		

⁻⁻ Quantity is zero; ‡ No facilities in this category.

Table 4.5c. Facility size in terms of number of clients in hospital inpatient treatment, by facility operation:

Number and row percent distribution, March 31, 2020

			Number	of facilities				Row j	percent distr	ibution of fa	cilities	
Facility operation	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more
Total	533	346	95	57	32	3	100.0	64.9	17.8	10.7	6.0	0.6
Facility operation												
Private non-profit	203	143	39	18	3		100.0	70.4	19.2	8.9	1.5	
Private for-profit	234	122	48	35	26	3	100.0	52.1	20.5	15.0	11.1	1.3
Local, county, or community govt.	23	20	2	1			100.0	87.0	8.7	4.3		
State government	27	18	4	2	3		100.0	66.7	14.8	7.4	11.1	
Federal government	45	42	2	1			100.0	93.3	4.4	2.2		
Dept. of Veterans Affairs	42	40	1	1			100.0	95.2	2.4	2.4		
Dept. of Defense	2	1	1				100.0	50.0	50.0			
Indian Health Service	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other	1	1					100.0	100.0				
Tribal government	1	1					100.0	100.0				

⁻⁻ Quantity is zero; ‡ No facilities in this category.

Table 4.6. Facility capacity and utilization of residential (non-hospital) care, by facility operation:

Number, utilization rate, and row percent distribution, March 31, 2020

					Nun	nber of faci	ilities		F	Row percent	distributio	n of facilitie	es
						Utilizati	ion rate¹				Utilizat	ion rate¹	
Facility operation	Designated beds¹	Overall utilization rate (%) ^{1,2}	Designated beds per facility¹	Total	50% or less	51– 90%	91– 100%	More than 100%	Total	50% or less	51– 90%	91– 100%	More than 100%
Total	61,743	79.0	32	1,920	402	810	554	154	100.0	20.9	42.2	28.9	8.0
Facility operation													
Private non-profit	42,657	79.3	34	1,249	233	577	357	82	100.0	18.7	46.2	28.6	6.6
Private for-profit	15,038	79.4	28	532	130	178	165	59	100.0	24.4	33.5	31.0	11.1
Local, county, or community govt.	1,020	60.7	32	32	17	7	5	3	100.0	53.1	21.9	15.6	9.4
State government	1,320	79.9	29	45	9	21	12	3	100.0	20.0	46.7	26.7	6.7
Federal government	1,406	79.4	31	45	9	22	8	6	100.0	20.0	48.9	17.8	13.3
Dept. of Veterans Affairs	1,307	80.0	34	38	8	18	6	6	100.0	21.1	47.4	15.8	15.8
Dept. of Defense	40	80.0	13	3		2	1		100.0		66.7	33.3	
Indian Health Service	59	66.1	15	4	1	2	1		100.0	25.0	50.0	25.0	
Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Tribal government	302	72.5	18	17	4	5	7	1	100.0	23.5	29.4	41.2	5.9

⁻⁻ Quantity is zero; ‡ No facilities in this category.

¹ The number of designated beds, overall utilization rate, and designated beds per facility are based on 1,920 facilities (61,743 designated beds and 48,764 clients) that reported offering residential (non-hospital) services and that reported both designated beds and clients for their facility alone.

² The utilization rates may be more than 100 percent, because the substance abuse treatment clients may also occupy non-designated beds.

Table 4.7. Facility capacity and utilization of hospital inpatient care, by facility operation: Number, utilization rate, and row percent distribution, March 31, 2020

					Num	ber of facil	lities		R	ow percent	distribution	of facilitie	s
						Utilizatio	on rate¹				Utilizatio	on rate¹	
Facility operation	Designated beds¹	Overall utilization rate (%) ^{1,2}	Designated beds per facility¹	Total	50% or less	51– 90%	91– 100%	More than 100%	Total	50% or less	51– 90%	91– 100%	More than 100%
Total	9,690	78.9	30	322	104	117	48	53	100.0	32.3	36.3	14.9	16.5
Facility operation													
Private non-profit	3,055	65.9	25	124	42	52	18	12	100.0	33.9	41.9	14.5	9.7
Private for-profit	5,968	85.1	36	164	53	53	23	35	100.0	32.3	32.3	14.0	21.3
Local, county, or community govt.	126	61.1	16	8	4	2	1	1	100.0	50.0	25.0	12.5	12.5
State government	404	82.4	29	14	3	7	3	1	100.0	21.4	50.0	21.4	7.1
Federal government	133	102.3	12	11	2	3	2	4	100.0	18.2	27.3	18.2	36.4
Dept. of Veterans Affairs	101	108.9	11	9	2	2	1	4	100.0	22.2	22.2	11.1	44.4
Dept. of Defense	32	81.3	16	2		1	1		100.0		50.0	50.0	
Indian Health Service	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Tribal government	4	100.0	4	1			1		100.0			100.0	

⁻⁻ Quantity is zero; ‡ No facilities in this category.

¹ The number of designated beds, overall utilization rate, and designated beds per facility are based on 322 facilities (9,690 designated beds and 7,641 clients) that reported offering hospital inpatient services and that reported both designated beds and clients for their facility alone.

² The utilization rates may be more than 100 percent, because the substance abuse treatment clients may also occupy non-designated beds.

Table 4.8a. Services provided, by facility operation: Number and column percent, 2020

			Numb	er of facilities	3					Colum	n percent of fa	acilities		
				Facility oper	ation						Facility op	eration		
Services	Total	Private non-profit	Private for-profit	Local, county, or community govt.	State govt.	Federal govt.	Tribal govt.	Total	Private non-profit	Private for-profit	Local, county, or community govt.	State govt.	Federal govt.	Tribal govt.
Total	16,066	8,004	6,535	670	285	323	249			*	-		_	
Assessment and pre-treatment services	15,945	7,928	6.494	668	284	323	248	99.2	99.1	99.4	99.7	99.6	100.0	99.6
Screening for substance abuse	15,594	7,720	6,397	651	271	308	247	97.1	96.5	97.9	97.2	95.1	95.4	99.2
Screening for mental disorders	12,787	6,634	4,808	592	235	294	224	79.6	82.9	73.6	88.4	82.5	91.0	90.0
Comprehensive substance abuse assessment or	,		,											
diagnosis	15,167	7,463	6,239	649	269	310	237	94.4	93.2	95.5	96.9	94.4	96.0	95.2
Comprehensive mental health assessment or														
diagnosis	9,344	4,805	3,469	452	194	267	157	58.2	60.0	53.1	67.5	68.1	82.7	63.1
Screening for tobacco use	12,187	6,369	4,540	537	240	304	197	75.9	79.6	69.5	80.1	84.2	94.1	79.1
Outreach to persons in community who may need														
treatment	10,653	5,508	4,026	504	183	220	212	66.3	68.8	61.6	75.2	64.2	68.1	85.1
Interim services for clients when immediate														
admission is not possible	8,043	4,330	2,614	473	165	261	200	50.1	54.1	40.0	70.6	57.9	80.8	80.3
Professional interventionist/educational consultant	3,446	1,420	1,694	117	54	89	72	21.4	17.7	25.9	17.5	18.9	27.6	28.9
Testing	14,653	7,312	5,928	617	269	315	212	91.2	91.4	90.7	92.1	94.4	97.5	85.1
Drug and alcohol oral fluid testing	5,144	2,363	2,356	227	57	66	75	32.0	29.5	36.1	33.9	20.0	20.4	30.1
Breathalyzer or other blood alcohol testing	10,244	4,935	4,329	411	168	275	126	63.8	61.7	66.2	61.3	58.9	85.1	50.6
Drug or alcohol urine screening	14,154	7,054	5,758	590	262	293	197	88.1	88.1	88.1	88.1	91.9	90.7	79.1
Testing for hepatitis B (HBV)	4,377	1,973	1,786	158	112	253	95	27.2	24.7	27.3	23.6	39.3	78.3	38.2
Testing for hepatitis C (HCV)	4,943	2,270	1,994	186	128	255	110	30.8	28.4	30.5	27.8	44.9	78.9	44.2
HIV testing	5,125	2,461	1,929	203	164	264	104	31.9	30.7	29.5	30.3	57.5	81.7	41.8
STD testing	4,223	1,888	1,723	142	127	247	96	26.3	23.6	26.4	21.2	44.6	76.5	38.6
TB screening	6,824	3,297	2,701	269	186	253	118	42.5	41.2	41.3	40.1	65.3	78.3	47.4
Testing for metabolic syndrome	1,603	723	580	95	38	125	42	10.0	9.0	8.9	14.2	13.3	38.7	16.9
Medical services	1,929	1,025	416	106	67	232	83	12.0	12.8	6.4	15.8	23.5	71.8	33.3
Hepatitis A (HAV) vaccination	1,779	944	376	101	63	216	79	11.1	11.8	5.8	15.1	22.1	66.9	31.7
Hepatitis B (HBV) vaccination	1,775	953	354	100	58	230	80	11.0	11.9	5.4	14.9	20.4	71.2	32.1
Transitional services	15,882	7,929	6,429	669	283	323	249	98.9	99.1	98.4	99.9	99.3	100.0	100.0
Discharge planning	15,354	7,718	6,164	653	276	300	243	95.6	96.4	94.3	97.5	96.8	92.9	97.6
Aftercare/continuing care	14,035	7,031	5,661	580	215	310	238	87.4	87.8	86.6	86.6	75.4	96.0	95.6
Naloxone and overdose education	9,655	4,843	3,806	427	176	253	150	60.1	60.5	58.2	63.7	61.8	78.3	60.2
Outcome follow-up after discharge	11,236	5,595	4,586	427	196	255	177	69.9	69.9	70.2	63.7	68.8	78.9	71.1

Table 4.8a. Services provided, by facility operation: Number and column percent, 2020 (continued)

			Numb	er of facilities	;					Colum	n percent of fa	acilities		
				Facility oper	ation						Facility op	eration		
Services	Total	Private	Private	Local, county, or community	State	Federal	Tribal	Total	Private	Private	Local, county, or community	State	Federal	Tribal
	Total	non-profit	for-profit	govt.	govt.	govt.	govt.	Total	non-profit	for-profit	govt.	govt.	govt.	govt.
	otal 16,066 14,292	8,004 7,486	6,535 5.366	670 638	285 272	323 291	249 239	89.0	93.5	82.1	95.2	95.4	90.1	96.0
Recovery support services Mentoring/peer support	10,123	5,519	3,581	424	210	228	161	63.0	69.0	54.8	63.3	73.7	70.6	64.7
Self-help groups	7.878	4,027	3,068	276	155	186	166	49.0	50.3	46.9	41.2	54.4	70.6 57.6	66.7
Assistance in locating housing for clients	10,213	5.565	3,552	497	198	244	157	63.6	69.5	54.4	74.2	69.5	75.5	63.1
Employment counseling or training for clients	7,132	3,971	2,440	306	144	191	80	44.4	49.6	37.3	45.7	50.5	73.3 59.1	32.1
Assistance with obtaining social services (for	7,102	3,971	2,440	300	144	131	00	44.4	43.0	37.3	43.7	30.3	33.1	JZ. 1
example, Medicaid, WIC, SSI, SSDI)	11,138	6,275	3.643	567	237	217	199	69.3	78.4	55.7	84.6	83.2	67.2	79.9
Recovery coach	4,446	2,376	1,704	165	60	64	77	27.7	29.7	26.1	24.6	21.1	19.8	30.9
Education and counseling services	16,018	7,989	6,503	670	284	323	249	99.7	99.8	99.5	100.0	99.6	100.0	100.0
HIV or AIDS education, counseling, or support	9,781	5,170	3,570	421	223	242	155	60.9	64.6	54.6	62.8	78.2	74.9	62.2
Hepatitis education, counseling, or support	8,860	4,643	3,262	365	200	245	145	55.1	58.0	49.9	54.5	70.2	75.9	58.2
Health education other than HIV/AIDS or hepatitis	9,553	5,089	3,425	410	212	258	159	59.5	63.6	52.4	61.2	74.4	79.9	63.9
Substance abuse education	15,660	7,815	6,342	659	282	317	245	97.5	97.6	97.0	98.4	98.9	98.1	98.4
Smoking/tobacco cessation counseling	9,926	5,199	3,623	437	219	285	163	61.8	65.0	55.4	65.2	76.8	88.2	65.5
Individual counseling	15,529	7,841	6,186	657	280	316	249	96.7	98.0	94.7	98.1	98.2	97.8	100.0
Group counseling	14,863	7.602	5,822	627	274	309	229	92.5	95.0	89.1	93.6	96.1	95.7	92.0
Family counseling	12,740	6,481	5,063	533	223	235	205	79.3	81.0	77.5	79.6	78.2	72.8	82.3
Marital/couples counseling	9,238	4,450	3,914	318	127	252	177	57.5	55.6	59.9	47.5	44.6	78.0	71.1
Vocational training or educational support	2,972	1,759	873	106	62	123	49	18.5	22.0	13.4	15.8	21.8	38.1	19.7
Ancillary services	15,560	7,852	6.200	660	281	318	249	96.9	98.1	94.9	98.5	98.6	98.5	100.0
Case management services	13,377	6,983	5,014	601	250	295	234	83.3	87.2	76.7	89.7	87.7	91.3	94.0
Social skills development	11,959	6,344	4,414	512	229	263	197	74.4	79.3	67.5	76.4	80.4	81.4	79.1
Child care for clients' children	884	640	120	74	25	4	21	5.5	8.0	1.8	11.0	8.8	1.2	8.4
Domestic violence services ¹	5,974	3,039	2,258	207	106	209	155	37.2	38.0	34.6	30.9	37.2	64.7	62.2
Early intervention for HIV	3,647	2,036	1,107	163	115	161	65	22.7	25.4	16.9	24.3	40.4	49.8	26.1
Transportation assistance to treatment	7,641	4,409	2,259	419	154	191	209	47.6	55.1	34.6	62.5	54.0	59.1	83.9
Mental health services	11,364	6,017	4,094	534	224	297	198	70.7	75.2	62.6	79.7	78.6	92.0	79.5
Acupuncture	950	362	394	35	16	109	34	5.9	4.5	6.0	5.2	5.6	33.7	13.7
Residential beds for clients' children	397	352	17	16	9		3	2.5	4.4	0.3	2.4	3.2		1.2
Other services	7,113	3,404	2,982	257	129	186	155	44.3	42.5	45.6	38.4	45.3	57.6	62.2
Treatment for gambling disorder	4,433	2,205	1,738	157	92	134	107	27.6	27.5	26.6	23.4	32.3	41.5	43.0
Treatment for Internet use disorder	2,686	1,114	1,387	58	23	55	49	16.7	13.9	21.2	8.7	8.1	17.0	19.7
Treatment for other addiction disorder (non-	,		•											
substance abuse)	5,920	2,650	2,718	201	84	150	117	36.8	33.1	41.6	30.0	29.5	46.4	47.0

Table 4.8a. Services provided, by facility operation: Number and column percent, 2020 (continued)

			Numb	er of facilities	;					Colum	n percent of fa	acilities		
				Facility oper	ation						Facility op	eration		
Services		Private	Private	Local, county, or community	State	Federal	Tribal		Private	Private	Local, county, or community	State	Federal	Tribal
	Total	non-profit	for-profit	govt.	govt.	govt.	govt.	Total	non-profit	for-profit	govt.	govt.	govt.	govt.
Total	16,066	8,004	6,535	670	285	323	249							
Pharmacotherapies	10,759	5,316	4,292	486	235	289	141	67.0	66.4	65.7	72.5	82.5	89.5	56.6
Disulfiram (Antabuse [®])	4,010	1,877	1,603	144	86	254	46	25.0	23.5	24.5	21.5	30.2	78.6	18.5
Naltrexone (oral)	6,174	3,003	2,496	245	114	252	64	38.4	37.5	38.2	36.6	40.0	78.0	25.7
Naltrexone (extended-release, injectable, for														
example, Vivitrol [®])	6,016	2,920	2,440	249	103	240	64	37.4	36.5	37.3	37.2	36.1	74.3	25.7
Acamprosate (Campral®)	4,220	1,977	1,691	166	99	251	36	26.3	24.7	25.9	24.8	34.7	77.7	14.5
Nicotine replacement	5,568	2,896	1,939	238	148	259	88	34.7	36.2	29.7	35.5	51.9	80.2	35.3
Non-nicotine smoking/tobacco cessation														
medications (for example, bupropion, varenicline)	4,676	2,333	1,701	204	114	257	67	29.1	29.1	26.0	30.4	40.0	79.6	26.9
Medications for psychiatric disorders	8,089	4,361	2,713	430	204	276	105	50.3	54.5	41.5	64.2	71.6	85.4	42.2
Methadone	1,627	492	1,020	40	32	35	8	10.1	6.1	15.6	6.0	11.2	10.8	3.2
Buprenorphine ²	7,066	3,154	3,268	235	114	234	61	44.0	39.4	50.0	35.1	40.0	72.4	24.5
Buprenorphine with naloxone (for example,														
Suboxone [®] , Bunavail [®] , Zubsolv [®] , Cassipa [®])	6,767	3,044	3,102	227	111	226	57	42.1	38.0	47.5	33.9	38.9	70.0	22.9
Buprenorphine without naloxone	4,839	2,038	2,405	149	67	143	37	30.1	25.5	36.8	22.2	23.5	44.3	14.9
Buprenorphine sub-dermal implant (Probuphine [®]) Buprenorphine (extended-release, injectable, for	547	212	305	16	4	9	1	3.4	2.6	4.7	2.4	1.4	2.8	0.4
example, Sublocade®) Medications for HIV treatment (for example,	2,329	923	1,224	65	28	72	17	14.5	11.5	18.7	9.7	9.8	22.3	6.8
antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine) Medications for hepatitis C (HCV) treatment (for	1,464	666	542	37	41	154	24	9.1	8.3	8.3	5.5	14.4	47.7	9.6
example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)	1,655	773	584	47	45	170	36	10.3	9.7	8.9	7.0	15.8	52.6	14.5
Lofexidine	895	353	480	24	45 9	25	4	5.6	9.7 4.4	7.3	3.6	3.2	7.7	14.5
Clonidine	695 4,597	2.054	2.000	192	104	25 195	52	28.6	4.4 25.7	7.3 30.6	3.6 28.7	3.∠ 36.5	60.4	20.9
Quantity is zero	7,007	2,004	2,000	102	104	100	02	20.0	20.7	50.0	20.1	50.5	00.7	20.9

^{- -} Quantity is zero.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Injectable naltrexone = extended-release injectable naltrexone.

¹ Domestic violence services includes family or partner violence services, for physical, sexual, or emotional abuse.

² Buprenorphine total is not the sum of buprenorphine with and without naloxone and sub-dermal implant, because a facility can provide one or more forms of buprenorphine.

Table 4.8b. Services provided, by facility type: Number and column percent, 2020

		Number	of facilities			Column perd	ent of facilities	
Services -			Facility type				Facility type	
Convices			Serving DUI		1		Serving DUI	
	Total	OTPs	and DWI 1	Other	Total	OTPs	and DWI 1	Other
Total	16,066	1,754	3,531	10,781				
Assessment and pre-treatment services	15,945	1,743	3,528	10,674	99.2	99.4	99.9	99.0
Screening for substance abuse	15,594	1,730	3,496	10,368	97.1	98.6	99.0	96.2
Screening for mental disorders	12,787	1,103	2,846	8,838	79.6	62.9	80.6	82.0
Comprehensive substance abuse assessment or								
diagnosis	15,167	1,668	3,457	10,042	94.4	95.1	97.9	93.1
Comprehensive mental health assessment or								
diagnosis	9,344	607	2,065	6,672	58.2	34.6	58.5	61.9
Screening for tobacco use	12,187	1,341	2,593	8,253	75.9	76.5	73.4	76.6
Outreach to persons in community who may need								
treatment	10,653	1,246	2,545	6,862	66.3	71.0	72.1	63.6
Interim services for clients when immediate								
admission is not possible	8,043	643	2,261	5,139	50.1	36.7	64.0	47.7
Professional interventionist/educational consultant	3,446	260	1,074	2,112	21.4	14.8	30.4	19.6
Testing	14,653	1,752	3,185	9,716	91.2	99.9	90.2	90.1
Drug and alcohol oral fluid testing	5,144	1,001	1,245	2,898	32.0	57.1	35.3	26.9
Breathalyzer or other blood alcohol testing	10,244	1,470	2,275	6,499	63.8	83.8	64.4	60.3
Drug or alcohol urine screening	14,154	1,741	3,020	9,393	88.1	99.3	85.5	87.1
Testing for hepatitis B (HBV)	4,377	953	468	2,956	27.2	54.3	13.3	27.4
Testing for hepatitis C (HCV)	4,943	1,140	538	3,265	30.8	65.0	15.2	30.3
HIV testing	5,125	1,034	591	3,500	31.9	59.0	16.7	32.5
STD testing	4,223	1,019	391	2,813	26.3	58.1	11.1	26.1
TB screening	6,824	1,661	873	4,290	42.5	94.7	24.7	39.8
Testing for metabolic syndrome	1,603	236	200	1,167	10.0	13.5	5.7	10.8
Medical services	1,929	314	221	1,394	12.0	17.9	6.3	12.9
Hepatitis A (HAV) vaccination	1,779	279	211	1,289	11.1	15.9	6.0	12.0
Hepatitis B (HBV) vaccination	1,775	267	208	1,300	11.0	15.2	5.9	12.1
Transitional services	15,882	1,753	3,484	10,645	98.9	99.9	98.7	98.7
Discharge planning	15,354	1,736	3,409	10,209	95.6	99.0	96.5	94.7
Aftercare/continuing care	14,035	1,439	3,309	9,287	87.4	82.0	93.7	86.1
Naloxone and overdose education	9,655	1,498	1,766	6,391	60.1	85.4	50.0	59.3
Outcome follow-up after discharge	11,236	1,410	2,452	7,374	69.9	80.4	69.4	68.4

Table 4.8b. Services provided, by facility type: Number and column percent, 2020 (continued)

		Number	of facilities			Column perd	ent of facilities	
Services -			Facility type				Facility type	
Services			Serving DUI		1		Serving DUI	
	Total	OTPs	and DWI 1	Other	Total	OTPs	and DWI 1	Other
Total	16,066	1,754	3,531	10,781				
Recovery support services	14,292	1,633	2,995	9,664	89.0	93.1	84.8	89.6
Mentoring/peer support	10,123	963	2,209	6,951	63.0	54.9	62.6	64.5
Self-help groups	7,878	778	1,514	5,586	49.0	44.4	42.9	51.8
Assistance in locating housing for clients	10,213	1,267	1,990	6,956	63.6	72.2	56.4	64.5
Employment counseling or training for clients	7,132	866	1,459	4,807	44.4	49.4	41.3	44.6
Assistance with obtaining social services (for								
example, Medicaid, WIC, SSI, SSDI)	11,138	1,402	2,184	7,552	69.3	79.9	61.9	70.0
Recovery coach	4,446	387	1,127	2,932	27.7	22.1	31.9	27.2
Education and counseling services	16,018	1,751	3,530	10,737	99.7	99.8	100.0	99.6
HIV or AIDS education, counseling, or support	9,781	1,489	1,946	6,346	60.9	84.9	55.1	58.9
Hepatitis education, counseling, or support	8,860	1,483	1,663	5,714	55.1	84.5	47.1	53.0
Health education other than HIV/AIDS or hepatitis	9,553	1,375	1,804	6,374	59.5	78.4	51.1	59.1
Substance abuse education	15,660	1,735	3,491	10,434	97.5	98.9	98.9	96.8
Smoking/tobacco cessation counseling	9,926	1,205	1,991	6,730	61.8	68.7	56.4	62.4
Individual counseling	15,529	1,744	3,488	10,297	96.7	99.4	98.8	95.5
Group counseling	14,863	1,563	3,436	9,864	92.5	89.1	97.3	91.5
Family counseling	12,740	1,169	2,963	8,608	79.3	66.6	83.9	79.8
Marital/couples counseling	9,238	823	2,433	5,982	57.5	46.9	68.9	55.5
Vocational training or educational support	2,972	251	507	2,214	18.5	14.3	14.4	20.5
Ancillary services	15,560	1,685	3,375	10,500	96.9	96.1	95.6	97.4
Case management services	13,377	1,581	2,811	8,985	83.3	90.1	79.6	83.3
Social skills development	11,959	1,259	2,605	8,095	74.4	71.8	73.8	75.1
Child care for clients' children	884	88	184	612	5.5	5.0	5.2	5.7
Domestic violence services ²	5,974	539	1,769	3,666	37.2	30.7	50.1	34.0
Early intervention for HIV	3,647	722	695	2,230	22.7	41.2	19.7	20.7
Transportation assistance to treatment	7,641	727	1,406	5,508	47.6	41.4	39.8	51.1
Mental health services	11,364	807	2,509	8,048	70.7	46.0	71.1	74.6
Acupuncture	950	139	147	664	5.9	7.9	4.2	6.2
Residential beds for clients' children	397	13	19	365	2.5	0.7	0.5	3.4
Other services	7,113	380	2,024	4,709	44.3	21.7	57.3	43.7
Treatment for gambling disorder	4,433	228	1,400	2,805	27.6	13.0	39.6	26.0
Treatment for Internet use disorder	2,686	62	832	1,792	16.7	3.5	23.6	16.6
Treatment for other addiction disorder (non-	•			-				
substance abuse)	5,920	268	1,645	4,007	36.8	15.3	46.6	37.2

Table 4.8b. Services provided, by facility type: Number and column percent, 2020 (continued)

		Number	of facilities			Column perd	ent of facilities	
Services			Facility type				Facility type	
oci vices			Serving DUI				Serving DUI	
	Total	OTPs	and DWI 1	Other	Total	OTPs	and DWI 1	Other
Total	16,066	1,754	3,531	10,781				
Pharmacotherapies	10,759	1,754	1,712	7,293	67.0	100.0	48.5	67.6
Disulfiram (Antabuse [®])	4,010	389	704	2,917	25.0	22.2	19.9	27.1
Naltrexone (oral)	6,174	571	1,059	4,544	38.4	32.6	30.0	42.1
Naltrexone (extended-release, injectable, for								
example, Vivitrol®)	6,016	690	1,040	4,286	37.4	39.3	29.5	39.8
Acamprosate (Campral®)	4,220	379	702	3,139	26.3	21.6	19.9	29.1
Nicotine replacement	5,568	500	777	4,291	34.7	28.5	22.0	39.8
Non-nicotine smoking/tobacco cessation								
medications (for example, bupropion, varenicline)	4,676	407	752	3,517	29.1	23.2	21.3	32.6
Medications for psychiatric disorders	8,089	570	1,413	6,106	50.3	32.5	40.0	56.6
Methadone	1,627	1,627			10.1	92.8		
Buprenorphine ³	7,066	1,406	1,122	4,538	44.0	80.2	31.8	42.1
Buprenorphine with naloxone (for example,								
Suboxone [®] , Bunavail [®] , Zubsolv [®] , Cassipa [®])	6,767	1,287	1,096	4,384	42.1	73.4	31.0	40.7
Buprenorphine without naloxone	4,839	1,012	711	3,116	30.1	57.7	20.1	28.9
Buprenorphine sub-dermal implant (Probuphine [®]) Buprenorphine (extended-release, injectable, for	547	85	104	358	3.4	4.8	2.9	3.3
example, Sublocade [®]) Medications for HIV treatment (for example, antiretroviral medications such as tenofovir,	2,329	273	411	1,645	14.5	15.6	11.6	15.3
efavirenz, emtricitabine, atazanavir, and lamivudine)	1,464	156	136	1,172	9.1	8.9	3.9	10.9
Medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon,								
peginterferon, ribavirin)	1,655	188	153	1,314	10.3	10.7	4.3	12.2
Lofexidine	895	90	141	664	5.6	5.1	4.0	6.2
Clonidine	4,597	369	649	3,579	28.6	21.0	18.4	33.2

^{- -} Quantity is zero.

DUI/DWI = driving under the influence/driving while intoxicated or impaired; Injectable naltrexone = extended-release injectable naltrexone.

¹ Excludes OTP facilities.

² Domestic violence services includes family or partner violence services, for physical, sexual, or emotional abuse.

³ Buprenorphine total is not the sum of buprenorphine with and without naloxone and sub-dermal implant, because a facility can provide one or more forms of buprenorphine. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 4.9a. Services provided, by type of care: Number, 2020

					Type of cal	re		
Services	Total	Outpatient only	Hospital inpatient only	Residential (non-hospital) only	Outpatient and hospital inpatient	Outpatient and residential (non-hospital)	Residential (non-hospital) and hospital inpatient	All three types of care
Total	16,066	11,726	280	2,477	235	1,002	148	198
Assessment and pre-treatment services	15,945	11,686	276	2,409	235	995	146	198
Screening for substance abuse	15,594	11,501	260	2,287	234	973	144	195
Screening for mental disorders	12,787	9,436	218	1,774	217	835	130	177
Comprehensive substance abuse assessment or								
diagnosis	15,167	11,277	234	2,142	219	958	141	196
Comprehensive mental health assessment or								
diagnosis	9,344	6,949	185	1,114	197	631	109	159
Screening for tobacco use	12,187	8,847	241	1,839	212	755	127	166
Outreach to persons in community who may need								
treatment	10,653	8,023	125	1,383	148	739	90	145
Interim services for clients when immediate								
admission is not possible	8,043	6,327	62	811	92	580	56	115
Professional interventionist/educational consultant	3,446	2,525	46	483	33	239	48	72
Testing	14,653	10,377	274	2,436	232	990	147	197
Drug and alcohol oral fluid testing	5,144	3,935	50	724	45	292	47	51
Breathalyzer or other blood alcohol testing	10,244	6,659	222	1,993	217	840	128	185
Drug or alcohol urine screening	14,154	9,934	272	2,396	231	979	145	197
Testing for hepatitis B (HBV)	4,377	2,614	221	722	182	381	98	159
Testing for hepatitis C (HCV)	4,943	3,005	231	830	186	416	106	169
HIV testing	5,125	3,052	232	907	189	463	108	174
STD testing	4,223	2,426	221	744	187	385	102	158
TB screening	6,824	4,075	250	1,376	195	615	136	177
Testing for metabolic syndrome	1,603	1,027	109	144	114	120	29	60
Medical services	1,929	1,166	109	281	100	160	32	81
Hepatitis A (HAV) vaccination	1,779	1,092	95	259	94	137	30	72
Hepatitis B (HBV) vaccination	1,775	1,094	102	248	94	141	23	73
Transitional services	15,882	11,565	278	2,460	235	1,000	146	198
Discharge planning	15,354	11,073	277	2,433	233	996	146	196
Aftercare/continuing care	14,035	10,330	189	2,007	219	966	133	191
Naloxone and overdose education	9,655	6,692	167	1,634	163	702	127	170
Outcome follow-up after discharge	11,236	7,739	170	2,006	162	854	131	174

Table 4.9a. Services provided, by type of care: Number, 2020 (continued)

					Type of car	re		
Services	Total	Outpatient only	Hospital inpatient only	Residential (non-hospital) only	Outpatient and hospital inpatient	Outpatient and residential (non-hospital)	Residential (non-hospital) and hospital inpatient	All three types of care
Total	16,066	11,726	280	2,477	235	1,002	148	198
Recovery support services	14,292	10,037	259	2,432	226	993	147	198
Mentoring/peer support	10,123	6,655	132	2,051	143	864	111	167
Self-help groups	7,878	4,179	201	2,115	193	869	138	183
Assistance in locating housing for clients	10,213	6,777	147	2,023	131	846	121	168
Employment counseling or training for clients Assistance with obtaining social services (for	7,132	4,698	25	1,532	56	634	68	119
example, Medicaid, WIC, SSI, SSDI)	11,138	7,756	202	1,984	153	797	94	152
Recovery coach	4,446	3,035	36	782	51	418	50	74
Education and counseling services	16,018	11,704	268	2,464	235	1,001	148	198
HIV or AIDS education, counseling, or support	9,781	6,566	185	1,826	141	765	125	173
Hepatitis education, counseling, or support	8,860	5,850	185	1,706	136	695	119	169
Health education other than HIV/AIDS or hepatitis	9,553	6,277	206	1,836	168	765	127	174
Substance abuse education	15,660	11,406	254	2,428	229	998	147	198
Smoking/tobacco cessation counseling	9,926	6,816	221	1,695	202	705	118	169
Individual counseling	15,529	11,359	228	2,385	214	998	148	197
Group counseling	14,863	10,669	236	2,386	233	993	148	198
Family counseling	12,740	9,265	166	1,900	202	883	135	189
Marital/couples counseling	9,238	7,086	80	1,126	119	586	91	150
Vocational training or educational support	2,972	1,601	24	884	29	329	37	68
Ancillary services	15,560	11,292	271	2,431	233	989	146	198
Case management services	13,377	9,494	219	2,235	191	921	136	181
Social skills development	11,959	8,269	159	2,198	156	892	116	169
Child care for clients' children	884	515	1	244	2	103	9	10
Domestic violence services ¹	5,974	4,383	58	887	76	409	59	102
Early intervention for HIV	3,647	2,273	72	766	59	329	59	89
Transportation assistance to treatment	7,641	4,823	116	1,629	130	700	95	148
Mental health services	11,364	8,268	195	1,602	219	780	122	178
Acupuncture	950	497	8	215	27	129	21	53
Residential beds for clients' children	397			296		89	5	7
Other services	7,113	5,466	58	895	89	441	56	108
Treatment for gambling disorder	4,433	3,436	27	531	57	270	31	81
Treatment for Internet use disorder	2,686	2,152	8	283	32	153	17	41
Treatment for other addiction disorder (non-	-	•						
substance abuse)	5,920	4,623	47	705	77	340	45	83

Table 4.9a. Services provided, by type of care: Number, 2020 (continued)

					Type of car	re		
Services	Total	Outpatient only	Hospital inpatient only	Residential (non-hospital) only	Outpatient and hospital inpatient	Outpatient and residential (non-hospital)	Residential (non-hospital) and hospital inpatient	All three types of care
Total	16,066	11,726	280	2,477	235	1,002	148	198
Pharmacotherapies	10,759	7,526	274	1,621	235	765	146	192
Disulfiram (Antabuse [®])	4,010	2,663	119	577	162	291	67	131
Naltrexone (oral)	6,174	3,963	163	1,023	199	522	127	177
Naltrexone (extended-release, injectable, for								
example, Vivitrol®)	6,016	3,975	116	955	167	520	111	172
Acamprosate (Campral®)	4,220	2,733	146	621	175	316	83	146
Nicotine replacement	5,568	3,007	256	1,233	225	553	120	174
Non-nicotine smoking/tobacco cessation								
medications (for example, bupropion, varenicline)	4,676	2,927	146	782	182	400	93	146
Medications for psychiatric disorders	8,089	5,347	238	1,321	224	639	133	187
Methadone	1,627	1,434	52	47	23	32	22	17
Buprenorphine ²	7,066	4,797	199	1,052	198	509	131	180
Buprenorphine with naloxone (for example,								
Suboxone [®] , Bunavail [®] , Zubsolv [®] , Cassipa [®])	6,767	4,612	177	1,005	183	492	124	174
Buprenorphine without naloxone	4,839	3,249	137	737	144	340	102	130
Buprenorphine sub-dermal implant (Probuphine [™]) Buprenorphine (extended-release, injectable, for	547	332	11	117	8	53	5	21
example, Sublocade [®])	2,329	1,595	34	346	45	202	36	71
Medications for HIV treatment (for example, antiretroviral medications such as tenofovir,	,	,						
efavirenz, emtricitabine, atazanavir, and lamivudine)	1,464	552	110	427	77	172	50	76
Medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon,								
peginterferon, ribavirin)	1,655	750	98	433	67	189	37	81
Lofexidine	895	520	27	187	30	69	27	35
Clonidine	4,597	2,602	224	862	196	437	121	155

^{- -} Quantity is zero.

Injectable naltrexone = extended-release injectable naltrexone.

Domestic violence services includes family or partner violence services, for physical, sexual, or emotional abuse.

² Buprenorphine total is not the sum of buprenorphine with and without naloxone and sub-dermal implant, because a facility can provide one or more forms of buprenorphine. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 4.9b. Services provided, by type of care: Column percent, 2020

					Type of car	e		
Services	Total	Outpatient only	Hospital inpatient only	Residential (non-hospital) only	Outpatient and hospital inpatient	Outpatient and residential (non-hospital)	Residential (non-hospital) and hospital inpatient	All three types of care
Assessment and pre-treatment services	99.2	99.7	98.6	97.3	100.0	99.3	98.6	100.0
Screening for substance abuse	97.1	98.1	92.9	92.3	99.6	97.1	97.3	98.5
Screening for mental disorders	79.6	80.5	77.9	71.6	92.3	83.3	87.8	89.4
Comprehensive substance abuse assessment or								
diagnosis	94.4	96.2	83.6	86.5	93.2	95.6	95.3	99.0
Comprehensive mental health assessment or								
diagnosis	58.2	59.3	66.1	45.0	83.8	63.0	73.6	80.3
Screening for tobacco use	75.9	75.4	86.1	74.2	90.2	75.3	85.8	83.8
Outreach to persons in community who may need								
treatment	66.3	68.4	44.6	55.8	63.0	73.8	60.8	73.2
Interim services for clients when immediate								
admission is not possible	50.1	54.0	22.1	32.7	39.1	57.9	37.8	58.1
Professional interventionist/educational consultant	21.4	21.5	16.4	19.5	14.0	23.9	32.4	36.4
Testing	91.2	88.5	97.9	98.3	98.7	98.8	99.3	99.5
Drug and alcohol oral fluid testing	32.0	33.6	17.9	29.2	19.1	29.1	31.8	25.8
Breathalyzer or other blood alcohol testing	63.8	56.8	79.3	80.5	92.3	83.8	86.5	93.4
Drug or alcohol urine screening	88.1	84.7	97.1	96.7	98.3	97.7	98.0	99.5
Testing for hepatitis B (HBV)	27.2	22.3	78.9	29.1	77.4	38.0	66.2	80.3
Testing for hepatitis C (HCV)	30.8	25.6	82.5	33.5	79.1	41.5	71.6	85.4
HIV testing	31.9	26.0	82.9	36.6	80.4	46.2	73.0	87.9
STD testing	26.3	20.7	78.9	30.0	79.6	38.4	68.9	79.8
TB screening	42.5	34.8	89.3	55.6	83.0	61.4	91.9	89.4
Testing for metabolic syndrome	10.0	8.8	38.9	5.8	48.5	12.0	19.6	30.3
Medical services	12.0	9.9	38.9	11.3	42.6	16.0	21.6	40.9
Hepatitis A (HAV) vaccination	11.1	9.3	33.9	10.5	40.0	13.7	20.3	36.4
Hepatitis B (HBV) vaccination	11.0	9.3	36.4	10.0	40.0	14.1	15.5	36.9
Transitional services	98.9	98.6	99.3	99.3	100.0	99.8	98.6	100.0
Discharge planning	95.6	94.4	98.9	98.2	99.1	99.4	98.6	99.0
Aftercare/continuing care	87.4	88.1	67.5	81.0	93.2	96.4	89.9	96.5
Naloxone and overdose education	60.1	57.1	59.6	66.0	69.4	70.1	85.8	85.9
Outcome follow-up after discharge	69.9	66.0	60.7	81.0	68.9	85.2	88.5	87.9

Table 4.9b. Services provided, by type of care: Column percent, 2020 (continued)

					Type of car	e		
Services	Total	Outpatient only	Hospital inpatient only	Residential (non-hospital) only	Outpatient and hospital inpatient	Outpatient and residential (non-hospital)	Residential (non-hospital) and hospital inpatient	All three types of care
Recovery support services	89.0	85.6	92.5	98.2	96.2	99.1	99.3	100.0
Mentoring/peer support	63.0	56.8	47.1	82.8	60.9	86.2	75.0	84.3
Self-help groups	49.0	35.6	71.8	85.4	82.1	86.7	93.2	92.4
Assistance in locating housing for clients	63.6	57.8	52.5	81.7	55.7	84.4	81.8	84.8
Employment counseling or training for clients Assistance with obtaining social services (for	44.4	40.1	8.9	61.8	23.8	63.3	45.9	60.1
example, Medicaid, WIC, SSI, SSDI)	69.3	66.1	72.1	80.1	65.1	79.5	63.5	76.8
Recovery coach	27.7	25.9	12.9	31.6	21.7	41.7	33.8	37.4
Education and counseling services	99.7	99.8	95.7	99.5	100.0	99.9	100.0	100.0
HIV or AIDS education, counseling, or support	60.9	56.0	66.1	73.7	60.0	76.3	84.5	87.4
Hepatitis education, counseling, or support	55.1	49.9	66.1	68.9	57.9	69.4	80.4	85.4
Health education other than HIV/AIDS or hepatitis	59.5	53.5	73.6	74.1	71.5	76.3	85.8	87.9
Substance abuse education	97.5	97.3	90.7	98.0	97.4	99.6	99.3	100.0
Smoking/tobacco cessation counseling	61.8	58.1	78.9	68.4	86.0	70.4	79.7	85.4
Individual counseling	96.7	96.9	81.4	96.3	91.1	99.6	100.0	99.5
Group counseling	92.5	91.0	84.3	96.3	99.1	99.1	100.0	100.0
Family counseling	79.3	79.0	59.3	76.7	86.0	88.1	91.2	95.5
Marital/couples counseling	57.5	60.4	28.6	45.5	50.6	58.5	61.5	75.8
Vocational training or educational support	18.5	13.7	8.6	35.7	12.3	32.8	25.0	34.3
Ancillary services	96.9	96.3	96.8	98.1	99.1	98.7	98.6	100.0
Case management services	83.3	81.0	78.2	90.2	81.3	91.9	91.9	91.4
Social skills development	74.4	70.5	56.8	88.7	66.4	89.0	78.4	85.4
Child care for clients' children	5.5	4.4	0.4	9.9	0.9	10.3	6.1	5.1
Domestic violence services ¹	37.2	37.4	20.7	35.8	32.3	40.8	39.9	51.5
Early intervention for HIV	22.7	19.4	25.7	30.9	25.1	32.8	39.9	44.9
Transportation assistance to treatment	47.6	41.1	41.4	65.8	55.3	69.9	64.2	74.7
Mental health services	70.7	70.5	69.6	64.7	93.2	77.8	82.4	89.9
Acupuncture	5.9	4.2	2.9	8.7	11.5	12.9	14.2	26.8
Residential beds for clients' children	2.5			11.9		8.9	3.4	3.5
Other services	44.3	46.6	20.7	36.1	37.9	44.0	37.8	54.5
Treatment for gambling disorder	27.6	29.3	9.6	21.4	24.3	26.9	20.9	40.9
Treatment for Internet use disorder	16.7	18.4	2.9	11.4	13.6	15.3	11.5	20.7
Treatment for other addiction disorder (non-								
substance abuse)	36.8	39.4	16.8	28.5	32.8	33.9	30.4	41.9

Table 4.9b. Services provided, by type of care: Column percent, 2020 (continued)

					Type of car	re		
Services	Total	Outpatient only	Hospital inpatient only	Residential (non-hospital) only	Outpatient and hospital inpatient	Outpatient and residential (non-hospital)	Residential (non-hospital) and hospital inpatient	All three types of care
Pharmacotherapies	67.0	64.2	97.9	65.4	100.0	76.3	98.6	97.0
Disulfiram (Antabuse [®])	25.0	22.7	42.5	23.3	68.9	29.0	45.3	66.2
Naltrexone (oral)	38.4	33.8	58.2	41.3	84.7	52.1	85.8	89.4
Naltrexone (extended-release, injectable, for								
example, Vivitrol®)	37.4	33.9	41.4	38.6	71.1	51.9	75.0	86.9
Acamprosate (Campral [®])	26.3	23.3	52.1	25.1	74.5	31.5	56.1	73.7
Nicotine replacement	34.7	25.6	91.4	49.8	95.7	55.2	81.1	87.9
Non-nicotine smoking/tobacco cessation								
medications (for example, bupropion, varenicline)	29.1	25.0	52.1	31.6	77.4	39.9	62.8	73.7
Medications for psychiatric disorders	50.3	45.6	85.0	53.3	95.3	63.8	89.9	94.4
Methadone	10.1	12.2	18.6	1.9	9.8	3.2	14.9	8.6
Buprenorphine ²	44.0	40.9	71.1	42.5	84.3	50.8	88.5	90.9
Buprenorphine with naloxone (for example,								
Suboxone [®] , Bunavail [®] , Zubsolv [®] , Cassipa [®])	42.1	39.3	63.2	40.6	77.9	49.1	83.8	87.9
Buprenorphine without naloxone	30.1	27.7	48.9	29.8	61.3	33.9	68.9	65.7
Buprenorphine sub-dermal implant								
(Probuphine®)	3.4	2.8	3.9	4.7	3.4	5.3	3.4	10.6
Buprenorphine (extended-release, injectable, for								
example, Sublocade [®])	14.5	13.6	12.1	14.0	19.1	20.2	24.3	35.9
Medications for HIV treatment (for example,								
antiretroviral medications such as tenofovir,								
efavirenz, emtricitabine, atazanavir, and lamivudine)	9.1	4.7	39.3	17.2	32.8	17.2	33.8	38.4
Medications for hepatitis C (HCV) treatment (for								
example, sofosbuvir, ledipasvir, interferon,	10.3	6.4	35.0	17.5	28.5	18.9	25.0	40.9
peginterferon, ribavirin)								
Lofexidine	5.6	4.4	9.6	7.5	12.8	6.9	18.2	17.7
Clonidine	28.6	22.2	80.0	34.8	83.4	43.6	81.8	78.3

^{- -} Quantity is zero.

Injectable naltrexone = extended-release injectable naltrexone.

¹ Domestic violence services includes family or partner violence services, for physical, sexual, or emotional abuse.

² Buprenorphine total is not the sum of buprenorphine with and without naloxone and sub-dermal implant, because a facility can provide one or more forms of buprenorphine. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 4.10. Clinical/therapeutic approaches used frequently, by facility type: Number and column percent, 2020

		Numbe	r of facilities			Column pe	ercent of facilitie	es
Clinical/therapeutic approaches	Total	OTPs	Serving DUI and DWI	Non-OTP and non-DUI/DWI	Total	OTPs	Serving DUI and DWI ¹	Non-OTP and non-DUI/DWI
Total	16,066	1,754	3,531	10,781	100.0	100.0	100.0	100.0
Substance abuse counseling	15,797	1,741	3,521	10,535	98.3	99.3	99.7	97.7
12-step facilitation	10,517	1,035	2,495	6,987	65.5	59.0	70.7	64.8
Brief intervention	13,124	1,409	3,057	8,658	81.7	80.3	86.6	80.3
Cognitive behavioral therapy	15,075	1,609	3,409	10,057	93.8	91.7	96.5	93.3
Dialectical behavior therapy	9,749	861	2,248	6,640	60.7	49.1	63.7	61.6
Contingency management/motivational incentives	8,690	1,069	1,946	5,675	54.1	60.9	55.1	52.6
Motivational interviewing	14,983	1,669	3,319	9,995	93.3	95.2	94.0	92.7
Trauma-related counseling	13,344	1,281	2,939	9,124	83.1	73.0	83.2	84.6
Anger management	12,742	1,235	2,979	8,528	79.3	70.4	84.4	79.1
Matrix model	7,240	743	1,928	4,569	45.1	42.4	54.6	42.4
Community reinforcement plus vouchers	1,668	164	454	1,050	10.4	9.4	12.9	9.7
Rational emotive behavioral therapy	6,845	675	1,875	4,295	42.6	38.5	53.1	39.8
Relapse prevention	15,430	1,716	3,454	10,260	96.0	97.8	97.8	95.2
Telemedicine/telehealth therapy	9,419	883	2,231	6,305	58.6	50.3	63.2	58.5
Other treatment approaches	1,951	118	462	1,371	12.1	6.7	13.1	12.7
We do not use any of these clinical/therapeutic approaches	72	5	1	66	0.4	0.3	*	0.6

^{*} Less than 0.05 percent.

DUI/DWI = driving under the influence/driving while intoxicated or impaired.

¹ Excludes OTP facilities.

Table 4.11a. Provision of MAT for opioid use disorder, by type of care: Number, 2020

					Type of care)		
Services	Total	Outpatient only	Hospital inpatient only	Residential (non-hospital) only	Outpatient and hospital inpatient	Outpatient and residential (non-hospital)	Residential (non- hospital) and hospital inpatient	All three types of care
Total	16,066	11,726	280	2,477	235	1,002	148	198
Treats opioid use disorder	14,465	10,344	257	2,338	229	953	147	197
This facility uses methadone or buprenorphine, but it is not a								
federally certified opioid treatment program (OTP)	1,220	580	58	297	66	128	35	56
This facility treats opioid use disorder, but it does not use MAT, nor								
does it accept clients using MAT to treat opioid use disorder	1,175	721	19	319	5	99	8	4
This facility accepts clients using MAT, but the medications								
originate from or are prescribed by another entity	8,230	5,833	98	1,529	77	561	71	61
Prescribing entity in same network	2,398	1,511	41	546	22	204	48	26
Business, contractual, or formal referral relationship								
with prescribing entity	3,065	1,949	27	751	14	268	32	24
Clients obtain prescription from facility with no formal relationship	6,170	4,534	63	1,043	59	388	48	35
This facility prescribes naltrexone to treat opioid use disorder	6,061	3,957	149	938	195	524	121	177
This facility prescribes buprenorphine to treat opioid use disorder	5,979	4,088	154	831	173	444	121	168
This facility is a federally certified opioid treatment program (OTP)	1,754	1,505	56	68	28	47	28	22
Facility provides services to opioid use disorder clients only	1,262	1,234	2	18		7		1

^{- -} Quantity is zero.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

MAT = medication assisted treatment.

Table 4.11b. Provision of MAT for opioid use disorder, by type of care: Column percent, 2020

					Type of care	9		
Services	Total	Outpatient only	Hospital inpatient only	Residential (non-hospital) only	Outpatient and hospital inpatient	Outpatient and residential (non-hospital)	Residential (non- hospital) and hospital inpatient	All three types of care
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Treats opioid use disorder	90.0	88.2	91.8	94.4	97.4	95.1	99.3	99.5
This facility uses methadone or buprenorphine, but it is not a								
federally certified opioid treatment program (OTP)	7.6	4.9	20.7	12.0	28.1	12.8	23.6	28.3
This facility treats opioid use disorder, but it does not use MAT, nor does it accept clients using MAT to treat opioid use			0.0	40.0	0.4		- 4	0.0
disorder	7.3	6.1	6.8	12.9	2.1	9.9	5.4	2.0
This facility accepts clients using MAT, but the medications								
originate from or are prescribed by another entity	51.2	49.7	35.0	61.7	32.8	56.0	48.0	30.8
Prescribing entity in same network	14.9	12.9	14.6	22.0	9.4	20.4	32.4	13.1
Business, contractual, or formal referral relationship	10.4	40.0	0.0	20.2	0.0	20.7	24.0	12.1
with prescribing entity	19.1	16.6	9.6	30.3	6.0	26.7	21.6	
Clients obtain prescription from facility with no formal relationship	38.4	38.7	22.5	42.1	25.1	38.7	32.4	17.7
This facility prescribes naltrexone to treat opioid use disorder	37.7	33.7	53.2	37.9	83.0	52.3	81.8	89.4
This facility prescribes buprenorphine to treat opioid use disorder	37.2	34.9	55.0	33.5	73.6	44.3	81.8	84.8
This facility is a federally certified opioid treatment program (OTP)	10.9	12.8	20.0	2.7	11.9	4.7	18.9	11.1
Facility provides services to opioid use disorder clients only	7.9	10.5	0.7	0.7		0.7		0.5

^{- -} Quantity is zero.

MAT = medication assisted treatment.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 4.12. Treatment of alcohol use disorder, by facility operation: Number and column percent, 2020

							I	acility op	eration						
	_				Number of fa	acilities					Column	percent of fac	cilities		
Services		Total	Private non-profit	Private for-profit	Local, county, or community govt.	State govt.	Federal govt.	Tribal govt.	Total	Private non-profit	Private for-profit	Local, county, or community govt.	State govt.	Federal govt.	Tribal govt.
	Total	16,066	8,004	6,535	670	285	323	249	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Treats alcohol use disorders		14,592	7,581	5,557	639	258	320	237	90.8	94.7	85.0	95.4	90.5	99.1	95.2
Treats alcohol use disorder without MAT		2,352	1,194	959	83	52	16	48	14.6	14.9	14.7	12.4	18.2	5.0	19.3
Treats clients with MAT with medications															
originating from another entity		8,232	4,500	3,007	382	116	72	155	51.2	56.2	46.0	57.0	40.7	22.3	62.2
Prescribing entity in same network		2,097	1,242	596	113	41	43	62	13.1	15.5	9.1	16.9	14.4	13.3	24.9
Business, contractual, or formal referral															
relationship with prescribing entity		2,772	1,563	959	146	33	22	49	17.3	19.5	14.7	21.8	11.6	6.8	19.7
Clients obtain prescription from a facility															
with no formal relationship		6,570	3,558	2,486	294	86	40	106	40.9	44.5	38.0	43.9	30.2	12.4	42.6
Administers/prescribes disulfiram,															
naltrexone, or acamprosate		6,189	2,981	2,479	267	126	265	71	38.5	37.2	37.9	39.9	44.2	82.0	28.5
Treats alcohol use disorder clients only		132	39	69	5	5	9	5	0.8	0.5	1.1	0.7	1.8	2.8	2.0

^{- -} Quantity is zero.

MAT = medication assisted treatment.

Table 4.13a. Provision of MAT for alcohol use disorder, by type of care: Number, 2020

					Type of care			
Services	Total	Outpatient only	Hospital inpatient only	Residential (non- hospital) only	Outpatient and hospital inpatient	Outpatient and residential (non-hospital)	Residential (non- hospital) and hospital inpatient	All three types of care
Tot	al 16,066	11,726	280	2,477	235	1,002	148	198
Treats alcohol use disorders	14,592	10,370	258	2,409	233	978	146	198
Treats alcohol use disorder without MAT	2,352	1,684	47	429	9	162	14	7
Treats clients with MAT with medications originating								
from another entity	8,232	6,024	78	1,470	48	511	59	42
Prescribing entity in same network	2,097	1,353	27	477	22	167	37	14
Business, contractual, or formal referral relationship								
with prescribing entity	2,772	1,768	17	696	13	239	26	13
Clients obtain prescription from a facility with no								
formal relationship	6,570	4,970	54	1,062	41	369	44	30
Administers/prescribes disulfiram, natrexone, or								
acamprosate	6,189	4,100	178	888	211	512	121	179
Treats alcohol use disorder clients only	132	99	5	18	4	4	1	1

^{- -} Quantity is zero.

MAT = medication assisted treatment.

Table 4.13b. Provision of MAT for alcohol use disorder, by type of care: Column percent, 2020

		Type of care										
Services	Total	Outpatient only	Hospital inpatient only	Residential (non- hospital) only	Outpatient and hospital inpatient	Outpatient and residential (non-hospital)	Residential (non- hospital) and hospital inpatient	All three types of care				
Treats alcohol use disorders	90.8	88.4	92.1	97.3	99.1	97.6	98.6	100.0				
Treats alcohol use disorder without MAT Treats clients with MAT with medications	14.6	14.4	16.8	17.3	3.8	16.2	9.5	3.5				
originating from another entity	51.2	51.4	27.9	59.3	20.4	51.0	39.9	21.2				
Prescribing entity in same network	13.1	11.5	9.6	19.3	9.4	16.7	25.0	7.1				
Business, contractual, or formal referral relationship with prescribing entity	17.3	15.1	6.1	28.1	5.5	23.9	17.6	6.6				
Clients obtain prescription from a facility with no formal relationship	40.9	42.4	19.3	42.9	17.4	36.8	29.7	15.2				
Administers/prescribes disulfiram, natrexone, or												
acamprosate	38.5	35.0	63.6	35.8	89.8	51.1	81.8	90.4				
Treats alcohol use disorder clients only	0.8	0.8	1.8	0.7	1.7	0.4	0.7	0.5				

^{- -} Quantity is zero.

MAT = medication assisted treatment.

Table 4.14a. Facilities offering special programs or groups for specific client types, by facility operation: Number, 2020

							Clie	nt type				
Facility operation	Total ¹	Any program or group	Adolescents	Young adults	Adult women	Pregnant or post-partum women	Adult men	Seniors or older adults	LGBTQ	Veterans	Active duty military	Members of military families
Total	16,066	13,502	3,818	5,111	8,141	4,140	7,867	3,976	3,901	3,690	2,183	2,482
Facility operation												
Private non-profit	8,004	6,905	2,091	2,344	3,899	1,931	3,725	1,700	1,723	1,467	762	963
Private for-profit	6,535	5,323	1,314	2,419	3,519	1,884	3,499	2,028	1,922	1,812	1,251	1,364
Local, county, or community govt.	670	554	224	137	341	166	300	77	78	65	27	43
State government	285	224	61	73	139	62	126	51	54	46	21	24
Federal govt.	323	303	15	41	109	31	91	50	57	241	93	51
Dept. of Veterans Affairs	228	222		18	81	19	62	36	41	220	41	29
Dept. of Defense	57	55		9	15	3	15	3	6	14	51	19
Indian Health												
Service	29	21	14	10	9	7	10	9	8	6	1	2
Other	9	5	1	4	4	2	4	2	2	1		1
Tribal government	249	193	113	97	134	66	126	70	67	59	29	37

Table 4.14a. Facilities offering special programs or groups for specific client types, by facility operation: Number, 2020 (continued)

							Clien	t type				
Facility operation	Total ¹	Any program or group	Criminal justice clients	Clients with co-occurring mental and substance use disorders	Clients with co-occurring pain and substance use	Clients with HIV or AIDS	Clients who have experienced sexual abuse	Clients who have experienced intimate partner or domestic violence	Clients who have experienced trauma	DUI/DWI clients	Other	No specifically tailored program or group offered ²
Total	16,066	13,502	6,103	8,907	3,499	3,366	4,780	4,752	7,269	3,702	836	2,564
Facility operation												
Private non-profit	8,004	6,905	3,244	4,619	1,443	1,651	2,220	2,172	3,709	1,654	371	1,099
Private for-profit	6,535	5,323	2,334	3,467	1,807	1,498	2,207	2,225	2,874	1,783	370	1,212
Local, county, or												
community govt.	670	554	271	363	66	71	113	117	281	151	28	116
State government	285	224	105	167	47	57	67	69	116	37	14	61
Federal govt.	323	303	61	178	87	44	96	80	174	25	8	20
Dept. of Veterans												
Affairs	228	222	50	141	69	33	75	59	143	14	5	6
Dept. of Defense Indian Health	57	55	2	17	9	3	9	10	16	6		2
Service	29	21	7	15	6	6	10	9	12	5	3	8
Other	9	5	2	5	3	2	2	2	3			4
Tribal government	249	193	88	113	49	- 45	- 77	- 89	115	52	45	56

^{- -} Quantity is zero.

DUI/DWI = driving under the influence/driving while intoxicated or impaired; LGBTQ = lesbian, gay, bisexual, transgender, or queer/questioning.

¹ Number of facilities sums to more than the total column, because a facility could offer special programs or groups for more than one client type.

² Facilities that did not indicate they provided any of the listed programs or groups, or a program or group tailored specifically for other types of clients, are assigned to "no program or group offered." SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 4.14b. Facilities offering special programs or groups for specific client types, by facility operation: Row percent, 2020

							Client t	type				
Facility operation	Total ¹	Any program or group	Adolescents	Young adults	Adult women	Pregnant or post-partum women	Adult men	Seniors or older adults	LGBTQ	Veterans	Active duty military	Members of military families
Total	16,066	84.0	23.8	31.8	50.7	25.8	49.0	24.7	24.3	23.0	13.6	15.4
Facility operation												
Private non-profit	8,004	86.3	26.1	29.3	48.7	24.1	46.5	21.2	21.5	18.3	9.5	12.0
Private for-profit	6,535	81.5	20.1	37.0	53.8	28.8	53.5	31.0	29.4	27.7	19.1	20.9
Local, county, or												
community govt.	670	82.7	33.4	20.4	50.9	24.8	44.8	11.5	11.6	9.7	4.0	6.4
State government	285	78.6	21.4	25.6	48.8	21.8	44.2	17.9	18.9	16.1	7.4	8.4
Federal government	323	93.8	4.6	12.7	33.7	9.6	28.2	15.5	17.6	74.6	28.8	15.8
Dept. of Veterans												
Affairs	228	97.4		7.9	35.5	8.3	27.2	15.8	18.0	96.5	18.0	12.7
Dept. of Defense	57	96.5		15.8	26.3	5.3	26.3	5.3	10.5	24.6	89.5	33.3
Indian Health												
Service	29	72.4	48.3	34.5	31.0	24.1	34.5	31.0	27.6	20.7	3.4	6.9
Other	9	55.6	11.1	44.4	44.4	22.2	44.4	22.2	22.2	11.1		11.1
Tribal government	249	77.5	45.4	39.0	53.8	26.5	50.6	28.1	26.9	23.7	11.6	14.9

Table 4.14b. Facilities offering special programs or groups for specific client types, by facility operation: Row percent, 2020 (continued)

							Client type					
Facility operation	Total ¹	Any program or group	Criminal justice clients	Clients with co-occurring mental and substance use disorders	Clients with co-occurring pain and substance use	Clients with HIV or AIDS	Clients who have experienced sexual abuse	Clients who have experienced intimate partner or domestic violence	Clients who have experienced trauma	DUI/DWI clients	Other	No specifically tailored program or group offered ²
Total	16,066	84.0	38.0	55.4	21.8	21.0	29.8	29.6	45.2	23.0	5.2	16.0
Facility operation												
Private non-profit	8,004	86.3	40.5	57.7	18.0	20.6	27.7	27.1	46.3	20.7	4.6	13.7
Private for-profit	6,535	81.5	35.7	53.1	27.7	22.9	33.8	34.0	44.0	27.3	5.7	18.5
Local, county, or												
community govt.	670	82.7	40.4	54.2	9.9	10.6	16.9	17.5	41.9	22.5	4.2	17.3
State government	285	78.6	36.8	58.6	16.5	20.0	23.5	24.2	40.7	13.0	4.9	21.4
Federal government	323	93.8	18.9	55.1	26.9	13.6	29.7	24.8	53.9	7.7	2.5	6.2
Dept. of Veterans												
Affairs	228	97.4	21.9	61.8	30.3	14.5	32.9	25.9	62.7	6.1	2.2	2.6
Dept. of Defense	57	96.5	3.5	29.8	15.8	5.3	15.8	17.5	28.1	10.5		3.5
Indian Health												
Service	29	72.4	24.1	51.7	20.7	20.7	34.5	31.0	41.4	17.2	10.3	27.6
Other	9	55.6	22.2	55.6	33.3	22.2	22.2	22.2	33.3			44.4
Tribal government	249	77.5	35.3	45.4	19.7	18.1	30.9	35.7	46.2	20.9	18.1	22.5

⁻⁻ Quantity is zero.

DUI/DWI = driving under the influence/driving while intoxicated or impaired; LGBTQ = lesbian, gay, bisexual, transgender, or queer/questioning.

¹ Percentages sum to more than 100 percent, because a facility could offer special programs or groups for more than one client type.

² Facilities that did not indicate they provided any of the listed programs or groups, or a program or group tailored specifically for other types of clients, are assigned to "no program or group offered." SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 4.15a. Facilities offering substance use treatment services in sign language for the deaf and hard-of-hearing and in languages other than English, by facility operation: Number, 2020

				Langu	age services pr	ovided by	Languages	s provided by staff	counselor¹
Facility operation	Total	Sign language	Any language other than English	Staff counselor only	On-call interpreter only²	Both staff counselor and on-call interpreter	Spanish	American Indian/Alaska Native Ianguage	Other
Total	16,066	5,848	8,792	1,893	4,748	2,151	3,784	87	852
Facility operation									
Private non-profit	8,004	3,772	5,158	889	3,047	1,222	2,008	29	376
Private for-profit	6,535	1,293	2,658	897	1,090	671	1,464	20	419
Local, county, or community govt.	670	467	551	39	325	187	212	1	42
State government	285	173	206	29	146	31	56		12
Federal government	323	96	133	12	98	23	32	3	3
Dept. of Veterans Affairs	228	76	100	8	73	19	27		2
Dept. of Defense	57	13	16		16				
Indian Health Service	29	4	10	3	4	3	3	3	1
Other	9	3	7	1	5	1	2		
Tribal government	249	47	86	27	42	17	12	34	
Facility type									
OTPs	1,754	602	1,127	339	413	375	679	4	167
DUI/DWI clients ³	3,531	1,140	1,983	562	947	474	963	27	248
Non-OTP and non-DUI/DWI	10,781	4,106	5,682	992	3,388	1,302	2,142	56	437

^{- -} Quantity is zero.

DUI/DWI = driving under the influence/driving while intoxicated or impaired.

¹ Number of facilities based on facilities where language services are provided by staff counselors only and by both staff counselors and on-call interpreters.

² Facilities that offered substance use treatment services in any language other than English but which did not have a valid response to language provider were classified as providing services by an on-call interpreter only.

³ Excludes OTP facilities.

Table 4.15b. Facilities offering substance use treatment services in sign language for the deaf and hard-of-hearing and in languages other than English, by facility operation: Row percent distribution, 2020

					Language serv	ices provided b	У	Languages	provided by staf	f counselor¹
Facility operation	Number of facilities	Sign language	Any language other than English	Total	Staff counselor only	On-call interpreter only²	Both staff counselor and on-call interpreter	Spanish	American Indian/Alaska Native Ianguage	Other
Total	16,066	36.4	54.7	100.0	21.5	54.0	24.5	93.6	2.2	21.1
Facility operation										
Private non-profit	8,004	47.1	64.4	100.0	17.2	59.1	23.7	95.1	1.4	17.8
Private for-profit	6,535	19.8	40.7	100.0	33.7	41.0	25.2	93.4	1.3	26.7
Local, county, or community govt.	670	69.7	82.2	100.0	7.1	59.0	33.9	93.8	0.4	18.6
State government	285	60.7	72.3	100.0	14.1	70.9	15.0	93.3		20.0
Federal government	323	29.7	41.2	100.0	9.0	73.7	17.3	91.4	8.6	8.6
Dept. of Veterans Affairs	228	33.3	43.9	100.0	8.0	73.0	19.0	100.0		7.4
Dept. of Defense	57	22.8	28.1	100.0		100.0				
Indian Health Service	29	13.8	34.5	100.0	30.0	40.0	30.0	50.0	50.0	16.7
Other	9	33.3	77.8	100.0		71.4	14.3	100.0		
Tribal government	249	18.9	34.5	100.0	31.4	48.8	19.8	27.3	77.3	
Facility type										
OTPs	1,754	34.3	64.3	100.0	30.1	36.6	33.3	95.1	0.6	23.4
DUI/DWI clients ³	3,531	32.3	56.2	100.0	28.3	47.8	23.9	93.0	2.6	23.9
Non-OTP and non-DUI/DWI	10,781	38.1	52.7	100.0	17.5	59.6	22.9	93.4	2.4	19.0

^{- -} Quantity is zero.

DUI/DWI = driving under the influence/driving while intoxicated or impaired.

¹ Percentage of facilities based on facilities where language services are provided by staff counselors only and by both staff counselors and on-call interpreters.

² Facilities that offered substance use treatment services in any language other than English but which did not have a valid response to language provider were classified as providing services by an on-call interpreter only.

³ Excludes OTP facilities.

Table 4.16. Facilities detoxifying clients, by substance and facility operation: Number and row percent, 2020

				Number	of facilities¹						Row	percent of f	acilities¹		
•				Detoxific	ation from			Routine			Detoxific	ation from			
Facility operation	Total ²	Opioids	Alcohol	Benzo- diaze- pines	Cocaine	Meth- amphet- amines	Other sub- stances	use of medica- tions during detox	Opioids	Alcohol	Benzo- diaze- pines	Cocaine	Meth- amphet- amines	Other sub- stances	Routine use of medica- tions during detox
Total	3,609	3,459	2,580	2,385	2,172	2,215	525	3,268	95.8	71.5	66.1	60.2	61.4	14.5	90.6
Facility operation															
Private non-profit	1,387	1,300	1,033	900	826	853	178	1,162	93.7	74.5	64.9	59.6	61.5	12.8	83.8
Private for-profit	1,910	1,872	1,277	1,245	1,162	1,172	326	1,818	98.0	66.9	65.2	60.8	61.4	17.1	95.2
Local, county, or community															
govt.	90	86	82	69	58	56	9	81	95.6	91.1	76.7	64.4	62.2	10.0	90.0
State government	62	57	48	44	36	41	7	57	91.9	77.4	71.0	58.1	66.1	11.3	91.9
Federal government	144	130	131	120	84	84	4	137	90.3	91.0	83.3	58.3	58.3	2.8	95.1
Dept. of Veterans Affairs	132	122	125	117	80	81	4	129	92.4	94.7	88.6	60.6	61.4	3.0	97.7
Dept. of Defense	6	3	3	2	1			4	50.0	50.0	33.3	16.7			66.7
Indian Health Service	3	3	1		1	1		2	100.0	33.3		33.3	33.3		66.7
Other	3	2	2	1	2	2		2	66.7	66.7	33.3	66.7	66.7		66.7
Tribal government	16	14	9	7	6	9	1	13	87.5	56.3	43.8	37.5	56.3	6.3	81.3

⁻⁻ Quantity is zero.

¹ Number of facilities sums to more than the total column, and percentages sum to more than 100 percent, because a facility could provide detoxification for more than one substance.

² Of 16,066 facilities, 3,609 facilities (22 percent) offered detoxification services.

Table 4.17. Facilities with client outreach, by facility operation: Number and percent, 2020

Equility energian		Outreach to persons treatme	•
Facility operation	Total number of facilities	Number of facilities	Percent of all facilities
Total	16,066	10,653	66.3
Facility operation			
Private non-profit	8,004	5,508	68.8
Private for-profit	6,535	4,026	61.6
Local, county, or community government	670	504	75.2
State government	285	183	64.2
Federal government	323	220	68.1
Dept. of Veterans Affairs	228	160	70.2
Dept. of Defense	57	31	54.4
Indian Health Service	29	23	79.3
Other	9	6	66.7
Tribal government	249	212	85.1

Table 4.18a. Facility licensing, certification, or accreditation, by facility operation: Number, 2020

					Lice	nsing, certifi	cation, or accred	litation org	anization				
Facility operation	Total ^{1,2}	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commission	CARF	NCQA	COA	HFAP	Other national organization or federal, state, or local agency	Not licensed, certified, or accredited
Total	16,066	15,087	12,329	6,346	7,689	734	3,674	4,763	367	717	151	741	891
Facility operation													
Private non-profit	8,004	7,709	6,542	3,668	3,916	428	1,559	2,623	233	495	86	279	253
Private for-profit	6,535	5,944	4,853	2,127	3,245	195	1,670	1,727	107	194	44	341	550
Local, county, or													
community govt.	670	650	577	364	308	28	70	134	7	11	3	22	18
State government	285	277	214	132	137	21	72	121	3	3	10	11	8
Federal government	323	313	29	10	17	53	274	121	14	10	8	25	9
Dept. of Veterans Affairs	228	227	10	6	5	43	225	111	10	9	5	10	1
Dept. of Defense	57	54	5		1	7	41	5	1		1	7	3
Indian Health Service	29	27	11	3	7	2	6	4	1		1	8	2
Other	9	5	3	1	4	1	2	1	2	1	1		3
Tribal government	249	194	114	45	66	9	29	37	3	4		63	53
Facility type													
OTPs	1,754	1,739	1,550	546	1,057	102	487	1,156	44	89	11	224	4
DUI/DWI clients ²	3,531	3,414	3,079	1,589	1,620	74	393	793	61	119	37	126	107
Non-OTP and non-DUI/DWI	10,781	9,934	7,700	4,211	5,012	558	2,794	2,814	262	509	103	391	780

⁻⁻ Quantity is zero.

CARF = Commission on Accreditation of Rehabilitation Facilities; COA = Council on Accreditation; DUI/DWI = driving under the influence/driving while intoxicated or impaired; HFAP = Healthcare Facilities Accreditation Program; NCQA = National Committee for Quality Assurance.

¹ Number of facilities sums to more than the total column, because a facility could report more than one licensing, certification, or accreditation organization. The number of facilities licensed, certified, or accredited and the number not licensed, certified, or accredited by any listed organization do not sum to the total number of facilities, because 88 facilities did not respond to the question.

² Excludes OTP facilities.

Table 4.18b. Facility licensing, certification, or accreditation, by facility operation: Row percent, 2020

					Lice	nsing, certif	ication, or accred	ditation org	anization]
Facility operation	Number of facilities ^{1,2}	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commission	CARF	NCQA	COA	HFAP	Other national organization or federal, state, or local agency	Not licensed, certified, or accredited
Total	16,066	93.9	76.7	39.5	47.9	4.6	22.9	29.6	2.3	4.5	0.9	4.6	5.5
Facility operation													
Private non-profit	8,004	96.3	81.7	45.8	48.9	5.3	19.5	32.8	2.9	6.2	1.1	3.5	3.2
Private for-profit	6,535	91.0	74.3	32.5	49.7	3.0	25.6	26.4	1.6	3.0	0.7	5.2	8.4
Local, county, or													
community govt.	670	97.0	86.1	54.3	46.0	4.2	10.4	20.0	1.0	1.6	0.4	3.3	2.7
State government	285	97.2	75.1	46.3	48.1	7.4	25.3	42.5	1.1	1.1	3.5	3.9	2.8
Federal government	323	96.9	9.0	3.1	5.3	16.4	84.8	37.5	4.3	3.1	2.5	7.7	2.8
Dept. of Veterans Affairs	228	99.6	4.4	2.6	2.2	18.9	98.7	48.7	4.4	3.9	2.2	4.4	0.4
Dept. of Defense	57	94.7	8.8		1.8	12.3	71.9	8.8	1.8		1.8	12.3	5.3
Indian Health Service	29	93.1	37.9	10.3	24.1	6.9	20.7	13.8	3.4		3.4	27.6	6.9
Other	9	55.6	33.3	11.1	44.4	11.1	22.2	11.1	22.2	11.1	11.1		33.3
Tribal government	249	77.9	45.8	18.1	26.5	3.6	11.6	14.9	1.2	1.6		25.3	21.3
Facility type													
OTPs	1,754	99.1	88.4	31.1	60.3	5.8	27.8	65.9	2.5	5.1	0.6	12.8	0.2
DUI/DWI clients ²	3,531	96.7	87.2	45.0	45.9	2.1	11.1	22.5	1.7	3.4	1.0	3.6	3.0
Non-OTP and non-DUI/DWI	10,781	92.1	71.4	39.1	46.5	5.2	25.9	26.1	2.4	4.7	1.0	3.6	7.2

^{- -} Quantity is zero.

CARF = Commission on Accreditation of Rehabilitation Facilities; COA = Council on Accreditation; DUI/DWI = driving under the influence/driving while intoxicated or impaired; HFAP = Healthcare Facilities Accreditation Program; NCQA = National Committee for Quality Assurance.

¹ Percentages sum to more than 100 percent, because a facility could report more than one licensing, certification, or accreditation organization. The percent of facilities licensed, certified, or accredited and the percent not licensed, certified, or accredited by any listed organization do not sum to 100 percent, because 88 facilities did not respond to the question.

² Excludes OTP facilities.

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 4.19a. Facility licensing, certification, or accreditation, by type of care offered: Number, 2020

					Facility lice	ensing, certifi	ication, or acci	reditation c	rganizatio	on			
Type of care offered	Total ^{1,2}	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commis- sion	CARF	NCQA	COA	HFAP	Other national organization or federal, state, or local agency	Not licensed, certified, or accredited
Total	16,066	15,087	12,329	6,346	7,689	734	3,674	4,763	367	717	151	741	891
Outpatient	13,161	12,310	10,113	5,566	6,011	558	2,834	3,922	325	643	118	623	781
Regular	12,249	11,483	9,513	5,285	5,483	449	2,469	3,624	307	613	111	556	705
Intensive	7,243	7,058	5,865	3,259	3,707	401	1,953	2,145	155	314	77	279	145
Detoxification	1,869	1,733	1,349	646	860	126	540	785	67	92	14	142	127
Day treatment/partial hospitalization	2,277	2,239	1,747	977	1,305	244	1,049	646	62	63	31	103	24
Methadone/buprenorphine maintenance													
or naltrexone treatment	5,829	5,419	4,470	2,332	2,691	332	1,558	2,199	205	242	47	375	377
Residential (non-hospital)	3,825	3,693	2,981	1,151	2,129	119	1,105	1,270	43	110	36	146	113
Detoxification	1,412	1,388	1,109	396	809	47	642	519	17	22	8	27	16
Short-term treatment (30 days or fewer)	2,427	2,387	1,896	770	1,435	98	948	883	32	62	19	73	23
Long-term treatment (more than 30 days)	2,972	2,849	2,317	882	1,622	66	728	948	27	88	30	110	107
Hospital inpatient	861	838	515	324	558	317	627	178	37	26	18	52	18
Detoxification	784	762	456	295	508	300	581	164	34	25	14	48	18
Treatment	658	647	398	256	454	257	502	126	30	19	15	37	7

CARF = Commission on Accreditation of Rehabilitation Facilities; COA = Council on Accreditation; HFAP = Healthcare Facilities Accreditation Program; NCQA = National Committee for Quality Assurance.

1 Number of facilities sums to more than the total column, because a facility could report more than one licensing, certification, or accreditation organization.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

² The number of facilities licensed, certified, or accredited and the number not licensed, certified, or accredited by any listed organization do not sum to the total number of facilities, because 88 facilities did not respond to the question.

Table 4.19b. Facility licensing, certification, or accreditation, by type of care offered: Row percent, 2020

					Facility lice	nsing, certific	cation, or acci	editation (organizatio	on			
Type of care offered	Number of facilities ^{1,2}	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commis- sion	CARF	NCQA	COA	HFAP	Other national organization or federal, state, or local agency	Not licensed, certified, or accredited
Total	16,066	93.9	76.7	39.5	47.9	4.6	22.9	29.6	2.3	4.5	0.9	4.6	5.5
Outpatient	13,161	93.5	76.8	42.3	45.7	4.2	21.5	29.8	2.5	4.9	0.9	4.7	5.9
Regular	12,249	93.7	77.7	43.1	44.8	3.7	20.2	29.6	2.5	5.0	0.9	4.5	5.8
Intensive	7,243	97.4	81.0	45.0	51.2	5.5	27.0	29.6	2.1	4.3	1.1	3.9	2.0
Detoxification	1,869	92.7	72.2	34.6	46.0	6.7	28.9	42.0	3.6	4.9	0.7	7.6	6.8
Day treatment/partial hospitalization	2,277	98.3	76.7	42.9	57.3	10.7	46.1	28.4	2.7	2.8	1.4	4.5	1.1
Methadone/buprenorphine maintenance or naltrexone treatment	5,829	93.0	76.7	40.0	46.2	5.7	26.7	37.7	3.5	4.2	0.8	6.4	6.5
Residential (non-hospital)	3,825	96.5	77.9	30.1	55.7	3.1	28.9	33.2	1.1	2.9	0.9	3.8	3.0
Detoxification	1,412	98.3	78.5	28.0	57.3	3.3	45.5	36.8	1.2	1.6	0.6	1.9	1.1
Short-term treatment (30 days or fewer)	2,427	98.4	78.1	31.7	59.1	4.0	39.1	36.4	1.3	2.6	0.8	3.0	0.9
Long-term treatment (more than 30 days)	2,972	95.9	78.0	29.7	54.6	2.2	24.5	31.9	0.9	3.0	1.0	3.7	3.6
Hospital inpatient	861	97.3	59.8	37.6	64.8	36.8	72.8	20.7	4.3	3.0	2.1	6.0	2.1
Detoxification	784	97.2	58.2	37.6	64.8	38.3	74.1	20.9	4.3	3.2	1.8	6.1	2.3
Treatment	658	98.3	60.5	38.9	69.0	39.1	76.3	19.1	4.6	2.9	2.3	5.6	1.1

CARF = Commission on Accreditation of Rehabilitation Facilities; COA = Council on Accreditation; HFAP = Healthcare Facilities Accreditation Program; NCQA = National Committee for Quality Assurance.

¹ Percentages sum to more than 100 percent, because a facility could report more than one licensing, certification, or accreditation organization.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

² The percent of facilities licensed, certified, or accredited and the percent not licensed, certified, or accredited by any listed organization do not sum to 100 percent, because 88 facilities did not respond to the question.

Table 4.20. Federally Qualified Health Centers providing substance use treatment, by type of care offered:

Number and percent, 2020

Time of core offered	Federally Qualific	ed Health Centers
Type of care offered ———	Number of facilities¹	Percent of all facilities ¹
Total	1,592	100.0
Type of care offered		
Outpatient	1,432	89.9
Regular	1,362	85.6
Intensive	699	43.9
Detoxification	240	15.1
Day treatment/partial hospitalization	164	10.3
Methadone/buprenorphine maintenance or		
naltrexone treatment	746	46.9
Residential (non-hospital)	237	14.9
Detoxification	79	5.0
Short-term treatment (30 days or fewer)	137	8.6
Long-term treatment (more than 30 days)	190	11.9
Hospital inpatient	62	3.9
Detoxification	59	3.7
Treatment	38	2.4

¹ Numbers of facilities sum to more than the total and percentages sum to more than 100, because a facility could provide more than one type of care. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 4.21a. Types of payments accepted, by facility operation: Number, 2020

					Туре о	f payment accep	ted				<u> </u>	
Facility operation	Total ¹	Cash or self- payment	Private health insurance	Medicare	Medicaid	State- financed health insurance plan other than Medicaid	Federal military insurance	No payment accepted	IHS/ Tribal/ Urban funds	Other	Sliding fee scale	Treatment at no charge for clients who cannot pay
Total	16,066	14,521	11,952	6,751	11,359	7,950	6,273	452	2,006	122	9,181	7,025
Facility operation												
Private non-profit	8,004	7,079	5,799	3,718	6,550	4,698	3,121	333	840	61	5,560	4,720
Private for-profit	6,535	6,376	5,087	2,205	3,665	2,430	2,352	14	823	59	2,811	1,385
Local, county, or community govt.	670	590	475	399	595	417	325	24	65	2	536	476
State government	285	232	199	152	230	176	122	31	37		188	207
Federal government	323	136	230	142	127	81	253	25	37		16	42
Dept. of Veterans Affairs	228	119	200	120	97	60	194	5	12			
Dept. of Defense	57		4	1	2	1	41	15				14
Indian Health Service	29	10	19	15	21	14	14	4	24		10	24
Other	9	7	7	6	7	6	4	1	1		6	4
Tribal government	249	108	162	135	192	148	100	25	204		70	195
Facility type												
OTPs	1,754	1,678	1,171	1,065	1,454	747	571	11	99	9	759	489
DUI/DWI clients ²	3,531	3,420	2,633	1,322	2,487	1,843	1,348	27	433	40	2,581	1,741
Non-OTP and non-DUI/DWI	10,781	9,423	8,148	4,364	7,418	5,360	4,354	414	1,474	73	5,841	4,795

^{- -} Quantity is zero.

DUI/DWI = driving under the influence/driving while intoxicated or impaired.

¹ Number of facilities sums to more than the total column, because a facility could accept more than one payment option.

² Excludes OTP facilities.

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 4.21b. Types of payments accepted, by facility operation: Row percent, 2020

					Туре о	f payment accep	ted					
Facility operation	Number of facilities ¹	Cash or self- payment	Private health insurance	Medicare	Medicaid	State- financed health insurance plan other than Medicaid	Federal military insurance	No payment accepted	IHS/ Tribal/ Urban funds	Other	Sliding fee scale	Treatment at no charge for clients who cannot pay
Total	16,066	90.4	74.4	42.0	70.7	49.5	39.0	2.8	12.5	0.8	57.1	43.7
Facility operation												
Private non-profit	8,004	88.4	72.5	46.5	81.8	58.7	39.0	4.2	10.5	8.0	69.5	59.0
Private for-profit	6,535	97.6	77.8	33.7	56.1	37.2	36.0	0.2	12.6	0.9	43.0	21.2
Local, county, or community govt.	670	88.1	70.9	59.6	88.8	62.2	48.5	3.6	9.7	0.3	80.0	71.0
State government	285	81.4	69.8	53.3	80.7	61.8	42.8	10.9	13.0		66.0	72.6
Federal government	323	42.1	71.2	44.0	39.3	25.1	78.3	7.7	11.5		5.0	13.0
Dept. of Veterans Affairs	228	52.2	87.7	52.6	42.5	26.3	85.1	2.2	5.3			
Dept. of Defense	57		7.0	1.8	3.5	1.8	71.9	26.3				24.6
Indian Health Service	29	34.5	65.5	51.7	72.4	48.3	48.3	13.8	82.8		34.5	82.8
Other	9	77.8	77.8	66.7	77.8	66.7	44.4	11.1	11.1		66.7	44.4
Tribal government	249	43.4	65.1	54.2	77.1	59.4	40.2	10.0	81.9		28.1	78.3
Facility type												
OTPs	1,754	95.7	66.8	60.7	82.9	42.6	32.6	0.6	5.6	0.5	43.3	27.9
DUI/DWI clients ²	3,531	96.9	74.6	37.4	70.4	52.2	38.2	0.8	12.3	1.1	73.1	49.3
Non-OTP and non-DUI/DWI	10,781	87.4	75.6	40.5	68.8	49.7	40.4	3.8	13.7	0.7	54.2	44.5

^{- -} Quantity is zero.

DUI/DWI = driving under the influence/driving while intoxicated or impaired.

¹ Percentages sum to more than 100 percent, because a facility could accept more than one payment option.

² Excludes OTP facilities.

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 4.22. Facility funding, by facility operation: Number and percent, 2020

Facility operation			· ·	r substance use treatment Irams
r acinty operation		Total number of facilities	Number of facilities	Percent of all facilities
	Total	16,066	8,262	51.4
Facility operation				
Private non-profit		8,004	5,861	73.2
Private for-profit		6,535	1,158	17.7
Local, county, or community government		670	582	86.9
State government		285	225	78.9
Federal government		323	221	68.4
Dept. of Veterans Affairs		228	175	76.8
Dept. of Defense		57	12	21.1
Indian Health Service		29	27	93.1
Other		9	7	77.8
Tribal government		249	215	86.3
Facility type				
OTPs		1,754	823	46.9
DUI/DWI clients ¹		3,531	1,790	50.7
Non-OTP and non-DUI/DWI		10,781	5,649	52.4

DUI/DWI = driving under the influence/driving while intoxicated or impaired.

¹ Excludes OTP facilities.

Table 4.23a. Medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by facility operation: Number, 2020

			oviding med opioid thera					OTP fa	ncilities ³					Non-O	TP facilities	
Facility operation	Any MAT type¹	ОТР	Bupren- orphine ²	Injectable naltrexone	Any MAT type	Metha- done only	Metha- done and bupren- orphine ²	Metha- done, bupren- orphine ² , and inject- able naltrexone	Metha- done and inject- able naltrex- one	Bupren- orphine ² and inject- able naltrex- one	Bupren- orphine ² only	Injectable naltrexone only	Any MAT type⁴	Bupren- orphine ²	Injectable naltrexone	Bupren- orphine ² and inject- able naltrex- one
Total	8,250	1,754	7,066	6,016	1,754	303	741	545	38	100	20	7	6,496	1,170	836	4,490
Facility operation																
Private non-profit	3,740	543	3,154	2,920	543	78	170	209	35	37	12	2	3,197	560	471	2,166
Private for-profit	3,709	1,085	3,268	2,440	1,085	202	551	265	2	54	6	5	2,624	510	232	1,882
Local, county, or community govt.	308	44	235	249	44	11	11	17	1	3	1		264	36	61	167
State government	149	35	114	103	35	10	5	17		3			114	31	25	58
Federal government	258	37	234	240	37	1	1	33		2			221	16	23	182
Dept. of Veterans Affairs	220	37	211	208	37	1	1	33		2			183	10	8	165
Dept. of Defense	18		7	17									18	1	11	6
Indian Health Service	12		10	10									12	2	2	8
Other	8		6	5									8	3	2	3
Tribal government	86	10	61	64	10	1	3	4		1	1		76	17	24	35

⁻⁻ Quantity is zero.

Injectable naltrexone = extended-release injectable naltrexone; MAT = medication assisted treatment.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

¹ Any MAT type for all facilities providing medication-assisted opioid therapy includes all facilities (OTP and non-OTP) providing methadone, buprenorphine, or injectable naltrexone.

² Buprenorphine includes buprenorphine with and without naloxone, buprenorphine sub-dermal implant, and extended-release injectable buprenorphine.

³ Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

⁴ Any MAT type for non-OTP facilities includes facilities providing buprenorphine or injectable naltrexone.

Table 4.23b. Medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by facility operation: Column percent distribution, 2020

	All fa	•	oviding me opioid ther					OTP fa	acilities ³					Non-O	TP facilities	
Facility operation	Any MAT type¹	ОТР	Bupren- orphine ²	Injectable naltrexone	Any MAT type	Metha- done only	Metha- done and bupren- orphine ²	Metha- done, bupren- orphine ² , and inject- able naltrexone	Metha- done and inject- able naltrex- one	Bupren- orphine ² and inject able naltrex- one	Bupren- orphine ² only	Injectable naltrexone only	Any MAT type⁴	Bupren- orphine ²	Injectable naltrexone	Bupren- orphine ² and inject- able naltrex- one
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Facility operation																
Private non-profit	45.3	31.0	44.6	48.5	31.0	25.7	22.9	38.3	92.1	37.0	60.0	28.6	49.2	47.9	56.3	48.2
Private for-profit	45.0	61.9	46.2	40.6	61.9	66.7	74.4	48.6	5.3	54.0	30.0	71.4	40.4	43.6	27.8	41.9
Local, county, or																
community govt.	3.7	2.5	3.3	4.1	2.5	3.6	1.5	3.1	2.6	3.0	5.0		4.1	3.1	7.3	3.7
State government	1.8	2.0	1.6	1.7	2.0	3.3	0.7	3.1		3.0			1.8	2.6	3.0	1.3
Federal government	3.1	2.1	3.3	4.0	2.1	0.3	0.1	6.1		2.0			3.4	1.4	2.8	4.1
Dept. of Veterans Affairs	2.7	2.1	3.0	3.5	2.1	0.3	0.1	6.1		2.0			2.8	0.9	1.0	3.7
Dept. of Defense	0.2		0.1	0.3									0.3	0.1	1.3	0.1
Indian Health Service	0.1		0.1	0.2									0.2	0.2	0.2	0.2
Other	0.1		0.1	0.1									0.1	0.3	0.2	0.1
Tribal government	1.0	0.6	0.9	1.1	0.6	0.3	0.4	0.7		1.0	5.0		1.2	1.5	2.9	8.0

⁻⁻ Quantity is zero; * Less than 0.05 percent.

Injectable naltrexone = extended-release injectable naltrexone; MAT = medication assisted treatment.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility. Percentages may not sum to 100 percent due to rounding.

¹ Includes all facilities (OTP and non-OTP) providing methadone, buprenorphine, or injectable naltrexone.

² Buprenorphine includes buprenorphine with and without naloxone, buprenorphine sub-dermal implant, and extended-release injectable buprenorphine.

³ Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

⁴ Includes facilities providing buprenorphine or injectable naltrexone.

Table 4.24a. Type of care offered in facilities with opioid treatment programs (OTPs), by facility operation: Number, 2020

							Type of care of	offered						
					Outpatient					Residentia non-hospit				spital atient
Facility operation	Total ^{1,2}	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
Total	1,754	1,602	1,291	517	106	734	1,570	165	129	87	100	134	96	125
Facility operation														
Private non-profit	543	460	388	212	45	162	453	75	53	51	35	66	50	61
Private for-profit	1,085	1,029	806	252	47	525	1,004	63	54	24	47	42	30	39
Local, county, or														
community govt.	44	40	33	11	2	9	40	4	3	1	3	5	2	4
State government	35	27	22	14	3	7	27	8	5	4	5	5	5	5
Federal government	37	36	34	25	8	27	36	15	14	7	10	15	9	15
Dept. of Veterans Affairs	37	36	34	25	8	27	36	15	14	7	10	15	9	15
Dept. of Defense	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Indian Health Service	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Tribal government	10	10	8	3	1	4	10					1		1

⁻⁻ Quantity is zero, ‡ No facilities in this category.

Injectable naltrexone = extended-release injectable naltrexone (Vivitrol®).

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

¹ Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

² Number of facilities sum to more than the total column, because a facility could provide more than one type of care.

Table 4.24b. Type of care offered in facilities with opioid treatment programs (OTPs), by facility operation: Row percent, 2020

							Type of care	offered						
					Outpatie	nt				Residentia non-hospita				spital atient
Facility operation	Number of facilities ^{1,2}	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
Total	1,754	91.3	73.6	29.5	6.0	41.8	89.5	9.4	7.4	5.0	5.7	7.6	5.5	7.1
Facility operation														
Private non-profit	543	84.7	71.5	39.0	8.3	29.8	83.4	13.8	9.8	9.4	6.4	12.2	9.2	11.2
Private for-profit	1,085	94.8	74.3	23.2	4.3	48.4	92.5	5.8	5.0	2.2	4.3	3.9	2.8	3.6
Local, county, or														
community govt.	44	90.9	75.0	25.0	4.5	20.5	90.9	9.1	6.8	2.3	6.8	11.4	4.5	9.1
State government	35	77.1	62.9	40.0	8.6	20.0	77.1	22.9	14.3	11.4	14.3	14.3	14.3	14.3
Federal government	37	97.3	91.9	67.6	21.6	73.0	97.3	40.5	37.8	18.9	27.0	40.5	24.3	40.5
Dept. of Veterans Affairs	37	97.3	91.9	67.6	21.6	73.0	97.3	40.5	37.8	18.9	27.0	40.5	24.3	40.5
Dept. of Defense	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Indian Health Service	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Tribal government	10	100.0	80.0	30.0	10.0	40.0	100.0					10		10

⁻⁻ Quantity is zero; ‡ No facilities in this category.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Injectable naltrexone = extended-release injectable naltrexone (Vivitrol®).

¹ Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

² Percentages sum to more than 100 percent, because a facility could provide more than one type of care.

Table 4.25a. Facility licensing, certification, or accreditation of facilities with opioid treatment programs (OTPs), by type of care offered: Number, 2020

					Facility lice	ensing, certif	ication, or a	ccreditation	n organiza	ntion			
Type of care offered	Total ^{1,2}	Any listed agency/ organi- zation	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commis- sion	CARF	NCQA	COA	HFAP	Other national organization or federal/state/ local agency	Not licensed, certified, or accredited
Tot	al 1,754	1,739	1,550	546	1,057	102	487	1,156	44	89	11	224	4
Outpatient													
Regular	1,291	1,283	1,153	430	761	58	310	907	30	69	4	168	4
Intensive	517	506	452	212	296	42	173	329	8	21	2	52	2
Detoxification	734	729	638	211	406	32	163	513	14	63	1	101	3
Day treatment/partial hospitalization	106	103	83	47	63	16	54	54	1	3		11	1
Methadone/buprenorphine maintenance or naltrexone	4 570	4.550	4.070	404	005	00	200	4.007	07	0.7	0	000	
treatment	1,570	1,556	1,378	481	925	69	382	1,087	37	87	6	208	4
Residential (non-hospital)													
Detoxification	100	99	86	36	63	6	61	49	4	3	2	5	
Short-term treatment (30 days or fewer)	129	127	110	50	78	11	79	53	4	3	4	9	1
Long-term treatment (more than 30 days)	87	85	76	38	49	7	38	46	2	2	4	5	1
Hospital inpatient													
Detoxification	125	125	101	49	87	43	103	34	5	3	2	15	
Treatment	96	96	78	36	66	28	80	25	3	2	2	10	

⁻⁻ Quantity is zero.

CARF = Commission on Accreditation of Rehabilitation Facilities; COA = Council on Accreditation; HFAP = Healthcare Facilities Accreditation Program; NCQA = National Committee for Quality Assurance.

¹ Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

² Number of facilities sums to more than the total column, because a facility could report more than one licensing, certification, or accreditation organization. The number of facilities licensed, certified, or accredited and the number not licensed, certified, or accredited by any listed organization do not sum to the total number of facilities, because one facility did not respond to the NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 4.25b. Facility licensing, certification, or accreditation of facilities with opioid treatment programs (OTPs), by type of care offered: Row percent, 2020

					Facility lice	nsing, certifi	cation, or ac	creditation	organizati	on			
Type of care offered	Number of facilities ^{1,2}	Any listed agency/ organi- zation	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commis- sion	CARF	NCQA	COA	HFAP	Other national organization or federal/state/ local agency	Not licensed, certified, or accredited
Total	1,754	99.1	88.4	31.1	60.3	5.8	27.8	65.9	2.5	5.1	0.6	12.8	0.2
Outpatient													
Regular	1,291	99.4	89.3	33.3	58.9	4.5	24.0	70.3	2.3	5.3	0.3	13.0	0.3
Intensive	517	97.9	87.4	41.0	57.3	8.1	33.5	63.6	1.5	4.1	0.4	10.1	0.4
Detoxification	734	99.3	86.9	28.7	55.3	4.4	22.2	69.9	1.9	8.6	0.1	13.8	0.4
Day treatment/partial hospitalization	106	97.2	78.3	44.3	59.4	15.1	50.9	50.9	0.9	2.8		10.4	0.9
Methadone/buprenorphine maintenance or naltrexone treatment	1,570	99.1	87.8	30.6	58.9	4.4	24.3	69.2	2.4	5.5	0.4	13.2	0.3
	1,570	33.1	07.0	30.0	30.9	7.7	24.0	03.2	2.4	3.3	0.4	13.2	0.5
Residential (non-hospital) Detoxification Short-term treatment (30 days	100	99.0	86.0	36.0	63.0	6.0	61.0	49.0	4.0	3.0	2.0	5.0	
or fewer) Long-term treatment (more than	129	98.4	85.3	38.8	60.5	8.5	61.2	41.1	3.1	2.3	3.1	7.0	0.8
30 days)	87	97.7	87.4	43.7	56.3	8.0	43.7	52.9	2.3	2.3	4.6	5.7	1.1
Hospital inpatient													
Detoxification	125	100.0	80.8	39.2	69.6	34.4	82.4	27.2	4.0	2.4	1.6	12.0	
Treatment	96	100.0	81.3	37.5	68.8	29.2	83.3	26.0	3.1	2.1	2.1	10.4	

^{- -} Quantity is zero.

CARF = Commission on Accreditation of Rehabilitation Facilities; COA = Council on Accreditation; HFAP = Healthcare Facilities Accreditation Program; NCQA = National Committee for Quality Assurance.

¹ Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

² Percentages sum to more than 100 percent, because a facility could report more than one licensing, certification, or accreditation organization. The percent of facilities licensed, certified, or accredited and the percent not licensed, certified, or accredited by any listed organization do not sum to 100 percent, because one facility did not respond to the question.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 4.26. Facility smoking policy, by facility operation: Number and row percent distribution, 2020

			N	umber of facili	ties					Row per	cent distributi	on of facilitie	es	
- -			T	ype of facility	smoking po	olicy					Type of facility	/ smoking po	olicy	
Facility operation	Total ¹	Not permitted to smoke anywhere outside or within any building	Per- mitted in desig- nated outdoor area(s)	Permitted anywhere outside	Per- mitted in desig- nated indoor area(s)	Permitted anywhere inside	Permitted anywhere without restriction	Total ¹	Not permitted to smoke anywhere outside or within any building	Per- mitted in desig- nated outdoor area(s)	Permitted anywhere outside	Per- mitted in desig- nated indoor area(s)	Permitted anywhere inside	Permitted anywhere without restriction
Total	15,980	5,750	9,140	1,046	31	3	10	100.0	36.0	57.2	6.5	0.2	*	0.1
Facility operation														
Private non-profit	7,960	3,447	4,170	321	19	1	2	100.0	43.3	52.4	4.0	0.2	*	*
Private for-profit	6,497	1,452	4,350	676	11	2	6	100.0	22.3	67.0	10.4	0.2	*	0.1
Local, county, or community govt.	669	350	296	22	1			100.0	52.3	44.2	3.3	0.1		
State government	285	183	96	6				100.0	64.2	33.7	2.1			
Federal government	321	233	85	2			1	100.0	72.6	26.5	0.6			0.3
Dept. of Veterans														
Affairs	227	189	37				1	100.0	83.3	16.3				0.4
Dept. of Defense	57	20	37					100.0	35.1	64.9				
Indian Health Service	29	18	9	2				100.0	62.1	31.0	6.9			
Other	8	6	2					100.0	75.0	25.0				
Tribal government	248	85	143	19			1	100.0	34.3	57.7	7.7			0.4

^{- -} Quantity is zero; * Less than 0.05 percent.

¹ Of 16,066 facilities, 86 facilities (less than 1 percent) did not respond to the question. Percentages are based on the remaining 15,980 facilities.

NOTE: Percentages may not sum to 100 percent due to rounding.

Table 4.27. Suicide prevention-related services provided by Veterans Affairs (VA) facilities: Number and percent, 2020

Cuiside augustina valeted equipes	V	/A facilities
Suicide prevention-related services ——	Number	Percent of all VA facilities
Total	228	100.0
Suicide prevention-related services		
Evidence-based suicide prevention interventions (interventions such as		
psychotherapies, medications, and/or public health strategies specifically		
aimed at decreasing rates of suicide)	206	90.4
Suicide risk screening	212	93.0
Suicide risk evaluation	213	93.4
Does not offer any of the above suicide prevention-related services		
Evidence-based suicide prevention interventions		
Cognitive therapy for suicide prevention (CBT-SP)	77	33.8
Cognitive behavioral therapy (CBT)	194	85.1
Dialectical Behavior Therapy (DBT)	139	61.0
Problem solving therapy (PST)	114	50.0
Safety planning/crisis response planning	188	82.5
Ketamine infusions	10	4.4
Lithium treatment	127	55.7
Clozapine treatment	107	46.9
Caring communications	88	38.6
Home support	66	28.9
World Health Organization–Brief Intervention and Contact (WHO-BIC)	9	3.9
Gate keeper training	43	18.9
Lethal means safety counseling	147	64.5
Other interventions	10	4.4
Standardized suicide screening tools		
Columbia-Suicide Severity Rating Scale (C-SSRS) screener	209	91.7
Patient Health Questionnaire (PHQ-9) Item 9	210	92.1
Other screening tools	36	15.8
Does not use standardized suicide screening tools		

Table 4.27. Suicide prevention-related services provided by Veterans Affairs (VA) facilities: Number and percent, 2020 (continued)

Suicido provention related convince		VA fac	cilities
Suicide prevention-related services		Number	Percent of all VA facilities
	Total	228	100.0
Standardized suicide evaluation tools			
Columbia-Suicide Severity Rating Scale (C-SSRS)		209	91.7
The Mini International Neuropsychiatric Interview (MINI)		27	11.8
VA Comprehensive Suicide Risk Evaluation (CSRE)		210	92.1
Suicide Assessment Five-Step Evaluation and Triage (SAFE-T)		21	9.2
Other evaluation tools			
Does not use standardized suicide evaluation tools			

^{- -} Quantity is zero.

Table 5.1a. Clients in treatment, by type of care received and facility operation: Number, March 31, 2020

							Type of cal	re received						
					Outpatier	nt			Reside	ntial (non-h	ospital)		Hospital	inpatient
Facility operation	Total	Total out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Total residential	Short- term	Long- term	Detox	Total hospital inpatient	Treat- ment	Detox
Tota	al 1,090,357	1,021,185	459,157	83,073	14,112	13,445	451,398	58,952	20,440	33,135	5,377	10,220	5,444	4,776
Facility operation														
Private non-profit	504,780	463,132	266,575	45,406	4,812	2,715	143,624	39,143	10,944	26,082	2,117	2,505	1,228	1,277
Private for-profit	485,411	463,601	133,436	30,213	8,518	10,027	281,407	16,037	8,271	4,803	2,963	5,773	3,636	2,137
Local, county, or														
community govt.	39,571	38,418	23,936	3,371	164	252	10,695	1,005	259	621	125	148	83	65
State government	19,601	16,836	8,651	1,094	495	109	6,487	1,273	506	620	147	1,492	352	1,140
Federal government	30,589	29,040	19,596	1,900	55	214	7,275	1,255	377	858	20	294	142	152
Dept. of Veterans Affairs	26,825	25,373	16,860	1,692	20	206	6,595	1,184	343	822	19	268	119	149
Dept. of Defense	2,278	2,220	1,975	190	35	5	15	32	25	6	1	26	23	3
Indian Health Service	502	463	446			3	14	39	9	30				
Other	984	984	315	18			651							
Tribal government	10,405	10,158	6,963	1,089	68	128	1,910	239	83	151	5	8	3	5

⁻⁻ Quantity is zero.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 5.1b. Clients in treatment, by type of care received and facility operation: Row percent distribution, March 31, 2020

							Type of car	e received						
					Outpatier	nt			Reside	ential (non-ho	spital)		Hospital	inpatient
Facility operation	Total	Total out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Total residential	Short- term	Long-term	Detox	Total hospital inpatient	Treat- ment	Detox
Total	100.0	93.7	42.1	7.6	1.3	1.2	41.4	5.4	1.9	3.0	0.5	0.9	0.5	0.4
Facility operation														
Private non-profit	100.0	91.7	52.8	9.0	1.0	0.5	28.5	7.8	2.2	5.2	0.4	0.5	0.2	0.3
Private for-profit	100.0	95.5	27.5	6.2	1.8	2.1	58.0	3.3	1.7	1.0	0.6	1.2	0.7	0.4
Local, county, or														
community govt.	100.0	97.1	60.5	8.5	0.4	0.6	27.0	2.5	0.7	1.6	0.3	0.4	0.2	0.2
State government	100.0	85.9	44.1	5.6	2.5	0.6	33.1	6.5	2.6	3.2	0.7	7.6	1.8	5.8
Federal government	100.0	94.9	64.1	6.2	0.2	0.7	23.8	4.1	1.2	2.8	0.1	1.0	0.5	0.5
Dept. of Veterans Affairs	100.0	94.6	62.9	6.3	0.1	0.8	24.6	4.4	1.3	3.1	0.1	1.0	0.4	0.6
Dept. of Defense	100.0	97.5	86.7	8.3	1.5	0.2	0.7	1.4	1.1	0.3	*	1.1	1.0	0.1
Indian Health Service	100.0	92.2	88.8			0.6	2.8	7.8	1.8	6.0				
Other	100.0	100.0	32.0	1.8			66.2							
Tribal government	100.0	97.6	66.9	10.5	0.7	1.2	18.4	2.3	0.8	1.5	*	0.1	*	*

⁻⁻ Quantity is zero; * Less than 0.05 percent.

NOTES: Percentages may not sum to 100 percent because of rounding. Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 5.1c. Clients in treatment, by type of care received and facility operation: Column percent distribution, March 31, 2020

							Type of care	received						
					Outpatie	nt			Resider	ntial (non-h	ospital)		Hospital	inpatient
Facility operation	Total	Total out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Total residential	Short- term	Long- term	Detox	Total hospital inpatient	Treat- ment	Detox
Facility operation														
Private non-profit	46.3	45.4	58.1	54.7	34.1	20.2	31.8	66.4	53.5	78.7	39.4	24.5	22.6	26.7
Private for-profit	44.5	45.4	29.1	36.4	60.4	74.6	62.3	27.2	40.5	14.5	55.1	56.5	66.8	44.7
Local, county, or														
community govt.	3.6	3.8	5.2	4.1	1.2	1.9	2.4	1.7	1.3	1.9	2.3	1.4	1.5	1.4
State government	1.8	1.6	1.9	1.3	3.5	8.0	1.4	2.2	2.5	1.9	2.7	14.6	6.5	23.9
Federal government	2.8	2.8	4.3	2.3	0.4	1.6	1.6	2.1	1.8	2.6	0.4	2.9	2.6	3.2
Dept. of Veterans Affairs	2.5	2.5	3.7	2.0	0.1	1.5	1.5	2.0	1.7	2.5	0.4	2.6	2.2	3.1
Dept. of Defense	0.2	0.2	0.4	0.2	0.2	*	*	0.1	0.1	*	*	0.3	0.4	0.1
Indian Health Service	*	*	0.1			*	*	0.1	*	0.1				
Other	0.1	0.1	0.1	*			0.1							
Tribal government	1.0	1.0	1.5	1.3	0.5	1.0	0.4	0.4	0.4	0.5	0.1	0.1	0.1	0.1
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

^{- -} Quantity is zero; * Less than 0.05 percent.

NOTES: Percentages may not sum to 100 percent because of rounding. Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 5.2. Clients in treatment and clients receiving buprenorphine, naltrexone, or methadone at Federally Qualified Health Centers providing substance use treatment: Number and percent, March 31, 2020

Time of come received	Federally Qualified	Health Center clients
Type of care received	Number of clients	Percent of all clients
Total	115,868	100.0
Type of care received		
Outpatient	111,276	96.0
Regular	51,672	44.6
Intensive	8,027	6.9
Detoxification	3,210	2.8
Day treatment/partial hospitalization	833	0.7
Methadone/buprenorphine maintenance		
or naltrexone treatment	47,534	41.0
Residential (non-hospital)	4,175	3.6
Detoxification	396	0.3
Short-term treatment (30 days or fewer)	1,099	0.9
Long-term treatment (more than 30 days)	2,680	2.3
Hospital inpatient	417	0.4
Detoxification	260	0.2
Treatment	157	0.1
Clients receiving buprenorphine or		
naltrexone		
Clients receiving buprenorphine	19,132	16.2
Clients receiving naltrexone	2,909	2.4
Clients receiving methadone (OTP facilities only)		
Clients receiving methadone	33,957	29.1

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 5.3. Clients in treatment at Veterans Affairs facilities identified as being at high suicide risk, by type of care:

Number and column percent distribution, March 31, 2020

Type of eare received		High suicide risk clients	in Veterans Affairs facilities
Type of care received		Number of clients	Column percent distribution of clients
	Total	2,598	100.0
Outpatient		2,325	89.5
Residential (non-hospital)		187	7.2
Inpatient hospital		86	3.3

Table 5.4. Clients in treatment, according to substance abuse problem and diagnosed co-occurring mental and substance use disorders, by facility operation: Number and row percent distribution, March 31, 2020

Facility operation		٨	lumber of clier		e abuse pr Row	oblem v percent disti	ribution of c	lients		Diagnos occurring m substan disore	nental and ce use
racinty operation	Total¹	Both alcohol and drug abuse	Drug abuse only	Alcohol abuse only	Total	Both alcohol and drug abuse	Drug abuse only	Alcohol abuse only	Total ²	Number of clients	Percent
Total	1,049,758	333,526	569,522	146,710	100.0	31.8	54.3	14.0	930,672	531,105	57.1
Facility operation											
Private non-profit	478,490	177,341	222,923	78,226	100.0	37.1	46.6	16.3	448,900	262,032	58.4
Private for-profit	474,126	119,100	308,809	46,217	100.0	25.1	65.1	9.7	390,389	217,322	55.7
Local, county, or community govt.	39,123	14,200	18,222	6,701	100.0	36.3	46.6	17.1	36,665	18,108	49.4
State government	19,506	5,924	10,263	3,318	100.0	30.4	52.6	17.0	18,141	8,852	48.8
Federal government	28,219	11,960	6,261	9,998	100.0	42.4	22.2	35.4	27,744	20,333	73.3
Dept. of Veterans Affairs	24,464	10,894	5,618	7,952	100.0	44.5	23.0	32.5	24,148	18,500	76.6
Dept. of Defense	2,278	473	197	1,608	100.0	20.7	8.7	70.6	2,119	979	46.2
Indian Health Service	493	241	139	114	100.0	48.8	28.1	23.1	493	317	64.4
Other	984	352	307	324	100.0	35.8	31.2	33.0	984	536	54.4
Tribal government	10,294	5,001	3,044	2,249	100.0	48.6	29.6	21.9	8,833	4,459	50.5

¹ Of 1,090,357 clients, 40,599 clients (4 percent) reported by the 632 facilities that did not respond to the substance abuse problem question (Question 34) were excluded.

² Of 1,090,357 clients, 60,369 clients (6 percent) reported by the 727 facilities that did not respond to the co-occurring disorders question (Question 35) and 99,316 clients (9 percent) reported by the 908 facilities that did respond to the co-occurring disorders question, but which reported no clients with a mental disorder, were excluded.

NOTE: Numbers and percentages may not sum to totals because of rounding.

Table 5.5. Clients under the age of 18 years in treatment, by type of care received and facility operation: Number and row percent distribution, March 31, 2020

	Numb	per of clients und	der the age of 18	years	Row percent	distribution of cl	ients under the ag	e of 18 years
		Ту	pe of care receive	ed		Ty	pe of care receive	ed
Facility operation	Total	Outpatient	Residential (non-hospital)	Hospital inpatient	Total	Outpatient	Residential (non-hospital)	Hospital inpatient
Total	39,271	35,612	3,197	462	100.0	90.7	8.1	1.2
Facility operation								
Private non-profit	24,049	22,423	1,580	46	100.0	93.2	6.6	0.2
Private for-profit	11,302	9,465	1,425	412	100.0	83.7	12.6	3.6
Local, county, or community govt.	1,881	1,873	4	4	100.0	99.6	0.2	0.2
State government	666	566	100		100.0	85.0	15.0	
Federal government	127	98	29		100.0	77.2	22.8	
Dept. of Veterans Affairs	‡	‡	‡	‡	‡	‡	‡	‡
Dept. of Defense	10	10			100.0	100.0		
Indian Health Service	117	88	29		100.0	75.2	24.8	
Other	‡	‡	‡	‡	‡	‡	‡	‡
Tribal government	1,246	1,187	59		100.0	95.3	4.7	

⁻⁻ Quantity is zero; ‡ No facilities in this category.

NOTE: Percentages may not sum to 100 percent because of rounding.

Table 5.6a. Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by facility operation: Number, March 31, 2020

	All clients n	eceiving medica	tion-assisted c	pioid therapy		OTP (clients		I	Non-OTP client	ts
Facility operation	Any MAT type¹	Methadone	Buprenor- phine	Naltrexone	Any MAT type¹	Methadone	Buprenor- phine	Naltrexone	Any MAT type²	Buprenor- phine	Naltrexone
Total	509,008	311,531	176,152	21,325	347,223	311,531	31,864	3,828	161,785	144,288	17,497
Facility operation											
Private non-profit	163,702	103,707	50,978	9,017	112,850	103,707	8,565	578	50,852	42,413	8,439
Private for-profit	314,328	191,625	113,040	9,663	214,598	191,625	20,295	2,678	99,730	92,745	6,985
Local, county, or community govt.	11,564	7,121	3,647	796	8,084	7,121	926	37	3,480	2,721	759
State government	8,014	6,312	1,470	232	6,756	6,312	395	49	1,258	1,075	183
Federal government	9,156	1,735	5,966	1,455	3,438	1,735	1,228	475	5,718	4,738	980
Dept. of Veterans Affairs	8,366	1,735	5,291	1,340	3,438	1,735	1,228	475	4,928	4,063	865
Dept. of Defense	22		17	5					22	17	5
Indian Health Service	17		7	10					17	7	10
Other	751		651	100					751	651	100
Tribal government	2,244	1,031	1,051	162	1,497	1,031	455	11	747	596	151

⁻⁻ Quantity is zero.

MAT = medication assisted treatment.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

¹ Includes clients receiving methadone, buprenorphine, or naltrexone.

² Includes clients receiving buprenorphine or naltrexone.

Table 5.6b. Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by facility operation: Column percent distribution, March 31, 2020

	All clients r	receiving medica	tion-assisted o	opioid therapy		OTP	clients		1	Non-OTP client	's
Facility operation	Any MAT type¹	Methadone	Buprenor- phine	Naltrexone	Any MAT type¹	Methadone	Buprenor- phine	Naltrexone	Any MAT type²	Buprenor- phine	Naltrexone
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Facility operation											
Private non-profit	32.2	33.3	28.9	42.3	32.5	33.3	26.9	15.1	31.4	29.4	48.2
Private for-profit	61.8	61.5	64.2	45.3	61.8	61.5	63.7	70.0	61.6	64.3	39.9
Local, county, or community govt.	2.3	2.3	2.1	3.7	2.3	2.3	2.9	1.0	2.2	1.9	4.3
State government	1.6	2.0	0.8	1.1	1.9	2.0	1.2	1.3	0.8	0.7	1.0
Federal government	1.8	0.6	3.4	6.8	1.0	0.6	3.9	12.4	3.5	3.3	5.6
Dept. of Veterans Affairs	1.6	0.6	3.0	6.3	1.0	0.6	3.9	12.4	3.0	2.8	4.9
Dept. of Defense	*		*						*	*	
Indian Health Service	*		*	*					*	*	0.1
Other	0.1		0.4	0.5					0.5	0.5	0.6
Tribal government	0.4	0.3	0.6	0.8	0.4	0.3	1.4	0.3	0.5	0.4	0.9

⁻⁻ Quantity is zero; * Less than 0.05 percent.

MAT = medication assisted treatment.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility. Percentages may not sum to 100 percent due to rounding.

¹ Includes clients receiving methadone, buprenorphine, or naltrexone.

² Includes clients receiving buprenorphine or naltrexone.

Table 5.7. Clients receiving medications for alcohol use disorder, by type of care received: Number and row percent distribution, March 31, 2020

		Numbe	er of clients			Row percent	distribution of clients	
Medications for alcohol use disorder		7	ype of care received	d			Type of care received	d
	Total	Outpatient	Residential (non-hospital)	Hospital inpatient	Total	Outpatient	Residential (non-hospital)	Hospital inpatient
Disulfiram (Antabuse [®])	3,810	3,365	216	229	100.0	88.3	5.7	6.0
Naltrexone	20,050	17,475	1,861	714	100.0	87.2	9.3	3.6
Acamprosate (Campral [®])	4,142	3,343	541	258	100.0	80.7	13.1	6.2

Table 6.1. N-SSATS facilities, by status, response rate, mode of response, and state or jurisdiction: Number and row percent, 2020

State or jurisdiction ¹				Elig	iible				Mode of re (row percent	,	
State of jurisdiction		Total facilities in survey	Closed/ ineligible²	Total eligible	Total respondents	Response rate ³ (row percent)	Total included in report⁴	Total	Internet	Mail	Telephone
	Total	19,926	1,742	18,184	16,394	90.2	16,066	100.0	95.2	0.7	4.1
Alabama		192	24	168	156	92.9	155	100.0	92.9		7.1
Alaska		114	8	106	105	99.1	105	100.0	99.0		1.0
Arizona		583	71	512	454	88.7	447	100.0	92.8	2.9	4.3
Arkansas		207	27	180	174	96.7	171	100.0	94.2	0.6	5.3
California		2,350	256	2,094	1,796	85.8	1,734	100.0	94.6	0.3	5.0
Colorado		517	53	464	397	85.6	393	100.0	96.7	0.8	2.5
Connecticut		252	17	235	213	90.6	210	100.0	98.6	0.5	1.0
Delaware		69	5	64	58	90.6	49	100.0	98.0	2.0	
District of Columbia		34	1	33	29	87.9	28	100.0	96.4	3.6	
Florida		939	113	826	736	89.1	712	100.0	94.4	0.6	5.1
Georgia		427	29	398	354	88.9	348	100.0	95.1	0.3	4.6
Hawaii		182	16	166	161	97.0	161	100.0	98.1	0.6	1.2
Idaho		174	38	136	118	86.8	110	100.0	93.6	2.7	3.6
Illinois		891	103	788	736	93.4	713	100.0	95.7	0.7	3.6
Indiana		520	56	464	423	91.2	416	100.0	96.2	1.2	2.6
lowa		219	27	192	185	96.4	185	100.0	98.4		1.6
Kansas		199	18	181	171	94.5	170	100.0	94.7	0.6	4.7
Kentucky		595	50	545	486	89.2	477	100.0	95.2	0.6	4.2
Louisiana		178	10	168	157	93.5	155	100.0	92.3	0.6	7.1
Maine		273	40	233	199	85.4	196	100.0	93.4	1.0	5.6
Maryland		547	41	506	439	86.8	432	100.0	95.6	0.7	3.7
Massachusetts		596	92	504	452	89.7	440	100.0	97.5	0.5	2.0
Michigan		534	34	500	460	92.0	455	100.0	95.8	0.7	3.5
Minnesota		480	34	446	405	90.8	401	100.0	94.3	2.0	3.7
Mississippi		125	12	113	106	93.8	105	100.0	96.2	1.0	2.9
Missouri		323	22	301	279	92.7	278	100.0	97.8		2.2
Montana		162	14	148	130	87.8	129	100.0	90.7	0.8	8.5
Nebraska		137	8	129	124	96.1	123	100.0	93.5		6.5
Nevada		142	20	122	110	90.2	109	100.0	91.7	0.9	7.3
New Hampshire		133	5	128	116	90.6	109	100.0	99.1		0.9

Table 6.1. N-SSATS facilities, by status, response rate, mode of response, and state or jurisdiction: Number and row percent, 2020 (continued)

0			Elig	rible				Mode of re (row percent	,	
State or jurisdiction ¹	Total facilities in survey	Closed/ ineligible²	Total eligible	Total respondents	Response rate ³ (row percent)	Total included in report⁴	Total	Internet	Mail	Telephone
New Jersey	443	19	424	388	91.5	383	100.0	95.0	0.5	4.4
New Mexico	204	21	183	164	89.6	162	100.0	97.5		2.5
New York	1,057	78	979	911	93.1	894	100.0	94.0	0.6	5.5
North Carolina	773	53	720	623	86.5	611	100.0	93.3	0.2	6.5
North Dakota	106	8	98	91	92.9	87	100.0	97.7		2.3
Ohio	725	38	687	625	91.0	619	100.0	94.7	1.0	4.4
Oklahoma	242	19	223	202	90.6	195	100.0	96.4	0.5	3.1
Oregon	291	18	273	250	91.6	247	100.0	95.1	1.2	3.6
Pennsylvania	687	40	647	605	93.5	604	100.0	96.9	0.5	2.6
Puerto Rico	130	9	121	105	86.8	101	100.0	91.1	1.0	7.9
Rhode Island	89	17	72	63	87.5	63	100.0	93.7		6.3
South Carolina	136	6	130	126	96.9	124	100.0	92.7	1.6	5.6
South Dakota	66	1	65	58	89.2	58	100.0	94.8	1.7	3.4
Tennessee	357	24	333	317	95.2	311	100.0	96.1		3.9
Texas	616	39	577	519	89.9	509	100.0	94.9		5.1
Utah	383	33	350	339	96.9	333	100.0	97.0	0.6	2.4
Vermont	61		61	56	91.8	52	100.0	98.1		1.9
Virginia	310	15	295	256	86.8	249	100.0	96.4	1.2	2.4
Washington	556	31	525	461	87.8	457	100.0	96.3	0.9	2.8
West Virginia	156	10	146	133	91.1	126	100.0	96.8		3.2
Wisconsin	357	9	348	302	86.8	295	100.0	94.6	1.4	4.1
Wyoming	74	10	64	60	93.8	60	100.0	98.3		1.7
Other jurisdictions ⁶	13		13	11	84.6	10	100.0	80.0		20.0

⁻⁻ Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² A facility was ineligible if it had closed or was not providing substance abuse treatment or detoxification.

³ Response rate calculated as total respondents divided by total eligible.

⁴ Of 16,394 total respondents, this report excludes 249 facilities deemed out of scope for this report (158 non-treatment halfway houses, 62 solo practices not approved by the state agency for inclusion, and 29 facilities that treated incarcerated clients only). See Chapter 1 for details.

⁵ Mode of response for the 16,066 facilities included in the report.

⁶ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTE: Percentages may not sum to 100 percent because of rounding.

Table 6.2a. Facilities and clients in treatment, by state or jurisdiction: Number, 2011–2020

State or jurisdiction ¹			Number o	of facilities					Number	of clients		
State of jurisdiction	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Total	13,720	14,148	13,873	13,585	15,961	16,066	1,224,127	1,249,629	1,305,647	1,356,015	1,460,706	1,090,357
Alabama	147	154	139	129	153	155	15,924	15,089	14,548	13,771	14,578	11,838
Alaska	76	93	88	89	96	105	2,840	3,900	3,363	3,556	9,477	3,213
Arizona	219	313	341	341	446	447	31,514	31,832	33,978	41,929	79,399	44,825
Arkansas	61	89	76	118	167	171	3,401	5,927	7,154	6,089	7,640	4,464
California	1,639	1,551	1,399	1,311	1,797	1,734	132,562	117,159	111,961	118,607	96,960	70,034
Colorado	448	488	403	381	408	393	38,927	42,256	34,793	32,213	52,388	30,083
Connecticut	188	212	215	210	220	210	25,914	33,267	37,817	41,873	43,404	23,433
Delaware	37	42	38	34	44	49	4,607	5,278	10,327	7,738	17,307	12,796
District of Columbia	36	37	33	27	26	28	4,166	3,833	2,824	2,763	1,827	1,761
Florida	617	622	669	668	725	712	51,201	53,641	63,287	62,427	57,335	45,620
Georgia	249	360	322	292	358	348	21,804	24,003	25,379	25,466	23,465	17,642
Hawaii	119	123	169	168	167	161	4,464	5,205	5,768	4,922	5,217	3,354
Idaho	103	117	132	124	124	110	5,171	6,619	6,287	7,026	5,634	3,891
Illinois	638	650	654	633	775	713	43,971	42,945	44,616	44,265	50,948	40,978
Indiana	274	275	263	305	393	416	25,186	28,288	25,465	33,301	37,077	43,865
Iowa	126	144	151	163	187	185	8,977	9,731	8,975	11,631	8,838	8,013
Kansas	220	210	208	182	179	170	11,381	10,863	11,471	10,710	10,492	6,387
Kentucky	318	328	334	359	449	477	20,481	24,071	23,565	29,228	28,452	27,353
Louisiana	143	166	159	136	146	155	11,180	9,903	12,011	10,066	10,633	8,638
Maine	213	222	208	199	186	196	10,769	11,373	10,849	11,801	14,550	10,299
Maryland	349	360	382	387	431	432	38,792	42,128	46,913	48,654	52,759	35,115
Massachusetts	322	316	321	351	438	440	46,891	44,133	45,438	58,280	66,912	52,270
Michigan	494	489	463	456	467	455	45,147	47,749	46,781	54,064	47,072	27,127
Minnesota	315	354	352	356	403	401	17,354	18,034	19,235	25,993	20,779	15,899
Mississippi	98	101	99	89	110	105	5,807	6,726	4,699	4,164	6,179	4,032
Missouri	289	258	265	257	281	278	21,455	23,028	25,015	21,914	19,996	12,401
Montana	57	72	66	70	88	129	9,885	4,429	5,064	5,762	4,537	4,976
Nebraska	123	114	132	125	131	123	6,354	6,374	5,735	6,461	5,868	3,554

Table 6.2a. Facilities and clients in treatment, by state or jurisdiction: Number, 2011–2020 (continued)

State or jurisdiction ¹			Number o	f facilities					Number	of clients		
State or jurisdiction	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Nevada	82	81	79	77	106	109	7,218	7,048	6,930	5,903	7,249	11,573
New Hampshire	54	55	58	67	80	109	5,931	6,702	8,164	8,631	6,473	9,576
New Jersey	361	372	377	344	370	383	31,777	36,605	36,708	35,659	38,326	26,198
New Mexico	145	139	159	136	166	162	12,664	12,868	15,062	18,808	18,111	16,133
New York	942	905	901	842	925	894	122,929	114,660	113,713	110,078	113,028	81,275
North Carolina	436	433	440	472	552	611	36,312	40,575	42,026	49,179	49,520	35,874
North Dakota	58	65	64	71	85	87	2,457	1,785	2,404	2,781	3,754	2,599
Ohio	373	378	370	409	554	619	37,238	37,262	45,129	56,197	66,296	69,478
Oklahoma	197	223	208	191	208	195	14,858	16,700	16,783	14,466	23,332	16,313
Oregon	235	246	237	226	234	247	23,166	21,898	30,401	24,027	20,268	20,264
Pennsylvania	578	539	523	502	600	604	53,377	57,715	59,584	64,303	66,969	45,588
Puerto Rico	152	161	146	97	97	101	16,166	15,169	11,358	9,232	6,312	5,938
Rhode Island	59	62	47	48	59	63	9,742	10,404	14,269	8,001	8,609	5,435
South Carolina	105	111	109	108	121	124	14,217	15,824	18,236	16,844	20,539	14,152
South Dakota	58	63	70	58	59	58	2,987	3,267	2,964	2,941	2,864	2,371
Tennessee	208	221	227	217	313	311	16,590	14,149	22,445	16,765	28,899	18,865
Texas	475	461	442	431	512	509	36,875	34,704	35,293	35,474	35,995	27,078
Utah	145	171	184	239	310	333	12,470	12,586	12,496	14,326	29,186	13,218
Vermont	42	44	44	42	48	52	4,182	5,230	7,380	7,015	6,055	7,098
Virginia	213	226	230	223	254	249	21,731	22,838	22,305	22,413	25,609	18,878
Washington	453	451	418	396	452	457	41,097	42,030	50,633	43,846	44,959	33,999
West Virginia	96	101	103	102	116	126	10,711	10,057	10,099	18,115	10,109	10,898
Wisconsin	265	318	288	273	276	295	19,413	28,657	24,371	22,628	25,574	19,740
Wyoming	60	53	59	47	57	60	3,396	2,798	3,261	3,236	2,499	3,802
Other jurisdictions ²	10	9	9	7	12	10	498	314	315	473	448	153

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States

NOTE: Survey reference dates were: March 31 for 2011, 2015, 2017, and 2020; and March 29 for 2013 and 2019. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time.

Table 6.2b. Facilities and clients in treatment, by state or jurisdiction: Column percent distribution, 2011–2020

State or jurisdiction1		Colu	ımn percent dis	tribution of faci	lities			Col	umn percent di	stribution of cli	ents	
State or jurisdiction ¹ -	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Alabama	1.1	1.1	1.0	0.9	1.0	1.0	1.3	1.2	1.1	1.0	1.0	1.1
Alaska	0.6	0.7	0.6	0.7	0.6	0.7	0.2	0.3	0.3	0.3	0.6	0.3
Arizona	1.6	2.2	2.5	2.5	2.8	2.8	2.6	2.5	2.6	3.1	5.4	4.1
Arkansas	0.4	0.6	0.5	0.9	1.0	1.1	0.3	0.5	0.5	0.4	0.5	0.4
California	11.9	11.0	10.1	9.7	11.3	10.8	10.8	9.4	8.6	8.7	6.6	6.4
Colorado	3.3	3.4	2.9	2.8	2.6	2.4	3.2	3.4	2.7	2.4	3.6	2.8
Connecticut	1.4	1.5	1.5	1.5	1.4	1.3	2.1	2.7	2.9	3.1	3.0	2.1
Delaware	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.8	0.6	1.2	1.2
District of Columbia	0.3	0.3	0.2	0.2	0.2	0.2	0.3	0.3	0.2	0.2	0.1	0.2
Florida	4.5	4.4	4.8	4.9	4.5	4.4	4.2	4.3	4.8	4.6	3.9	4.2
Georgia	1.8	2.5	2.3	2.1	2.2	2.2	1.8	1.9	1.9	1.9	1.6	1.6
Hawaii	0.9	0.9	1.2	1.2	1.0	1.0	0.4	0.4	0.4	0.4	0.4	0.3
Idaho	0.8	0.8	1.0	0.9	0.8	0.7	0.4	0.5	0.5	0.5	0.4	0.4
Illinois	4.7	4.6	4.7	4.7	4.9	4.4	3.6	3.4	3.4	3.3	3.5	3.8
Indiana	2.0	1.9	1.9	2.2	2.5	2.6	2.1	2.3	2.0	2.5	2.5	4.0
Iowa	0.9	1.0	1.1	1.2	1.2	1.2	0.7	0.8	0.7	0.9	0.6	0.7
Kansas	1.6	1.5	1.5	1.3	1.1	1.1	0.9	0.9	0.9	0.8	0.7	0.6
Kentucky	2.3	2.3	2.4	2.6	2.8	3.0	1.7	1.9	1.8	2.2	1.9	2.5
Louisiana	1.0	1.2	1.1	1.0	0.9	1.0	0.9	0.8	0.9	0.7	0.7	0.8
Maine	1.6	1.6	1.5	1.5	1.2	1.2	0.9	0.9	0.8	0.9	1.0	0.9
Maryland	2.5	2.5	2.8	2.8	2.7	2.7	3.2	3.4	3.6	3.6	3.6	3.2
Massachusetts	2.3	2.2	2.3	2.6	2.7	2.7	3.8	3.5	3.5	4.3	4.6	4.8
Michigan	3.6	3.5	3.3	3.4	2.9	2.8	3.7	3.8	3.6	4.0	3.2	2.5
Minnesota	2.3	2.5	2.5	2.6	2.5	2.5	1.4	1.4	1.5	1.9	1.4	1.5
Mississippi	0.7	0.7	0.7	0.7	0.7	0.7	0.5	0.5	0.4	0.3	0.4	0.4
Missouri	2.1	1.8	1.9	1.9	1.8	1.7	1.8	1.8	1.9	1.6	1.4	1.1
Montana	0.4	0.5	0.5	0.5	0.6	8.0	0.8	0.4	0.4	0.4	0.3	0.5
Nebraska	0.9	0.8	1.0	0.9	0.8	0.8	0.5	0.5	0.4	0.5	0.4	0.3

Table 6.2b. Facilities and clients in treatment, by state or jurisdiction: Column percent distribution, 2011–2020 (continued)

State or jurisdiction1		Colu	mn percent dis	tribution of faci	lities			Col	umn percent di	stribution of clie	ents	
State or jurisdiction ¹	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Nevada	0.6	0.6	0.6	0.6	0.7	0.7	0.6	0.6	0.5	0.4	0.5	1.1
New Hampshire	0.4	0.4	0.4	0.5	0.5	0.7	0.5	0.5	0.6	0.6	0.4	0.9
New Jersey	2.6	2.6	2.7	2.5	2.3	2.4	2.6	2.9	2.8	2.6	2.6	2.4
New Mexico	1.1	1.0	1.1	1.0	1.0	1.0	1.0	1.0	1.2	1.4	1.2	1.5
New York	6.9	6.4	6.5	6.2	5.8	5.6	10.0	9.2	8.7	8.1	7.7	7.5
North Carolina	3.2	3.1	3.2	3.5	3.5	3.8	3.0	3.2	3.2	3.6	3.4	3.3
North Dakota	0.4	0.5	0.5	0.5	0.5	0.5	0.2	0.1	0.2	0.2	0.3	0.2
Ohio	2.7	2.7	2.7	3.0	3.5	3.9	3.0	3.0	3.5	4.1	4.5	6.4
Oklahoma	1.4	1.6	1.5	1.4	1.3	1.2	1.2	1.3	1.3	1.1	1.6	1.5
Oregon	1.7	1.7	1.7	1.7	1.5	1.5	1.9	1.8	2.3	1.8	1.4	1.9
Pennsylvania	4.2	3.8	3.8	3.7	3.8	3.8	4.4	4.6	4.6	4.7	4.6	4.2
Puerto Rico	1.1	1.1	1.1	0.7	0.6	0.6	1.3	1.2	0.9	0.7	0.4	0.5
Rhode Island	0.4	0.4	0.3	0.4	0.4	0.4	0.8	0.8	1.1	0.6	0.6	0.5
South Carolina	0.8	0.8	0.8	0.8	8.0	8.0	1.2	1.3	1.4	1.2	1.4	1.3
South Dakota	0.4	0.4	0.5	0.4	0.4	0.4	0.2	0.3	0.2	0.2	0.2	0.2
Tennessee	1.5	1.6	1.6	1.6	2.0	1.9	1.4	1.1	1.7	1.2	2.0	1.7
Texas	3.5	3.3	3.2	3.2	3.2	3.2	3.0	2.8	2.7	2.6	2.5	2.5
Utah	1.1	1.2	1.3	1.8	1.9	2.1	1.0	1.0	1.0	1.1	2.0	1.2
Vermont	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.6	0.5	0.4	0.7
Virginia	1.6	1.6	1.7	1.6	1.6	1.5	1.8	1.8	1.7	1.7	1.8	1.7
Washington	3.3	3.2	3.0	2.9	2.8	2.8	3.4	3.4	3.9	3.2	3.1	3.1
West Virginia	0.7	0.7	0.7	0.8	0.7	0.8	0.9	0.8	0.8	1.3	0.7	1.0
Wisconsin	1.9	2.2	2.1	2.0	1.7	1.8	1.6	2.3	1.9	1.7	1.8	1.8
Wyoming	0.4	0.4	0.4	0.3	0.4	0.4	0.3	0.2	0.2	0.2	0.2	0.3
Other jurisdictions ²	0.1	0.1	0.1	0.1	0.1	0.1	*	*	*	*	*	*

^{*} Less than 0.05 percent.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTE: Survey reference dates were: March 31 for 2011, 2015, 2017, and 2020; and March 29 for 2013 and 2019. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time.

Table 6.3a. Clients under the age of 18 years in treatment, and clients under the age of 18 years in facilities offering special programs or groups for adolescents, by state or jurisdiction: Number, 2011–2020

State or		Number	of clients und	er the age of	18 years²		Number		-	18 years² in fa ps for adoleso		g special
jurisdiction¹	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Total	82,532	78,156	72,977	62,862	59,854	39,271	65,918	65,276	54,650	46,253	43,996	27,944
Alabama	787	540	387	447	284	171	586	512	351	436	254	171
Alaska	294	268	279	253	183	161	275	240	206	207	172	99
Arizona	1,702	2,300	3,320	2,206	4,052	2,043	1,143	2,033	2,487	1,722	2,421	1,302
Arkansas	125	1,176	636	457	506	269	109	1,116	610	428	462	164
California	12,798	10,364	6,292	5,013	3,606	2,287	11,818	9,632	5,481	4,745	3,269	2,169
Colorado	2,585	2,129	1,313	1,254	4,475	758	2,261	1,860	1,079	1,079	4,281	488
Connecticut	612	454	795	693	1,291	395	378	399	731	588	1,171	215
Delaware	328	258	237	92	163	7	226	250	232	83	25	7
District of Columbia	76	36	72	61	10	22	61	36	47	61	10	22
Florida	3,720	3,812	3,673	3,660	3,486	1,965	3,115	3,364	2,977	2,278	1,603	984
Georgia	845	1,460	1,144	645	1,209	376	568	1,207	1,025	574	1,039	230
Hawaii	1,361	1,422	1,646	1,337	1,312	494	1,283	1,395	1,624	1,334	1,296	487
Idaho	593	695	665	625	366	163	529	665	499	620	349	163
Illinois	3,434	3,090	2,712	1,945	2,080	856	2,954	2,708	2,198	1,619	1,664	653
Indiana	1,234	1,599	1,064	1,775	1,386	1,992	849	890	603	1,459	1,179	604
Iowa	811	915	723	688	641	438	696	734	552	483	313	274
Kansas	1,221	872	722	802	510	267	975	724	566	475	459	187
Kentucky	1,041	1,502	910	2,416	810	473	721	961	705	1,007	542	271
Louisiana	974	409	414	174	362	392	531	377	332	165	194	306
Maine	703	821	441	450	828	207	470	431	246	233	224	118
Maryland	1,751	1,670	2,094	925	1,160	416	1,606	1,605	1,464	664	1,039	400
Massachusetts	1,312	1,642	1,770	1,470	2,421	2,028	676	1,156	690	659	1,333	515
Michigan	2,956	3,033	3,071	2,491	1,574	715	1,697	1,663	1,315	1,558	562	327
Minnesota	892	1,085	792	801	638	338	833	1,029	739	786	574	250
Mississippi	510	344	486	644	221	31	130	201	274	328	174	27
Missouri	1,150	1,021	2,295	1,224	730	245	985	854	777	1,108	321	212
Montana	418	371	446	228	249	297	399	339	431	206	226	281
Nebraska	815	767	945	537	239	780	669	627	832	309	162	375

Table 6.3a. Clients under the age of 18 years in treatment, and clients under the age of 18 years in facilities offering special programs or groups for adolescents, by state or jurisdiction: Number, 2011–2020 (continued)

State or		Number	of clients unde	er the age of 1	8 years²	-	Number			18 years² in fa os for adolesc		g special
jurisdiction¹	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Nevada	529	430	544	202	244	2,142	383	394	473	172	227	2,141
New Hampshire	441	409	124	60	113	107	126	58	77	50	104	10
New Jersey	1,921	1,903	1,408	1,036	1,032	814	1,643	1,626	1,254	991	952	723
New Mexico	987	911	1,080	1,199	1,154	1,292	648	680	721	848	607	1,070
New York	4,826	3,926	3,884	2,708	1,884	1,363	4,199	3,568	3,237	2,211	1,645	1,117
North Carolina	2,008	2,012	1,476	2,329	1,498	2,183	1,622	1,597	933	826	1,069	1,170
North Dakota	259	167	120	135	180	158	218	123	111	113	129	152
Ohio	3,342	2,997	3,131	3,371	4,453	3,162	2,799	2,561	2,713	2,361	2,922	1,986
Oklahoma	1,573	1,347	1,393	833	1,418	981	1,346	1,091	1,097	650	1,004	928
Oregon	1,653	1,514	2,561	977	1,060	841	1,468	1,421	1,268	800	1,001	667
Pennsylvania	2,897	2,586	2,389	1,944	2,495	906	2,332	2,151	1,841	1,566	1,537	768
Puerto Rico	2,174	680	1,074	1,097	271	30	672	680	261	221	89	28
Rhode Island	1,006	252	148	51	24	13	940	240	89	19	10	3
South Carolina	1,480	1,161	1,747	1,594	1,946	823	997	1,068	1,572	1,387	1,793	758
South Dakota	430	440	456	301	186	195	318	363	386	260	176	190
Tennessee	958	1,153	1,668	788	1,214	1,094	763	672	749	676	517	1,054
Texas	2,591	2,954	2,739	1,727	1,126	1,216	2,306	2,886	2,643	1,684	1,102	1,182
Utah	1,511	1,326	1,201	1,366	1,058	686	1,311	1,222	1,104	1,220	883	639
Vermont	330	350	310	362	71	24	292	308	267	335	67	24
Virginia	1,629	1,595	1,590	1,784	554	364	1,052	826	1,366	1,309	364	164
Virginia	3,170	3,707	2,563	2,386	1,777	1,209	2,920	3,523	2,195	2,235	1,688	1,162
West Virginia	343	449	699	1,447	201	175	161	276	439	254	179	94
Wisconsin	1,156	1,535	1,070	1,588	959	664	659	725	558	610	505	466
Wyoming	197	256	223	193	134	147	128	168	188	192	98	109
Other jurisdictions ³	73	41	35	71	10	96	72	41	35	49	10	38

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

NOTE: Survey reference dates were: March 31 for 2011, 2015, 2017, and 2020; and March 29 for 2013 and 2019. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time.

² Excludes clients in facilities that did not respond to the question about clients under the age of 18 years (in 2009, 346 total clients reported by five facilities; in 2011, 1,417 total clients reported by nine facilities; in 2013, 2,520 clients reported by 19 facilities; in 2015, 41 clients reported by one facility; in 2017, 62 clients reported by two facilities; in 2019, 4,684 clients reported by 37 facilities; and in 2020, all facilities responded to this question, no clients are excluded).

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.3b. Clients under the age of 18 years in treatment, and clients under the age of 18 years in facilities offering special programs or groups for adolescents, by state or jurisdiction: Percent, 2011–2020

State or	-	Percent	of clients unde	er the age of 1	18 years²	-	Percent	of clients unde prog	_	18 years² in fa os for adolesc		g special
jurisdiction¹	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Total	6.7	6.3	5.6	4.6	4.1	3.6	79.9	83.5	74.9	73.6	73.5	71.2
Alabama	4.9	3.6	2.7	3.2	1.9	1.4	74.5	94.8	90.7	97.5	89.4	100.0
Alaska	10.4	6.9	8.3	7.1	1.9	5.0	93.5	89.6	73.8	81.8	94.0	61.5
Arizona	5.4	7.2	9.8	5.3	5.1	4.6	67.2	88.4	74.9	78.1	59.7	63.7
Arkansas	3.7	19.8	8.9	7.5	6.6	6.0	87.2	94.9	95.9	93.7	91.3	61.0
California	9.7	8.8	5.6	4.2	3.7	3.3	92.3	92.9	87.1	94.7	90.7	94.8
Colorado	6.6	5.0	3.8	3.9	8.5	2.5	87.5	87.4	82.2	86.0	95.7	64.4
Connecticut	2.4	1.4	2.1	1.7	3.0	1.7	61.8	87.9	91.9	84.8	90.7	54.4
Delaware	7.1	4.9	2.3	1.2	0.9	0.1	68.9	96.9	97.9	90.2	15.3	100.0
District of Columbia	1.8	0.9	2.5	2.2	0.5	1.2	80.3	100.0	65.3	100.0	100.0	100.0
Florida	7.3	7.1	5.8	5.9	6.1	4.3	83.7	88.2	81.1	62.2	46.0	50.1
Georgia	3.9	6.1	4.5	2.5	5.2	2.1	67.2	82.7	89.6	89.0	85.9	61.2
Hawaii	30.5	27.3	28.5	27.2	25.1	14.7	94.3	98.1	98.7	99.8	98.8	98.6
Idaho	11.5	10.5	10.6	8.9	6.5	4.2	89.2	95.7	75.0	99.2	95.4	100.0
Illinois	7.8	7.2	6.1	4.4	4.1	2.1	86.0	87.6	81.0	83.2	80.0	76.3
Indiana	4.9	5.7	4.2	5.3	3.7	4.5	68.8	55.7	56.7	82.2	85.1	30.3
Iowa	9.0	9.4	8.1	5.9	7.3	5.5	85.8	80.2	76.3	70.2	48.8	62.6
Kansas	10.7	8.0	6.3	7.5	4.9	4.2	79.9	83.0	78.4	59.2	90.0	70.0
Kentucky	5.1	6.2	3.9	8.3	2.8	1.7	69.3	64.0	77.5	41.7	66.9	57.3
Louisiana	8.7	4.1	3.4	1.7	3.4	4.5	54.5	92.2	80.2	94.8	53.6	78.1
Maine	6.5	7.2	4.1	3.8	5.7	2.0	66.9	52.5	55.8	51.8	27.1	57.0
Maryland	4.5	4.0	4.5	1.9	2.2	1.2	91.7	96.1	69.9	71.8	89.6	96.2
Massachusetts	2.8	3.7	3.9	2.5	3.6	3.9	51.5	70.4	39.0	44.8	55.1	25.4
Michigan	6.5	6.4	6.6	4.6	3.3	2.6	57.4	54.8	42.8	62.5	35.7	45.7
Minnesota	5.1	6.0	4.1	3.1	3.1	2.1	93.4	94.8	93.3	98.1	90.0	74.0
Mississippi	8.8	5.1	10.3	15.5	3.6	8.0	25.5	58.4	56.4	50.9	78.7	87.1
Missouri	5.4	4.4	9.2	5.6	3.7	2.0	85.7	83.6	33.9	90.5	44.0	86.5
Montana	4.2	8.4	8.8	4.0	5.5	6.0	95.5	91.4	96.6	90.4	90.8	94.6
Nebraska	12.8	12.0	16.5	8.3	4.1	21.9	82.1	81.7	88.0	57.5	67.8	48.1

Table 6.3b. Clients under the age of 18 years in treatment, and clients under the age of 18 years in facilities offering special programs or groups for adolescents, by state or jurisdiction: Percent, 2011–2020 (continued)

State or		Percent	of clients und	er the age of 1	18 years²		Percent	of clients und prog	er the age of grams or group	-		g special
jurisdiction¹	2011	2013	2015	2017	2019	2020	2011	2013	2015	2017	2019	2020
Nevada	7.3	6.1	7.8	3.4	3.4	18.5	72.4	91.6	86.9	85.1	93.0	100.0
New Hampshire	7.4	6.1	1.5	0.7	1.7	1.1	28.6	14.2	62.1	83.3	92.0	9.3
New Jersey	6.0	5.2	3.8	2.9	2.7	3.1	85.5	85.4	89.1	95.7	92.2	88.8
New Mexico	7.8	7.1	7.2	6.4	6.4	8.0	65.7	74.6	66.8	70.7	52.6	82.8
New York	3.9	3.4	3.4	2.5	1.7	1.7	87.0	90.9	83.3	81.6	87.3	82.0
North Carolina	5.5	5.0	3.5	4.7	3.0	6.1	80.8	79.4	63.2	35.5	71.4	53.6
North Dakota	10.5	9.4	5.0	4.9	4.8	6.1	84.2	73.7	92.5	83.7	71.7	96.2
Ohio	9.0	8.0	6.9	6.0	6.7	4.6	83.8	85.5	86.6	70.0	65.6	62.8
Oklahoma	10.6	8.1	8.3	5.8	6.1	6.0	85.6	81.0	78.8	78.0	70.8	94.6
Oregon	7.1	6.9	8.4	4.1	5.2	4.2	88.8	93.9	49.5	81.9	94.4	79.3
Pennsylvania	5.4	4.5	4.0	3.0	3.7	2.0	80.5	83.2	77.1	80.6	61.6	84.8
Puerto Rico	13.4	4.5	9.5	11.9	4.3	0.5	30.9	100.0	24.3	20.1	32.8	93.3
Rhode Island	10.3	2.4	1.0	0.6	0.3	0.2	93.4	95.2	60.1	37.3	41.7	23.1
South Carolina	10.4	7.3	9.6	9.5	9.5	5.8	67.4	92.0	90.0	87.0	92.1	92.1
South Dakota	14.4	13.5	15.4	10.2	6.5	8.2	74.0	82.5	84.6	86.4	94.6	97.4
Tennessee	5.8	8.1	7.4	4.7	4.2	5.8	79.6	58.3	44.9	85.8	42.6	96.3
Texas	7.0	8.5	7.8	4.9	3.1	4.5	89.0	97.7	96.5	97.5	97.9	97.2
Utah	12.1	10.5	9.6	9.5	3.6	5.2	86.8	92.2	91.9	89.3	83.5	93.1
Vermont	7.9	6.7	4.2	5.2	1.2	0.3	88.5	88.0	86.1	92.5	94.4	100.0
Virginia	7.5	7.0	7.1	8.0	2.2	1.9	64.6	51.8	85.9	73.4	65.7	45.1
Virginia	7.7	8.8	5.1	5.4	4.0	3.6	92.1	95.0	85.6	93.7	95.0	96.1
West Virginia	3.2	4.5	6.9	8.0	2.0	1.6	46.9	61.5	62.8	17.6	89.1	53.7
Wisconsin	6.0	5.4	4.4	7.0	3.7	3.4	57.0	47.2	52.1	38.4	52.7	70.2
Wyoming	5.8	9.1	6.8	6.0	5.4	3.9	65.0	65.6	84.3	99.5	73.1	74.1
Other jurisdictions ³	14.7	13.1	11.1	15.0	2.2	62.7	98.6	100.0	100.0	69.0	100.0	39.6

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

NOTE: Survey reference dates were: March 31 for 2011, 2015, 2017, and 2020; and March 29 for 2013 and 2019. See Appendix A for changes in the survey base, methods, and instruments that affect analysis of trends over time.

² Excludes clients in facilities that did not respond to the question about clients under the age of 18 years (in 2009, 346 total clients reported by five facilities; in 2011, 1,417 total clients reported by nine facilities; in 2013, 2,520 clients reported by 19 facilities; in 2015, 41 clients reported by one facility; in 2017, 62 clients reported by two facilities; in 2019, 4,684 clients reported by 37 facilities; and in 2020, all facilities responded to this question, no clients are excluded).

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.4a. Facility operation, by state or jurisdiction: Number, 2020

							Facility	operation /				
State or jurisdiction ¹					Local,				Federa	l govt.		_
		Total	Private non-profit	Private for-profit	county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
	Total	16,066	8,004	6,535	670	285	323	228	57	29	9	249
Alabama		155	91	50	5	4	5	4	1			
Alaska		105	59	15	4	1	7	1	2	4		19
Arizona		447	205	208	5	1	9	3	3	3		19
Arkansas		171	118	46		3	4	4				
California		1,734	777	761	131	8	41	26	6	8	1	16
Colorado		393	152	220	4	9	7	3	3	1		1
Connecticut		210	178	21	1	5	3	2	1			2
Delaware		49	25	23			1	1				
District of Columbia		28	19	6		1	2	1	1			
Florida		712	290	388	15	3	16	14	2			
Georgia		348	101	189	6	43	9	6	2		1	
Hawaii		161	125	32		2	2	1	1			
Idaho		110	11	85	8		2	1	1			4
Illinois		713	408	265	23	10	7	7				
Indiana		416	221	183	5	1	6	5			1	
lowa		185	143	37	1	1	2	2				1
Kansas		170	91	53	20	1	5	3	1	1		
Kentucky		477	221	251	2		3	2	1			
Louisiana		155	37	73	17	20	6	4	2			2
Maine		196	80	108	2		3	1	1		1	3
Maryland		432	129	268	11	17	7	2	4		1	
Massachusetts		440	290	138	2	3	7	5		1	1	
Michigan		455	251	149	31	2	5	5				17
Minnesota		401	163	195	7	3	3	2		1		30
Mississippi		105	55	27	16	4	3	2	1			
Missouri		278	205	63		1	9	7	1		1	
Montana		129	74	38		3	7	5	1	1		7
Nebraska		123	74	29	6	1	5	3	1	1		8

Table 6.4a. Facility operation, by state or jurisdiction: Number, 2020 (continued)

						Facility	∕ operation				
State or jurisdiction ¹				Local,				Federa	al govt.		
·	Total	Private non-profit	Private for-profit	county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Nevada	109	58	38		2	5	2	2	1		6
New Hampshire	109	55	53			1				1	
New Jersey	383	175	191	9	5	3	1	2			
New Mexico	162	85	51	3	4	2			1	1	17
New York	894	643	149	51	33	13	11	2			5
North Carolina	611	218	360	10	9	12	9	3			2
North Dakota	87	25	41	2	12	1	1				6
Ohio	619	397	190	10	4	18	18				
Oklahoma	195	104	40	2	15	5	3	1	1		29
Oregon	247	137	74	23	1	4	3		1		8
Pennsylvania	604	322	273			9	9				
Puerto Rico	101	69	19		12	1	1				
Rhode Island	63	41	19			2	1	1			1
South Carolina	124	43	42	22	13	4	2	2			
South Dakota	58	34	9	1	2	6	4		2		6
Tennessee	311	196	110		1	4	4				
Texas	509	199	257	25	8	19	17	2			1
Utah	333	72	228	28	1	2	1	1			2
Vermont	52	38	11		1	2	2				
Virginia	249	46	103	87	5	8	4	4			
Washington	457	211	186	20	3	6	4	1	1		31
West Virginia	126	91	27	2	2	4	4				
Wisconsin	295	111	130	44	1	4	3		1		5
Wyoming	60	37	12	8		2	2				1
Other jurisdictions ²	10	4	1	1	4						

⁻⁻ Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.4b. Facility operation, by state or jurisdiction: Row percent distribution, 2020

						Facilit	y operation				
State or jurisdiction ¹				Local,				Federa	l govt.		
·	Total	Private non-profit	Private for-profit	county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Total	100.0	49.8	40.7	4.2	1.8	2.0	1.4	0.4	0.2	0.1	1.5
Alabama	100.0	58.7	32.3	3.2	2.6	3.2	2.6	0.6			
Alaska	100.0	56.2	14.3	3.8	1.0	6.7	1.0	1.9	3.8		18.1
Arizona	100.0	45.9	46.5	1.1	0.2	2.0	0.7	0.7	0.7		4.3
Arkansas	100.0	69.0	26.9		1.8	2.3	2.3				
California	100.0	44.8	43.9	7.6	0.5	2.4	1.5	0.3	0.5	0.1	0.9
Colorado	100.0	38.7	56.0	1.0	2.3	1.8	0.8	0.8	0.3		0.3
Connecticut	100.0	84.8	10.0	0.5	2.4	1.4	1.0	0.5			1.0
Delaware	100.0	51.0	46.9			2.0	2.0				
District of Columbia	100.0	67.9	21.4		3.6	7.1	3.6	3.6			
Florida	100.0	40.7	54.5	2.1	0.4	2.2	2.0	0.3			
Georgia	100.0	29.0	54.3	1.7	12.4	2.6	1.7	0.6		0.3	
Hawaii	100.0	77.6	19.9		1.2	1.2	0.6	0.6			
Idaho	100.0	10.0	77.3	7.3		1.8	0.9	0.9			3.6
Illinois	100.0	57.2	37.2	3.2	1.4	1.0	1.0				
Indiana	100.0	53.1	44.0	1.2	0.2	1.4	1.2			0.2	
lowa	100.0	77.3	20.0	0.5	0.5	1.1	1.1				0.5
Kansas	100.0	53.5	31.2	11.8	0.6	2.9	1.8	0.6	0.6		
Kentucky	100.0	46.3	52.6	0.4		0.6	0.4	0.2			
Louisiana	100.0	23.9	47.1	11.0	12.9	3.9	2.6	1.3			1.3
Maine	100.0	40.8	55.1	1.0		1.5	0.5	0.5		0.5	1.5
Maryland	100.0	29.9	62.0	2.5	3.9	1.6	0.5	0.9		0.2	
Massachusetts	100.0	65.9	31.4	0.5	0.7	1.6	1.1		0.2	0.2	
Michigan	100.0	55.2	32.7	6.8	0.4	1.1	1.1				3.7
Minnesota	100.0	40.6	48.6	1.7	0.7	0.7	0.5		0.2		7.5
Mississippi	100.0	52.4	25.7	15.2	3.8	2.9	1.9	1.0			
Missouri	100.0	73.7	22.7		0.4	3.2	2.5	0.4		0.4	
Montana	100.0	57.4	29.5		2.3	5.4	3.9	0.8	0.8		5.4
Nebraska	100.0	60.2	23.6	4.9	0.8	4.1	2.4	0.8	0.8		6.5

Table 6.4b. Facility operation, by state or jurisdiction: Row percent distribution, 2020 (continued)

						Facilit	y operation				
0				Local.				Federa	l govt.		
State or jurisdiction ¹	Total	Private non-profit	Private for-profit	county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Nevada	100.0	53.2	34.9		1.8	4.6	1.8	1.8	0.9		5.5
New Hampshire	100.0	50.5	48.6			0.9				0.9	
New Jersey	100.0	45.7	49.9	2.3	1.3	0.8	0.3	0.5			
New Mexico	100.0	52.5	31.5	1.9	2.5	1.2			0.6	0.6	10.5
New York	100.0	71.9	16.7	5.7	3.7	1.5	1.2	0.2			0.6
North Carolina	100.0	35.7	58.9	1.6	1.5	2.0	1.5	0.5			0.3
North Dakota	100.0	28.7	47.1	2.3	13.8	1.1	1.1				6.9
Ohio	100.0	64.1	30.7	1.6	0.6	2.9	2.9				
Oklahoma	100.0	53.3	20.5	1.0	7.7	2.6	1.5	0.5	0.5		14.9
Oregon	100.0	55.5	30.0	9.3	0.4	1.6	1.2		0.4		3.2
Pennsylvania	100.0	53.3	45.2			1.5	1.5				
Puerto Rico	100.0	68.3	18.8		11.9	1.0	1.0				
Rhode Island	100.0	65.1	30.2			3.2	1.6	1.6			1.6
South Carolina	100.0	34.7	33.9	17.7	10.5	3.2	1.6	1.6			
South Dakota	100.0	58.6	15.5	1.7	3.4	10.3	6.9		3.4		10.3
Tennessee	100.0	63.0	35.4		0.3	1.3	1.3				
Texas	100.0	39.1	50.5	4.9	1.6	3.7	3.3	0.4			0.2
Utah	100.0	21.6	68.5	8.4	0.3	0.6	0.3	0.3			0.6
Vermont	100.0	73.1	21.2		1.9	3.8	3.8				
Virginia	100.0	18.5	41.4	34.9	2.0	3.2	1.6	1.6			
Washington	100.0	46.2	40.7	4.4	0.7	1.3	0.9	0.2	0.2		6.8
West Virginia	100.0	72.2	21.4	1.6	1.6	3.2	3.2				
Wisconsin	100.0	37.6	44.1	14.9	0.3	1.4	1.0		0.3		1.7
Wyoming	100.0	61.7	20.0	13.3		3.3	3.3				1.7
Other jurisdictions ²	100.0	40.0	10.0	10.0	40.0						

⁻⁻ Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTE: Percentages may not sum to 100 percent because of rounding.

Table 6.5a. Type of care offered, by state or jurisdiction: Number, 2020

							Type of ca	re offered						
					Outpatient				Resider	ntial (non-h	ospital)		Hospital	inpatient
State or jurisdiction ¹	Total ²	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
Total	16,066	13,161	12,249	7,243	2,277	1,869	5,829	3,825	2,427	2,972	1,412	861	658	784
Alabama	155	111	101	48	7	16	50	34	14	26	2	15	7	15
Alaska	105	86	83	52	8	9	30	25	15	21	2	3	2	2
Arizona	447	376	349	217	86	69	170	98	69	78	22	27	21	27
Arkansas	171	158	156	74	37	11	47	25	22	23	10	12	8	11
California	1,734	1,043	948	621	294	246	382	771	616	653	434	66	51	64
Colorado	393	365	353	178	33	30	130	51	26	38	24	15	14	13
Connecticut	210	171	156	119	22	26	120	48	26	29	8	11	8	10
Delaware	49	45	45	25	3	7	29	7	3	6	1	3	3	3
District of Columbia	28	26	25	15	2	4	10	5	5	2	1	1	1	1
Florida	712	587	533	295	178	80	244	215	143	151	91	74	58	68
Georgia	348	290	249	135	62	59	112	77	33	60	18	21	20	21
Hawaii	161	151	149	79	23	12	16	23	14	19	9			
Idaho	110	105	102	78	8	9	33	12	9	10	8	5	5	5
Illinois	713	665	649	420	78	80	238	84	56	51	32	24	14	23
Indiana	416	379	335	164	50	61	184	58	33	45	18	29	24	26
lowa	185	172	169	104	21	10	37	30	28	24	10	10	6	8
Kansas	170	158	156	84	8	6	33	30	21	19	15	5	3	5
Kentucky	477	416	394	225	43	50	158	92	69	66	46	16	15	14
Louisiana	155	120	109	82	33	24	57	48	32	33	22	22	18	21
Maine	196	177	172	48	4	9	86	21	7	16	2	4	1	4
Maryland	432	384	363	260	54	83	228	86	34	78	21	15	13	15
Massachusetts	440	303	262	87	47	43	204	143	46	112	22	36	29	34
Michigan	455	406	397	148	42	36	139	93	77	71	42	10	6	9
Minnesota	401	315	279	253	63	9	75	121	71	98	16	3	3	2
Mississippi	105	81	74	44	20	11	24	36	27	33	13	13	10	13
Missouri	278	257	245	167	88	31	156	61	52	29	25	11	6	9
Montana	129	119	118	69	6	6	29	17	10	8	3	5	5	5
Nebraska	123	101	100	38	3	5	15	36	14	27	8	2	1	2

Table 6.5a. Type of care offered, by state or jurisdiction: Number, 2020 (continued)

							Type of ca	re offered						
					Outpatient				Resider	ntial (non-h	ospital)		Hospital	inpatient
State or jurisdiction ¹	Total ²	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
Nevada	109	93	91	67	21	28	39	28	18	24	11	9	9	9
New Hampshire	109	100	95	31	8	17	66	16	13	9	4	2	2	2
New Jersey	383	343	326	250	99	37	161	52	23	38	20	12	11	11
New Mexico	162	150	146	69	11	17	56	19	12	16	5	3	2	3
New York	894	612	562	233	67	98	521	246	75	188	57	66	51	43
North Carolina	611	536	496	220	86	97	259	87	30	69	20	35	23	33
North Dakota	87	79	79	41	28	7	16	29	20	23	15	5	5	3
Ohio	619	548	524	375	119	115	307	129	99	98	51	40	24	36
Oklahoma	195	163	158	62	8	20	53	44	22	38	9	9	5	9
Oregon	247	216	205	136	39	20	87	40	24	31	19	8	4	8
Pennsylvania	604	461	425	307	100	40	242	164	112	124	58	30	21	29
Puerto Rico	101	39	33	14	17	13	23	55	11	49	11	15	13	10
Rhode Island	63	48	48	22	4	18	30	18	12	16	2	5	3	5
South Carolina	124	102	86	50	11	15	62	22	12	15	3	15	11	13
South Dakota	58	50	49	35	6	3	9	16	10	11	3	5	5	2
Tennessee	311	283	242	174	48	33	114	76	50	63	26	15	10	15
Texas	509	430	354	276	96	73	154	122	101	98	58	43	39	42
Utah	333	260	246	170	88	57	111	109	76	93	43	12	10	11
Vermont	52	47	43	14	2	5	29	5	2	3	2	3	3	3
Virginia	249	217	188	81	20	37	118	37	25	26	15	11	10	11
Washington	457	404	396	315	26	22	151	65	48	34	22	16	12	15
West Virginia	126	97	95	34	6	26	61	33	16	27	10	8	7	7
Wisconsin	295	258	234	98	37	23	104	45	28	34	8	30	21	28
Wyoming	60	48	47	33	4	3	17	17	12	15	12	4	4	4
Other jurisdictions ³	10	10	10	7	3	3	3	4	4	4	3	2	1	2

⁻⁻ Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sum to more than the total column, because a facility could provide more than one type of care.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 6.5b. Type of care offered, by state or jurisdiction: Row percent, 2020

							Type of care	offered						
					Outpatient				Reside	ntial (non-l	nospital)		Hospital	inpatient
State or jurisdiction ¹	Number of facilities²	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
Tot	al 16,066	81.9	76.2	45.1	14.2	11.6	36.3	23.8	15.1	18.5	8.8	5.4	4.1	4.9
Alabama	155	71.6	65.2	31.0	4.5	10.3	32.3	21.9	9.0	16.8	1.3	9.7	4.5	9.7
Alaska	105	81.9	79.0	49.5	7.6	8.6	28.6	23.8	14.3	20.0	1.9	2.9	1.9	1.9
Arizona	447	84.1	78.1	48.5	19.2	15.4	38.0	21.9	15.4	17.4	4.9	6.0	4.7	6.0
Arkansas	171	92.4	91.2	43.3	21.6	6.4	27.5	14.6	12.9	13.5	5.8	7.0	4.7	6.4
California	1,734	60.1	54.7	35.8	17.0	14.2	22.0	44.5	35.5	37.7	25.0	3.8	2.9	3.7
Colorado	393	92.9	89.8	45.3	8.4	7.6	33.1	13.0	6.6	9.7	6.1	3.8	3.6	3.3
Connecticut	210	81.4	74.3	56.7	10.5	12.4	57.1	22.9	12.4	13.8	3.8	5.2	3.8	4.8
Delaware	49	91.8	91.8	51.0	6.1	14.3	59.2	14.3	6.1	12.2	2.0	6.1	6.1	6.1
District of Columbia	28	92.9	89.3	53.6	7.1	14.3	35.7	17.9	17.9	7.1	3.6	3.6	3.6	3.6
Florida	712	82.4	74.9	41.4	25.0	11.2	34.3	30.2	20.1	21.2	12.8	10.4	8.1	9.6
Georgia	348	83.3	71.6	38.8	17.8	17.0	32.2	22.1	9.5	17.2	5.2	6.0	5.7	6.0
Hawaii	161	93.8	92.5	49.1	14.3	7.5	9.9	14.3	8.7	11.8	5.6			
Idaho	110	95.5	92.7	70.9	7.3	8.2	30.0	10.9	8.2	9.1	7.3	4.5	4.5	4.5
Illinois	713	93.3	91.0	58.9	10.9	11.2	33.4	11.8	7.9	7.2	4.5	3.4	2.0	3.2
Indiana	416	91.1	80.5	39.4	12.0	14.7	44.2	13.9	7.9	10.8	4.3	7.0	5.8	6.3
Iowa	185	93.0	91.4	56.2	11.4	5.4	20.0	16.2	15.1	13.0	5.4	5.4	3.2	4.3
Kansas	170	92.9	91.8	49.4	4.7	3.5	19.4	17.6	12.4	11.2	8.8	2.9	1.8	2.9
Kentucky	477	87.2	82.6	47.2	9.0	10.5	33.1	19.3	14.5	13.8	9.6	3.4	3.1	2.9
Louisiana	155	77.4	70.3	52.9	21.3	15.5	36.8	31.0	20.6	21.3	14.2	14.2	11.6	13.5
Maine	196	90.3	87.8	24.5	2.0	4.6	43.9	10.7	3.6	8.2	1.0	2.0	0.5	2.0
Maryland	432	88.9	84.0	60.2	12.5	19.2	52.8	19.9	7.9	18.1	4.9	3.5	3.0	3.5
Massachusetts	440	68.9	59.5	19.8	10.7	9.8	46.4	32.5	10.5	25.5	5.0	8.2	6.6	7.7
Michigan	455	89.2	87.3	32.5	9.2	7.9	30.5	20.4	16.9	15.6	9.2	2.2	1.3	2.0
Minnesota	401	78.6	69.6	63.1	15.7	2.2	18.7	30.2	17.7	24.4	4.0	0.7	0.7	0.5
Mississippi	105	77.1	70.5	41.9	19.0	10.5	22.9	34.3	25.7	31.4	12.4	12.4	9.5	12.4
Missouri	278	92.4	88.1	60.1	31.7	11.2	56.1	21.9	18.7	10.4	9.0	4.0	2.2	3.2
Montana	129	92.2	91.5	53.5	4.7	4.7	22.5	13.2	7.8	6.2	2.3	3.9	3.9	3.9
Nebraska	123	82.1	81.3	30.9	2.4	4.1	12.2	29.3	11.4	22.0	6.5	1.6	8.0	1.6

Table 6.5b. Type of care offered, by state or jurisdiction: Row percent, 2020 (continued)

							Type of care	offered						
					Outpatient				Reside	ntial (non-l	hospital)		Hospital	' inpatient
State or jurisdiction ¹	Number of facilities²	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
Nevada	109	85.3	83.5	61.5	19.3	25.7	35.8	25.7	16.5	22.0	10.1	8.3	8.3	8.3
New Hampshire	109	91.7	87.2	28.4	7.3	15.6	60.6	14.7	11.9	8.3	3.7	1.8	1.8	1.8
New Jersey	383	89.6	85.1	65.3	25.8	9.7	42.0	13.6	6.0	9.9	5.2	3.1	2.9	2.9
New Mexico	162	92.6	90.1	42.6	6.8	10.5	34.6	11.7	7.4	9.9	3.1	1.9	1.2	1.9
New York	894	68.5	62.9	26.1	7.5	11.0	58.3	27.5	8.4	21.0	6.4	7.4	5.7	4.8
North Carolina	611	87.7	81.2	36.0	14.1	15.9	42.4	14.2	4.9	11.3	3.3	5.7	3.8	5.4
North Dakota	87	90.8	90.8	47.1	32.2	8.0	18.4	33.3	23.0	26.4	17.2	5.7	5.7	3.4
Ohio	619	88.5	84.7	60.6	19.2	18.6	49.6	20.8	16.0	15.8	8.2	6.5	3.9	5.8
Oklahoma	195	83.6	81.0	31.8	4.1	10.3	27.2	22.6	11.3	19.5	4.6	4.6	2.6	4.6
Oregon	247	87.4	83.0	55.1	15.8	8.1	35.2	16.2	9.7	12.6	7.7	3.2	1.6	3.2
Pennsylvania	604	76.3	70.4	50.8	16.6	6.6	40.1	27.2	18.5	20.5	9.6	5.0	3.5	4.8
Puerto Rico	101	38.6	32.7	13.9	16.8	12.9	22.8	54.5	10.9	48.5	10.9	14.9	12.9	9.9
Rhode Island	63	76.2	76.2	34.9	6.3	28.6	47.6	28.6	19.0	25.4	3.2	7.9	4.8	7.9
South Carolina	124	82.3	69.4	40.3	8.9	12.1	50.0	17.7	9.7	12.1	2.4	12.1	8.9	10.5
South Dakota	58	86.2	84.5	60.3	10.3	5.2	15.5	27.6	17.2	19.0	5.2	8.6	8.6	3.4
Tennessee	311	91.0	77.8	55.9	15.4	10.6	36.7	24.4	16.1	20.3	8.4	4.8	3.2	4.8
Texas	509	84.5	69.5	54.2	18.9	14.3	30.3	24.0	19.8	19.3	11.4	8.4	7.7	8.3
Utah	333	78.1	73.9	51.1	26.4	17.1	33.3	32.7	22.8	27.9	12.9	3.6	3.0	3.3
Vermont	52	90.4	82.7	26.9	3.8	9.6	55.8	9.6	3.8	5.8	3.8	5.8	5.8	5.8
Virginia	249	87.1	75.5	32.5	8.0	14.9	47.4	14.9	10.0	10.4	6.0	4.4	4.0	4.4
Washington	457	88.4	86.7	68.9	5.7	4.8	33.0	14.2	10.5	7.4	4.8	3.5	2.6	3.3
West Virginia	126	77.0	75.4	27.0	4.8	20.6	48.4	26.2	12.7	21.4	7.9	6.3	5.6	5.6
Wisconsin	295	87.5	79.3	33.2	12.5	7.8	35.3	15.3	9.5	11.5	2.7	10.2	7.1	9.5
Wyoming	60	80.0	78.3	55.0	6.7	5.0	28.3	28.3	20.0	25.0	20.0	6.7	6.7	6.7
Other jurisdictions ³	10	100.0	100.0	70.0	30.0	30.0	30.0	40.0	40.0	40.0	30.0	20.0	10.0	20.0

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Percentages sum to more than 100 percent, because a facility could provide more than one type of care.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 6.6a. Type of assessment and pre-treatment services offered by facilities, by state or jurisdiction: Number, 2020

					Assessment	t and pre-treatme	ent services			
State or jurisdiction	Total²	Screening for substance abuse	Screening for mental health disorders	Comprehensive substance abuse assessment or diagnosis	Comprehensive mental health assessment or diagnosis	Screening for tobacco use	Outreach to persons in the community who may need treatment	Interim services for clients when immediate admission is not possible	Professional interventionist/ educational consultant	None of these assessment and pre- treatment services offered
To	tal 16,066	15,594	12,787	15,167	9,344	12,187	10,653	8,043	3,446	121
Alabama	155	153	95	141	55	104	129	101	28	2
Alaska	105	102	94	100	77	91	83	80	21	
Arizona	447	434	373	422	303	311	296	227	95	6
Arkansas	171	165	150	158	117	128	145	99	34	1
California	1,734	1,689	1,305	1,600	829	1,178	1,199	788	409	29
Colorado	393	387	312	375	231	273	251	207	80	2
Connecticut	210	204	196	197	167	184	125	83	33	4
Delaware	49	45	46	48	41	34	35	28	10	
District of Columbia	28	27	22	26	17	21	21	10	11	
Florida	712	695	604	678	476	506	446	346	189	4
Georgia	348	341	261	321	193	197	234	141	65	2
Hawaii	161	156	85	154	45	138	92	94	34	1
Idaho	110	109	100	108	91	69	80	61	22	
Illinois	713	699	545	675	387	482	452	374	173	5
Indiana	416	402	336	388	244	329	256	174	67	5
Iowa	185	180	152	181	87	162	129	134	34	1
Kansas	170	170	99	165	73	90	111	119	34	
Kentucky	477	473	376	458	305	314	330	218	129	1
Louisiana	155	154	111	149	81	115	119	88	44	
Maine	196	193	167	193	115	178	90	66	43	
Maryland	432	413	316	406	249	350	302	184	103	10
Massachusetts	440	425	321	409	235	411	253	139	73	8
Michigan	455	443	392	436	270	310	281	213	87	1
Minnesota	401	369	299	385	221	286	237	141	70	4
Mississippi	105	104	89	96	74	64	78	57	23	
Missouri	278	272	222	256	163	219	164	166	50	4
Montana	129	126	122	122	87	105	105	92	34	
Nebraska	123	122	112	115	80	98	75	87	26	1

Table 6.6a. Type of assessment and pre-treatment services offered by facilities, by state or jurisdiction: Number, 2020 (continued)

					Assessment	and pre-treatme	ent services			
State or jurisdiction ¹	Total ²	Screening for substance abuse	Screening for mental health disorders	Comprehensive substance abuse assessment or diagnosis	Comprehensive mental health assessment or diagnosis	Screening for tobacco use	Outreach to persons in the community who may need treatment	Interim services for clients when immediate admission is not possible	Professional interventionist/ educational consultant	None of these assessment and pre- treatment services offered
Nevada	109	107	101	103	75	84	84	62	29	
New Hampshire	109	107	92	102	56	89	67	46	9	2
New Jersey	383	369	328	373	277	297	251	224	114	
New Mexico	162	159	143	158	115	119	118	105	51	1
New York	894	870	789	860	563	865	566	437	148	2
North Carolina	611	591	487	559	393	472	388	272	130	3
North Dakota	87	85	61	81	40	78	53	55	22	
Ohio	619	583	489	595	396	451	432	278	115	2
Oklahoma	195	192	171	179	104	175	167	145	46	
Oregon	247	233	195	239	121	232	170	159	53	
Pennsylvania	604	584	425	559	266	480	388	281	67	6
Puerto Rico	101	99	62	84	75	40	66	38	66	
Rhode Island	63	60	47	58	40	55	42	31	13	
South Carolina	124	118	77	116	35	89	94	71	29	
South Dakota	58	54	47	54	27	49	43	48	16	1
Tennessee	311	310	265	294	176	224	226	138	65	
Texas	509	504	367	492	226	407	337	278	122	1
Utah	333	319	293	309	240	247	232	140	89	4
Vermont	52	50	46	49	34	49	40	41	7	
Virginia	249	238	197	234	157	179	164	139	44	1
Washington	457	434	370	440	263	408	313	305	78	2
West Virginia	126	123	118	118	103	80	92	70	34	
Wisconsin	295	287	254	281	200	212	145	113	47	4
Wyoming	60	56	53	58	44	52	47	41	26	1
Other jurisdictions ³	10	10	8	10	5	7	10	9	5	

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, because a facility could offer more than one assessment and pre-treatment service.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.6b. Type of assessment and pre-treatment services offered by facilities, by state or jurisdiction: Row percent, 2020

					Assessm	ent and pre-trea	tment services			
State or jurisdiction ¹	Number of facilities ²	Screening for substance abuse	Screening for mental health disorders	Comprehensive substance abuse assessment or diagnosis	Comprehensive mental health assessment or diagnosis	Screening for tobacco use	Outreach to persons in the community who may need treatment	Interim services for clients when immediate admission is not possible	Professional interventionist/ educational consultant	None of these assessment and pre- treatment services offered
Total	16,066	97.1	79.6	94.4	58.2	75.9	66.3	50.1	21.4	0.8
Alabama	155	98.7	61.3	91.0	35.5	67.1	83.2	65.2	18.1	1.3
Alaska	105	97.1	89.5	95.2	73.3	86.7	79.0	76.2	20.0	
Arizona	447	97.1	83.4	94.4	67.8	69.6	66.2	50.8	21.3	1.3
Arkansas	171	96.5	87.7	92.4	68.4	74.9	84.8	57.9	19.9	0.6
California	1,734	97.4	75.3	92.3	47.8	67.9	69.1	45.4	23.6	1.7
Colorado	393	98.5	79.4	95.4	58.8	69.5	63.9	52.7	20.4	0.5
Connecticut	210	97.1	93.3	93.8	79.5	87.6	59.5	39.5	15.7	1.9
Delaware	49	91.8	93.9	98.0	83.7	69.4	71.4	57.1	20.4	
District of Columbia	28	96.4	78.6	92.9	60.7	75.0	75.0	35.7	39.3	
Florida	712	97.6	84.8	95.2	66.9	71.1	62.6	48.6	26.5	0.7
Georgia	348	98.0	75.0	92.2	55.5	56.6	67.2	40.5	18.7	0.6
Hawaii	161	96.9	52.8	95.7	28.0	85.7	57.1	58.4	21.1	0.6
Idaho	110	99.1	90.9	98.2	82.7	62.7	72.7	55.5	20.0	
Illinois	713	98.0	76.4	94.7	54.3	67.6	63.4	52.5	24.3	0.7
Indiana	416	96.6	80.8	93.3	58.7	79.1	61.5	41.8	16.1	1.2
Iowa	185	97.3	82.2	97.8	47.0	87.6	69.7	72.4	18.4	0.5
Kansas	170	100.0	58.2	97.1	42.9	52.9	65.3	70.0	20.0	
Kentucky	477	99.2	78.8	96.0	63.9	65.8	69.2	45.7	27.0	0.2
Louisiana	155	99.4	71.6	96.1	52.3	74.2	76.8	56.8	28.4	
Maine	196	98.5	85.2	98.5	58.7	90.8	45.9	33.7	21.9	
Maryland	432	95.6	73.1	94.0	57.6	81.0	69.9	42.6	23.8	2.3
Massachusetts	440	96.6	73.0	93.0	53.4	93.4	57.5	31.6	16.6	1.8
Michigan	455	97.4	86.2	95.8	59.3	68.1	61.8	46.8	19.1	0.2
Minnesota	401	92.0	74.6	96.0	55.1	71.3	59.1	35.2	17.5	1.0
Mississippi	105	99.0	84.8	91.4	70.5	61.0	74.3	54.3	21.9	
Missouri	278	97.8	79.9	92.1	58.6	78.8	59.0	59.7	18.0	1.4
Montana	129	97.7	94.6	94.6	67.4	81.4	81.4	71.3	26.4	
Nebraska	123	99.2	91.1	93.5	65.0	79.7	61.0	70.7	21.1	0.8

Table 6.6b. Type of assessment and pre-treatment services offered by facilities, by state or jurisdiction: Row percent, 2020 (continued)

					Assessm	ent and pre-trea	tment services			
State or jurisdiction ¹	Number of facilities²	Screening for substance abuse	Screening for mental health disorders	Comprehensive substance abuse assessment or diagnosis	Comprehensive mental health assessment or diagnosis	Screening for tobacco use	Outreach to persons in the community who may need treatment	Interim services for clients when immediate admission is not possible	Professional interventionist/ educational consultant	None of these assessment and pre- treatment services offered
Nevada	109	98.2	92.7	94.5	68.8	77.1	77.1	56.9	26.6	
New Hampshire	109	98.2	84.4	93.6	51.4	81.7	61.5	42.2	8.3	1.8
New Jersey	383	96.3	85.6	97.4	72.3	77.5	65.5	58.5	29.8	
New Mexico	162	98.1	88.3	97.5	71.0	73.5	72.8	64.8	31.5	0.6
New York	894	97.3	88.3	96.2	63.0	96.8	63.3	48.9	16.6	0.2
North Carolina	611	96.7	79.7	91.5	64.3	77.3	63.5	44.5	21.3	0.5
North Dakota	87	97.7	70.1	93.1	46.0	89.7	60.9	63.2	25.3	
Ohio	619	94.2	79.0	96.1	64.0	72.9	69.8	44.9	18.6	0.3
Oklahoma	195	98.5	87.7	91.8	53.3	89.7	85.6	74.4	23.6	
Oregon	247	94.3	78.9	96.8	49.0	93.9	68.8	64.4	21.5	
Pennsylvania	604	96.7	70.4	92.5	44.0	79.5	64.2	46.5	11.1	1.2
Puerto Rico	101	98.0	61.4	83.2	74.3	39.6	65.3	37.6	65.3	
Rhode Island	63	95.2	74.6	92.1	63.5	87.3	66.7	49.2	20.6	
South Carolina	124	95.2	62.1	93.5	28.2	71.8	75.8	57.3	23.4	
South Dakota	58	93.1	81.0	93.1	46.6	84.5	74.1	82.8	27.6	1.7
Tennessee	311	99.7	85.2	94.5	56.6	72.0	72.7	44.4	20.9	
Texas	509	99.0	72.1	96.7	44.4	80.0	66.2	54.6	24.0	0.2
Utah	333	95.8	88.0	92.8	72.1	74.2	69.7	42.0	26.7	1.2
Vermont	52	96.2	88.5	94.2	65.4	94.2	76.9	78.8	13.5	
Virginia	249	95.6	79.1	94.0	63.1	71.9	65.9	55.8	17.7	0.4
Washington	457	95.0	81.0	96.3	57.5	89.3	68.5	66.7	17.1	0.4
West Virginia	126	97.6	93.7	93.7	81.7	63.5	73.0	55.6	27.0	
Wisconsin	295	97.3	86.1	95.3	67.8	71.9	49.2	38.3	15.9	1.4
Wyoming	60	93.3	88.3	96.7	73.3	86.7	78.3	68.3	43.3	1.7
Other jurisdictions ³	10	100.0	80.0	100.0	50.0	70.0	100.0	90.0	50.0	

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Percentages sum to more than 100 percent, because a facility could offer more than one assessment and pre-treatment service.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.7a. Type of testing offered by facilities, by state or jurisdiction: Number, 2020

						Testir	ng type				
State or jurisdiction ¹	Total ²	Drug and alcohol oral fluid testing	Breathalyzer or other blood alcohol testing	Drug or alcohol urine screening	Testing for hepatitis B (HBV)	Testing for hepatitis C (HCV)	HIV testing	STD testing	TB screening	Testing for metabolic syndrome	None of these testing services offered
Total	16,066	5,144	10,244	14,154	4,377	4,943	5,125	4,223	6,824	1,603	1,496
Alabama	155	57	87	151	36	42	63	36	120	17	3
Alaska	105	37	63	83	23	24	29	24	26	13	20
Arizona	447	142	218	321	140	152	158	161	217	76	101
Arkansas	171	35	61	136	20	20	20	22	25	10	34
California	1,734	581	1,274	1,585	408	482	540	470	837	146	105
Colorado	393	111	289	304	85	88	68	49	132	17	51
Connecticut	210	102	176	197	64	75	77	61	69	21	10
Delaware	49	14	33	40	19	25	26	21	24	3	9
District of Columbia	28	9	25	25	12	14	18	12	16	4	1
Florida	712	209	526	665	262	295	373	278	365	73	37
Georgia	348	113	220	323	120	140	164	139	214	28	16
Hawaii	161	37	53	69	14	15	17	9	21	4	91
Idaho	110	59	56	90	14	15	17	17	15	7	20
Illinois	713	165	477	617	173	185	191	193	311	56	57
Indiana	416	162	226	354	118	142	136	95	193	42	31
lowa	185	46	116	171	24	23	31	25	59	2	13
Kansas	170	36	92	113	19	21	21	23	49	14	50
Kentucky	477	151	238	383	130	144	142	106	139	44	84
Louisiana	155	57	119	153	70	78	98	82	103	25	2
Maine	196	69	70	147	28	30	28	24	54	17	46
Maryland	432	180	359	421	117	132	148	112	195	33	7
Massachusetts	440	147	250	356	194	212	201	173	252	65	63
Michigan	455	129	264	357	110	115	112	96	155	42	92
Minnesota	401	166	294	372	47	56	56	57	105	9	25
Mississippi	105	34	53	94	22	25	39	21	58	11	7
Missouri	278	65	192	260	64	77	73	71	80	104	12
Montana	129	31	60	91	28	31	28	29	27	9	37
Nebraska	123	19	66	83	22	22	19	17	37	3	36

Table 6.7a. Type of testing offered by facilities, by state or jurisdiction: Number, 2020 (continued)

						Testin	ng type				
State or jurisdiction ¹	Total²	Drug and alcohol oral fluid testing	Breathalyzer or other blood alcohol testing	Drug or alcohol urine screening	Testing for hepatitis B (HBV)	Testing for hepatitis C (HCV)	HIV testing	STD testing	TB screening	Testing for metabolic syndrome	None of these testing services offered
Nevada	109	21	73	95	42	39	61	39	59	13	11
New Hampshire	109	21	54	93	24	29	29	19	33	11	16
New Jersey	383	174	219	361	93	105	104	82	127	29	18
New Mexico	162	39	89	115	40	45	44	44	51	14	41
New York	894	459	767	878	401	440	397	322	487	113	11
North Carolina	611	209	388	564	140	166	178	154	207	67	37
North Dakota	87	30	63	75	7	9	13	13	20	5	10
Ohio	619	147	367	567	208	223	226	171	199	68	49
Oklahoma	195	32	70	158	43	53	51	43	80	27	26
Oregon	247	105	121	244	62	69	66	60	85	33	3
Pennsylvania	604	173	406	567	180	227	204	155	290	69	27
Puerto Rico	101	27	11	97	28	31	45	28	48	4	2
Rhode Island	63	22	44	58	23	23	23	16	29	5	4
South Carolina	124	45	87	119	37	48	52	31	65	10	4
South Dakota	58	11	37	41	11	12	14	16	36	6	6
Tennessee	311	79	155	285	68	93	102	79	205	20	7
Texas	509	134	303	475	176	203	228	188	230	61	26
Utah	333	99	191	286	70	80	66	75	142	44	44
Vermont	52	4	36	46	20	21	20	13	23	5	5
Virginia	249	86	198	229	72	89	82	44	107	36	12
Washington	457	142	281	439	101	104	89	90	233	21	12
West Virginia	126	32	96	112	55	55	46	36	46	19	11
Wisconsin	295	74	188	236	75	82	73	64	102	23	43
Wyoming	60	12	36	43	12	12	13	13	17	4	11
Other jurisdictions ³	10	4	7	10	6	5	6	5	5	1	

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the Total, column because a facility could offer more than one testing type.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.7b. Type of testing offered by facilities, by state or jurisdiction: Row percent, 2020

						Testir	ng type				
State or jurisdiction ¹	Number of facilities ²	Drug and alcohol oral fluid testing	Breathalyzer or other blood alcohol testing	Drug or alcohol urine screening	Testing for hepatitis B (HBV)	Testing for hepatitis C (HCV)	HIV testing	STD testing	TB screening	Testing for metabolic syndrome	None of these testing services offered
Total	16,066	32.0	63.8	88.1	27.2	30.8	31.9	26.3	42.5	10.0	9.3
Alabama	155	36.8	56.1	97.4	23.2	27.1	40.6	23.2	77.4	11.0	1.9
Alaska	105	35.2	60.0	79.0	21.9	22.9	27.6	22.9	24.8	12.4	19.0
Arizona	447	31.8	48.8	71.8	31.3	34.0	35.3	36.0	48.5	17.0	22.6
Arkansas	171	20.5	35.7	79.5	11.7	11.7	11.7	12.9	14.6	5.8	19.9
California	1,734	33.5	73.5	91.4	23.5	27.8	31.1	27.1	48.3	8.4	6.1
Colorado	393	28.2	73.5	77.4	21.6	22.4	17.3	12.5	33.6	4.3	13.0
Connecticut	210	48.6	83.8	93.8	30.5	35.7	36.7	29.0	32.9	10.0	4.8
Delaware	49	28.6	67.3	81.6	38.8	51.0	53.1	42.9	49.0	6.1	18.4
District of Columbia	28	32.1	89.3	89.3	42.9	50.0	64.3	42.9	57.1	14.3	3.6
Florida	712	29.4	73.9	93.4	36.8	41.4	52.4	39.0	51.3	10.3	5.2
Georgia	348	32.5	63.2	92.8	34.5	40.2	47.1	39.9	61.5	8.0	4.6
Hawaii	161	23.0	32.9	42.9	8.7	9.3	10.6	5.6	13.0	2.5	56.5
Idaho	110	53.6	50.9	81.8	12.7	13.6	15.5	15.5	13.6	6.4	18.2
Illinois	713	23.1	66.9	86.5	24.3	25.9	26.8	27.1	43.6	7.9	8.0
Indiana	416	38.9	54.3	85.1	28.4	34.1	32.7	22.8	46.4	10.1	7.5
lowa	185	24.9	62.7	92.4	13.0	12.4	16.8	13.5	31.9	1.1	7.0
Kansas	170	21.2	54.1	66.5	11.2	12.4	12.4	13.5	28.8	8.2	29.4
Kentucky	477	31.7	49.9	80.3	27.3	30.2	29.8	22.2	29.1	9.2	17.6
Louisiana	155	36.8	76.8	98.7	45.2	50.3	63.2	52.9	66.5	16.1	1.3
Maine	196	35.2	35.7	75.0	14.3	15.3	14.3	12.2	27.6	8.7	23.5
Maryland	432	41.7	83.1	97.5	27.1	30.6	34.3	25.9	45.1	7.6	1.6
Massachusetts	440	33.4	56.8	80.9	44.1	48.2	45.7	39.3	57.3	14.8	14.3
Michigan	455	28.4	58.0	78.5	24.2	25.3	24.6	21.1	34.1	9.2	20.2
Minnesota	401	41.4	73.3	92.8	11.7	14.0	14.0	14.2	26.2	2.2	6.2
Mississippi	105	32.4	50.5	89.5	21.0	23.8	37.1	20.0	55.2	10.5	6.7
Missouri	278	23.4	69.1	93.5	23.0	27.7	26.3	25.5	28.8	37.4	4.3
Montana	129	24.0	46.5	70.5	21.7	24.0	21.7	22.5	20.9	7.0	28.7
Nebraska	123	15.4	53.7	67.5	17.9	17.9	15.4	13.8	30.1	2.4	29.3

Table 6.7b. Type of testing offered by facilities, by state or jurisdiction: Row percent, 2020 (continued)

						Testin	ng type				
State or jurisdiction ¹	Number of facilities ²	Drug and alcohol oral fluid testing	Breathalyzer or other blood alcohol testing	Drug or alcohol urine screening	Testing for hepatitis B (HBV)	Testing for hepatitis C (HCV)	HIV testing	STD testing	TB screening	Testing for metabolic syndrome	None of these testing services offered
Nevada	109	19.3	67.0	87.2	38.5	35.8	56.0	35.8	54.1	11.9	10.1
New Hampshire	109	19.3	49.5	85.3	22.0	26.6	26.6	17.4	30.3	10.1	14.7
New Jersey	383	45.4	57.2	94.3	24.3	27.4	27.2	21.4	33.2	7.6	4.7
New Mexico	162	24.1	54.9	71.0	24.7	27.8	27.2	27.2	31.5	8.6	25.3
New York	894	51.3	85.8	98.2	44.9	49.2	44.4	36.0	54.5	12.6	1.2
North Carolina	611	34.2	63.5	92.3	22.9	27.2	29.1	25.2	33.9	11.0	6.1
North Dakota	87	34.5	72.4	86.2	8.0	10.3	14.9	14.9	23.0	5.7	11.5
Ohio	619	23.7	59.3	91.6	33.6	36.0	36.5	27.6	32.1	11.0	7.9
Oklahoma	195	16.4	35.9	81.0	22.1	27.2	26.2	22.1	41.0	13.8	13.3
Oregon	247	42.5	49.0	98.8	25.1	27.9	26.7	24.3	34.4	13.4	1.2
Pennsylvania	604	28.6	67.2	93.9	29.8	37.6	33.8	25.7	48.0	11.4	4.5
Puerto Rico	101	26.7	10.9	96.0	27.7	30.7	44.6	27.7	47.5	4.0	2.0
Rhode Island	63	34.9	69.8	92.1	36.5	36.5	36.5	25.4	46.0	7.9	6.3
South Carolina	124	36.3	70.2	96.0	29.8	38.7	41.9	25.0	52.4	8.1	3.2
South Dakota	58	19.0	63.8	70.7	19.0	20.7	24.1	27.6	62.1	10.3	10.3
Tennessee	311	25.4	49.8	91.6	21.9	29.9	32.8	25.4	65.9	6.4	2.3
Texas	509	26.3	59.5	93.3	34.6	39.9	44.8	36.9	45.2	12.0	5.1
Utah	333	29.7	57.4	85.9	21.0	24.0	19.8	22.5	42.6	13.2	13.2
Vermont	52	7.7	69.2	88.5	38.5	40.4	38.5	25.0	44.2	9.6	9.6
Virginia	249	34.5	79.5	92.0	28.9	35.7	32.9	17.7	43.0	14.5	4.8
Washington	457	31.1	61.5	96.1	22.1	22.8	19.5	19.7	51.0	4.6	2.6
West Virginia	126	25.4	76.2	88.9	43.7	43.7	36.5	28.6	36.5	15.1	8.7
Wisconsin	295	25.1	63.7	80.0	25.4	27.8	24.7	21.7	34.6	7.8	14.6
Wyoming	60	20.0	60.0	71.7	20.0	20.0	21.7	21.7	28.3	6.7	18.3
Other jurisdictions ³	10	40.0	70.0	100.0	60.0	50.0	60.0	50.0	50.0	10.0	

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Percentages sum to more than 100 percent, because a facility could offer more than one testing type.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.8. Type of medical services offered by facilities, by state or jurisdiction: Number and row percent, 2020

					Medical se	ervice type		
State or jurisdiction ¹				Number of facilities ²			Row percent of facilities	S ²
		Number of facilities	Hepatitis A (HAV) vaccination	Hepatitis B (HBV) vaccination	None of these medical services offered	Hepatitis A (HAV) vaccination	Hepatitis B (HBV) vaccination	None of these medical services offered
	Total	16,066	1,779	1,775	14,137	11.1	11.0	88.0
Alabama		155	13	13	142	8.4	8.4	91.6
Alaska		105	17	19	86	16.2	18.1	81.9
Arizona		447	81	94	353	18.1	21.0	79.0
Arkansas		171	5	6	165	2.9	3.5	96.5
California		1,734	154	159	1,569	8.9	9.2	90.5
Colorado		393	13	16	376	3.3	4.1	95.7
Connecticut		210	39	41	169	18.6	19.5	80.5
Delaware		49	14	14	33	28.6	28.6	67.3
District of Columbia		28	8	9	19	28.6	32.1	67.9
Florida		712	116	96	588	16.3	13.5	82.6
Georgia		348	22	25	319	6.3	7.2	91.7
Hawaii		161	7	7	154	4.3	4.3	95.7
Idaho		110	4	6	104	3.6	5.5	94.5
Illinois		713	114	116	597	16.0	16.3	83.7
Indiana		416	37	47	368	8.9	11.3	88.5
lowa		185	10	12	173	5.4	6.5	93.5
Kansas		170	9	10	160	5.3	5.9	94.1
Kentucky		477	59	49	416	12.4	10.3	87.2
Louisiana		155	25	20	130	16.1	12.9	83.9
Maine		196	19	20	176	9.7	10.2	89.8
Maryland		432	38	35	389	8.8	8.1	90.0
Massachusetts		440	82	69	356	18.6	15.7	80.9
Michigan		455	67	64	385	14.7	14.1	84.6
Minnesota		401	28	21	373	7.0	5.2	93.0
Mississippi		105	6	8	97	5.7	7.6	92.4
Missouri		278	26	25	252	9.4	9.0	90.6
Montana		129	14	15	114	10.9	11.6	88.4
Nebraska		123	12	12	111	9.8	9.8	90.2

Table 6.8. Type of medical services offered by facilities, by state or jurisdiction: Number and row percent, 2020 (continued)

				Medical se	rvice type		
State or jurisdiction ¹			Number of facilities ²			Row percent of facilities	S ²
,	Number of facilities	Hepatitis A (HAV) vaccination	Hepatitis B (HBV) vaccination	None of these medical services offered	Hepatitis A (HAV) vaccination	Hepatitis B (HBV) vaccination	None of these medical services offered
Nevada	109	12	12	97	11.0	11.0	89.0
New Hampshire	109	18	11	91	16.5	10.1	83.5
New Jersey	383	17	18	364	4.4	4.7	95.0
New Mexico	162	31	32	129	19.1	19.8	79.6
New York	894	144	154	738	16.1	17.2	82.6
North Carolina	611	44	43	564	7.2	7.0	92.3
North Dakota	87	4	5	82	4.6	5.7	94.3
Ohio	619	83	77	531	13.4	12.4	85.8
Oklahoma	195	23	23	172	11.8	11.8	88.2
Oregon	247	34	32	212	13.8	13.0	85.8
Pennsylvania	604	44	50	550	7.3	8.3	91.1
Puerto Rico	101	18	18	83	17.8	17.8	82.2
Rhode Island	63	11	12	51	17.5	19.0	81.0
South Carolina	124	16	9	108	12.9	7.3	87.1
South Dakota	58	9	10	48	15.5	17.2	82.8
Tennessee	311	39	31	272	12.5	10.0	87.5
Texas	509	44	56	453	8.6	11.0	89.0
Utah	333	28	28	305	8.4	8.4	91.6
Vermont	52	3	3	49	5.8	5.8	94.2
Virginia	249	16	15	233	6.4	6.0	93.6
Washington	457	28	37	420	6.1	8.1	91.9
West Virginia	126	37	30	88	29.4	23.8	69.8
Wisconsin	295	26	30	264	8.8	10.2	89.5
Wyoming	60	9	9	51	15.0	15.0	85.0
Other jurisdictions ³	10	2	2	8	20.0	20.0	80.0

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, and percentages sum to more than 100 percent, because a facility could offer more than one other service.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.9. Type of transitional services offered by facilities, by state or jurisdiction: Number and row percent, 2020

						Transition	al services				
			ı	Number of facilitie	es²			F	Row percent facil	ities²	
State or jurisdiction ¹	Number of facilities	Discharge planning	Aftercare/ continuing care	Naloxone and overdose education	Outcome follow-up after discharge	None of these transitional services offered	Discharge planning	Aftercare/ continuing care	Naloxone and overdose education	Outcome follow-up after discharge	None of these transitional services offered
Total	16,066	15,354	14,035	9,655	11,236	184	95.6	87.4	60.1	69.9	1.1
Alabama	155	146	134	86	131		94.2	86.5	55.5	84.5	
Alaska	105	102	95	68	74	1	97.1	90.5	64.8	70.5	1.0
Arizona	447	423	370	262	262	5	94.6	82.8	58.6	58.6	1.1
Arkansas	171	165	148	58	126	4	96.5	86.5	33.9	73.7	2.3
California	1,734	1,648	1,458	1,018	1,407	38	95.0	84.1	58.7	81.1	2.2
Colorado	393	373	341	176	240	7	94.9	86.8	44.8	61.1	1.8
Connecticut	210	204	181	171	134		97.1	86.2	81.4	63.8	
Delaware	49	46	41	36	30	2	93.9	83.7	73.5	61.2	4.1
District of Columbia	28	28	25	14	24		100.0	89.3	50.0	85.7	
Florida	712	690	597	423	556	7	96.9	83.8	59.4	78.1	1.0
Georgia	348	337	307	162	266		96.8	88.2	46.6	76.4	
Hawaii	161	159	129	23	151		98.8	80.1	14.3	93.8	
Idaho	110	108	101	46	68		98.2	91.8	41.8	61.8	
Illinois	713	667	661	418	481	6	93.5	92.7	58.6	67.5	0.8
Indiana	416	390	337	240	234	13	93.8	81.0	57.7	56.3	3.1
Iowa	185	180	171	89	122	5	97.3	92.4	48.1	65.9	2.7
Kansas	170	169	154	52	109	1	99.4	90.6	30.6	64.1	0.6
Kentucky	477	457	422	226	262	7	95.8	88.5	47.4	54.9	1.5
Louisiana	155	153	133	90	120	2	98.7	85.8	58.1	77.4	1.3
Maine	196	176	171	113	92	3	89.8	87.2	57.7	46.9	1.5
Maryland	432	418	371	302	317	2	96.8	85.9	69.9	73.4	0.5
Massachusetts	440	416	395	375	329		94.5	89.8	85.2	74.8	
Michigan	455	433	408	241	332	3	95.2	89.7	53.0	73.0	0.7
Minnesota	401	390	376	245	250	3	97.3	93.8	61.1	62.3	0.7
Mississippi	105	101	99	47	78		96.2	94.3	44.8	74.3	
Missouri	278	269	266	175	183	2	96.8	95.7	62.9	65.8	0.7
Montana	129	124	121	52	98		96.1	93.8	40.3	76.0	
Nebraska	123	120	113	25	94	2	97.6	91.9	20.3	76.4	1.6

Table 6.9. Type of transitional services offered by facilities, by state or jurisdiction: Number and row percent, 2020 (continued)

						Transition	al services				
			,	Number of facilitie	es²			F	Row percent facil	lities²	
State or jurisdiction ¹	Number of facilities	Discharge planning	Aftercare/ continuing care	Naloxone and overdose education	Outcome follow-up after discharge	None of these transitional services offered	Discharge planning	Aftercare/ continuing care	Naloxone and overdose education	Outcome follow-up after discharge	None of these transitional services offered
Nevada	109	106	102	68	91		97.2	93.6	62.4	83.5	
New Hampshire	109	93	94	70	64	9	85.3	86.2	64.2	58.7	8.3
New Jersey	383	366	343	238	260	6	95.6	89.6	62.1	67.9	1.6
New Mexico	162	143	139	83	96	2	88.3	85.8	51.2	59.3	1.2
New York	894	873	763	799	488	3	97.7	85.3	89.4	54.6	0.3
North Carolina	611	557	475	333	398	10	91.2	77.7	54.5	65.1	1.6
North Dakota	87	81	81	41	45	2	93.1	93.1	47.1	51.7	2.3
Ohio	619	605	535	407	431	5	97.7	86.4	65.8	69.6	0.8
Oklahoma	195	189	179	111	168	1	96.9	91.8	56.9	86.2	0.5
Oregon	247	244	224	140	161		98.8	90.7	56.7	65.2	
Pennsylvania	604	591	571	506	553		97.8	94.5	83.8	91.6	
Puerto Rico	101	84	64	30	70	10	83.2	63.4	29.7	69.3	9.9
Rhode Island	63	62	59	55	45		98.4	93.7	87.3	71.4	
South Carolina	124	117	105	89	103	2	94.4	84.7	71.8	83.1	1.6
South Dakota	58	56	55	13	39		96.6	94.8	22.4	67.2	
Tennessee	311	299	290	188	208	2	96.1	93.2	60.5	66.9	0.6
Texas	509	496	442	299	454	1	97.4	86.8	58.7	89.2	0.2
Utah	333	312	299	222	235	7	93.7	89.8	66.7	70.6	2.1
Vermont	52	49	45	40	30		94.2	86.5	76.9	57.7	
Virginia	249	237	212	163	144	2	95.2	85.1	65.5	57.8	8.0
Washington	457	441	407	273	255	2	96.5	89.1	59.7	55.8	0.4
West Virginia	126	117	112	77	79		92.9	88.9	61.1	62.7	
Wisconsin	295	278	252	145	192	5	94.2	85.4	49.2	65.1	1.7
Wyoming	60	56	53	30	48	2	93.3	88.3	50.0	80.0	3.3
Other jurisdictions ³	10	10	9	2	9		100.0	90.0	20.0	90.0	

^{- -} Quantity is zero

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, and percentages sum to more than 100 percent, because a facility could offer more than one transitional service.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.10a. Type of recovery support services offered by facilities, by state or jurisdiction: Number, 2020

					Rec	overy support se	vices		
State or jurisdiction ¹		Total ²	Mentoring/peer support	Self-help groups (for example, AA, NA, SMART Recovery)	Assistance in locating housing for clients	Employment counseling or training for clients	Assistance with obtaining social services (for example, Medicaid, WIC, SSI, SSDI)	Recovery coach	None of these recovery support services offered
	Total	16,066	10,123	7,878	10,213	7,132	11,138	4,446	1,774
Alabama		155	111	69	83	66	100	28	11
Alaska		105	56	43	81	49	89	18	7
Arizona		447	326	235	316	264	333	167	46
Arkansas		171	123	66	111	75	128	51	14
California		1,734	1,272	1,159	1,276	964	1,320	408	103
Colorado		393	241	111	200	172	201	105	81
Connecticut		210	141	127	134	105	173	98	11
Delaware		49	33	25	40	36	40	22	5
District of Columbia		28	23	12	18	15	20	14	1
Florida		712	441	408	440	315	415	179	89
Georgia		348	224	176	224	183	215	76	23
Hawaii		161	137	42	48	97	54	16	11
Idaho		110	72	40	91	40	88	33	8
Illinois		713	348	302	325	215	399	197	137
Indiana		416	260	137	238	172	293	161	59
Iowa		185	85	69	90	59	122	38	29
Kansas		170	98	73	109	75	114	29	21
Kentucky		477	319	202	325	239	346	127	65
Louisiana		155	95	84	102	52	114	21	18
Maine		196	112	50	114	41	129	73	39
Maryland		432	265	210	297	202	320	139	52
Massachusetts		440	265	219	260	160	295	168	62
Michigan		455	282	235	254	164	296	240	72
Minnesota		401	293	257	277	127	271	139	29
Mississippi		105	74	59	65	47	74	15	12
Missouri		278	196	133	187	165	213	87	24
Montana		129	56	33	70	26	84	14	34
Nebraska		123	64	72	65	43	65	16	28

Table 6.10a. Type of recovery support services offered by facilities, by state or jurisdiction: Number, 2020 (continued)

				Rec	covery support se	rvices		
State or jurisdiction ¹	Total ²	Mentoring/peer support	Self-help groups (for example, AA, NA, SMART Recovery)	Assistance in locating housing for clients	Employment counseling or training for clients	Assistance with obtaining social services (for example, Medicaid, WIC, SSI, SSDI)	Recovery coach	None of these recovery support services offered
Nevada	109	79	71	81	59	88	28	4
New Hampshire	109	56	43	62	36	80	29	18
New Jersey	383	205	201	234	174	262	84	51
New Mexico	162	101	70	121	82	136	36	10
New York	894	633	477	587	464	744	288	20
North Carolina	611	287	231	325	236	344	98	108
North Dakota	87	41	34	47	24	51	19	16
Ohio	619	378	280	471	311	524	152	39
Oklahoma	195	142	76	140	83	159	70	8
Oregon	247	177	128	203	111	199	70	11
Pennsylvania	604	377	330	406	235	474	126	56
Puerto Rico	101	56	35	57	49	77	32	11
Rhode Island	63	43	27	44	30	49	30	6
South Carolina	124	75	69	66	40	78	28	12
South Dakota	58	31	32	32	18	37	10	6
Tennessee	311	178	160	215	136	189	90	22
Texas	509	354	274	298	236	292	191	55
Utah	333	230	198	188	175	196	101	45
Vermont	52	33	13	45	29	51	10	1
Virginia	249	159	108	157	82	162	57	29
Washington	457	227	192	316	172	328	72	45
West Virginia	126	86	54	88	41	95	68	11
Wisconsin	295	108	96	133	91	152	52	96
Wyoming	60	46	24	49	42	53	20	3
Other jurisdictions ³	10	9	7	8	8	7	6	

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, because a facility could offer more than one recovery support service.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.10b. Type of recovery support services offered by facilities, by state or jurisdiction: Row percent, 2020

					Rec	overy support se	rvices		
State or jurisdiction ¹		Number of facilities²	Mentoring/peer support	Self-help groups (for example, AA, NA, SMART Recovery)	Assistance in locating housing for clients	Employment counseling or training for clients	Assistance with obtaining social services (for example, Medicaid, WIC, SSI, SSDI)	Recovery coach	None of these recovery support services offered
	Total	16,066	63.0	49.0	63.6	44.4	69.3	27.7	11.0
Alabama		155	71.6	44.5	53.5	42.6	64.5	18.1	7.1
Alaska		105	53.3	41.0	77.1	46.7	84.8	17.1	6.7
Arizona		447	72.9	52.6	70.7	59.1	74.5	37.4	10.3
Arkansas		171	71.9	38.6	64.9	43.9	74.9	29.8	8.2
California		1,734	73.4	66.8	73.6	55.6	76.1	23.5	5.9
Colorado		393	61.3	28.2	50.9	43.8	51.1	26.7	20.6
Connecticut		210	67.1	60.5	63.8	50.0	82.4	46.7	5.2
Delaware		49	67.3	51.0	81.6	73.5	81.6	44.9	10.2
District of Columbia		28	82.1	42.9	64.3	53.6	71.4	50.0	3.6
Florida		712	61.9	57.3	61.8	44.2	58.3	25.1	12.5
Georgia		348	64.4	50.6	64.4	52.6	61.8	21.8	6.6
Hawaii		161	85.1	26.1	29.8	60.2	33.5	9.9	6.8
Idaho		110	65.5	36.4	82.7	36.4	80.0	30.0	7.3
Illinois		713	48.8	42.4	45.6	30.2	56.0	27.6	19.2
Indiana		416	62.5	32.9	57.2	41.3	70.4	38.7	14.2
lowa		185	45.9	37.3	48.6	31.9	65.9	20.5	15.7
Kansas		170	57.6	42.9	64.1	44.1	67.1	17.1	12.4
Kentucky		477	66.9	42.3	68.1	50.1	72.5	26.6	13.6
Louisiana		155	61.3	54.2	65.8	33.5	73.5	13.5	11.6
Maine		196	57.1	25.5	58.2	20.9	65.8	37.2	19.9
Maryland		432	61.3	48.6	68.8	46.8	74.1	32.2	12.0
Massachusetts		440	60.2	49.8	59.1	36.4	67.0	38.2	14.1
Michigan		455	62.0	51.6	55.8	36.0	65.1	52.7	15.8
Minnesota		401	73.1	64.1	69.1	31.7	67.6	34.7	7.2
Mississippi		105	70.5	56.2	61.9	44.8	70.5	14.3	11.4
Missouri		278	70.5	47.8	67.3	59.4	76.6	31.3	8.6
Montana		129	43.4	25.6	54.3	20.2	65.1	10.9	26.4
Nebraska		123	52.0	58.5	52.8	35.0	52.8	13.0	22.8

Table 6.10b. Type of recovery support services offered by facilities, by state or jurisdiction: Row percent, 2020 (continued)

				Red	overy support se	rvices		
State or jurisdiction ¹	Number of facilities ²	Mentoring/peer support	Self-help groups (for example, AA, NA, SMART Recovery)	Assistance in locating housing for clients	Employment counseling or training for clients	Assistance with obtaining social services (for example, Medicaid, WIC, SSI, SSDI)	Recovery coach	None of these recovery support services offered
Nevada	109	72.5	65.1	74.3	54.1	80.7	25.7	3.7
New Hampshire	109	51.4	39.4	56.9	33.0	73.4	26.6	16.5
New Jersey	383	53.5	52.5	61.1	45.4	68.4	21.9	13.3
New Mexico	162	62.3	43.2	74.7	50.6	84.0	22.2	6.2
New York	894	70.8	53.4	65.7	51.9	83.2	32.2	2.2
North Carolina	611	47.0	37.8	53.2	38.6	56.3	16.0	17.7
North Dakota	87	47.1	39.1	54.0	27.6	58.6	21.8	18.4
Ohio	619	61.1	45.2	76.1	50.2	84.7	24.6	6.3
Oklahoma	195	72.8	39.0	71.8	42.6	81.5	35.9	4.1
Oregon	247	71.7	51.8	82.2	44.9	80.6	28.3	4.5
Pennsylvania	604	62.4	54.6	67.2	38.9	78.5	20.9	9.3
Puerto Rico	101	55.4	34.7	56.4	48.5	76.2	31.7	10.9
Rhode Island	63	68.3	42.9	69.8	47.6	77.8	47.6	9.5
South Carolina	124	60.5	55.6	53.2	32.3	62.9	22.6	9.7
South Dakota	58	53.4	55.2	55.2	31.0	63.8	17.2	10.3
Tennessee	311	57.2	51.4	69.1	43.7	60.8	28.9	7.1
Texas	509	69.5	53.8	58.5	46.4	57.4	37.5	10.8
Utah	333	69.1	59.5	56.5	52.6	58.9	30.3	13.5
Vermont	52	63.5	25.0	86.5	55.8	98.1	19.2	1.9
Virginia	249	63.9	43.4	63.1	32.9	65.1	22.9	11.6
Washington	457	49.7	42.0	69.1	37.6	71.8	15.8	9.8
West Virginia	126	68.3	42.9	69.8	32.5	75.4	54.0	8.7
Wisconsin	295	36.6	32.5	45.1	30.8	51.5	17.6	32.5
Wyoming	60	76.7	40.0	81.7	70.0	88.3	33.3	5.0
Other jurisdictions ³	10	90.0	70.0	80.0	80.0	70.0	60.0	

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Percentages sum to more than 100 percent, because a facility could offer more than one recovery support service.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.11a. Type of education and counseling services offered by facilities, by state or jurisdiction: Number, 2020

						Education	and counseli	ng services				
State or jurisdiction ¹	Total ²	HIV or AIDS education, counseling, or support	Hepatitis education, counseling, or support	Health education other than HIV/AIDS or hepatitis	Substance abuse education	Smoking/ tobacco cessation counseling	Individual counseling	Group counseling	Family counseling	Marital/ couples counseling	Vocational training or educational support	None of these education and counseling services offered
Total	16,066	9,781	8,860	9,553	15,660	9,926	15,529	14,863	12,740	9,238	2,972	48
Alabama	155	111	88	93	150	80	146	141	126	85	36	2
Alaska	105	83	80	81	104	67	98	94	81	59	28	
Arizona	447	193	205	259	439	241	416	420	336	266	132	2
Arkansas	171	106	92	88	155	104	166	162	151	110	36	2
California	1,734	1,128	1,020	1,112	1,714	986	1,712	1,632	1,326	889	476	6
Colorado	393	132	117	156	385	189	384	375	284	253	81	1
Connecticut	210	102	92	122	208	147	201	202	180	143	45	
Delaware	49	26	25	29	46	30	49	43	39	35	7	
District of Columbia	28	25	19	21	26	17	28	26	25	18	6	
Florida	712	573	421	448	693	411	699	673	609	463	117	
Georgia	348	219	180	210	344	168	341	327	286	189	66	
Hawaii	161	67	57	63	159	108	160	151	115	51	23	
Idaho	110	37	33	45	108	45	106	105	98	87	16	
Illinois	713	516	405	415	701	343	694	653	517	378	76	1
Indiana	416	206	205	197	406	262	363	369	317	242	45	
Iowa	185	78	61	82	184	109	185	163	167	133	11	
Kansas	170	103	90	85	159	86	166	153	133	110	15	2
Kentucky	477	281	259	235	465	213	462	441	358	282	77	1
Louisiana	155	93	89	96	154	100	150	148	127	92	17	1
Maine	196	77	77	87	188	135	182	154	141	118	13	
Maryland	432	282	265	274	412	270	411	400	327	237	71	2
Massachusetts	440	359	335	319	423	395	416	411	338	260	45	1
Michigan	455	207	194	227	430	240	448	405	381	309	67	3
Minnesota	401	325	294	295	394	206	397	387	304	196	69	
Mississippi	105	81	66	68	101	51	100	96	96	75	16	1
Missouri	278	161	155	192	272	173	270	269	220	170	43	
Montana	129	46	46	41	125	76	118	106	106	50	5	
Nebraska	123	52	42	56	120	72	121	102	114	99	18	

Table 6.11a. Type of education and counseling services offered by facilities, by state or jurisdiction: Number, 2020 (continued)

						Education	and counseli	ng services				
State or jurisdiction ¹	Total²	HIV or AIDS education, counseling, or support	Hepatitis education, counseling, or support	Health education other than HIV/AIDS or hepatitis	Substance abuse education	Smoking/ tobacco cessation counseling	Individual counseling	Group counseling	Family counseling	Marital/ couples counseling	Vocational training or educational support	None of these education and counseling services offered
Nevada	109	67	53	67	104	79	108	104	71	62	24	
New Hampshire	109	60	56	67	106	81	98	92	57	35	10	
New Jersey	383	242	213	245	376	262	372	362	348	262	70	1
New Mexico	162	73	84	98	159	103	161	150	144	135	34	
New York	894	738	726	744	885	821	887	867	712	445	265	2
North Carolina	611	290	250	281	588	382	571	531	432	310	86	3
North Dakota	87	30	33	42	83	46	79	72	60	42	8	
Ohio	619	334	328	352	597	333	607	586	489	354	133	
Oklahoma	195	158	134	146	189	168	194	185	168	129	40	
Oregon	247	154	149	161	236	189	239	235	193	126	45	
Pennsylvania	604	346	341	346	593	363	592	566	547	385	98	1
Puerto Rico	101	76	56	79	101	53	100	98	97	69	48	
Rhode Island	63	48	49	51	63	51	58	59	40	29	9	
South Carolina	124	81	66	63	121	76	120	106	99	74	19	1
South Dakota	58	32	23	29	56	38	56	54	50	36	11	
Tennessee	311	179	165	178	307	172	305	294	265	180	60	
Texas	509	396	359	341	501	392	499	464	421	263	86	3
Utah	333	115	119	168	315	229	319	311	303	260	80	6
Vermont	52	34	37	38	52	44	49	44	39	34	14	
Virginia	249	127	115	132	242	135	238	233	193	128	25	2
Washington	457	325	288	303	451	296	419	410	316	157	81	1
West Virginia	126	64	65	65	126	78	124	115	89	63	19	
Wisconsin	295	100	102	115	278	162	277	252	242	206	27	1
Wyoming	60	35	32	38	56	43	58	56	54	49	19	2
Other jurisdictions ³	10	8	5	8	10	6	10	9	9	6	4	<u>-</u> -

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, because a facility could offer more than one education and counseling service.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.11b. Type of education and counseling services offered by facilities, by state or jurisdiction: Row percent, 2020

						Educatio	n and counsel	ing services				
State or jurisdiction ¹	Number of facilities ²	HIV or AIDS education, counseling, or support	Hepatitis education, counseling, or support	Health education other than HIV/AIDS or hepatitis	Substance abuse education	Smoking/ tobacco cessation counseling	Individual counseling	Group counseling	Family counseling	Marital/ couples counseling	Vocational training or educational support	None of these education and counseling services offered
Total	16,066	60.9	55.1	59.5	97.5	61.8	96.7	92.5	79.3	57.5	18.5	0.3
Alabama	155	71.6	56.8	60.0	96.8	51.6	94.2	91.0	81.3	54.8	23.2	1.3
Alaska	105	79.0	76.2	77.1	99.0	63.8	93.3	89.5	77.1	56.2	26.7	
Arizona	447	43.2	45.9	57.9	98.2	53.9	93.1	94.0	75.2	59.5	29.5	0.4
Arkansas	171	62.0	53.8	51.5	90.6	60.8	97.1	94.7	88.3	64.3	21.1	1.2
California	1,734	65.1	58.8	64.1	98.8	56.9	98.7	94.1	76.5	51.3	27.5	0.3
Colorado	393	33.6	29.8	39.7	98.0	48.1	97.7	95.4	72.3	64.4	20.6	0.3
Connecticut	210	48.6	43.8	58.1	99.0	70.0	95.7	96.2	85.7	68.1	21.4	
Delaware	49	53.1	51.0	59.2	93.9	61.2	100.0	87.8	79.6	71.4	14.3	
District of Columbia	28	89.3	67.9	75.0	92.9	60.7	100.0	92.9	89.3	64.3	21.4	
Florida	712	80.5	59.1	62.9	97.3	57.7	98.2	94.5	85.5	65.0	16.4	
Georgia	348	62.9	51.7	60.3	98.9	48.3	98.0	94.0	82.2	54.3	19.0	
Hawaii	161	41.6	35.4	39.1	98.8	67.1	99.4	93.8	71.4	31.7	14.3	
Idaho	110	33.6	30.0	40.9	98.2	40.9	96.4	95.5	89.1	79.1	14.5	
Illinois	713	72.4	56.8	58.2	98.3	48.1	97.3	91.6	72.5	53.0	10.7	0.1
Indiana	416	49.5	49.3	47.4	97.6	63.0	87.3	88.7	76.2	58.2	10.8	
Iowa	185	42.2	33.0	44.3	99.5	58.9	100.0	88.1	90.3	71.9	5.9	
Kansas	170	60.6	52.9	50.0	93.5	50.6	97.6	90.0	78.2	64.7	8.8	1.2
Kentucky	477	58.9	54.3	49.3	97.5	44.7	96.9	92.5	75.1	59.1	16.1	0.2
Louisiana	155	60.0	57.4	61.9	99.4	64.5	96.8	95.5	81.9	59.4	11.0	0.6
Maine	196	39.3	39.3	44.4	95.9	68.9	92.9	78.6	71.9	60.2	6.6	
Maryland	432	65.3	61.3	63.4	95.4	62.5	95.1	92.6	75.7	54.9	16.4	0.5
Massachusetts	440	81.6	76.1	72.5	96.1	89.8	94.5	93.4	76.8	59.1	10.2	0.2
Michigan	455	45.5	42.6	49.9	94.5	52.7	98.5	89.0	83.7	67.9	14.7	0.7
Minnesota	401	81.0	73.3	73.6	98.3	51.4	99.0	96.5	75.8	48.9	17.2	
Mississippi	105	77.1	62.9	64.8	96.2	48.6	95.2	91.4	91.4	71.4	15.2	1.0
Missouri	278	57.9	55.8	69.1	97.8	62.2	97.1	96.8	79.1	61.2	15.5	
Montana	129	35.7	35.7	31.8	96.9	58.9	91.5	82.2	82.2	38.8	3.9	
Nebraska	123	42.3	34.1	45.5	97.6	58.5	98.4	82.9	92.7	80.5	14.6	

Table 6.11b. Type of education and counseling services offered by facilities, by state or jurisdiction: Row percent, 2020 (continued)

						Educatio	n and counsel	ing services				
State or jurisdiction ¹	Number of facilities²	HIV or AIDS education, counseling, or support	Hepatitis education, counseling, or support	Health education other than HIV/AIDS or hepatitis	Substance abuse education	Smoking/ tobacco cessation counseling	Individual counseling	Group counseling	Family counseling	Marital/ couples counseling	Vocational training or educational support	None of these education and counseling services offered
Nevada	109	61.5	48.6	61.5	95.4	72.5	99.1	95.4	65.1	56.9	22.0	
New Hampshire	109	55.0	51.4	61.5	97.2	74.3	89.9	84.4	52.3	32.1	9.2	
New Jersey	383	63.2	55.6	64.0	98.2	68.4	97.1	94.5	90.9	68.4	18.3	0.3
New Mexico	162	45.1	51.9	60.5	98.1	63.6	99.4	92.6	88.9	83.3	21.0	
New York	894	82.6	81.2	83.2	99.0	91.8	99.2	97.0	79.6	49.8	29.6	0.2
North Carolina	611	47.5	40.9	46.0	96.2	62.5	93.5	86.9	70.7	50.7	14.1	0.5
North Dakota	87	34.5	37.9	48.3	95.4	52.9	90.8	82.8	69.0	48.3	9.2	
Ohio	619	54.0	53.0	56.9	96.4	53.8	98.1	94.7	79.0	57.2	21.5	
Oklahoma	195	81.0	68.7	74.9	96.9	86.2	99.5	94.9	86.2	66.2	20.5	
Oregon	247	62.3	60.3	65.2	95.5	76.5	96.8	95.1	78.1	51.0	18.2	
Pennsylvania	604	57.3	56.5	57.3	98.2	60.1	98.0	93.7	90.6	63.7	16.2	0.2
Puerto Rico	101	75.2	55.4	78.2	100.0	52.5	99.0	97.0	96.0	68.3	47.5	
Rhode Island	63	76.2	77.8	81.0	100.0	81.0	92.1	93.7	63.5	46.0	14.3	
South Carolina	124	65.3	53.2	50.8	97.6	61.3	96.8	85.5	79.8	59.7	15.3	8.0
South Dakota	58	55.2	39.7	50.0	96.6	65.5	96.6	93.1	86.2	62.1	19.0	
Tennessee	311	57.6	53.1	57.2	98.7	55.3	98.1	94.5	85.2	57.9	19.3	
Texas	509	77.8	70.5	67.0	98.4	77.0	98.0	91.2	82.7	51.7	16.9	0.6
Utah	333	34.5	35.7	50.5	94.6	68.8	95.8	93.4	91.0	78.1	24.0	1.8
Vermont	52	65.4	71.2	73.1	100.0	84.6	94.2	84.6	75.0	65.4	26.9	
Virginia	249	51.0	46.2	53.0	97.2	54.2	95.6	93.6	77.5	51.4	10.0	8.0
Washington	457	71.1	63.0	66.3	98.7	64.8	91.7	89.7	69.1	34.4	17.7	0.2
West Virginia	126	50.8	51.6	51.6	100.0	61.9	98.4	91.3	70.6	50.0	15.1	
Wisconsin	295	33.9	34.6	39.0	94.2	54.9	93.9	85.4	82.0	69.8	9.2	0.3
Wyoming	60	58.3	53.3	63.3	93.3	71.7	96.7	93.3	90.0	81.7	31.7	3.3
Other jurisdictions ³	10	80.0	50.0	80.0	100.0	60.0	100.0	90.0	90.0	60.0	40.0	

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Percentages sum to more than 100 percent, because a facility could offer more than one education and counseling service.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.12a. Type of pharmacotherapies offered by facilities, by state or jurisdiction: Number, 2020

					Phar	rmacotherapies			
State or jurisdiction ¹	Total²	Disulfiram (Antabuse [®])	Naltrexone (oral)	Naltrexone (extended- release, injectable, for example, Vivitrol®)	Acamprosate (Campral [®])	Nicotine replacement	Non-nicotine smoking/tobacco cessation medications (for example, bupropion, varenicline)	Medications for psychiatric disorders	Methadone ³
Total	16,066	4,010	6,174	6,016	4,220	5,568	4,676	8,089	1,627
Alabama	155	34	35	28	34	33	28	69	18
Alaska	105	24	34	34	26	38	29	48	4
Arizona	447	110	182	190	119	164	156	266	59
Arkansas	171	13	28	50	11	30	22	94	6
California	1,734	446	639	584	389	584	456	759	155
Colorado	393	132	148	127	115	83	97	163	28
Connecticut	210	113	132	125	117	121	112	174	43
Delaware	49	23	33	32	19	12	13	38	15
District of Columbia	28	7	8	9	5	10	6	13	4
Florida	712	160	311	323	188	284	218	412	58
Georgia	348	50	86	71	50	90	79	189	70
Hawaii	161	17	13	9	15	28	20	23	4
Idaho	110	21	31	26	19	18	26	39	4
Illinois	713	119	193	214	138	179	159	279	85
Indiana	416	107	178	187	147	148	154	220	20
lowa	185	50	67	46	55	71	50	77	8
Kansas	170	39	59	51	39	42	37	64	7
Kentucky	477	62	149	181	51	116	63	251	26
Louisiana	155	36	69	71	53	78	66	91	11
Maine	196	41	57	51	44	42	37	68	10
Maryland	432	120	162	168	100	143	113	190	86
Massachusetts	440	167	233	218	191	207	170	236	77
Michigan	455	102	118	137	86	127	105	230	43
Minnesota	401	60	88	72	59	108	87	124	16
Mississippi	105	12	36	33	18	36	27	79	5
Missouri	278	114	179	176	127	133	126	184	16
Montana	129	23	39	37	29	32	26	34	3
Nebraska	123	17	19	12	18	29	28	56	3

Table 6.12a. Type of pharmacotherapies offered by facilities, by state or jurisdiction: Number, 2020 (continued)

					Pha	rmacotherapies			
State or jurisdiction ¹	Total ²	Disulfiram (Antabuse [®])	Naltrexone (oral)	Naltrexone (extended- release, injectable, for example, Vivitrol®)	Acamprosate (Campral®)	Nicotine replacement	Non-nicotine smoking/tobacco cessation medications (for example, bupropion, varenicline)	Medications for psychiatric disorders	Methadone ³
Nevada	109	21	39	30	17	38	36	50	14
New Hampshire	109	35	39	37	31	35	32	42	7
New Jersey	383	90	174	165	103	122	116	244	38
New Mexico	162	36	59	50	35	52	52	89	14
New York	894	400	616	549	491	619	481	642	159
North Carolina	611	163	195	182	159	195	181	327	75
North Dakota	87	24	28	24	22	29	25	32	3
Ohio	619	138	323	331	187	209	180	332	43
Oklahoma	195	24	39	37	39	70	47	90	19
Oregon	247	62	80	71	54	90	77	101	19
Pennsylvania	604	119	263	291	132	193	157	308	90
Puerto Rico	101	11	11	2	13	18	20	33	6
Rhode Island	63	27	22	30	19	32	16	34	21
South Carolina	124	20	41	38	23	29	23	29	22
South Dakota	58	6	15	10	11	15	12	21	1
Tennessee	311	59	106	124	49	100	87	162	9
Texas	509	93	148	129	115	167	119	199	86
Utah	333	117	161	166	101	154	139	193	18
Vermont	52	34	34	25	30	32	26	33	8
Virginia	249	62	103	102	69	71	68	157	34
Washington	457	98	151	139	81	134	102	219	29
West Virginia	126	48	60	79	45	58	46	89	8
Wisconsin	295	84	118	125	116	96	100	150	19
Wyoming	60	18	21	17	14	21	21	37	
Other jurisdictions ⁴	10	2	2	1	2	3	3	6	1

Table 6.12a. Type of pharmacotherapies offered by facilities, by state or jurisdiction: Number, 2020 (continued)

						Pharmacotherapies				
State or jurisdiction¹	Total ²	Buprenorphine with naloxone (for example, Suboxone®, Bunavail®, Zubsolv®, Cassipa®)	Buprenorphine without naloxone	Buprenorphine sub-dermal implant (Probuphine [®])	Buprenorphine (extended- release, injectable, for example, Sublocade [®])	Medications for HIV treatment (for example, antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine)	Medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)	Lofexidine	Clonidine	None of these pharmacotherapy services offered
Total	16,066	6,767	4,839	547	2,329	1,464	1,655	895	4,597	5,304
Alabama	155	54	38	3	12	14	13	12	39	49
Alaska	105	34	27	7	24	10	12	5	30	39
Arizona	447	201	159	25	83	45	60	40	161	122
Arkansas	171	59	33	3	11	8	7	1	32	54
California	1,734	751	575	100	277	261	263	137	544	704
Colorado	393	143	87	11	33	18	17	18	85	152
Connecticut	210	139	83	18	66	23	34	27	108	21
Delaware	49	29	23	3	9	11	12	2	17	4
District of Columbia	28	8	7	1	6	8	6		4	9
Florida	712	326	251	33	118	104	113	55	274	213
Georgia	348	86	76	4	31	20	24	8	100	79
Hawaii	161	16	13	1	5	5	5	4	13	125
Idaho	110	29	20	3	14	5	5	6	26	63
Illinois	713	226	145	10	77	73	85	27	118	349
Indiana	416	181	119	8	62	24	35	32	137	128
Iowa	185	45	36	1	7	7	7	2	45	84
Kansas	170	28	24	2	6	11	12	3	31	81
Kentucky	477	168	105	7	47	14	29	9	97	144
Louisiana	155	68	48	2	34	26	25	3	64	31
Maine	196	88	56	7	16	20	21	4	43	86
Maryland	432	241	174	18	86	34	31	24	87	124
Massachusetts	440	232	183	30	109	65	69	34	193	95
Michigan	455	144	81	10	52	16	24	14	92	144
Minnesota	401	94	61	15	26	21	20	10	58	222
Mississippi	105	43	26	4	8	8	7	3	37	15
Missouri	278	184	136	14	54	16	21	40	106	68
Montana	129	37	29	3	19	3	13	3	29	78
Nebraska	123	21	10	1	5	4	4	3	23	59

Table 6.12a. Type of pharmacotherapies offered by facilities, by state or jurisdiction: Number, 2020 (continued)

						Pharmacotherapies				
State or jurisdiction ¹	Total ²	Buprenorphine with naloxone (for example, Suboxone®, Bunavail®, Zubsolv®, Cassipa®)	Buprenorphine without naloxone	Buprenorphine sub-dermal implant (Probuphine®)	Buprenorphine (extended- release, injectable, for example, Sublocade®)	Medications for HIV treatment (for example, antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine)	Medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)	Lofexidine	Clonidine	None of these pharmacotherapy services offered
Nevada	109	44	35	4	15	12	10	6	30	43
New Hampshire	109	70	31	1	15	5	7	1	29	29
New Jersey	383	160	109	5	32	27	28	13	103	94
New Mexico	162	56	40	4	23	4	20	2	34	55
New York	894	675	471	34	223	148	162	77	345	104
North Carolina	611	259	221	18	82	33	38	38	188	187
North Dakota	87	18	13		11	3	3		25	47
Ohio	619	312	238	35	136	31	38	59	234	157
Oklahoma	195	57	30	3	15	16	21	13	39	69
Oregon	247	97	63	7	32	20	21	16	72	91
Pennsylvania	604	274	179	17	100	78	73	21	130	162
Puerto Rico	101	23	10		1	21	7	2	17	42
Rhode Island	63	32	18	3	15	6	5	2	15	18
South Carolina	124	52	48	2	11	10	10	4	23	54
South Dakota	58	9	9	2	5	5	4		14	30
Tennessee	311	103	69	2	29	10	17	9	75	84
Texas	509	180	120	10	39	52	50	16	128	189
Utah	333	163	133	32	62	40	38	49	140	109
Vermont	52	33	32		10	2	3		23	8
Virginia	249	132	84	3	41	10	16	5	68	48
Washington	457	165	126	8	67	23	58	7	119	194
West Virginia	126	64	45	2	19	12	19	7	49	17
Wisconsin	295	92	73	2	38	19	24	14	85	107
Wyoming	60	21	16	7	10	2	8	7	16	20
Other jurisdictions ⁴	10	1	1	2	1	1	1	1	3	4
Quantity is zero.										

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, because a facility could offer more than one pharmacotherapy.

³ Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.12b. Type of pharmacotherapies offered by facilities, by state or jurisdiction: Row percent, 2020

					Pharm	acotherapies			
State or jurisdiction ¹	Number of facilities ²	Disulfiram (Antabuse [®])	Naltrexone (oral)	Naltrexone (extended-release, injectable, for example, Vivitrol®)	Acamprosate (Campral [®])	Nicotine replacement	Non-nicotine smoking/tobacco cessation medications (for example, bupropion, varenicline)	Medications for psychiatric disorders	Methadone ³
Total	16,066	25.0	38.4	37.4	26.3	34.7	29.1	50.3	10.1
Alabama	155	21.9	22.6	18.1	21.9	21.3	18.1	44.5	11.6
Alaska	105	22.9	32.4	32.4	24.8	36.2	27.6	45.7	3.8
Arizona	447	24.6	40.7	42.5	26.6	36.7	34.9	59.5	13.2
Arkansas	171	7.6	16.4	29.2	6.4	17.5	12.9	55.0	3.5
California	1,734	25.7	36.9	33.7	22.4	33.7	26.3	43.8	8.9
Colorado	393	33.6	37.7	32.3	29.3	21.1	24.7	41.5	7.1
Connecticut	210	53.8	62.9	59.5	55.7	57.6	53.3	82.9	20.5
Delaware	49	46.9	67.3	65.3	38.8	24.5	26.5	77.6	30.6
District of									
Columbia	28	25.0	28.6	32.1	17.9	35.7	21.4	46.4	14.3
Florida	712	22.5	43.7	45.4	26.4	39.9	30.6	57.9	8.1
Georgia	348	14.4	24.7	20.4	14.4	25.9	22.7	54.3	20.1
Hawaii	161	10.6	8.1	5.6	9.3	17.4	12.4	14.3	2.5
Idaho	110	19.1	28.2	23.6	17.3	16.4	23.6	35.5	3.6
Illinois	713	16.7	27.1	30.0	19.4	25.1	22.3	39.1	11.9
Indiana	416	25.7	42.8	45.0	35.3	35.6	37.0	52.9	4.8
Iowa	185	27.0	36.2	24.9	29.7	38.4	27.0	41.6	4.3
Kansas	170	22.9	34.7	30.0	22.9	24.7	21.8	37.6	4.1
Kentucky	477	13.0	31.2	37.9	10.7	24.3	13.2	52.6	5.5
Louisiana	155	23.2	44.5	45.8	34.2	50.3	42.6	58.7	7.1
Maine	196	20.9	29.1	26.0	22.4	21.4	18.9	34.7	5.1
Maryland	432	27.8	37.5	38.9	23.1	33.1	26.2	44.0	19.9
Massachusetts	440	38.0	53.0	49.5	43.4	47.0	38.6	53.6	17.5
Michigan	455	22.4	25.9	30.1	18.9	27.9	23.1	50.5	9.5
Minnesota	401	15.0	21.9	18.0	14.7	26.9	21.7	30.9	4.0
Mississippi	105	11.4	34.3	31.4	17.1	34.3	25.7	75.2	4.8
Missouri	278	41.0	64.4	63.3	45.7	47.8	45.3	66.2	5.8
Montana	129	17.8	30.2	28.7	22.5	24.8	20.2	26.4	2.3
Nebraska	123	13.8	15.4	9.8	14.6	23.6	22.8	45.5	2.4

Table 6.12b. Type of pharmacotherapies offered by facilities, by state or jurisdiction: Row percent, 2020 (continued)

					Pharm	acotherapies			
State or jurisdiction ¹	Number of facilities²	Disulfiram (Antabuse [®])	Naltrexone (oral)	Naltrexone (extended-release, injectable, for example, Vivitrol®)	Acamprosate (Campral [®])	Nicotine replacement	Non-nicotine smoking/tobacco cessation medications (for example, bupropion, varenicline)	Medications for psychiatric disorders	Methadone ³
Nevada	109	19.3	35.8	27.5	15.6	34.9	33.0	45.9	12.8
New Hampshire	109	32.1	35.8	33.9	28.4	32.1	29.4	38.5	6.4
New Jersey	383	23.5	45.4	43.1	26.9	31.9	30.3	63.7	9.9
New Mexico	162	22.2	36.4	30.9	21.6	32.1	32.1	54.9	8.6
New York	894	44.7	68.9	61.4	54.9	69.2	53.8	71.8	17.8
North Carolina	611	26.7	31.9	29.8	26.0	31.9	29.6	53.5	12.3
North Dakota	87	27.6	32.2	27.6	25.3	33.3	28.7	36.8	3.4
Ohio	619	22.3	52.2	53.5	30.2	33.8	29.1	53.6	6.9
Oklahoma	195	12.3	20.0	19.0	20.0	35.9	24.1	46.2	9.7
Oregon	247	25.1	32.4	28.7	21.9	36.4	31.2	40.9	7.7
Pennsylvania	604	19.7	43.5	48.2	21.9	32.0	26.0	51.0	14.9
Puerto Rico	101	10.9	10.9	2.0	12.9	17.8	19.8	32.7	5.9
Rhode Island	63	42.9	34.9	47.6	30.2	50.8	25.4	54.0	33.3
South Carolina	124	16.1	33.1	30.6	18.5	23.4	18.5	23.4	17.7
South Dakota	58	10.3	25.9	17.2	19.0	25.9	20.7	36.2	1.7
Tennessee	311	19.0	34.1	39.9	15.8	32.2	28.0	52.1	2.9
Texas	509	18.3	29.1	25.3	22.6	32.8	23.4	39.1	16.9
Utah	333	35.1	48.3	49.8	30.3	46.2	41.7	58.0	5.4
Vermont	52	65.4	65.4	48.1	57.7	61.5	50.0	63.5	15.4
Virginia	249	24.9	41.4	41.0	27.7	28.5	27.3	63.1	13.7
Washington	457	21.4	33.0	30.4	17.7	29.3	22.3	47.9	6.3
West Virginia	126	38.1	47.6	62.7	35.7	46.0	36.5	70.6	6.3
Wisconsin	295	28.5	40.0	42.4	39.3	32.5	33.9	50.8	6.4
Wyoming	60	30.0	35.0	28.3	23.3	35.0	35.0	61.7	
Other jurisdictions ⁴	10	20.0	20.0	10.0	20.0	30.0	30.0	60.0	10.0

Table 6.12b. Type of pharmacotherapies offered by facilities, by state or jurisdiction: Row percent, 2020 (continued)

						Pharmacotherapies				
State or jurisdiction ¹	Number of facilities²	Buprenorphine with naloxone (for example, Suboxone®, Bunavail®, Zubsolv®, Cassipa®)	Buprenorphine without naloxone	Buprenorphine sub-dermal implant (Probuphine®)	Buprenorphine (extended- release, injectable, for example, Sublocade®)	Medications for HIV treatment (for example, antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine)	Medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)	Lofexidine	Clonidine	None of these pharmacotherapy services offered
To	tal 16,066	42.1	30.1	3.4	14.5	9.1	10.3	5.6	28.6	33.0
Alabama	155	34.8	24.5	1.9	7.7	9.0	8.4	7.7	25.2	31.6
Alaska	105	32.4	25.7	6.7	22.9	9.5	11.4	4.8	28.6	37.1
Arizona	447	45.0	35.6	5.6	18.6	10.1	13.4	8.9	36.0	27.3
Arkansas	171	34.5	19.3	1.8	6.4	4.7	4.1	0.6	18.7	31.6
California	1,734	43.3	33.2	5.8	16.0	15.1	15.2	7.9	31.4	40.6
Colorado	393	36.4	22.1	2.8	8.4	4.6	4.3	4.6	21.6	38.7
Connecticut	210	66.2	39.5	8.6	31.4	11.0	16.2	12.9	51.4	10.0
Delaware	49	59.2	46.9	6.1	18.4	22.4	24.5	4.1	34.7	8.2
District of										
Columbia	28	28.6	25.0	3.6	21.4	28.6	21.4		14.3	32.1
Florida	712	45.8	35.3	4.6	16.6	14.6	15.9	7.7	38.5	29.9
Georgia	348	24.7	21.8	1.1	8.9	5.7	6.9	2.3	28.7	22.7
Hawaii	161	9.9	8.1	0.6	3.1	3.1	3.1	2.5	8.1	77.6
Idaho	110	26.4	18.2	2.7	12.7	4.5	4.5	5.5	23.6	57.3
Illinois	713	31.7	20.3	1.4	10.8	10.2	11.9	3.8	16.5	48.9
Indiana	416	43.5	28.6	1.9	14.9	5.8	8.4	7.7	32.9	30.8
Iowa	185	24.3	19.5	0.5	3.8	3.8	3.8	1.1	24.3	45.4
Kansas	170	16.5	14.1	1.2	3.5	6.5	7.1	1.8	18.2	47.6
Kentucky	477	35.2	22.0	1.5	9.9	2.9	6.1	1.9	20.3	30.2
Louisiana	155	43.9	31.0	1.3	21.9	16.8	16.1	1.9	41.3	20.0
Maine	196	44.9	28.6	3.6	8.2	10.2	10.7	2.0	21.9	43.9
Maryland	432	55.8	40.3	4.2	19.9	7.9	7.2	5.6	20.1	28.7
Massachusetts	440	52.7	41.6	6.8	24.8	14.8	15.7	7.7	43.9	21.6
Michigan	455	31.6	17.8	2.2	11.4	3.5	5.3	3.1	20.2	31.6
Minnesota	401	23.4	15.2	3.7	6.5	5.2	5.0	2.5	14.5	55.4
Mississippi	105	41.0	24.8	3.8	7.6	7.6	6.7	2.9	35.2	14.3
Missouri	278	66.2	48.9	5.0	19.4	5.8	7.6	14.4	38.1	24.5
Montana	129	28.7	22.5	2.3	14.7	2.3	10.1	2.3	22.5	60.5
Nebraska	123	17.1	8.1	0.8	4.1	3.3	3.3	2.4	18.7	48.0

Table 6.12b. Type of pharmacotherapies offered by facilities, by state or jurisdiction: Row percent, 2020 (continued)

						Pharmacotherapies				
State or jurisdiction ¹	Number of facilities²	Buprenorphine with naloxone (for example, Suboxone [®] , Bunavail [®] , Zubsolv [®] , Cassipa [®])	Buprenorphine without naloxone	Buprenorphine sub-dermal implant (Probuphine®)	Buprenorphine (extended- release, injectable, for example, Sublocade®)	Medications for HIV treatment (for example, antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine)	Medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)	Lofexidine	Clonidine	None of these pharmacotherapy services offered
Nevada	109	40.4	32.1	3.7	13.8	11.0	9.2	5.5	27.5	39.4
New Hampshire	109	64.2	28.4	0.9	13.8	4.6	6.4	0.9	26.6	26.6
New Jersey	383	41.8	28.5	1.3	8.4	7.0	7.3	3.4	26.9	24.5
New Mexico	162	34.6	24.7	2.5	14.2	2.5	12.3	1.2	21.0	34.0
New York	894	75.5	52.7	3.8	24.9	16.6	18.1	8.6	38.6	11.6
North Carolina	611	42.4	36.2	2.9	13.4	5.4	6.2	6.2	30.8	30.6
North Dakota	87	20.7	14.9		12.6	3.4	3.4		28.7	54.0
Ohio	619	50.4	38.4	5.7	22.0	5.0	6.1	9.5	37.8	25.4
Oklahoma	195	29.2	15.4	1.5	7.7	8.2	10.8	6.7	20.0	35.4
Oregon	247	39.3	25.5	2.8	13.0	8.1	8.5	6.5	29.1	36.8
Pennsylvania	604	45.4	29.6	2.8	16.6	12.9	12.1	3.5	21.5	26.8
Puerto Rico	101	22.8	9.9		1.0	20.8	6.9	2.0	16.8	41.6
Rhode Island	63	50.8	28.6	4.8	23.8	9.5	7.9	3.2	23.8	28.6
South Carolina	124	41.9	38.7	1.6	8.9	8.1	8.1	3.2	18.5	43.5
South Dakota	58	15.5	15.5	3.4	8.6	8.6	6.9		24.1	51.7
Tennessee	311	33.1	22.2	0.6	9.3	3.2	5.5	2.9	24.1	27.0
Texas	509	35.4	23.6	2.0	7.7	10.2	9.8	3.1	25.1	37.1
Utah	333	48.9	39.9	9.6	18.6	12.0	11.4	14.7	42.0	32.7
Vermont	52	63.5	61.5		19.2	3.8	5.8		44.2	15.4
Virginia	249	53.0	33.7	1.2	16.5	4.0	6.4	2.0	27.3	19.3
Washington	457	36.1	27.6	1.8	14.7	5.0	12.7	1.5	26.0	42.5
West Virginia	126	50.8	35.7	1.6	15.1	9.5	15.1	5.6	38.9	13.5
Wisconsin	295	31.2	24.7	0.7	12.9	6.4	8.1	4.7	28.8	36.3
Wyoming	60	35.0	26.7	11.7	16.7	3.3	13.3	11.7	26.7	33.3
Other jurisdictions ⁴	10	10.0	10.0	20.0	10.0	10.0	10.0	10.0	30.0	40.0

^{- -} Quantity is zero

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Percentages sum to more than 100 percent, because a facility could offer more than one pharmacotherapy.

³ Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.13a. Type of ancillary services offered by facilities, by state or jurisdiction: Number, 2020

						Ancillary se	ervices				
State or jurisdiction ¹	Total ²	Case management services	Social skills development	Child care for clients' children	Domestic violence services ³	Early intervention for HIV	Transportation assistance to treatment	Mental health services	Acupuncture	Residential beds for clients' children	None of these ancillary services offered
Total	16,066	13,377	11,959	884	5,974	3,647	7,641	11,364	950	397	506
Alabama	155	140	109	5	43	46	50	81	2	2	7
Alaska	105	94	85	6	51	20	57	87		5	2
Arizona	447	381	365	11	207	81	310	353	34	8	11
Arkansas	171	162	151	11	61	32	76	138		5	
California	1,734	1,597	1,480	182	683	475	964	1,130	159	85	32
Colorado	393	323	288	20	126	43	141	289	56	3	18
Connecticut	210	175	165	17	89	61	125	194	61	6	1
Delaware	49	38	39		25	21	30	43	3		1
District of Columbia	28	25	20		9	14	15	21	4		
Florida	712	583	530	15	307	252	273	550	66	15	11
Georgia	348	311	287	11	127	112	125	235	3	12	6
Hawaii	161	143	148	29	32	12	91	57	5	3	
Idaho	110	101	86	6	46	11	45	100	1	1	1
Illinois	713	614	429	27	227	185	251	475	18	6	28
Indiana	416	346	283	13	181	44	157	298	15	5	11
lowa	185	131	125	6	72	25	57	115	3	6	8
Kansas	170	116	121	4	59	26	63	93	5	3	17
Kentucky	477	413	348	9	258	104	173	351	2	9	22
Louisiana	155	136	110	9	49	59	76	107	6	5	5
Maine	196	126	117	3	59	32	51	139	6	2	17
Maryland	432	344	297	21	143	132	219	278	48	7	24
Massachusetts	440	388	304	16	147	139	229	294	26	14	10
Michigan	455	324	323	41	245	96	238	372	77	13	9
Minnesota	401	331	326	19	119	53	179	266	13	8	6
Mississippi	105	85	85	2	47	38	39	86	2	3	4
Missouri	278	239	220	17	88	35	148	208	6	9	6
Montana	129	95	93	2	26	17	54	98	6	3	2
Nebraska	123	97	95	5	54	9	43	106	3	4	2

Table 6.13a. Type of ancillary services offered by facilities, by state or jurisdiction: Number, 2020 (continued)

						Ancillary se	ervices				
State or jurisdiction ¹	Total²	Case management services	Social skills development	Child care for clients' children	Domestic violence services ³	Early intervention for HIV	Transportation assistance to treatment	Mental health services	Acupuncture	Residential beds for clients' children	None of these ancillary services offered
Nevada	109	96	80	3	52	39	58	90	4	1	2
New Hampshire	109	77	58	6	18	13	33	64	7	1	4
New Jersey	383	326	298	29	176	110	204	324	14	4	8
New Mexico	162	141	134	6	95	21	80	140	23	3	
New York	894	718	682	37	316	273	561	634	32	21	22
North Carolina	611	411	370	27	184	82	205	427	18	16	46
North Dakota	87	61	57	3	29	1	35	59	4	2	8
Ohio	619	586	472	54	220	98	342	464	11	17	12
Oklahoma	195	182	165	9	83	48	93	148		6	2
Oregon	247	218	198	29	104	56	147	155	20	10	15
Pennsylvania	604	419	415	33	172	132	320	332	26	12	34
Puerto Rico	101	75	87	6	37	41	60	63	9	3	
Rhode Island	63	56	53	3	23	21	43	51	8	1	1
South Carolina	124	109	80	6	47	41	55	57	5	3	8
South Dakota	58	47	43	3	23	7	30	38	2	2	3
Tennessee	311	270	213	13	111	58	130	223	15	4	24
Texas	509	440	398	22	136	140	218	308	36	10	14
Utah	333	259	269	15	138	49	132	291	10	13	9
Vermont	52	47	44	3	22	13	31	40	2	1	
Virginia	249	212	168	16	76	33	108	182	41	4	10
Washington	457	402	322	28	106	104	254	287	18	8	14
West Virginia	126	107	79	2	52	25	69	112	5	6	2
Wisconsin	295	196	185	13	128	39	106	244	4	2	6
Wyoming	60	54	50	8	41	23	40	59	5	5	1
Other jurisdictions⁴	10	10	10	3	5	6	8	8	1		

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, and percentages sum to more than 100 percent, because a facility could offer more than one ancillary service.

³ Domestic violence services includes family or partner violence services, for physical, sexual, or emotional abuse.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.13b. Type of ancillary services offered by facilities, by state or jurisdiction: Row percent, 2020

							Ancillary se	rvices				
State or jurisdiction ¹		Number of facilities ²	Case management services	Social skills development	Child care for clients' children	Domestic violence services ³	Early intervention for HIV	Transportation assistance to treatment	Mental health services	Acupuncture	Residential beds for clients' children	None of these ancillary services offered
	Total	16,066	83.3	74.4	5.5	37.2	22.7	47.6	70.7	5.9	2.5	3.1
Alabama		155	90.3	70.3	3.2	27.7	29.7	32.3	52.3	1.3	1.3	4.5
Alaska		105	89.5	81.0	5.7	48.6	19.0	54.3	82.9		4.8	1.9
Arizona		447	85.2	81.7	2.5	46.3	18.1	69.4	79.0	7.6	1.8	2.5
Arkansas		171	94.7	88.3	6.4	35.7	18.7	44.4	80.7		2.9	
California		1,734	92.1	85.4	10.5	39.4	27.4	55.6	65.2	9.2	4.9	1.8
Colorado		393	82.2	73.3	5.1	32.1	10.9	35.9	73.5	14.2	0.8	4.6
Connecticut		210	83.3	78.6	8.1	42.4	29.0	59.5	92.4	29.0	2.9	0.5
Delaware		49	77.6	79.6		51.0	42.9	61.2	87.8	6.1		2.0
District of Colun	nbia	28	89.3	71.4		32.1	50.0	53.6	75.0	14.3		
Florida		712	81.9	74.4	2.1	43.1	35.4	38.3	77.2	9.3	2.1	1.5
Georgia		348	89.4	82.5	3.2	36.5	32.2	35.9	67.5	0.9	3.4	1.7
Hawaii		161	88.8	91.9	18.0	19.9	7.5	56.5	35.4	3.1	1.9	
Idaho		110	91.8	78.2	5.5	41.8	10.0	40.9	90.9	0.9	0.9	0.9
Illinois		713	86.1	60.2	3.8	31.8	25.9	35.2	66.6	2.5	0.8	3.9
Indiana		416	83.2	68.0	3.1	43.5	10.6	37.7	71.6	3.6	1.2	2.6
Iowa		185	70.8	67.6	3.2	38.9	13.5	30.8	62.2	1.6	3.2	4.3
Kansas		170	68.2	71.2	2.4	34.7	15.3	37.1	54.7	2.9	1.8	10.0
Kentucky		477	86.6	73.0	1.9	54.1	21.8	36.3	73.6	0.4	1.9	4.6
Louisiana		155	87.7	71.0	5.8	31.6	38.1	49.0	69.0	3.9	3.2	3.2
Maine		196	64.3	59.7	1.5	30.1	16.3	26.0	70.9	3.1	1.0	8.7
Maryland		432	79.6	68.8	4.9	33.1	30.6	50.7	64.4	11.1	1.6	5.6
Massachusetts		440	88.2	69.1	3.6	33.4	31.6	52.0	66.8	5.9	3.2	2.3
Michigan		455	71.2	71.0	9.0	53.8	21.1	52.3	81.8	16.9	2.9	2.0
Minnesota		401	82.5	81.3	4.7	29.7	13.2	44.6	66.3	3.2	2.0	1.5
Mississippi		105	81.0	81.0	1.9	44.8	36.2	37.1	81.9	1.9	2.9	3.8
Missouri		278	86.0	79.1	6.1	31.7	12.6	53.2	74.8	2.2	3.2	2.2
Montana		129	73.6	72.1	1.6	20.2	13.2	41.9	76.0	4.7	2.3	1.6
Nebraska		123	78.9	77.2	4.1	43.9	7.3	35.0	86.2	2.4	3.3	1.6

Table 6.13b. Type of ancillary services offered by facilities, by state or jurisdiction: Row percent, 2020 (continued)

						Ancillary se	ervices				
State or jurisdiction ¹	Number of facilities²	Case management services	Social skills development	Child care for clients' children	Domestic violence services ³	Early intervention for HIV	Transportation assistance to treatment	Mental health services	Acupuncture	Residential beds for clients' children	None of these ancillary services offered
Nevada	109	88.1	73.4	2.8	47.7	35.8	53.2	82.6	3.7	0.9	1.8
New Hampshire	109	70.6	53.2	5.5	16.5	11.9	30.3	58.7	6.4	0.9	3.7
New Jersey	383	85.1	77.8	7.6	46.0	28.7	53.3	84.6	3.7	1.0	2.1
New Mexico	162	87.0	82.7	3.7	58.6	13.0	49.4	86.4	14.2	1.9	
New York	894	80.3	76.3	4.1	35.3	30.5	62.8	70.9	3.6	2.3	2.5
North Carolina	611	67.3	60.6	4.4	30.1	13.4	33.6	69.9	2.9	2.6	7.5
North Dakota	87	70.1	65.5	3.4	33.3	1.1	40.2	67.8	4.6	2.3	9.2
Ohio	619	94.7	76.3	8.7	35.5	15.8	55.3	75.0	1.8	2.7	1.9
Oklahoma	195	93.3	84.6	4.6	42.6	24.6	47.7	75.9		3.1	1.0
Oregon	247	88.3	80.2	11.7	42.1	22.7	59.5	62.8	8.1	4.0	6.1
Pennsylvania	604	69.4	68.7	5.5	28.5	21.9	53.0	55.0	4.3	2.0	5.6
Puerto Rico	101	74.3	86.1	5.9	36.6	40.6	59.4	62.4	8.9	3.0	
Rhode Island	63	88.9	84.1	4.8	36.5	33.3	68.3	81.0	12.7	1.6	1.6
South Carolina	124	87.9	64.5	4.8	37.9	33.1	44.4	46.0	4.0	2.4	6.5
South Dakota	58	81.0	74.1	5.2	39.7	12.1	51.7	65.5	3.4	3.4	5.2
Tennessee	311	86.8	68.5	4.2	35.7	18.6	41.8	71.7	4.8	1.3	7.7
Texas	509	86.4	78.2	4.3	26.7	27.5	42.8	60.5	7.1	2.0	2.8
Utah	333	77.8	80.8	4.5	41.4	14.7	39.6	87.4	3.0	3.9	2.7
Vermont	52	90.4	84.6	5.8	42.3	25.0	59.6	76.9	3.8	1.9	
Virginia	249	85.1	67.5	6.4	30.5	13.3	43.4	73.1	16.5	1.6	4.0
Washington	457	88.0	70.5	6.1	23.2	22.8	55.6	62.8	3.9	1.8	3.1
West Virginia	126	84.9	62.7	1.6	41.3	19.8	54.8	88.9	4.0	4.8	1.6
Wisconsin	295	66.4	62.7	4.4	43.4	13.2	35.9	82.7	1.4	0.7	2.0
Wyoming	60	90.0	83.3	13.3	68.3	38.3	66.7	98.3	8.3	8.3	1.7
Other jurisdictions ⁴	10	100.0	100.0	30.0	50.0	60.0	80.0	80.0	10.0		

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, and percentages sum to more than 100 percent, because a facility could offer more than one ancillary service.

³ Domestic violence services includes family or partner violence services, for physical, sexual, or emotional abuse.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.14. Type of other services offered by facilities, by state or jurisdiction: Number and row percent, 2020

	_		ı	Number of facilitie	2S ²			Row percer	nt of facilities²	
				Other .	services			Other	services	
State or jurisdiction ¹		Total	Treatment for gambling disorder	Treatment for Internet use disorder	Treatment for other addiction disorder (non- substance abuse)	None of these 'other' services offered	Treatment for gambling disorder	Treatment for Internet use disorder	Treatment for other addiction disorder (non- substance abuse)	None of these 'other' services offered
	Total	16,066	4,433	2,686	5,920	8,953	27.6	16.7	36.8	55.7
Alabama		155	18	16	37	115	11.6	10.3	23.9	74.2
Alaska		105	20	19	43	61	19.0	18.1	41.0	58.1
Arizona		447	103	87	192	246	23.0	19.5	43.0	55.0
Arkansas		171	51	43	77	90	29.8	25.1	45.0	52.6
California		1,734	307	263	561	1,124	17.7	15.2	32.4	64.8
Colorado		393	70	60	166	209	17.8	15.3	42.2	53.2
Connecticut		210	105	39	109	69	50.0	18.6	51.9	32.9
Delaware		49	17	10	21	24	34.7	20.4	42.9	49.0
District of Columbia		28	6	4	7	18	21.4	14.3	25.0	64.3
Florida		712	207	187	323	374	29.1	26.3	45.4	52.5
Georgia		348	57	50	137	207	16.4	14.4	39.4	59.5
Hawaii		161	24	22	26	135	14.9	13.7	16.1	83.9
Idaho		110	38	36	66	44	34.5	32.7	60.0	40.0
Illinois		713	211	125	227	416	29.6	17.5	31.8	58.3
Indiana		416	151	90	192	195	36.3	21.6	46.2	46.9
Iowa		185	92	35	86	47	49.7	18.9	46.5	25.4
Kansas		170	32	23	44	111	18.8	13.5	25.9	65.3
Kentucky		477	136	122	210	258	28.5	25.6	44.0	54.1
Louisiana		155	57	16	58	77	36.8	10.3	37.4	49.7
Maine		196	54	42	102	91	27.6	21.4	52.0	46.4
Maryland		432	178	68	150	202	41.2	15.7	34.7	46.8
Massachusetts		440	173	78	185	206	39.3	17.7	42.0	46.8
Michigan		455	167	129	221	206	36.7	28.4	48.6	45.3
Minnesota		401	49	18	69	307	12.2	4.5	17.2	76.6
Mississippi		105	36	21	54	47	34.3	20.0	51.4	44.8
Missouri		278	59	28	61	186	21.2	10.1	21.9	66.9
Montana		129	83	28	40	43	64.3	21.7	31.0	33.3
Nebraska		123	43	33	71	44	35.0	26.8	57.7	35.8

Table 6.14. Type of other services offered by facilities, by state or jurisdiction: Number and row percent, 2020 (continued)

		I	Number of facilitie	S ²			Row percer	nt of facilities²	
			Other:	services			Other	services	
State or jurisdiction ¹	Total	Treatment for gambling disorder	Treatment for Internet use disorder	Treatment for other addiction disorder (non- substance abuse)	None of these 'other' services offered	Treatment for gambling disorder	Treatment for Internet use disorder	Treatment for other addiction disorder (non- substance abuse)	None of these 'other' services offered
Nevada	109	43	28	43	53	39.4	25.7	39.4	48.6
New Hampshire	109	13	9	31	77	11.9	8.3	28.4	70.6
New Jersey	383	144	73	188	165	37.6	19.1	49.1	43.1
New Mexico	162	77	51	93	59	47.5	31.5	57.4	36.4
New York	894	247	55	193	560	27.6	6.2	21.6	62.6
North Carolina	611	149	124	240	358	24.4	20.3	39.3	58.6
North Dakota	87	7	7	22	64	8.0	8.0	25.3	73.6
Ohio	619	216	82	230	319	34.9	13.2	37.2	51.5
Oklahoma	195	68	29	73	100	34.9	14.9	37.4	51.3
Oregon	247	81	19	76	128	32.8	7.7	30.8	51.8
Pennsylvania	604	175	51	184	342	29.0	8.4	30.5	56.6
Puerto Rico	101	22	17	45	52	21.8	16.8	44.6	51.5
Rhode Island	63	26	8	22	27	41.3	12.7	34.9	42.9
South Carolina	124	58	12	39	52	46.8	9.7	31.5	41.9
South Dakota	58	28	7	21	19	48.3	12.1	36.2	32.8
Tennessee	311	52	42	96	209	16.7	13.5	30.9	67.2
Texas	509	57	51	117	386	11.2	10.0	23.0	75.8
Utah	333	101	118	215	114	30.3	35.4	64.6	34.2
Vermont	52	19	14	27	24	36.5	26.9	51.9	46.2
Virginia	249	31	36	80	167	12.4	14.5	32.1	67.1
Washington	457	61	22	71	351	13.3	4.8	15.5	76.8
West Virginia	126	57	33	55	54	45.2	26.2	43.7	42.9
Wisconsin	295	126	83	179	99	42.7	28.1	60.7	33.6
Wyoming	60	29	22	42	16	48.3	36.7	70.0	26.7
Other jurisdictions ³	10	2	1	3	6	20.0	10.0	30.0	60.0

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, and percentages sum to more than 100 percent, because a facility could offer more than one other service.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.15. Type of client substance abuse problem treated and treatment of clients with diagnosed co-occurring mental and substance use disorders, by state or jurisdiction: Number and row percent, 2020

				Number of facil	lities ^{2,3}			Row perc	ent of facilities²	
			Client	substance abuse pi	roblem		Client	substance abuse pi	roblem	
State or jurisdiction ¹		Total ²	Treats clients with both alcohol and drug abuse	Treats clients with drug abuse only	Treats clients with alcohol abuse only	Treats clients with diagnosed co-occurring mental and substance use disorders	Treats clients with both alcohol and drug abuse	Treats clients with drug abuse only	Treats clients with alcohol abuse only	Treats clients with diagnosed co-occurring mental and substance use disorders
То	tal	8,474	7,389	7,276	6,310	7,467	87.2	85.9	74.5	88.1
Alabama		92	78	83	67	82	84.8	90.2	72.8	89.1
Alaska		61	50	48	46	45	82.0	78.7	75.4	73.8
Arizona		220	185	178	155	193	84.1	80.9	70.5	87.7
Arkansas		69	54	54	38	63	78.3	78.3	55.1	91.3
California		981	868	790	709	870	88.5	80.5	72.3	88.7
Colorado		202	184	168	177	177	91.1	83.2	87.6	87.6
Connecticut		98	95	86	80	93	96.9	87.8	81.6	94.9
Delaware		31	28	25	21	31	90.3	80.6	67.7	100.0
District of Columbia		20	18	16	15	18	90.0	80.0	75.0	90.0
Florida		378	332	328	294	339	87.8	86.8	77.8	89.7
Georgia		195	150	163	127	167	76.9	83.6	65.1	85.6
Hawaii		75	71	57	37	46	94.7	76.0	49.3	61.3
Idaho		50	47	45	41	45	94.0	90.0	82.0	90.0
Illinois		338	292	294	266	267	86.4	87.0	78.7	79.0
Indiana		212	173	189	144	165	81.6	89.2	67.9	77.8
Iowa		86	79	72	72	70	91.9	83.7	83.7	81.4
Kansas		100	95	82	84	87	95.0	82.0	84.0	87.0
Kentucky		237	199	222	169	207	84.0	93.7	71.3	87.3
Louisiana		83	75	73	65	74	90.4	88.0	78.3	89.2
Maine		114	89	89	76	93	78.1	78.1	66.7	81.6
Maryland		222	192	197	146	198	86.5	88.7	65.8	89.2
Massachusetts		241	212	210	187	223	88.0	87.1	77.6	92.5
Michigan		209	192	186	175	190	91.9	89.0	83.7	90.9
Minnesota		252	224	202	185	238	88.9	80.2	73.4	94.4
Mississippi		53	48	50	43	47	90.6	94.3	81.1	88.7
Missouri		116	103	109	98	104	88.8	94.0	84.5	89.7
Montana		58	53	50	40	47	91.4	86.2	69.0	81.0
Nebraska		65	61	55	53	64	93.8	84.6	81.5	98.5

Table 6.15. Type of client substance abuse problem treated and treatment of clients with diagnosed co-occurring mental and substance use disorders, by state or jurisdiction: Number and row percent, 2020 (continued)

			Number of faci	lities ^{2,3}			Row perc	ent of facilities²	
		Client	substance abuse p	roblem		Client	substance abuse p	roblem	
State or jurisdiction¹	Total ²	Treats clients with both alcohol and drug abuse	Treats clients with drug abuse only	Treats clients with alcohol abuse only	Treats clients with diagnosed co-occurring mental and substance use disorders	Treats clients with both alcohol and drug abuse	Treats clients with drug abuse only	Treats clients with alcohol abuse only	Treats clients with diagnosed co- occurring mental and substance use disorders
Nevada	50	45	42	37	44	90.0	84.0	74.0	88.0
New Hampshire	62	45	56	40	50	72.6	90.3	64.5	80.6
New Jersey	225	210	187	192	207	93.3	83.1	85.3	92.0
New Mexico	93	81	82	75	87	87.1	88.2	80.6	93.5
New York	507	472	451	406	487	93.1	89.0	80.1	96.1
North Carolina	332	270	290	233	295	81.3	87.3	70.2	88.9
North Dakota	34	28	25	25	25	82.4	73.5	73.5	73.5
Ohio	295	250	266	219	258	84.7	90.2	74.2	87.5
Oklahoma	96	88	84	76	82	91.7	87.5	79.2	85.4
Oregon	125	112	105	92	104	89.6	84.0	73.6	83.2
Pennsylvania	345	315	303	269	330	91.3	87.8	78.0	95.7
Puerto Rico	57	40	40	30	44	70.2	70.2	52.6	77.2
Rhode Island	23	22	21	14	23	95.7	91.3	60.9	100.0
South Carolina	75	60	69	56	57	80.0	92.0	74.7	76.0
South Dakota	31	31	24	27	25	100.0	77.4	87.1	80.6
Tennessee	170	139	154	127	150	81.8	90.6	74.7	88.2
Texas	279	216	252	194	245	77.4	90.3	69.5	87.8
Utah	173	153	136	117	154	88.4	78.6	67.6	89.0
Vermont	21	18	20	16	19	85.7	95.2	76.2	90.5
Virginia	116	98	100	84	104	84.5	86.2	72.4	89.7
Washington	241	221	208	160	182	91.7	86.3	66.4	75.5
West Virginia	68	51	67	42	62	75.0	98.5	61.8	91.2
Wisconsin	153	133	133	128	148	86.9	86.9	83.7	96.7
Wyoming	41	40	37	37	38	97.6	90.2	90.2	92.7
Other jurisdictions⁴	4	4	3	4	4	100.0	75.0	100.0	100.0

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, and percentages sum to more than 100 percent, because a facility could treat more than one type of client substance abuse problem.

³ Of 16,066 facilities, 7,592 facilities (47 percent) did not respond to the questions on client substance abuse problem and diagnosed co-occurring mental and substance use disorders; percentages are based on the remaining 8,474 facilities.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.16. Facility size, by type of care offered and state or jurisdiction at facilities with opioid treatment programs (OTPs):

Median number of clients per facility, March 31, 2020

							Type of c	are offered						
					Outpatient				Reside	ntial (non-l	nospital)		Hospital ii	npatient
State or jurisdiction ¹	AII facilitie:	Total out- 2 patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Total residential	Short- term	Long- term	Detox	Total inpatient hospital	Treatment	Detox
To	tal 260	280	55	13	20	5	270	31	21	30	14	23	19	15
Alabama	376	376	683			5	363							
Alaska	259	259					259							
Arizona	320	320	84	40	14	100	219							
Arkansas	197		223				164	19		19				
California	227	220	140	30		3	220	164	27	137		62		62
Colorado	260	260	54				197	21	16	2	12			
Connecticut	567	632	25	15			605	15	16	65	14	11		11
Delaware	360	599	546	20			360	12	1	7	16	12	1	11
District of Columbia	460	460					460							
Florida	263	283	20	5	23	5	324	10	12	8	3	13	4	9
Georgia	142	142	183			10	142							
Hawaii	112						112							
Idaho	386	386					386							
Illinois	208	216	19	10		3	195	9	8	10	7	36	22	15
Indiana	424	424	154		130	2	453							
Iowa	330	330	1				330							
Kansas	313						313							
Kentucky	352	352	276	6	28		351					68	48	20
Louisiana	439	439	30			900	600	30		30				
Maine	395	395					395							
Maryland	253	257	10	11		6	264	65	29	70	28	61	31	30
Massachusetts	196		25	10	16	5	475	34	32	74	31	29	48	28
Michigan	218		10	5		59	218	58	45		14			
Minnesota	248	260	10	28			255					23	22	1
Mississippi	213		13				200							
Missouri	232	232	85			7	236							
Montana	229						229							
Nebraska	216		290			113	135							
Nevada	254			14		320	287	7	7			5	4	3
New Hampshire	363					18	363							

Table 6.16. Facility size, by type of care offered and state or jurisdiction at facilities with opioid treatment programs (OTPs):

Median number of clients per facility, March 31, 2020 (continued)

							Type of c	are offered						
					Outpatient				Reside	ntial (non-h	ospital)		Hospital in	npatient
State or jurisdiction¹	All facilities²	All Total out-	Treatment	Detox										
New Jersey	237	411	25	24		30	500	60	17	94	15	64	45	19
New Mexico	386	386	55			297	298							
New York	223	334	80	12	18	7	328	37	31	34	12	13	14	8
North Carolina	245	248	93	53	8	3	223	20	20			26	11	15
North Dakota	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Ohio	337	350	220	12			320	20	20		1	10		10
Oklahoma	160	160	134	50			145					30	15	15
Oregon	521	521	119				428							
Pennsylvania	261	330	46	48	35		315	144	91	54	12	16	8	22
Puerto Rico	389	389	318				460							
Rhode Island	361	361	8	10	21	5	351					15	3	13
South Carolina	274	274	283	30		60	274	4	2	2				
South Dakota	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Tennessee	784	786					786	80	73		7			
Texas	170	170	206	10		2	150					8		8
Utah	205	184	123				184	123		123				
Vermont	387	387					387							
Virginia	351	363	152	14	40	3	330	41	5	72		16		16
Washington				20	10	10								
West Virginia	527	538	271			6	580	9	9					
Wisconsin	365	365				25	361							
Wyoming	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other jurisdictions ³	‡	#	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

⁻⁻ Quantity is zero; ‡ No facilities in this category.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Of 1,754 OTP facilities, 657 facilities (37 percent) whose client counts were reported by another facility were not asked to respond to these questions. Of the remaining 1,097 OTP facilities, 37 facilities (3 percent) that included client counts for other facilities were excluded from tabulations for this table, and thus, tabulations are based on 1,060 OTP facilities that reported client counts for their facility alone.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 6.17. Facility size, by type of care offered and state or jurisdiction at facilities without opioid treatment programs (non-OTPs):

Median number of clients per facility, March 31, 2020

								Type of ca	re offered						
						Outpatient				Resider	ntial (non-l	nospital)		Hospital ii	npatient
State or jurisdiction ¹		All facilities²	Total out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Total residential	Short- term	Long- term	Detox	Total inpatient hospital	Treatment	Detox
7	Γotal	31	39	29	14	10	5	25	16	12	15	5	10	10	5
Alabama		24	35	25	24	75	42	40	19	9	20		6	5	9
Alaska		26	40	20	15	10		44	10	13	8		11	9	7
Arizona		30	40	29	17	9	5	19	15	15	9	6	16	31	8
Arkansas		19	19	19	7	7	8	11	17	11	9	10	8	9	2
California		20	31	25	12	8	10	8	10	6	12	3	8	6	5
Colorado		55	60	61	10	10	3	4	12	10	11	6	18	15	6
Connecticut		50	82	94	20	15	21	20	15	17	11	13	6	10	2
Delaware		87	106	15	35	10	5	106	28	2	27		4	2	2
District of Columbia		25	22	18	12			17	40	35	15				
Florida		32	32	25	10	10	5	10	20	12	19	9	15	20	9
Georgia		21	25	20	12	12	7	11	18	12	17	11	12	9	5
Hawaii		13	12	7	14	12	3	10	19	19	16	4			
Idaho		31	38	20	15	35	1	35	9	9	5	2	12	9	5
Illinois		21	20	16	7	7	7	20	16	17	8	7	9	9	5
Indiana		50	55	44	11	13	10	57	15	16	13	11	14	11	5
Iowa		27	28	24	8	3	30	30	13	12	9	4	4	12	4
Kansas		29	28	25	10	10	2	36	24	22	7	6	12	10	7
Kentucky		34	33	25	11	16	175	50	16	16	15	8	22	16	20
Louisiana		32	26	20	15	4	5	15	22	21	20	5	18	11	8
Maine		24	30	20	19	7		32	11	5	12	3	15	10	5
Maryland		48	48	20	17	20	6	30	20	13	17	7	8	24	11
Massachusetts		31	80	50	20	19	3	42	20	23	20	24	22	17	7
Michigan		32	33	30	10	20	5	19	18	14	12	7	8	6	13
Minnesota		20	23	13	15	15	3	12	14	12	13	8	16	11	20
Mississippi		33	41	56	7	10		13	17	9	11	2	6		6
Missouri		37	40	20	23	15	5	16	14	13	12	3	8	8	
Montana		54	52	20	24	12	51	65	18	20	18		5	3	3
Nebraska		19	19	15	10	6		3	17	16	14	7	1		1
Nevada		43	50	30	24	3	15	30	2	8	2	1	10	5	5
New Hampshire		39	49	29	17	15	5	45	15	15	15		23	21	5

Table 6.17. Facility size, by type of care offered and state or jurisdiction at facilities without opioid treatment programs (non-OTPs):

Median number of clients per facility, March 31, 2020 (continued)

							Type of ca	are offered						
					Outpatient				Resider	ntial (non-h	nospital)		Hospital ii	npatient
State or jurisdiction ¹	AII facilities²	Total out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Total residential	Short- term	Long- term	Detox	Total inpatient hospital	Treatment	Detox
New Jersey	40	40	24	20	20	63	10	29	32	23	15	29	26	27
New Mexico	60	64	60	14	15	60	20	16	15	10	76	8		8
New York	60	90	82	14	36	4	20	22	18	22	15	16	19	9
North Carolina	28	32	25	13	12	5	15	11	9	11	9	12	13	11
North Dakota	17	18	10	16	6		129	8	10	5				
Ohio	53	58	31	18	13	7	30	16	15	14	6	17	25	7
Oklahoma	30	42	35	10	5	5	26	19	18	20	2	12	3	8
Oregon	40	42	31	16	6	118	38	15	10	14	28	7	34	7
Pennsylvania	45	58	43	15	7	5	23	22	23	17	7	11	20	8
Puerto Rico	16	31	35	7	2	6	42	16		16	1	6	6	2
Rhode Island	71	181	112	10		5	118	24	13	14				
South Carolina	100	100	88	24	8	11	78	14	8	11	6	10	42	10
South Dakota	32	42	29	21		10	12	22	11	23	5	14	14	1
Tennessee	29	28	24	13	7	2	78	16	14	12	3	11	6	8
Texas	27	24	20	13	7	4	23	19	14	12	6	8	8	4
Utah	24	24	14	11	7	7	9	14	10	13	3	14	34	3
Vermont	69	74	69	15		44	80	2			2	2		2
Virginia	35	35	38	19	8	2	16	12	10	7	1	18	14	4
Washington	50	56	30	15	11	6	95	14	14	16	6	10	20	6
West Virginia	36	58	54	14		6	69	16	13	15	2	11	8	3
Wisconsin	40	45	43	12	10	1,000	14	14	15	12		4	5	4
Wyoming	42	42	31	13	12	27	28	29	17	29	12	10	8	2
Other jurisdictions ³	40	33	20	18				8		7	2			

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Of 14,312 non-OTP facilities, 6,307 facilities (44 percent) whose client counts were reported by another facility were not asked to respond to these questions. Of the remaining 8,005 non-OTP facilities, 516 facilities (6 percent) that included client counts for other facilities were excluded from tabulations for this table, tabulations are based on 7,489 facilities that reported client counts for their facility alone.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 6.18a. Facility size in terms of number of clients in outpatient treatment, by state or jurisdiction: Number and row percent distribution, March 31, 2020

			Number o	f facilities				Row	percent distri	ibution of faci	lities	
State or jurisdiction ¹	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more
Total	8,624	2,134	1,344	1,449	1,305	2,392	100.0	24.7	15.6	16.8	15.1	27.7
Alabama	81	11	18	20	8	24	100.0	13.6	22.2	24.7	9.9	29.6
Alaska	55	17	7	12	12	7	100.0	30.9	12.7	21.8	21.8	12.7
Arizona	231	77	22	31	26	75	100.0	33.3	9.5	13.4	11.3	32.5
Arkansas	94	43	16	21	4	10	100.0	45.7	17.0	22.3	4.3	10.6
California	727	214	129	136	102	146	100.0	29.4	17.7	18.7	14.0	20.1
Colorado	221	34	35	19	57	76	100.0	15.4	15.8	8.6	25.8	34.4
Connecticut	96	7	14	13	12	50	100.0	7.3	14.6	13.5	12.5	52.1
Delaware	30	8	1	1	3	17	100.0	26.7	3.3	3.3	10.0	56.7
District of Columbia	21	5	9	1	2	4	100.0	23.8	42.9	4.8	9.5	19.0
Florida	388	114	73	70	46	85	100.0	29.4	18.8	18.0	11.9	21.9
Georgia	176	61	22	22	25	46	100.0	34.7	12.5	12.5	14.2	26.1
Hawaii	80	47	15	7	4	7	100.0	58.8	18.8	8.8	5.0	8.8
Idaho	53	13	10	12	11	7	100.0	24.5	18.9	22.6	20.8	13.2
Illinois	428	136	83	83	47	79	100.0	31.8	19.4	19.4	11.0	18.5
Indiana	273	38	26	37	62	110	100.0	13.9	9.5	13.6	22.7	40.3
lowa	118	42	21	28	9	18	100.0	35.6	17.8	23.7	7.6	15.3
Kansas	100	28	30	17	11	14	100.0	28.0	30.0	17.0	11.0	14.0
Kentucky	272	59	44	57	40	72	100.0	21.7	16.2	21.0	14.7	26.5
Louisiana	78	29	12	15	6	16	100.0	37.2	15.4	19.2	7.7	20.5
Maine	125	42	18	20	20	25	100.0	33.6	14.4	16.0	16.0	20.0
Maryland	246	47	35	35	48	81	100.0	19.1	14.2	14.2	19.5	32.9
Massachusetts	197	33	16	18	21	109	100.0	16.8	8.1	9.1	10.7	55.3
Michigan	263	63	49	36	54	61	100.0	24.0	18.6	13.7	20.5	23.2
Minnesota	226	69	61	55	23	18	100.0	30.5	27.0	24.3	10.2	8.0
Mississippi	51	23	4	8	9	7	100.0	45.1	7.8	15.7	17.6	13.7
Missouri	153	44	35	21	32	21	100.0	28.8	22.9	13.7	20.9	13.7
Montana	69	23	11	8	17	10	100.0	33.3	15.9	11.6	24.6	14.5
Nebraska	74	27	17	17	7	6	100.0	36.5	23.0	23.0	9.5	8.1

Table 6.18a. Facility size in terms of number of clients in outpatient treatment, by state or jurisdiction: Number and row percent distribution, March 31, 2020 (continued)

			Number o	f facilities				Row	percent distri	ibution of faci	lities	
State or jurisdiction ¹	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more
Nevada	54	20	5	4	2	23	100.0	37.0	9.3	7.4	3.7	42.6
New Hampshire	89	16	27	11	14	21	100.0	18.0	30.3	12.4	15.7	23.6
New Jersey	229	46	38	43	51	51	100.0	20.1	16.6	18.8	22.3	22.3
New Mexico	103	22	12	12	24	33	100.0	21.4	11.7	11.7	23.3	32.0
New York	403	32	21	41	105	204	100.0	7.9	5.2	10.2	26.1	50.6
North Carolina	345	100	59	51	52	83	100.0	29.0	17.1	14.8	15.1	24.1
North Dakota	43	19	5	7	2	10	100.0	44.2	11.6	16.3	4.7	23.3
Ohio	370	75	40	54	53	148	100.0	20.3	10.8	14.6	14.3	40.0
Oklahoma	101	22	17	18	14	30	100.0	21.8	16.8	17.8	13.9	29.7
Oregon	143	19	19	34	21	50	100.0	13.3	13.3	23.8	14.7	35.0
Pennsylvania	301	41	43	54	47	116	100.0	13.6	14.3	17.9	15.6	38.5
Puerto Rico	27	11	1	4	2	9	100.0	40.7	3.7	14.8	7.4	33.3
Rhode Island	25	8	1	1	3	12	100.0	32.0	4.0	4.0	12.0	48.0
South Carolina	73	12	6	5	14	36	100.0	16.4	8.2	6.8	19.2	49.3
South Dakota	33	10	5	6	4	8	100.0	30.3	15.2	18.2	12.1	24.2
Tennessee	202	73	38	36	23	32	100.0	36.1	18.8	17.8	11.4	15.8
Texas	289	81	49	51	43	65	100.0	28.0	17.0	17.6	14.9	22.5
Utah	174	58	34	36	13	33	100.0	33.3	19.5	20.7	7.5	19.0
Vermont	27	1	2	3	10	11	100.0	3.7	7.4	11.1	37.0	40.7
Virginia	144	28	23	15	18	60	100.0	19.4	16.0	10.4	12.5	41.7
Washington	248	24	28	77	37	82	100.0	9.7	11.3	31.0	14.9	33.1
West Virginia	68	20	6	14	9	19	100.0	29.4	8.8	20.6	13.2	27.9
Wisconsin	165	36	22	36	22	49	100.0	21.8	13.3	21.8	13.3	29.7
Wyoming	38	6	9	13	4	6	100.0	15.8	23.7	34.2	10.5	15.8
Other jurisdictions ²	4		1	3			100.0	0.0	25.0	75.0		

⁻⁻ Quantity is zero.

NOTE: Percentages may not sum to 100 percent because of rounding.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.18b. Facility size in terms of number of clients in residential (non-hospital) treatment, by state or jurisdiction:

Number and row percent distribution, March 31, 2020

_			Number o	f facilities				Row	percent distri	bution of faci	lities	
State or jurisdiction ¹	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more
Total	2,512	1,239	699	372	158	44	100.0	49.3	27.8	14.8	6.3	1.8
Alabama	28	6	14	5	3		100.0	21.4	50.0	17.9	10.7	
Alaska	18	17		1			100.0	94.4		5.6		
Arizona	67	37	16	10	4		100.0	55.2	23.9	14.9	6.0	
Arkansas	8	3	4	1			100.0	37.5	50.0	12.5		
California	549	383	82	54	22	8	100.0	69.8	14.9	9.8	4.0	1.5
Colorado	35	23	8	3	1		100.0	65.7	22.9	8.6	2.9	
Connecticut	29	14	8	3	4		100.0	48.3	27.6	10.3	13.8	
Delaware	4	1	2	1			100.0	25.0	50.0	25.0		
District of Columbia	4			3	1		100.0			75.0	25.0	
Florida	139	48	52	23	13	3	100.0	34.5	37.4	16.5	9.4	2.2
Georgia	53	22	18	9	4		100.0	41.5	34.0	17.0	7.5	
Hawaii	11	3	6	1	1		100.0	27.3	54.5	9.1	9.1	
daho	6	5	1				100.0	83.3	16.7			
llinois	59	32	13	10	4		100.0	54.2	22.0	16.9	6.8	
Indiana	38	20	12	4	2		100.0	52.6	31.6	10.5	5.3	
owa	27	15	9	3			100.0	55.6	33.3	11.1		
Kansas	22	11	5	5	1		100.0	50.0	22.7	22.7	4.5	
Kentucky	72	27	21	16	7	1	100.0	37.5	29.2	22.2	9.7	1.4
Louisiana	32	13	8	7	3	1	100.0	40.6	25.0	21.9	9.4	3.1
Maine	14	9	5				100.0	64.3	35.7			
Maryland	40	18	10	7	5		100.0	45.0	25.0	17.5	12.5	
Massachusetts	98	19	52	22	3	2	100.0	19.4	53.1	22.4	3.1	2.0
Michigan	61	30	15	8	7	1	100.0	49.2	24.6	13.1	11.5	1.6
Minnesota	78	41	26	8	1	2	100.0	52.6	33.3	10.3	1.3	2.6
Mississippi	25	11	7	6	1		100.0	44.0	28.0	24.0	4.0	
Missouri	30	18	9	2	1		100.0	60.0	30.0	6.7	3.3	
Montana	11	5	3	2	1		100.0	45.5	27.3	18.2	9.1	
Nebraska	24	13	7	3	1		100.0	54.2	29.2	12.5	4.2	

Table 6.18b. Facility size in terms of number of clients in residential (non-hospital) treatment, by state or jurisdiction:

Number and row percent distribution, March 31, 2020 (continued)

			Number o	of facilities				Row	percent distri	bution of faci	lities	
State or jurisdiction ¹	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more
Nevada	17	11	4	1	1		100.0	64.7	23.5	5.9	5.9	
New Hampshire	13	5	7	1			100.0	38.5	53.8	7.7		
New Jersey	36	8	12	7	9		100.0	22.2	33.3	19.4	25.0	
New Mexico	12	6	3	2		1	100.0	50.0	25.0	16.7		8.3
New York	167	42	63	46	12	4	100.0	25.1	37.7	27.5	7.2	2.4
North Carolina	49	35	8	2	2	2	100.0	71.4	16.3	4.1	4.1	4.1
North Dakota	14	11	1	2			100.0	78.6	7.1	14.3		
Ohio	76	36	22	10	5	3	100.0	47.4	28.9	13.2	6.6	3.9
Oklahoma	29	12	10	5	1	1	100.0	41.4	34.5	17.2	3.4	3.4
Oregon	20	10	6	1	3		100.0	50.0	30.0	5.0	15.0	
Pennsylvania	108	25	44	21	9	9	100.0	23.1	40.7	19.4	8.3	8.3
Puerto Rico	42	19	16	2	2	3	100.0	45.2	38.1	4.8	4.8	7.1
Rhode Island	8	2	3	3			100.0	25.0	37.5	37.5		
South Carolina	12	7	2	1	2		100.0	58.3	16.7	8.3	16.7	
South Dakota	7	3	2	2			100.0	42.9	28.6	28.6		
Tennessee	51	25	14	9	3		100.0	49.0	27.5	17.6	5.9	
Texas	73	25	25	15	7	1	100.0	34.2	34.2	20.5	9.6	1.4
Utah	63	36	16	8	2	1	100.0	57.1	25.4	12.7	3.2	1.6
Vermont	4	3	1				100.0	75.0	25.0			
Virginia	25	16	3	4	1	1	100.0	64.0	12.0	16.0	4.0	4.0
Washington	42	27	6	5	4		100.0	64.3	14.3	11.9	9.5	
West Virginia	25	13	7	3	2		100.0	52.0	28.0	12.0	8.0	
Wisconsin	22	13	7	2			100.0	59.1	31.8	9.1		
Wyoming	13	3	4	3	3		100.0	23.1	30.8	23.1	23.1	
Other jurisdictions ²	2	2					100.0	100.0				

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

NOTE: Percentages may not sum to 100 percent because of rounding.

Table 6.18c. Facility size in terms of number of clients in hospital inpatient treatment, by state or jurisdiction:

Number and row percent distribution, March 31, 2020

State or				Number o	of facilities		l		Row	percent distri	bution of facil	lities	
jurisdiction ¹	_	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more
	Total	533	346	95	57	32	3	100.0	64.9	17.8	10.7	6.0	0.6
Alabama		9	7	2				100.0	77.8	22.2			
Alaska		3	2	1				100.0	66.7	33.3			
Arizona		16	9	1	3	3		100.0	56.3	6.3	18.8	18.8	
Arkansas		11	9	1		1		100.0	81.8	9.1		9.1	
California		42	35	4	2	1		100.0	83.3	9.5	4.8	2.4	
Colorado		11	6	2	2	1		100.0	54.5	18.2	18.2	9.1	
Connecticut		5	3			2		100.0	60.0			40.0	
Delaware		2	2					100.0	100.0				
District of Columbia		‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	•
Florida		42	22	13	2	4	1	100.0	52.4	31.0	4.8	9.5	2.4
Georgia		16	10	2	3	1		100.0	62.5	12.5	18.8	6.3	
Hawaii		‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
daho		4	3	1				100.0	75.0	25.0			
Ilinois		16	12	1	3			100.0	75.0	6.3	18.8		
ndiana		16	12	3	1			100.0	75.0	18.8	6.3		
owa		6	6					100.0	100.0				
Kansas		4	3	1				100.0	75.0	25.0			
Kentucky		7	2	2	2	1		100.0	28.6	28.6	28.6	14.3	
_ouisiana		13	5	5	2	1		100.0	38.5	38.5	15.4	7.7	
Maine		2	1	1				100.0	50.0	50.0			
Maryland		11	8		1	2		100.0	72.7		9.1	18.2	
Massachusetts		27	6	10	9	2		100.0	22.2	37.0	33.3	7.4	
/lichigan		5	5					100.0	100.0				
Minnesota		3	1	2				100.0	33.3	66.7			
Mississippi		7	7					100.0	100.0				
Missouri		3	3					100.0	100.0				
Montana		3	3					100.0	100.0				
Nebraska		2	2					100.0	100.0				

Table 6.18c. Facility size in terms of number of clients in hospital inpatient treatment, by state or jurisdiction: Number and row percent distribution, March 31, 2020 (continued)

Ctata ar			Number	of facilities				Row	percent distri	bution of faci	lities	
State or jurisdiction ¹	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more	Total	Fewer than 15 clients	15–29 clients	30–59 clients	60–119 clients	120 clients or more
Nevada	8	8					100.0	100.0				
New Hampshire	2	1		1			100.0	50.0		50.0		
New Jersey	9	3	2	1	3		100.0	33.3	22.2	11.1	33.3	
New Mexico	2	2					100.0	100.0				
New York	40	25	11	3		1	100.0	62.5	27.5	7.5		2.5
North Carolina	17	9	4	4			100.0	52.9	23.5	23.5		
North Dakota	1	1					100.0	100.0				
Ohio	27	16	6	4	1		100.0	59.3	22.2	14.8	3.7	
Oklahoma	5	3	1	1			100.0	60.0	20.0	20.0		
Oregon	4	3			1		100.0	75.0			25	
Pennsylvania	18	10	4	2	1	1	100.0	55.6	22.2	11.1	5.6	5.6
Puerto Rico	10	9	1				100.0	90.0	10.0			
Rhode Island	2	1	1				100.0	50.0	50.0			
South Carolina	10	6		1	3		100.0	60.0		10.0	30.0	
South Dakota	3	2	1				100.0	66.7	33.3			
Tennessee	8	8					100.0	100.0				
Texas	34	22	6	2	4		100.0	64.7	17.6	5.9	11.8	
Utah	5	4		1			100.0	80.0		20.0		
Vermont	2	2					100.0	100.0				
Virginia	7	2	3	2			100.0	28.6	42.9	28.6		
Washington	6	4	1	1			100.0	66.7	16.7	16.7		
West Virginia	4	3	1				100.0	75.0	25.0			
Wisconsin	19	15	1	3			100.0	78.9	5.3	15.8		
Wyoming	3	2		1			100.0	66.7		33.3		
Other jurisdictions ²	1	1				'	100.0	100.0				

⁻⁻ Quantity is zero; ‡ No facilities in this category.

NOTE: Percentages may not sum to 100 percent because of rounding.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.19. Facility capacity and utilization of residential (non-hospital) and hospital inpatient care, by state or jurisdiction:

Number and utilization rate, March 31, 2020

	Resident	tial and hospital	inpatient 2,3		Res	idential (non-h	ospital)²				Hospital inpa	tient³	
State or jurisdiction ¹	No. of clients	No. of designated beds ^{2,3}	Utilization rate (%) ^{2,3,4}	No. of facilities	No. of clients	No. of designated beds ²	Utilization rate (%) ^{2,4}	Designated beds per facility ²	No. of facilities	No. of clients	No. of designated beds ³	Utilization rate (%) ^{3,4}	Designated beds per facility³
Total	56,405	71,433	79.0	1,920	48,764	61,743	79.0	32	322	7,641	9,690	78.9	30
Alabama	571	681	83.8	22	517	626	82.6	28	5	54	55	98.2	11
Alaska	159	220	72.3	12	137	198	69.2	17	2	22	22	100	11
Arizona	1,556	1,903	81.8	51	1,209	1,606	75.3	31	11	347	297	116.8	27
Arkansas	227	372	61.0	7	119	200	59.5	29	6	108	172	62.8	29
California	7,639	9,781	78.1	381	7,320	9,269	79.0	24	22	319	512	62.3	23
Colorado	732	1,033	70.9	31	529	761	69.5	25	9	203	272	74.6	30
Connecticut	527	624	84.5	22	506	602	84.1	27	2	21	22	95.5	11
Delaware	92	119	77.3	4	80	103	77.7	26	1	12	16	75.0	16
District of Columbia	170	197	86.3	4	170	197	86.3	49					
Florida	3,647	4,465	81.7	98	2,901	3,685	78.7	38	23	746	780	95.6	34
Georgia	1,371	1,553	88.3	43	1,115	1,232	90.5	29	8	256	321	79.8	40
Hawaii	306	456	67.1	10	306	456	67.1	46					
Idaho	78	117	66.7	3	36	42	85.7	14	3	42	75	56.0	25
Illinois	1,123	1,610	69.8	44	970	1,422	68.2	32	7	153	188	81.4	27
Indiana	786	826	95.2	30	641	601	106.7	20	9	145	225	64.4	25
Iowa	301	515	58.4	18	283	490	57.8	27	2	18	25	72.0	13
Kansas	447	629	71.1	17	424	594	71.4	35	2	23	35	65.7	18
Kentucky	1,596	1,867	85.5	47	1,397	1,612	86.7	34	7	199	255	78.0	36
Louisiana	947	1,283	73.8	25	775	1,065	72.8	43	8	172	218	78.9	27
Maine	141	170	82.9	11	126	152	82.9	14	1	15	18	83.3	18
Maryland	1,147	1,555	73.8	30	955	1,210	78.9	40	5	192	345	55.7	69
Massachusetts	3,242	3,663	88.5	87	2,479	2,791	88.8	32	22	763	872	87.5	40
Michigan	1,228	2,234	55.0	40	1,204	2,150	56.0	54	3	24	84	28.6	28
Minnesota	1,678	2,037	82.4	70	1,624	1,981	82.0	28	3	54	56	96.4	19
Mississippi	446	708	63.0	19	433	676	64.1	36	2	13	32	40.6	16
Missouri	437	706	61.9	26	437	706	61.9	27					
Montana	252	267	94.4	10	242	251	96.4	25	2	10	16	62.5	8
Nebraska	358	495	72.3	18	357	492	72.6	27	1	1	3	33	3
Nevada	101	214	47.2	7	71	134	53.0	19	4	30	80	37.5	20
New Hampshire	218	271	80.4	10	172	241	71.4	24	2	46	30	153.3	15
New Jersey	1,647	2,305	71.5	32	1,323	1,811	73.1	57	7	324	494	65.6	71
New Mexico	338	384	88.0	10	330	369	89.4	37	1	8	15	53.3	15
New York	5,514	7,003	78.7	150	4,767	6,283	75.9	42	28	747	720	103.8	26

Table 6.19. Facility capacity and utilization of residential (non-hospital) and hospital inpatient care, by state or jurisdiction:

Number and utilization rate, March 31, 2020 (continued)

	Resident	ial and hospital	inpatient ^{2,3}		Res	idential (non-h	ospital)²				Hospital inpa	tient³	
State or jurisdiction ¹	No. of clients	No. of designated beds ^{2,3}	Utilization rate (%) ^{2,3,4}	No. of facilities	No. of clients	No. of designated beds ²	Utilization rate (%) ^{2,4}	Designated beds per facility²	No. of facilities	No. of clients	No. of designated beds ³	Utilization rate (%) ^{3,4}	Designated beds per facility³
North Carolina	1,124	1,274	88.2	37	871	977	89.2	26	11	253	297	85.2	27
North Dakota	49	85	57.6	7	49	85	57.6	12					
Ohio	2,071	2,584	80.1	57	1,654	1,948	84.9	34	21	417	636	65.6	30
Oklahoma	606	862	70.3	26	552	738	74.8	28	3	54	124	43.5	41
Oregon	572	747	76.6	19	470	580	81.0	31	4	102	167	61.1	42
Pennsylvania	4,302	5,407	79.6	94	3,865	4,725	81.8	50	13	437	682	64.1	52
Puerto Rico	1,082	715	151.3	26	1,038	616	168.5	24	5	44	99	44.4	20
Rhode Island	162	134	120.9	6	134	106	126.4	18	1	28	28	100.0	28
South Carolina	603	587	102.7	12	260	367	70.8	31	8	343	220	155.9	28
South Dakota	144	167	86.2	5	98	107	91.6	21	3	46	60	76.7	20
Tennessee	1,022	1,471	69.5	45	984	1,404	70.1	31	4	38	67	56.7	17
Texas	2,291	2,902	78.9	64	1,858	2,321	80.1	36	17	433	581	74.5	34
Utah	825	926	89.1	37	736	846	87.0	23	5	89	80	111.3	16
Vermont	2	3	66.7	1	2	3	66.7	3					
Virginia	459	623	73.7	14	369	523	70.6	37	5	90	100	90.0	20
Washington	856	1,107	77.3	32	755	962	78.5	30	5	101	145	69.7	29
West Virginia	615	722	85.2	21	586	680	86.2	32	2	29	42	69.0	21
Wisconsin	385	573	67.2	18	315	466	67.6	26	7	70	107	65.4	15
Wyoming	198	241	82.2	8	198	241	82.2	30					
Other jurisdictions⁵	15	40	37.5	2	15	40	37.5	20					

⁻⁻ Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² For facilities offering residential (non-hospital) services, the number of designated beds, overall utilization rate, and designated beds per facility are based on 1,920 facilities (61,743 designated beds and 48,764 clients) that reported offering residential (non-hospital) services and reported both designated beds and clients for their facility alone.

³ For facilities offering hospital inpatient services, the number of designated beds, overall utilization rate, and designated beds per facility are based on 322 facilities (9690 designated beds and 7641 clients) that reported offering hospital inpatient services and reported both designated beds and clients for their facility alone.

⁴ Utilization rates may be more than 100 percent, because the substance abuse treatment clients may also occupy non-designated beds.

⁵ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.20a. Clinical/therapeutic approaches used frequently, by state or jurisdiction: Number, 2020

								Cli	inical/thera _l	peutic appr	oaches use	d frequenti	'y					
State or jurisdiction ¹		Total ²	Sub- stance abuse coun- seling	12-step facili- tation	Brief interv- ention	Cogn- itive behav- ioral therapy	Dialect- ical behavior therapy	Contin- gency manage- ment/ motiv- ational incent- ives	Motiva- tional inter- viewing	Trauma- related counsel- ing	Anger manage- ment	Matrix model	Comm- unity reinforce- ment plus vouch- ers	Rational emotive behav- ioral therapy (REBT)	Re- lapse preven- tion	Tele- medicine/ telehealth therapy	Other treat- ment approa- ches	Do not use any listed approa- ches
	Total	16,066	15,797	10,517	13,124	15,075	9,749	8,690	14,983	13,344	12,742	7,240	1,668	6,845	15,430	9,419	1,951	40
Alabama		155	147	113	117	139	86	90	141	123	127	75	18	78	145	90	7	3
Alaska		105	104	56	84	92	68	58	95	86	81	60	10	42	104	77	23	1
Arizona		447	433	230	355	421	275	229	420	360	349	201	51	170	413	282	80	1
Arkansas		171	163	88	148	161	88	76	144	148	159	90	13	57	150	111	22	
California		1,734	1,721	1,259	1,426	1,621	1,107	1,057	1,619	1,467	1,422	909	252	625	1,683	920	213	2
Colorado		393	385	157	307	366	275	194	378	331	324	169	71	112	378	243	64	1
Connecticut		210	207	142	184	200	142	109	202	191	184	73	24	69	206	108	31	
Delaware		49	48	33	42	43	31	29	49	45	40	18	16	23	48	33	1	
District of																		
Columbia		28	27	19	23	25	14	19	26	23	25	18	3	12	26	18	5	
Florida		712	702	523	604	681	453	397	651	625	615	298	80	385	677	457	120	1
Georgia		348	344	235	273	328	207	210	310	290	288	185	30	156	335	188	42	
Hawaii		161	161	75	127	133	48	94	155	129	146	48	13	32	157	52	11	
Idaho		110	110	59	95	105	94	63	104	102	94	85	18	55	109	91	14	
Illinois		713	699	467	597	674	444	358	665	541	565	332	58	327	678	357	83	1
Indiana		416	412	239	273	393	247	161	379	334	298	212	24	116	393	258	44	1
Iowa		185	185	119	147	183	109	95	183	156	157	108	23	90	182	115	32	
Kansas		170	166	115	135	164	78	76	157	123	116	104	8	86	165	93	16	
Kentucky		477	470	334	373	447	270	215	425	386	353	214	46	230	458	300	28	1
Louisiana		155	151	113	129	136	87	74	141	117	126	81	11	83	149	88	11	3
Maine		196	194	91	141	186	125	81	177	170	139	72	14	58	189	125	23	
Maryland		432	419	295	341	396	209	260	388	327	312	166	40	170	403	232	27	1
Massachuset	tts	440	430	261	352	410	269	227	427	378	323	105	29	113	428	268	29	
Michigan		455	448	310	392	436	313	220	422	412	382	130	42	191	444	272	40	
Minnesota		401	399	319	300	378	247	246	386	329	288	241	57	190	395	248	59	
Mississippi		105	101	79	85	97	70	59	92	91	93	42	7	60	97	56	11	2
Missouri		278	273	210	244	256	140	146	258	239	234	182	26	99	264	194	37	
Montana		129	129	77	98	118	80	63	117	116	78	63	14	61	122	110	12	
Nebraska		123	121	92	106	122	99	69	119	118	109	56	25	78	117	77	28	

Table 6.20a. Clinical/therapeutic approaches used frequently, by state or jurisdiction: Number, 2020 (continued)

							Cli	inical/thera	peutic appr	oaches use	d frequent	ly					
State or jurisdiction ¹	Total ²	Sub- stance abuse coun- seling	12-step facili- tation	Brief interv- ention	Cogn- itive behav- ioral therapy	Dialect- ical behavior therapy	Contin- gency manage- ment/ motiv- ational incent- ives	Motiva- tional inter- viewing	Trauma- related counsel- ing	Anger manage- ment	Matrix model	Comm- unity reinforce- ment plus vouch- ers	Rational emotive behav- ioral therapy (REBT)	Re- lapse preven- tion	Tele- medicine/ telehealth therapy	Other treat- ment approa- ches	Do not use any listed approa- ches
Nevada	109	104	78	99	101	78	64	103	93	88	58	11	48	103	65	14	. 1
New Hampshire	109	108	58	86	100	85	61	97	92	82	33	4	29	103	67	12	
New Jersey	383	378	326	336	372	269	248	371	329	339	192	48	233	374	235	43	3
New Mexico	162	162	84	140	154	88	98	154	152	138	93	25	73	152	98	37	
New York	894	885	580	799	859	521	486	882	750	751	297	67	403	877	514	74	. 1
North Carolina	611	592	368	480	542	314	305	543	428	434	288	55	228	553	335	75	3
North Dakota	87	84	57	66	74	38	40	73	51	44	25	15	17	82	53	11	
Ohio	619	611	413	499	604	380	367	588	528	505	297	71	264	603	418	47	1
Oklahoma	195	195	112	173	190	104	106	187	182	173	117	11	92	184	117	15	
Oregon	247	243	149	194	226	190	138	233	217	178	136	33	99	242	178	38	
Pennsylvania	604	592	476	506	591	377	320	586	511	479	198	60	295	596	303	66	
Puerto Rico	101	101	29	84	82	33	53	72	56	86	20	9	51	88	31	8	
Rhode Island	63	57	37	55	59	40	38	56	53	51	16	9	16	63	33	3	
South Carolina	124	122	81	101	112	46	56	111	95	90	57	8	57	121	62	10	1
South Dakota	58	57	47	54	54	38	37	53	44	42	36	9	21	57	31	7	
Tennessee	311	309	213	261	292	168	131	289	278	248	146	21	120	304	187	26	
Texas	509	502	379	424	487	266	286	477	392	404	261	40	292	495	264	74	2
Utah	333	322	205	249	317	276	232	313	304	285	144	55	193	315	198	97	3
Vermont	52	51	25	47	50	25	26	51	44	45	17	4	11	50	28	9	
Virginia	249	246	155	205	236	133	128	242	211	192	110	18	96	238	170	30	1
Washington	457	452	248	365	396	275	205	409	332	255	159	22	163	448	271	99	1
West Virginia	126	117	75	98	115	75	66	121	117	111	49	7	90	114	80	4	1
Wisconsin	295	289	170	245	283	197	180	279	260	234	119	29	136	285	165	30	1
Wyoming	60	59	37	50	59	55	36	53	59	52	28	10	43	59	49	8	
Other jurisdictions ³	10	10	5	10	9	3	8	10	9	9	7	4	7	9	4	1	

⁻⁻ Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, because a facility could use more than one clinical/therapeutic approach.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.20b. Clinical/therapeutic approaches used frequently, by state or jurisdiction: Row percent, 2020

							Cli	inical/thera	peutic app	roaches us	ed freque	ntly					
State or jurisdiction ¹	Number of faci- lities²	Sub- stance abuse coun- seling	12-step facili- tation	Brief interv- ention	Cogn- itive behav- ioral therapy	Dialect- ical behavior therapy	Contin- gency manage- ment/ motiv- ational incent- ives	Motiva- tional inter- viewing	Trauma- related counsel- ing	Anger manage- ment	Matrix model	Comm- unity reinforce- ment plus vouch- ers	Rational emotive behav- ioral therapy (REBT)	Re- lapse preven- tion	Tele- medicine/ telehealth therapy	Other treat- ment approa- ches	Do not use any listed approa- ches
Total	16,066	98.3	65.5	81.7	93.8	60.7	54.1	93.3	83.1	79.3	45.1	10.4	42.6	96.0	58.6	12.1	0.2
Alabama	155	94.8	72.9	75.5	89.7	55.5	58.1	91.0	79.4	81.9	48.4	11.6	50.3	93.5	58.1	4.5	1.9
Alaska	105	99.0	53.3	80.0	87.6	64.8	55.2	90.5	81.9	77.1	57.1	9.5	40.0	99.0	73.3	21.9	1.0
Arizona	447	96.9	51.5	79.4	94.2	61.5	51.2	94.0	80.5	78.1	45.0	11.4	38.0	92.4	63.1	17.9	0.2
Arkansas	171	95.3	51.5	86.5	94.2	51.5	44.4	84.2	86.5	93.0	52.6	7.6	33.3	87.7	64.9	12.9	0.6
California	1,734	99.3	72.6	82.2	93.5	63.8	61.0	93.4	84.6	82.0	52.4	14.5	36.0	97.1	53.1	12.3	0.1
Colorado	393	98.0	39.9	78.1	93.1	70.0	49.4	96.2	84.2	82.4	43.0	18.1	28.5	96.2	61.8	16.3	0.3
Connecticut	210	98.6	67.6	87.6	95.2	67.6	51.9	96.2	91.0	87.6	34.8	11.4	32.9	98.1	51.4	14.8	
Delaware	49	98.0	67.3	85.7	87.8	63.3	59.2	100.0	91.8	81.6	36.7	32.7	46.9	98.0	67.3	2.0	
District of																	
Columbia	28	96.4	67.9	82.1	89.3	50.0	67.9	92.9	82.1	89.3	64.3	10.7	42.9	92.9	64.3	17.9	
Florida	712	98.6	73.5	84.8	95.6	63.6	55.8	91.4	87.8	86.4	41.9	11.2	54.1	95.1	64.2	16.9	0.1
Georgia	348	98.9	67.5	78.4	94.3	59.5	60.3	89.1	83.3	82.8	53.2	8.6	44.8	96.3	54.0	12.1	
Hawaii	161	100.0	46.6	78.9	82.6	29.8	58.4	96.3	80.1	90.7	29.8	8.1	19.9	97.5	32.3	6.8	
Idaho	110	100.0	53.6	86.4	95.5	85.5	57.3	94.5	92.7	85.5	77.3	16.4	50.0	99.1	82.7	12.7	
Illinois	713	98.0	65.5	83.7	94.5	62.3	50.2	93.3	75.9	79.2	46.6	8.1	45.9	95.1	50.1	11.6	0.1
Indiana	416	99.0	57.5	65.6	94.5	59.4	38.7	91.1	80.3	71.6	51.0	5.8	27.9	94.5	62.0	10.6	0.2
lowa	185	100.0	64.3	79.5	98.9	58.9	51.4	98.9	84.3	84.9	58.4	12.4	48.6	98.4	62.2	17.3	
Kansas	170	97.6	67.6	79.4	96.5	45.9	44.7	92.4	72.4	68.2	61.2	4.7	50.6	97.1	54.7	9.4	1.2
Kentucky	477	98.5	70.0	78.2	93.7	56.6	45.1	89.1	80.9	74.0	44.9	9.6	48.2	96.0	62.9	5.9	0.2
Louisiana	155	97.4	72.9	83.2	87.7	56.1	47.7	91.0	75.5	81.3	52.3	7.1	53.5	96.1	56.8	7.1	1.9
Maine	196	99.0	46.4	71.9	94.9	63.8	41.3	90.3	86.7	70.9	36.7	7.1	29.6	96.4	63.8	11.7	
Maryland	432	97.0	68.3	78.9	91.7	48.4	60.2	89.8	75.7	72.2	38.4	9.3	39.4	93.3	53.7	6.3	0.2
Massachusetts	440	97.7	59.3	80.0	93.2	61.1	51.6	97.0	85.9	73.4	23.9	6.6	25.7	97.3	60.9	6.6	
Michigan	455	98.5	68.1	86.2	95.8	68.8	48.4	92.7	90.5	84.0	28.6	9.2	42.0	97.6	59.8	8.8	
Minnesota	401	99.5	79.6	74.8	94.3	61.6	61.3	96.3	82.0	71.8	60.1	14.2	47.4	98.5	61.8	14.7	
Mississippi	105	96.2	75.2	81.0	92.4	66.7	56.2	87.6	86.7	88.6	40.0	6.7	57.1	92.4	53.3	10.5	1.9
Missouri	278	98.2	75.5	87.8	92.1	50.4	52.5	92.8	86.0	84.2	65.5	9.4	35.6	95.0	69.8	13.3	
Montana	129	100.0	59.7	76.0	91.5	62.0	48.8	90.7	89.9	60.5	48.8	10.9	47.3	94.6	85.3	9.3	
Nebraska	123	98.4	74.8	86.2	99.2	80.5	56.1	96.7	95.9	88.6	45.5	20.3	63.4	95.1	62.6	22.8	
Nevada	109	95.4	71.6	90.8	92.7	71.6	58.7	94.5	85.3	80.7	53.2	10.1	44.0	94.5	59.6	12.8	0.9
INEVAUA	108	90.4	1 1.0	90.0	9∠.1	11.0	JU.1	<i>9</i> 4.J	00.0	00.1	JJ.Z	10.1	++.∪	<i>3</i> 4.J	JJ.U	12.0	0.8

Table 6.20b. Clinical/therapeutic approaches used frequently, by state or jurisdiction: Row percent, 2020 (continued)

							Cli	nical/thera	apeutic app	roaches us	ed freque	ently					
State or jurisdiction ¹	Number of faci- lities²	Sub- stance abuse coun- seling	12-step facili- tation	Brief interv- ention	Cogn- itive behav- ioral therapy	Dialect- ical behavior therapy	Contin- gency manage- ment/ motiv- ational incent- ives	Motiva- tional inter- viewing	Trauma- related counsel- ing	Anger manage- ment	Matrix model	Comm- unity reinforce- ment plus vouch- ers	Rational emotive behav- ioral therapy (REBT)	Re- lapse preven- tion	Tele- medicine/ telehealth therapy	Other treat- ment approa- ches	Do not use any listed approa- ches
New Hampshire	109	99.1	53.2	78.9	91.7	78.0	56.0	89.0	84.4	75.2	30.3	3.7	26.6	94.5	61.5	11.0	
New Jersey	383	98.7	85.1	87.7	97.1	70.2	64.8	96.9	85.9	88.5	50.1	12.5	60.8	97.7	61.4	11.2	8.0
New Mexico	162	100.0	51.9	86.4	95.1	54.3	60.5	95.1	93.8	85.2	57.4	15.4	45.1	93.8	60.5	22.8	
New York	894	99.0	64.9	89.4	96.1	58.3	54.4	98.7	83.9	84.0	33.2	7.5	45.1	98.1	57.5	8.3	0.1
North Carolina	611	96.9	60.2	78.6	88.7	51.4	49.9	88.9	70.0	71.0	47.1	9.0	37.3	90.5	54.8	12.3	0.5
North Dakota	87	96.6	65.5	75.9	85.1	43.7	46.0	83.9	58.6	50.6	28.7	17.2	19.5	94.3	60.9	12.6	
Ohio	619	98.7	66.7	80.6	97.6	61.4	59.3	95.0	85.3	81.6	48.0	11.5	42.6	97.4	67.5	7.6	0.2
Oklahoma	195	100.0	57.4	88.7	97.4	53.3	54.4	95.9	93.3	88.7	60.0	5.6	47.2	94.4	60.0	7.7	
Oregon	247	98.4	60.3	78.5	91.5	76.9	55.9	94.3	87.9	72.1	55.1	13.4	40.1	98.0	72.1	15.4	
Pennsylvania	604	98.0	78.8	83.8	97.8	62.4	53.0	97.0	84.6	79.3	32.8	9.9	48.8	98.7	50.2	10.9	
Puerto Rico	101	100.0	28.7	83.2	81.2	32.7	52.5	71.3	55.4	85.1	19.8	8.9	50.5	87.1	30.7	7.9	
Rhode Island	63	90.5	58.7	87.3	93.7	63.5	60.3	88.9	84.1	81.0	25.4	14.3	25.4	100.0	52.4	4.8	
South Carolina	124	98.4	65.3	81.5	90.3	37.1	45.2	89.5	76.6	72.6	46.0	6.5	46.0	97.6	50.0	8.1	8.0
South Dakota	58	98.3	81.0	93.1	93.1	65.5	63.8	91.4	75.9	72.4	62.1	15.5	36.2	98.3	53.4	12.1	
Tennessee	311	99.4	68.5	83.9	93.9	54.0	42.1	92.9	89.4	79.7	46.9	6.8	38.6	97.7	60.1	8.4	
Texas	509	98.6	74.5	83.3	95.7	52.3	56.2	93.7	77.0	79.4	51.3	7.9	57.4	97.2	51.9	14.5	0.4
Utah	333	96.7	61.6	74.8	95.2	82.9	69.7	94.0	91.3	85.6	43.2	16.5	58.0	94.6	59.5	29.1	0.9
Vermont	52	98.1	48.1	90.4	96.2	48.1	50.0	98.1	84.6	86.5	32.7	7.7	21.2	96.2	53.8	17.3	
Virginia	249	98.8	62.2	82.3	94.8	53.4	51.4	97.2	84.7	77.1	44.2	7.2	38.6	95.6	68.3	12.0	0.4
Washington	457	98.9	54.3	79.9	86.7	60.2	44.9	89.5	72.6	55.8	34.8	4.8	35.7	98.0	59.3	21.7	0.2
West Virginia	126	92.9	59.5	77.8	91.3	59.5	52.4	96.0	92.9	88.1	38.9	5.6	71.4	90.5	63.5	3.2	8.0
Wisconsin	295	98.0	57.6	83.1	95.9	66.8	61.0	94.6	88.1	79.3	40.3	9.8	46.1	96.6	55.9	10.2	0.3
Wyoming	60	98.3	61.7	83.3	98.3	91.7	60.0	88.3	98.3	86.7	46.7	16.7	71.7	98.3	81.7	13.3	
Other jurisdictions ³	10	100.0	50.0	100.0	90.0	30.0	80.0	100.0	90.0	90.0	70.0	40.0	70.0	90.0	40.0	10.0	

 ⁻ Quantity is zero

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Percentages sum to more than 100 percent, because a facility could use more than one clinical/therapeutic approach.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.21a. Facilities offering special programs or groups for specific client types, by state or jurisdiction: Number, 2020

							Clier	nt type				
State or jurisdiction ¹	Total²	Any program or group	Adolescents	Young adults	Adult women	Pregnant or post-partum women	Adult men	Seniors or older adults	LGBTQ	Veterans	Active duty military	Members of military families
Total	16,066	13,502	3,818	5,111	8,141	4,140	7,867	3,976	3,901	3,690	2,183	2,482
Alabama	155	117	30	34	58	35	66	27	26	33	16	16
Alaska	105	84	34	31	47	23	43	15	12	14	10	8
Arizona	447	385	126	165	238	124	226	135	127	122	83	91
Arkansas	171	138	59	49	64	15	63	36	34	29	10	13
California	1,734	1,552	330	649	986	496	966	526	582	503	250	342
Colorado	393	358	133	157	234	109	210	125	101	80	43	51
Connecticut	210	189	47	82	138	57	136	57	59	44	22	24
Delaware District of	49	40	13	23	26	21	23	16	12	12	7	9
Columbia	28	24	3	9	18	10	18	12	15	9	6	6
Florida	712	614	150	235	387	211	372	223	213	246	157	177
	348	282	72	112	170	90	158	82	89	100	53	57
Georgia Hawaii	161	153	105	29	43	90 25	43	62 27	28	25	21	20
Idaho	110	102	50	40	43 78	39	43 74	28	26 25	31	24	22
Illinois	713	597	180	215	287	124	295	158	141	127	73	91
Indiana	416	299	91	119	186	81	169	59	61	62	35	42
	185	155	71	49	72	32	64	33	24	21	17	19
lowa Kansas	170	127	57	49 42	69	32 36	58	33 32	28	26	16	24
Kentucky	477	419	98	141	225	145	208	32 87	26 91	88	61	67
Louisiana	155	135	33	44	84	43	73	29	42	41	30	33
Maine	196	147	28	44	65	40	59	37	34	36	26	27
	432	375	90	176	243	118	248	140	128	105	71	71
Maryland Massachusetts	432	360	57	150	243	155	220	118	120	108	63	7 1 74
	440 455	354	86	120	234	119	235	116	120	115	56	62
Michigan Minnesota	401	341	77	83	23 4 174	78	179	76	81	54	31	36
Mississippi	105	90	17	32	52	78 28	49	76 28	22	24	17	16
		230										
Missouri	278		49 50	60	121	45	108	42	35	43	27	25
Montana	129 123	107 82	50 24	31 27	49 45	23 15	44 44	22 25	22 19	27 19	21 13	16 13
Nebraska Continued See no			24	۷1	40	ıυ	44	20	19	18	13	13

Table 6.21a. Facilities offering special programs or groups for specific client types, by state or jurisdiction: Number, 2020 (continued)

							Clier	nt type				
State or jurisdiction ¹	Total²	Any program or group	Adolescents	Young adults	Adult women	Pregnant or post-partum women	Adult men	Seniors or older adults	LGBTQ	Veterans	Active duty military	Members of military families
Nevada	109	100	36	43	65	45	59	43	44	43	30	31
New Hampshire	109	80	14	28	57	36	57	20	33	36	18	19
New Jersey	383	341	109	166	248	131	232	145	131	124	80	93
New Mexico	162	137	56	68	88	53	93	57	58	55	39	44
New York	894	802	231	322	586	206	601	245	230	195	93	98
North Carolina	611	467	125	219	303	205	287	186	185	174	112	138
North Dakota	87	65	23	20	24	9	21	4	4	6	4	4
Ohio	619	495	133	168	296	139	280	109	114	107	61	64
Oklahoma	195	157	57	60	118	59	110	54	55	59	35	42
Oregon	247	236	70	80	144	58	132	47	51	43	24	21
Pennsylvania	604	543	140	191	332	152	309	133	133	118	69	65
Puerto Rico	101	91	22	59	41	23	76	62	35	38	18	28
Rhode Island	63	59	5	18	34	24	31	19	14	16	9	8
South Carolina	124	97	44	31	59	36	51	23	14	15	10	10
South Dakota	58	53	25	24	25	14	24	9	9	13	7	9
Tennessee	311	252	58	80	124	84	119	62	60	62	38	43
Texas	509	430	133	151	263	146	252	130	125	133	74	88
Utah	333	302	91	132	190	91	196	110	117	99	74	89
Vermont	52	45	14	17	21	18	23	12	6	8	5	3
Virginia	249	200	56	72	133	89	125	48	49	50	34	37
Washington	457	347	124	110	184	91	163	65	69	66	41	42
West Virginia	126	99	17	25	48	30	46	20	27	29	15	14
Wisconsin	295	195	54	58	110	48	96	43	42	38	21	26
Wyoming	60	44	18	19	26	14	27	16	17	18	13	13
Other												
jurisdictions ³	10	9	3	2	6	2	6	3	1	1		1

Table 6.21a. Facilities offering special programs or groups for specific client types, by state or jurisdiction: Number, 2020 (continued)

							Clien	t type				
State or jurisdiction ¹	Total ²	Any program or group	Criminal justice clients (other than DUI/DWI)	Clients with co-occurring mental and substance use disorders	Clients with co-occurring pain and substance use	Clients with HIV or AIDS	Clients who have experienced sexual abuse	Clients who have experienced intimate partner or domestic violence	Clients who have experienced trauma	DUI/DWI clients	Other	No specifically tailored programs or groups offered
Total	16,066	13,502	6,103	8,907	3,499	3,366	4,780	4,752	7,269	3,702	836	2,564
Alabama	155	117	35	58	21	32	26	31	40	15	5	38
Alaska	105	84	31	55	17	11	21	24	55	27	8	21
Arizona	447	385	193	260	132	106	168	182	222	91	17	62
Arkansas	171	138	78	100	30	25	47	49	72	58	5	33
California	1,734	1,552	713	1,047	477	477	644	619	939	116	116	182
Colorado	393	358	207	234	93	71	137	125	230	198	12	35
Connecticut	210	189	83	164	41	52	85	75	136	16	9	21
Delaware	49	40	22	29	22	14	12	14	22	12	1	9
District of Columbia	28	24	10	17	5	13	15	13	16	9	2	4
Florida	712	614	286	438	221	222	281	263	383	152	39	98
	348	282	125	182	67	74	111	116	164	43	15	66
Georgia Hawaii	161	153	50	44	25	23	24	31	37	43 16	6	8
Idaho	110	102	69	78	35	15	48	50	69	40	6	8
Illinois	713	597	235	316	111	138	138	168	224	325	42	116
Indiana	416	299	128	190	63	51	111	99	184	59	15	117
Iowa	185	155	62	108	25	18	38	37	59	49	3	30
Kansas	170	127	75	65	26	22	30	35	48	60	4	43
Kentucky	477	419	192	228	82	88	145	142	188	177	13	58
Louisiana	155	135	58	88	34	38	48	45	73	27	5	20
Maine	196	147	53	98	37	26	44	41	65	71	4	49
Maryland	432	375	174	241	95	109	121	130	180	175	26	57
Massachusetts	440	360	132	265	108	138	144	149	221	47	34	80
Michigan	455	354	181	252	106	85	142	137	213	105	33	101
Minnesota	401	341	108	234	62	52	95	91	142	77	39	60
Mississippi	105	90	41	67	21	29	34	31	49	40	6	15
Missouri	278	230	95	147	65	33	53	53	118	83	4	48
Montana	129	107	47	60	31	24	45	43	52	57	7	22
Nebraska	123	82	28	59	19	12	25	26	52	12	4	41

Table 6.21a. Facilities offering special programs or groups for specific client types, by state or jurisdiction: Number, 2020 (continued)

							Clien	t type				
State or jurisdiction ¹	Total²	Any program or group	Criminal justice clients (other than DUI/DWI)	Clients with co-occurring mental and substance use disorders	Clients with co-occurring pain and substance use	Clients with HIV or AIDS	Clients who have experienced sexual abuse	Clients who have experienced intimate partner or domestic violence	Clients who have experienced trauma	DUI/DWI clients	Other	No specifically tailored programs or groups offered
Nevada	109	100	60	74	35	37	50	47	61	22	8	9
New Hampshire	109	80	46	44	17	19	22	23	35	13	1	29
New Jersey	383	341	180	265	111	118	150	154	206	147	29	42
New Mexico	162	137	80	106	45	44	65	72	88	29	15	25
New York	894	802	377	584	183	214	252	274	461	232	80	92
North Carolina	611	467	196	309	161	141	205	179	258	127	19	144
North Dakota	87	65	23	33	5	3	7	15	26	32	7	22
Ohio	619	495	247	322	95	83	145	151	241	47	19	124
Oklahoma	195	157	105	110	54	48	69	66	102	32	8	38
Oregon	247	236	115	144	64	28	66	77	137	141	21	11
Pennsylvania	604	543	230	331	111	123	176	170	277	109	36	61
Puerto Rico	101	91	38	46	26	48	32	35	46	4	2	10
Rhode Island	63	59	26	45	18	14	17	16	25	13	8	4
South Carolina	124	97	45	47	17	21	27	26	42	49	5	27
South Dakota	58	53	33	31	14	9	15	13	29	30	2	5
Tennessee	311	252	81	187	65	58	71	68	103	54	6	59
Texas	509	430	182	273	115	117	141	134	193	61	19	79
Utah	333	302	162	234	110	79	183	163	231	103	24	31
Vermont	52	45	19	31	8	5	8	10	22	10	3	7
Virginia	249	200	74	145	42	41	53	47	113	34	7	49
Washington	457	347	129	197	56	52	85	85	142	120	19	110
West Virginia	126	99	36	62	19	17	28	27	45	31	1	27
Wisconsin	295	195	69	121	39	33	56	54	96	72	16	100
Wyoming	60	44	36	37	17	14	21	23	32	27	1	16
Other												
jurisdictions ³	10	9	3	5	1	2	4	4	5	6		1

⁻⁻ Quantity is zero.

DUI/DWI = driving under the influence/driving while intoxicated or impaired; LGBTQ = lesbian, gay, bisexual, transgender, or queer/questioning.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, because a facility could offer special programs or groups for more than one client type.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.21b. Facilities offering special programs or groups for specific client types, by state or jurisdiction: Row percent, 2020

							Clier	nt type				
State or jurisdiction ¹	No. of facilities²	Any program or group	Adolescents	Young adults	Adult women	Pregnant or post-partum women	Adult men	Seniors or older adults	LGBTQ	Veterans	Active duty military	Members of military families
Total	16,066	84.0	23.8	31.8	50.7	25.8	49.0	24.7	24.3	23.0	13.6	15.4
Alabama	155	75.5	19.4	21.9	37.4	22.6	42.6	17.4	16.8	21.3	10.3	10.3
Alaska	105	80.0	32.4	29.5	44.8	21.9	41.0	14.3	11.4	13.3	9.5	7.6
Arizona	447	86.1	28.2	36.9	53.2	27.7	50.6	30.2	28.4	27.3	18.6	20.4
Arkansas	171	80.7	34.5	28.7	37.4	8.8	36.8	21.1	19.9	17.0	5.8	7.6
California	1,734	89.5	19.0	37.4	56.9	28.6	55.7	30.3	33.6	29.0	14.4	19.7
Colorado	393	91.1	33.8	39.9	59.5	27.7	53.4	31.8	25.7	20.4	10.9	13.0
Connecticut	210	90.0	22.4	39.0	65.7	27.1	64.8	27.1	28.1	21.0	10.5	11.4
Delaware	49	81.6	26.5	46.9	53.1	42.9	46.9	32.7	24.5	24.5	14.3	18.4
District of												
Columbia	28	85.7	10.7	32.1	64.3	35.7	64.3	42.9	53.6	32.1	21.4	21.4
Florida	712	86.2	21.1	33.0	54.4	29.6	52.2	31.3	29.9	34.6	22.1	24.9
Georgia	348	81.0	20.7	32.2	48.9	25.9	45.4	23.6	25.6	28.7	15.2	16.4
Hawaii	161	95.0	65.2	18.0	26.7	15.5	26.7	16.8	17.4	15.5	13.0	12.4
Idaho	110	92.7	45.5	36.4	70.9	35.5	67.3	25.5	22.7	28.2	21.8	20.0
Illinois	713	83.7	25.2	30.2	40.3	17.4	41.4	22.2	19.8	17.8	10.2	12.8
Indiana	416	71.9	21.9	28.6	44.7	19.5	40.6	14.2	14.7	14.9	8.4	10.1
Iowa	185	83.8	38.4	26.5	38.9	17.3	34.6	17.8	13.0	11.4	9.2	10.3
Kansas	170	74.7	33.5	24.7	40.6	21.2	34.1	18.8	16.5	15.3	9.4	14.1
Kentucky	477	87.8	20.5	29.6	47.2	30.4	43.6	18.2	19.1	18.4	12.8	14.0
Louisiana	155	87.1	21.3	28.4	54.2	27.7	47.1	18.7	27.1	26.5	19.4	21.3
Maine	196	75.0	14.3	22.4	33.2	20.4	30.1	18.9	17.3	18.4	13.3	13.8
Maryland	432	86.8	20.8	40.7	56.3	27.3	57.4	32.4	29.6	24.3	16.4	16.4
Massachusetts	440	81.8	13.0	34.1	50.7	35.2	50.0	26.8	27.3	24.5	14.3	16.8
Michigan	455	77.8	18.9	26.4	51.4	26.2	51.6	25.5	23.5	25.3	12.3	13.6
Minnesota	401	85.0	19.2	20.7	43.4	19.5	44.6	19.0	20.2	13.5	7.7	9.0
Mississippi	105	85.7	16.2	30.5	49.5	26.7	46.7	26.7	21.0	22.9	16.2	15.2
Missouri	278	82.7	17.6	21.6	43.5	16.2	38.8	15.1	12.6	15.5	9.7	9.0
Montana	129	82.9	38.8	24.0	38.0	17.8	34.1	17.1	17.1	20.9	16.3	12.4
Nebraska	123	66.7	19.5	22.0	36.6	12.2	35.8	20.3	15.4	15.4	10.6	10.6

Table 6.21b. Facilities offering special programs or groups for specific client types, by state or jurisdiction: Row percent, 2020 (continued)

							Clier	nt type				
State or jurisdiction ¹	No. of facilities ²	Any program or group	Adolescents	Young adults	Adult women	Pregnant or post-partum women	Adult men	Seniors or older adults	LGBTQ	Veterans	Active duty military	Members of military families
Nevada	109	91.7	33.0	39.4	59.6	41.3	54.1	39.4	40.4	39.4	27.5	28.4
New Hampshire	109	73.4	12.8	25.7	52.3	33.0	52.3	18.3	30.3	33.0	16.5	17.4
New Jersey	383	89.0	28.5	43.3	64.8	34.2	60.6	37.9	34.2	32.4	20.9	24.3
New Mexico	162	84.6	34.6	42.0	54.3	32.7	57.4	35.2	35.8	34.0	24.1	27.2
New York	894	89.7	25.8	36.0	65.5	23.0	67.2	27.4	25.7	21.8	10.4	11.0
North Carolina	611	76.4	20.5	35.8	49.6	33.6	47.0	30.4	30.3	28.5	18.3	22.6
North Dakota	87	74.7	26.4	23.0	27.6	10.3	24.1	4.6	4.6	6.9	4.6	4.6
Ohio	619	80.0	21.5	27.1	47.8	22.5	45.2	17.6	18.4	17.3	9.9	10.3
Oklahoma	195	80.5	29.2	30.8	60.5	30.3	56.4	27.7	28.2	30.3	17.9	21.5
Oregon	247	95.5	28.3	32.4	58.3	23.5	53.4	19.0	20.6	17.4	9.7	8.5
Pennsylvania	604	89.9	23.2	31.6	55.0	25.2	51.2	22.0	22.0	19.5	11.4	10.8
Puerto Rico	101	90.1	21.8	58.4	40.6	22.8	75.2	61.4	34.7	37.6	17.8	27.7
Rhode Island	63	93.7	7.9	28.6	54.0	38.1	49.2	30.2	22.2	25.4	14.3	12.7
South Carolina	124	78.2	35.5	25.0	47.6	29.0	41.1	18.5	11.3	12.1	8.1	8.1
South Dakota	58	91.4	43.1	41.4	43.1	24.1	41.4	15.5	15.5	22.4	12.1	15.5
Tennessee	311	81.0	18.6	25.7	39.9	27.0	38.3	19.9	19.3	19.9	12.2	13.8
Texas	509	84.5	26.1	29.7	51.7	28.7	49.5	25.5	24.6	26.1	14.5	17.3
Utah	333	90.7	27.3	39.6	57.1	27.3	58.9	33.0	35.1	29.7	22.2	26.7
Vermont	52	86.5	26.9	32.7	40.4	34.6	44.2	23.1	11.5	15.4	9.6	5.8
Virginia	249	80.3	22.5	28.9	53.4	35.7	50.2	19.3	19.7	20.1	13.7	14.9
Washington	457	75.9	27.1	24.1	40.3	19.9	35.7	14.2	15.1	14.4	9.0	9.2
West Virginia	126	78.6	13.5	19.8	38.1	23.8	36.5	15.9	21.4	23.0	11.9	11.1
Wisconsin	295	66.1	18.3	19.7	37.3	16.3	32.5	14.6	14.2	12.9	7.1	8.8
Wyoming	60	73.3	30.0	31.7	43.3	23.3	45.0	26.7	28.3	30.0	21.7	21.7
Other												
jurisdictions ³	10	90.0	30.0	20.0	60.0	20.0	60.0	30.0	10.0	10.0		10.0

Table 6.21b. Facilities offering special programs or groups for specific client types, by state or jurisdiction: Row percent, 2020 (continued)

							Clien	t type				
State or jurisdiction ¹	No. of facilities²	Any program or group	Criminal justice clients (other than DUI/DWI)	Clients with co-occurring mental and substance use disorders	Clients with co-occurring pain and substance use	Clients with HIV or AIDS	Clients who have experienced sexual abuse	Clients who have experienced intimate partner or domestic violence	Clients who have experienced trauma	DUI/DWI clients	Other	No specifically tailored programs or groups offered
Total	16,066	84.0	38.0	55.4	21.8	21.0	29.8	29.6	45.2	23.0	5.2	16.0
Alabama	155	75.5	22.6	37.4	13.5	20.6	16.8	20.0	25.8	9.7	3.2	24.5
Alaska	105	80.0	29.5	52.4	16.2	10.5	20.0	22.9	52.4	25.7	7.6	20.0
Arizona	447	86.1	43.2	58.2	29.5	23.7	37.6	40.7	49.7	20.4	3.8	13.9
Arkansas	171	80.7	45.6	58.5	17.5	14.6	27.5	28.7	42.1	33.9	2.9	19.3
California	1,734	89.5	41.1	60.4	27.5	27.5	37.1	35.7	54.2	6.7	6.7	10.5
Colorado	393	91.1	52.7	59.5	23.7	18.1	34.9	31.8	58.5	50.4	3.1	8.9
Connecticut	210	90.0	39.5	78.1	19.5	24.8	40.5	35.7	64.8	7.6	4.3	10.0
Delaware District of	49	81.6	44.9	59.2	44.9	28.6	24.5	28.6	44.9	24.5	2.0	18.4
Columbia	28	85.7	35.7	60.7	17.9	46.4	53.6	46.4	57.1	32.1	7.1	14.3
Florida	712	86.2	40.2	61.5	31.0	31.2	39.5	36.9	53.8	21.3	5.5	13.8
Georgia	348	81.0	35.9	52.3	19.3	21.3	31.9	33.3	47.1	12.4	4.3	19.0
Hawaii	161	95.0	31.1	27.3	15.5	14.3	14.9	19.3	23.0	9.9	3.7	5.0
Idaho	110	92.7	62.7	70.9	31.8	13.6	43.6	45.5	62.7	36.4	5.5	7.3
Illinois	713	83.7	33.0	44.3	15.6	19.4	19.4	23.6	31.4	45.6	5.9	16.3
Indiana	416	71.9	30.8	45.7	15.1	12.3	26.7	23.8	44.2	14.2	3.6	28.1
Iowa	185	83.8	33.5	58.4	13.5	9.7	20.5	20.0	31.9	26.5	1.6	16.2
Kansas	170	74.7	44.1	38.2	15.3	12.9	17.6	20.6	28.2	35.3	2.4	25.3
Kentucky	477	87.8	40.3	47.8	17.2	18.4	30.4	29.8	39.4	37.1	2.7	12.2
Louisiana	155	87.1	37.4	56.8	21.9	24.5	31.0	29.0	47.1	17.4	3.2	12.9
Maine	196	75.0	27.0	50.0	18.9	13.3	22.4	20.9	33.2	36.2	2.0	25.0
Maryland	432	86.8	40.3	55.8	22.0	25.2	28.0	30.1	41.7	40.5	6.0	13.2
Massachusetts	440	81.8	30.0	60.2	24.5	31.4	32.7	33.9	50.2	10.7	7.7	18.2
Michigan	455	77.8	39.8	55.4	23.3	18.7	31.2	30.1	46.8	23.1	7.3	22.2
Minnesota	401	85.0	26.9	58.4	15.5	13.0	23.7	22.7	35.4	19.2	9.7	15.0
Mississippi	105	85.7	39.0	63.8	20.0	27.6	32.4	29.5	46.7	38.1	5.7	14.3
Missouri	278	82.7	34.2	52.9	23.4	11.9	19.1	19.1	42.4	29.9	1.4	17.3
Montana	129	82.9	36.4	46.5	24.0	18.6	34.9	33.3	40.3	44.2	5.4	17.1
Nebraska	123	66.7	22.8	48.0	15.4	9.8	20.3	21.1	42.3	9.8	3.3	33.3

Table 6.21b. Facilities offering special programs or groups for specific client types, by state or jurisdiction: Row percent, 2020 (continued)

							Clien	t type				
State or jurisdiction ¹	No. of facilities ²	Any program or group	Criminal justice clients (other than DUI/DWI)	Clients with co-occurring mental and substance use disorders	Clients with co-occurring pain and substance use	Clients with HIV or AIDS	Clients who have experienced sexual abuse	Clients who have experienced intimate partner or domestic violence	Clients who have experienced trauma	DUI/DWI clients	Other	No specifically tailored programs or groups offered
Nevada	109	91.7	55.0	67.9	32.1	33.9	45.9	43.1	56.0	20.2	7.3	8.3
New Hampshire	109	73.4	42.2	40.4	15.6	17.4	20.2	21.1	32.1	11.9	0.9	26.6
New Jersey	383	89.0	47.0	69.2	29.0	30.8	39.2	40.2	53.8	38.4	7.6	11.0
New Mexico	162	84.6	49.4	65.4	27.8	27.2	40.1	44.4	54.3	17.9	9.3	15.4
New York	894	89.7	42.2	65.3	20.5	23.9	28.2	30.6	51.6	26.0	8.9	10.3
North Carolina	611	76.4	32.1	50.6	26.4	23.1	33.6	29.3	42.2	20.8	3.1	23.6
North Dakota	87	74.7	26.4	37.9	5.7	3.4	8.0	17.2	29.9	36.8	8.0	25.3
Ohio	619	80.0	39.9	52.0	15.3	13.4	23.4	24.4	38.9	7.6	3.1	20.0
Oklahoma	195	80.5	53.8	56.4	27.7	24.6	35.4	33.8	52.3	16.4	4.1	19.5
Oregon	247	95.5	46.6	58.3	25.9	11.3	26.7	31.2	55.5	57.1	8.5	4.5
Pennsylvania	604	89.9	38.1	54.8	18.4	20.4	29.1	28.1	45.9	18.0	6.0	10.1
Puerto Rico	101	90.1	37.6	45.5	25.7	47.5	31.7	34.7	45.5	4.0	2.0	9.9
Rhode Island	63	93.7	41.3	71.4	28.6	22.2	27.0	25.4	39.7	20.6	12.7	6.3
South Carolina	124	78.2	36.3	37.9	13.7	16.9	21.8	21.0	33.9	39.5	4.0	21.8
South Dakota	58	91.4	56.9	53.4	24.1	15.5	25.9	22.4	50.0	51.7	3.4	8.6
Tennessee	311	81.0	26.0	60.1	20.9	18.6	22.8	21.9	33.1	17.4	1.9	19.0
Texas	509	84.5	35.8	53.6	22.6	23.0	27.7	26.3	37.9	12.0	3.7	15.5
Utah	333	90.7	48.6	70.3	33.0	23.7	55.0	48.9	69.4	30.9	7.2	9.3
Vermont	52	86.5	36.5	59.6	15.4	9.6	15.4	19.2	42.3	19.2	5.8	13.5
Virginia	249	80.3	29.7	58.2	16.9	16.5	21.3	18.9	45.4	13.7	2.8	19.7
Washington	457	75.9	28.2	43.1	12.3	11.4	18.6	18.6	31.1	26.3	4.2	24.1
West Virginia	126	78.6	28.6	49.2	15.1	13.5	22.2	21.4	35.7	24.6	8.0	21.4
Wisconsin	295	66.1	23.4	41.0	13.2	11.2	19.0	18.3	32.5	24.4	5.4	33.9
Wyoming	60	73.3	60.0	61.7	28.3	23.3	35.0	38.3	53.3	45.0	1.7	26.7
Other jurisdictions ³	10	90.0	30.0	50.0	10.0	20.0	40.0	40.0	50.0	60.0		10.0
Quantity is 7		90.0	30.0	30.0	10.0	20.0	40.0	40.0	30.0	00.0		10.0

^{- -} Quantity is zero.

DUI/DWI = driving under the influence/driving while intoxicated or impaired; LGBTQ = lesbian, gay, bisexual, transgender, or queer/questioning.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, because a facility could offer special programs or groups for more than one client type.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.22a. Facilities offering substance use treatment services in sign language for the deaf and hard-of-hearing and in languages other than English, by state or jurisdiction: Number, 2020

				Lang	guage services pro	vided by	Langua	ges provided by staff co	unselor²
State or jurisdiction ¹	Total	Sign language	Any language other than English	Staff counselor only	On-call interpreter only ³	Both staff counselor and on-call interpreter	Spanish	American Indian/Alaska Native language	Other
Total	16,066	5,848	8,792	1,893	4,748	2,151	3,784	87	852
Alabama	155	86	72		67	5	5		1
Alaska	105	34	50	6	36	8	8	8	2
Arizona	447	228	304	41	109	154	179	31	18
Arkansas	171	73	92	4	78	10	14		
California	1,734	420	914	318	186	410	695	6	156
Colorado	393	110	181	47	56	78	122	1	6
Connecticut	210	79	146	42	40	64	105		27
Delaware	49	14	25	8	10	7	15		2
District of Columbia	28	13	15	2	9	4	6		1
Florida	712	296	469	164	153	152	309		77
Georgia	348	117	154	29	98	27	54		9
Hawaii	161	64	72	3	65	4	5		7
Idaho	110	14	42	10	23	9	18	1	
Illinois	713	212	408	142	185	81	206		74
Indiana	416	208	251	17	187	47	60		4
Iowa	185	64	86	8	70	8	16		
Kansas	170	46	74	10	51	13	23		2
Kentucky	477	226	241	15	210	16	30		1
Louisiana	155	50	54	7	44	3	10		1
Maine	196	85	90	3	81	6	2	1	7
Maryland	432	108	169	47	95	27	68		25
Massachusetts	440	214	336	60	105	171	219		90
Michigan	455	228	271	16	220	35	38	3	17
Minnesota	401	73	113	16	90	7	10	1	13
Mississippi	105	47	55		51	4	3		2
Missouri	278	185	188	4	180	4	8		1
Montana	129	36	37	3	33	1	2	2	
Nebraska	123	26	55	6	44	5	10	1	1

Table 6.22a. Facilities offering substance use treatment services in sign language for the deaf and hard-of-hearing and in languages other than English, by state or jurisdiction: Number, 2020 (continued)

				Lang	guage services pro	vided by	Langua	ges provided by staff co	unselor²
State or jurisdiction ¹	Total	Sign language	Any language other than English	Staff counselor only	On-call interpreter only³	Both staff counselor and on-call interpreter	Spanish	American Indian/Alaska Native language	Other
Nevada	109	25	67	32	19	16	47		10
New Hampshire	109	38	63	3	56	4	7		1
New Jersey	383	58	163	83	46	34	109		39
New Mexico	162	37	124	54	30	40	79	23	3
New York	894	253	573	211	212	150	340		101
North Carolina	611	165	272	38	190	44	73		16
North Dakota	87	27	35	2	29	4	4	1	1
Ohio	619	396	400	12	350	38	43		10
Oklahoma	195	106	112	9	85	18	24	1	3
Oregon	247	123	175	35	110	30	59		9
Pennsylvania	604	165	255	64	146	45	102		20
Puerto Rico	101	19	98	70	8	20	90		
Rhode Island	63	24	45	10	22	13	22		7
South Carolina	124	58	68	5	48	15	20	1	2
South Dakota	58	21	27	2	22	3	3	2	1
Tennessee	311	154	193	13	164	16	24		8
Гехаѕ	509	150	300	121	75	104	223		8
Jtah	333	87	147	44	45	58	101	3	21
Vermont	52	29	34	1	30	3	4		2
Virginia	249	107	131	20	87	24	42		9
Washington	457	244	297	23	211	63	74		20
West Virginia	126	57	48	1	43	4	4		2
Wisconsin	295	134	158	7	123	28	33		10
Wyoming	60	12	34	2	19	13	14	1	
Other jurisdictions ⁴	10	3	9	3	2	4	3		5

⁻⁻ Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities based on facilities where language services are provided by staff counselors only and by both staff counselors and on-call interpreters.

³ Facilities that offered substance use treatment services in any language other than English but which did not have a valid response to language provider were classified as providing services by an on-call interpreter only.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.22b. Facilities offering substance use treatment services in sign language for the deaf and hard-of-hearing and in languages other than English, by state or jurisdiction: Row percent distribution, 2020

						Language s	ervices provid	ed by	Languag	es provided by staff co	ounselor ²
State or jurisdiction ¹		Number of facilities	Sign language	Any language other than English	Total	Staff counselor only	On-call interpreter only³	Both staff counselor and on-call interpreter	Spanish	American Indian/Alaska Native language	Other
	Total	16,066	36.4	54.7	100.0	21.5	54.0	24.5	93.6	2.2	21.1
Alabama		155	55.5	46.5	100.0		93.1	6.9	100.0		20.0
Alaska		105	32.4	47.6	100.0	12.0	72.0	16.0	57.1	57.1	14.3
Arizona		447	51.0	68.0	100.0	13.5	35.9	50.7	91.8	15.9	9.2
Arkansas		171	42.7	53.8	100.0	4.3	84.8	10.9	100.0		
California		1,734	24.2	52.7	100.0	34.8	20.4	44.9	95.5	0.8	21.4
Colorado		393	28.0	46.1	100.0	26.0	30.9	43.1	97.6	0.8	4.8
Connecticut		210	37.6	69.5	100.0	28.8	27.4	43.8	99.1		25.5
Delaware		49	28.6	51.0	100.0	32.0	40.0	28.0	100.0		13.3
District of Columbia		28	46.4	53.6	100.0	13.3	60.0	26.7	100.0		16.7
Florida		712	41.6	65.9	100.0	35.0	32.6	32.4	97.8		24.4
Georgia		348	33.6	44.3	100.0	18.8	63.6	17.5	96.4		16.1
Hawaii		161	39.8	44.7	100.0	4.2	90.3	5.6	71.4		100.0
Idaho		110	12.7	38.2	100.0	23.8	54.8	21.4	94.7	5.3	
Illinois		713	29.7	57.2	100.0	34.8	45.3	19.9	92.4		33.2
Indiana		416	50.0	60.3	100.0	6.8	74.5	18.7	93.8		6.3
lowa		185	34.6	46.5	100.0	9.3	81.4	9.3	100.0		
Kansas		170	27.1	43.5	100.0	13.5	68.9	17.6	100.0		8.7
Kentucky		477	47.4	50.5	100.0	6.2	87.1	6.6	96.8		3.2
Louisiana		155	32.3	34.8	100.0	13.0	81.5	5.6	100.0		10.0
Maine		196	43.4	45.9	100.0	3.3	90.0	6.7	22.2	11.1	77.8
Maryland		432	25.0	39.1	100.0	27.8	56.2	16.0	91.9		33.8
Massachusetts		440	48.6	76.4	100.0	17.9	31.3	50.9	94.8		39.0
Michigan		455	50.1	59.6	100.0	5.9	81.2	12.9	74.5	5.9	33.3
Minnesota		401	18.2	28.2	100.0	14.2	79.6	6.2	43.5	4.3	56.5
Mississippi		105	44.8	52.4	100.0		92.7	7.3	75.0		50.0
Missouri		278	66.5	67.6	100.0	2.1	95.7	2.1	100.0		12.5
Montana		129	27.9	28.7	100.0	8.1	89.2	2.7	50.0	50.0	
Nebraska		123	21.1	44.7	100.0	10.9	80.0	9.1	90.9	9.1	9.1

Table 6.22b. Facilities offering substance use treatment services in sign language for the deaf and hard-of-hearing and in languages other than English, by state or jurisdiction: Row percent distribution, 2020 (continued)

					Language s	ervices provid	ed by	Languag	es provided by staff co	ounselor ²
State or jurisdiction ¹	Number of facilities	Sign language	Any language other than English	Total	Staff counselor only	On-call interpreter only³	Both staff counselor and on-call interpreter	Spanish	American Indian/Alaska Native language	Other
Nevada	109	22.9	61.5	100.0	47.8	28.4	23.9	97.9		20.8
New Hampshire	109	34.9	57.8	100.0	4.8	88.9	6.3	100.0		14.3
New Jersey	383	15.1	42.6	100.0	50.9	28.2	20.9	93.2		33.3
New Mexico	162	22.8	76.5	100.0	43.5	24.2	32.3	84.0	24.5	3.2
New York	894	28.3	64.1	100.0	36.8	37.0	26.2	94.2		28.0
North Carolina	611	27.0	44.5	100.0	14.0	69.9	16.2	89.0		19.5
North Dakota	87	31.0	40.2	100.0	5.7	82.9	11.4	66.7	16.7	16.7
Ohio	619	64.0	64.6	100.0	3.0	87.5	9.5	86.0		20.0
Oklahoma	195	54.4	57.4	100.0	8.0	75.9	16.1	88.9	3.7	11.1
Oregon	247	49.8	70.9	100.0	20.0	62.9	17.1	90.8		13.8
Pennsylvania	604	27.3	42.2	100.0	25.1	57.3	17.6	93.6		18.3
Puerto Rico	101	18.8	97.0	100.0	71.4	8.2	20.4	100.0		
Rhode Island	63	38.1	71.4	100.0	22.2	48.9	28.9	95.7		30.4
South Carolina	124	46.8	54.8	100.0	7.4	70.6	22.1	100.0	5.0	10.0
South Dakota	58	36.2	46.6	100.0	7.4	81.5	11.1	60.0	40.0	20.0
Tennessee	311	49.5	62.1	100.0	6.7	85.0	8.3	82.8		27.6
Texas	509	29.5	58.9	100.0	40.3	25.0	34.7	99.1		3.6
Utah	333	26.1	44.1	100.0	29.9	30.6	39.5	99.0	2.9	20.6
Vermont	52	55.8	65.4	100.0	2.9	88.2	8.8	100.0		50.0
Virginia	249	43.0	52.6	100.0	15.3	66.4	18.3	95.5		20.5
Washington	457	53.4	65.0	100.0	7.7	71.0	21.2	86.0		23.3
West Virginia	126	45.2	38.1	100.0	2.1	89.6	8.3	80.0		40.0
Wisconsin	295	45.4	53.6	100.0	4.4	77.8	17.7	94.3		28.6
Wyoming	60	20.0	56.7	100.0	5.9	55.9	38.2	93.3	6.7	
Other jurisdictions ⁴	10	30.0	90.0	100.0	33.3	22.2	44.4	42.9		71.4

⁻⁻ Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Percentage of facilities based on facilities where language services are provided by staff counselors only and by both staff counselors and on-call interpreters.

³ Facilities that offered substance use treatment services in any language other than English but which did not have a valid response to language provider were classified as providing services by an on-call interpreter only.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.23. Facilities detoxifying clients, by substance and state or jurisdiction: Number and row percent, 2020

				Numbe	r of facilities	S ²					Row	percent of f	acilities²		
				Detoxific	ation from						Detoxific	ation from			
State or jurisdiction¹				Ben-		Meth-		Routine use of medi-					Meth-		Routine use of medi-
	T-4-13	0 - 1 - 1 - 1 -	A111	zodia-	0	amphet-	Other sub-	cations during	Outstale	A111	Benzodia-	0	amphet-	Other sub-	cations during
	Total ³	Opioids	Alcohol	zepines	Cocaine	amines	stances	detox	Opioids	Alcohol	zepines	Cocaine	amines	stances	detox
Total	3,609	3,459	2,580	2,385	2,172	2,215	525	3,268	95.8	71.5	66.1	60.2	61.4	14.5	90.6
Alabama	31	31	22	23	17	19	2	29	100.0	71.0	74.2	54.8	61.3	6.5	93.5
Alaska	12	12	7	4	5	5		10	100.0	58.3	33.3	41.7	41.7		83.3
Arizona	104	97	69	64	57	68	9	90	93.3	66.3	61.5	54.8	65.4	8.7	86.5
Arkansas	26 682	22	21 516	19 496	15 496	17 498	3 170	18 605	84.6 95.6	80.8 75.7	73.1 72.7	57.7	65.4 73.0	11.5 26.1	69.2
California		652					178					72.7			88.7
Colorado	60	52	47	38	42	41	10	45	86.7	78.3	63.3	70.0	68.3	16.7	75.0
Connecticut	38	38	23	22	10	15	2	37	100.0	60.5	57.9	26.3	39.5	5.3	97.4
Delaware	8	8	6	4	3	3		8	100.0	75.0	50.0	37.5	37.5		100.0
District of	_	_						_							
Columbia	5	5	2	2	2	2		5	100.0	40.0	40.0	40.0	40.0		100.0
Florida	194	192	160	157	141	145	38	184	99.0	82.5	80.9	72.7	74.7	19.6	94.8
Georgia	91	85	54	53	41	43	7	82	93.4	59.3	58.2	45.1	47.3	7.7	90.1
Hawaii	20	19	11	10	10	11	2	17	95.0	55.0	50.0	50.0	55.0	10.0	85.0
Idaho	16	16	11	12	11	11	2	12	100.0	8.86	75.0	68.8	68.8	12.5	75.0
Illinois	125	125	76	60	60	57	11	116	100.0	60.8	48.0	48.0	45.6	8.8	92.8
Indiana	94	93	75	67	56	58	11	84	98.9	79.8	71.3	59.6	61.7	11.7	89.4
Iowa	22	22	19	17	17	17	2	19	100.0	86.4	77.3	77.3	77.3	9.1	86.4
Kansas	23	23	19	18	18	18	4	16	100.0	82.6	78.3	78.3	78.3	17.4	69.6
Kentucky	98	92	54	53	71	71	7	81	93.9	55.1	54.1	72.4	72.4	7.1	82.7
Louisiana	54	54	42	41	37	39	11	53	100.0	77.8	75.9	68.5	72.2	20.4	98.1
Maine	14	14	8	5	6	6	1	14	100.0	57.1	35.7	42.9	42.9	7.1	100.0
Maryland	104	100	67	65	53	44	15	98	96.2	64.4	62.5	51.0	42.3	14.4	94.2
Massachusetts	87	84	56	53	41	37	8	80	96.6	64.4	60.9	47.1	42.5	9.2	92.0
Michigan	80	80	50	36	42	42	10	78	100.0	62.5	45.0	52.5	52.5	12.5	97.5
Minnesota	27	27	23	24	23	23	4	24	100.0	85.2	88.9	85.2	85.2	14.8	88.9
Mississippi	34	32	23	22	18	20	4	31	94.1	67.6	64.7	52.9	58.8	11.8	91.2
Missouri	57	57	46	39	36	36	4	56	100.0	80.7	68.4	63.2	63.2	7.0	98.2
Montana	11	11	9	9	8	9	1	10	100.0	81.8	81.8	72.7	81.8	9.1	90.9
Nebraska	13	12	11	9	10	10		12	92.3	84.6	69.2	76.9	76.9		92.3

Table 6.23. Facilities detoxifying clients, by substance and state or jurisdiction: Number and row percent, 2020 (continued)

				Numbe	r of facilities	2					Row	percent of t	acilities²		
State or				Detoxific	cation from			Routine use			Detoxific	ation from			Routine use
jurisdiction ¹	Total³	Opioids	Alcohol	Ben- zodia- zepines	Cocaine	Meth- amphet- amines	Other sub- stances	of medi- cations during detox	Opioids	Alcohol	Benzodia- zepines	Cocaine	Meth- amphet- amines	Other sub- stances	of medi- cations during detox
Nevada	40	37	25	25	27	28	6	31	92.5	62.5	62.5	67.5	70.0	15.0	77.5
New Hampshire	22	21	13	9	5	4		18	95.5	59.1	40.9	22.7	18.2		81.8
New Jersey	65	64	43	39	26	27	13	62	98.5	66.2	60.0	40.0	41.5	20.0	95.4
New Mexico	25	23	14	14	14	16	3	19	92.0	56.0	56.0	56.0	64.0	12.0	76.0
New York	183	180	145	127	87	88	21	174	98.4	79.2	69.4	47.5	48.1	11.5	95.1
North Carolina	139	136	104	86	72	78	10	134	97.8	74.8	61.9	51.8	56.1	7.2	96.4
North Dakota	19	16	17	15	14	16	1	10	84.2	89.5	78.9	73.7	84.2	5.3	52.6
Ohio	178	175	101	110	108	115	10	172	98.3	56.7	61.8	60.7	64.6	5.6	96.6
Oklahoma	32	30	21	19	13	13	2	29	93.8	65.6	59.4	40.6	40.6	6.3	90.6
Oregon	40	34	24	21	26	24	9	34	85.0	60.0	52.5	65.0	60.0	22.5	85.0
Pennsylvania	111	107	86	86	65	66	19	108	96.4	77.5	77.5	58.6	59.5	17.1	97.3
Puerto Rico	29	23	21	22	26	18	3	24	79.3	72.4	75.9	89.7	62.1	10.3	82.8
Rhode Island	23	22	8	7	7	5	1	22	95.7	34.8	30.4	30.4	21.7	4.3	95.7
South Carolina	26	25	19	20	12	12	4	23	96.2	73.1	76.9	46.2	46.2	15.4	88.5
South Dakota	7	7	6	6	5	5	3	7	100.0	85.7	85.7	71.4	71.4	42.9	100.0
Tennessee	64	58	43	43	38	40	9	52	90.6	67.2	67.2	59.4	62.5	14.1	81.3
Texas	149	145	104	101	84	87	24	140	97.3	69.8	67.8	56.4	58.4	16.1	94.0
Utah	97	92	78	69	66	70	13	85	94.8	80.4	71.1	68.0	72.2	13.4	87.6
Vermont	10	10	8	4	6	5	1	9	100.0	80.0	40.0	60.0	50.0	10.0	90.0
Virginia	57	56	41	33	33	32	10	56	98.2	71.9	57.9	57.9	56.1	17.5	98.2
Washington	51	48	39	29	33	33	3	44	94.1	76.5	56.9	64.7	64.7	5.9	86.3
West Virginia	40	36	30	26	17	21	5	36	90.0	75.0	65.0	42.5	52.5	12.5	90.0
Wisconsin	49	39	40	33	22	27	4	48	79.6	81.6	67.3	44.9	55.1	8.2	98.0
Wyoming Other	16	15	16	14	15	15	1	12	93.8	100.0	87.5	93.8	93.8	6.3	75.0
Otner jurisdictions⁴	7	5	7	5	5	5	4	5	71.4	100.0	71.4	71.4	71.4	57.1	71.4

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, and percentages sum to more than 100 percent, because a facility could provide detoxification for more than one substance.

³ Of 16,066 facilities, 3,609 facilities (22 percent) offered detoxification services.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.24. Facilities with client outreach, by state or jurisdiction: Number and percent, 2020

				ersons who may reatment			•	ersons who may reatment
State or jurisdiction ¹		Total number of facilities	Number of facilities	Percent of all facilities	State or jurisdiction ¹	Total number of facilities	Number of facilities	Percent of all facilities
	Total	16,066	10,653	66.3				
Alabama		155	129	83.2	Nevada	109	84	77.1
Alaska		105	83	79.0	New Hampshire	109	67	61.5
Arizona		447	296	66.2	New Jersey	383	251	65.5
Arkansas		171	145	84.8	New Mexico	162	118	72.8
California		1,734	1,199	69.1	New York	894	566	63.3
Colorado		393	251	63.9	North Carolina	611	388	63.5
Connecticut		210	125	59.5	North Dakota	87	53	60.9
Delaware		49	35	71.4	Ohio	619	432	69.8
District of Columbia		28	21	75.0	Oklahoma	195	167	85.6
Florida		712	446	62.6	Oregon	247	170	68.8
Georgia		348	234	67.2	Pennsylvania	604	388	64.2
Hawaii		161	92	57.1	Puerto Rico	101	66	65.3
Idaho		110	80	72.7	Rhode Island	63	42	66.7
Illinois		713	452	63.4	South Carolina	124	94	75.8
Indiana		416	256	61.5	South Dakota	58	43	74.1
Iowa		185	129	69.7	Tennessee	311	226	72.7
Kansas		170	111	65.3	Texas	509	337	66.2
Kentucky		477	330	69.2	Utah	333	232	69.7
Louisiana		155	119	76.8	Vermont	52	40	76.9
Maine		196	90	45.9	Virginia	249	164	65.9
Maryland		432	302	69.9	Washington	457	313	68.5
Massachusetts		440	253	57.5	West Virginia	126	92	73.0
Michigan		455	281	61.8	Wisconsin	295	145	49.2
Minnesota		401	237	59.1	Wyoming	60	47	78.3
Mississippi		105	78	74.3	Other jurisdictions ²	10	10	100.0
Missouri		278	164	59.0				
Montana		129	105	81.4				
Nebraska		123	75	61.0				

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.25a. Facility licensing, certification, or accreditation, by state or jurisdiction: Number, 2020

						Licensin	g, certification,	or accredit	ation organ	ization			
State or jurisdiction ¹	Total ²	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commission	CARF	NCQA	COA	HFAP	Other organization/ federal/state/ local agency	Not licensed, certified, or accredited
Total	16,066	15,978	12,329	6,346	7,689	734	3,674	4,763	367	717	151	741	891
Alabama	155	155	115	119	29	8	29	19	3	4	2	6	16
Alaska	105	105	67	58	48	4	34	46	2	6		4	10
Arizona	447	445	172	179	359	17	104	133	1	16	4	13	25
Arkansas	171	167	149	104	45	5	31	104	12	29	9	4	5
California	1,734	1,722	1,216	222	957	40	523	420	46	69	9	81	87
Colorado	393	391	357	181	139	11	50	32	1	4	1	12	17
Connecticut	210	202	135	139	180	15	91	57	8	13		9	5
Delaware	49	49	37	23	26	1	13	20	3	5	1	2	8
District of Columbia	28	28	25	18	17		3	6		2	3	3	1
Florida	712	708	571	193	303	38	275	278	10	20	4	62	28
Georgia	348	347	240	134	176	14	84	196	15	26	17	24	16
Hawaii	161	161	89	23	80	1	6	100	7	3		2	32
Idaho	110	110	84	56	58	2	8	13	3			4	8
Illinois	713	711	639	198	176	31	172	181	29	34	8	24	13
Indiana	416	416	305	276	121	45	134	128	11	23	8	15	32
Iowa	185	185	133	45	143	6	30	80	1	13		3	
Kansas	170	167	158	58	32	7	23	14	4	6	2	4	3
Kentucky	477	476	375	242	105	11	91	171	6	31	2	8	26
Louisiana	155	154	101	42	118	26	35	72	2	8	1	6	9
Maine	196	196	172	125	52	6	15	29	10	11		14	16
Maryland	432	431	348	202	301	11	107	245	14	14	12	62	16
Massachusetts	440	434	384	118	369	32	124	129	24	24	3	12	6
Michigan	455	453	404	148	195	19	83	262	8	49	4	20	9
Minnesota	401	397	328	119	264	9	49	53	3	8	5	33	10
Mississippi	105	104	49	81	28	6	19	23	2	3	1	2	5
Missouri	278	276	227	209	82	10	43	173	9	10	1	8	7
Montana	129	129	98	55	35	2	6	33	5	6	1	4	13
Nebraska	123	123	74	35	51	8	30	53	2	8		2	16

Table 6.25a. Facility licensing, certification, or accreditation, by state or jurisdiction: Number, 2020 (continued)

					Lice	nsing, certi	fication, or accr	editation or	ganization				
State or jurisdiction ¹	Total ²	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commission	CARF	NCQA	COA	HFAP	Other organization/ federal/state/ local agency	Not licensed, certified, or accredited
Nevada	109	109	85	28	57	7	20	20	3	3	1	9	8
New Hampshire	109	109	36	15	28	2	8	28				4	45
New Jersey	383	382	303	169	213	22	97	88	4	15		7	50
New Mexico	162	157	59	61	89	6	36	26	6	12	1	13	29
New York	894	893	845	146	304	90	253	100	12	33	10	27	11
North Carolina	611	602	358	276	254	18	88	258	19	27	5	39	83
North Dakota	87	87	76	38	14	4	10	6		2		4	6
Ohio	619	616	541	433	113	24	160	287	7	60	12	32	14
Oklahoma	195	195	155	138	36	5	41	78	7	4	2	10	12
Oregon	247	245	225	131	95	5	19	33	3	10	1	12	7
Pennsylvania	604	604	535	134	379	32	125	182	8	14	1	19	17
Puerto Rico	101	100	94	80	68	16	24	7	2	2	4	3	2
Rhode Island	63	63	50	42	37	5	14	29	1	5	1	2	3
South Carolina	124	124	83	6	87	6	19	75	5	3		9	9
South Dakota	58	58	46	11	30	3	9	9	1	1		6	5
Tennessee	311	310	243	249	98	8	79	96	5	25	3	8	7
Texas	509	504	385	117	350	25	166	122	9	17	5	23	22
Utah	333	332	235	190	189	6	98	27	4	2	2	33	17
Vermont	52	52	37	22	33	8	15	8	5	1		1	6
Virginia	249	249	186	162	67	13	36	54	4	5		13	33
Washington	457	455	351	181	385	8	66	68	7	7	1	9	32
West Virginia	126	126	79	73	71	4	9	18	2	14	3	4	4
Wisconsin	295	294	222	193	146	26	63	26	10	10	1	8	27
Wyoming	60	60	46	46	52	4	6	47	1			3	
Other jurisdictions ³	10	10	2	3	5	2	11	1	11				3

^{- -} Quantity is zero.

CARF = Commission on Accreditation of Rehabilitation Facilities; COA = Council on Accreditation; HFAP = Healthcare Facilities Accreditation Program; NCQA = National Committee for Quality Assurance.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, because a facility could report more than one licensing, certification, or accreditation organization. The number of facilities licensed, certified, or accredited and the number not licensed, certified, or accredited by any listed organization do not sum to the total number of facilities, because 88 facilities did not respond to the question.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.25b. Facility licensing, certification, or accreditation, by state or jurisdiction: Row percent, 2020

			Licensing, certification, or accreditation organization										
State or jurisdiction ¹	Number of facilities ²	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commission	CARF	NCQA	COA	HFAP	Other organization/ federal/state/ local agency	Not licensed, certified, or accredited
Total	16,066	99.5	76.7	39.5	47.9	4.6	22.9	29.6	2.3	4.5	0.9	4.6	5.5
Alabama	155	100.0	74.2	76.8	18.7	5.2	18.7	12.3	1.9	2.6	1.3	3.9	10.3
Alaska	105	100.0	63.8	55.2	45.7	3.8	32.4	43.8	1.9	5.7		3.8	9.5
Arizona	447	99.6	38.5	40.0	80.3	3.8	23.3	29.8	0.2	3.6	0.9	2.9	5.6
Arkansas	171	97.7	87.1	60.8	26.3	2.9	18.1	60.8	7.0	17.0	5.3	2.3	2.9
California	1,734	99.3	70.1	12.8	55.2	2.3	30.2	24.2	2.7	4.0	0.5	4.7	5.0
Colorado	393	99.5	90.8	46.1	35.4	2.8	12.7	8.1	0.3	1.0	0.3	3.1	4.3
Connecticut	210	96.2	64.3	66.2	85.7	7.1	43.3	27.1	3.8	6.2		4.3	2.4
Delaware	49	100.0	75.5	46.9	53.1	2.0	26.5	40.8	6.1	10.2	2.0	4.1	16.3
District of Columbia	28	100.0	89.3	64.3	60.7		10.7	21.4		7.1	10.7	10.7	3.6
Florida	712	99.4	80.2	27.1	42.6	5.3	38.6	39.0	1.4	2.8	0.6	8.7	3.9
Georgia	348	99.7	69.0	38.5	50.6	4.0	24.1	56.3	4.3	7.5	4.9	6.9	4.6
Hawaii	161	100.0	55.3	14.3	49.7	0.6	3.7	62.1	4.3	1.9		1.2	19.9
Idaho	110	100.0	76.4	50.9	52.7	1.8	7.3	11.8	2.7			3.6	7.3
Illinois	713	99.7	89.6	27.8	24.7	4.3	24.1	25.4	4.1	4.8	1.1	3.4	1.8
Indiana	416	100.0	73.3	66.3	29.1	10.8	32.2	30.8	2.6	5.5	1.9	3.6	7.7
Iowa	185	100.0	71.9	24.3	77.3	3.2	16.2	43.2	0.5	7.0		1.6	
Kansas	170	98.2	92.9	34.1	18.8	4.1	13.5	8.2	2.4	3.5	1.2	2.4	1.8
Kentucky	477	99.8	78.6	50.7	22.0	2.3	19.1	35.8	1.3	6.5	0.4	1.7	5.5
Louisiana	155	99.4	65.2	27.1	76.1	16.8	22.6	46.5	1.3	5.2	0.6	3.9	5.8
Maine	196	100.0	87.8	63.8	26.5	3.1	7.7	14.8	5.1	5.6		7.1	8.2
Maryland	432	99.8	80.6	46.8	69.7	2.5	24.8	56.7	3.2	3.2	2.8	14.4	3.7
Massachusetts	440	98.6	87.3	26.8	83.9	7.3	28.2	29.3	5.5	5.5	0.7	2.7	1.4
Michigan	455	99.6	88.8	32.5	42.9	4.2	18.2	57.6	1.8	10.8	0.9	4.4	2.0
Minnesota	401	99.0	81.8	29.7	65.8	2.2	12.2	13.2	0.7	2.0	1.2	8.2	2.5
Mississippi	105	99.0	46.7	77.1	26.7	5.7	18.1	21.9	1.9	2.9	1.0	1.9	4.8
Missouri	278	99.3	81.7	75.2	29.5	3.6	15.5	62.2	3.2	3.6	0.4	2.9	2.5
Montana	129	100.0	76.0	42.6	27.1	1.6	4.7	25.6	3.9	4.7	0.8	3.1	10.1
Nebraska	123	100.0	60.2	28.5	41.5	6.5	24.4	43.1	1.6	6.5		1.6	13.0

Table 6.25b. Facility licensing, certification, or accreditation, by state or jurisdiction: Row percent, 2020 (continued)

						Licensing,	certification, or	accredita	ition organ	nization			
State or jurisdiction ¹	Number of facilities ²	² organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commission	CARF	NCQA	COA	HFAP	Other organization/ federal/state/ local agency	Not licensed, certified, or accredited
Nevada	109	100.0	78.0	25.7	52.3	6.4	18.3	18.3	2.8	2.8	0.9	8.3	7.3
New Hampshire	109	100.0	33.0	13.8	25.7	1.8	7.3	25.7				3.7	41.3
New Jersey	383	99.7	79.1	44.1	55.6	5.7	25.3	23.0	1.0	3.9		1.8	13.1
New Mexico	162	96.9	36.4	37.7	54.9	3.7	22.2	16.0	3.7	7.4	0.6	8.0	17.9
New York	894	99.9	94.5	16.3	34.0	10.1	28.3	11.2	1.3	3.7	1.1	3.0	1.2
North Carolina	611	98.5	58.6	45.2	41.6	2.9	14.4	42.2	3.1	4.4	0.8	6.4	13.6
North Dakota	87	100.0	87.4	43.7	16.1	4.6	11.5	6.9		2.3		4.6	6.9
Ohio	619	99.5	87.4	70.0	18.3	3.9	25.8	46.4	1.1	9.7	1.9	5.2	2.3
Oklahoma	195	100.0	79.5	70.8	18.5	2.6	21.0	40.0	3.6	2.1	1.0	5.1	6.2
Oregon	247	99.2	91.1	53.0	38.5	2.0	7.7	13.4	1.2	4.0	0.4	4.9	2.8
Pennsylvania	604	100.0	88.6	22.2	62.7	5.3	20.7	30.1	1.3	2.3	0.2	3.1	2.8
Puerto Rico	101	99.0	93.1	79.2	67.3	15.8	23.8	6.9	2.0	2.0	4.0	3.0	2.0
Rhode Island	63	100.0	79.4	66.7	58.7	7.9	22.2	46.0	1.6	7.9	1.6	3.2	4.8
South Carolina	124	100.0	66.9	4.8	70.2	4.8	15.3	60.5	4.0	2.4		7.3	7.3
South Dakota	58	100.0	79.3	19.0	51.7	5.2	15.5	15.5	1.7	1.7		10.3	8.6
Tennessee	311	99.7	78.1	80.1	31.5	2.6	25.4	30.9	1.6	8.0	1.0	2.6	2.3
Texas	509	99.0	75.6	23.0	68.8	4.9	32.6	24.0	1.8	3.3	1.0	4.5	4.3
Utah	333	99.7	70.6	57.1	56.8	1.8	29.4	8.1	1.2	0.6	0.6	9.9	5.1
Vermont	52	100.0	71.2	42.3	63.5	15.4	28.8	15.4	9.6	1.9		1.9	11.5
Virginia	249	100.0	74.7	65.1	26.9	5.2	14.5	21.7	1.6	2.0		5.2	13.3
Washington	457	99.6	76.8	39.6	84.2	1.8	14.4	14.9	1.5	1.5	0.2	2.0	7.0
West Virginia	126	100.0	62.7	57.9	56.3	3.2	7.1	14.3	1.6	11.1	2.4	3.2	3.2
Wisconsin	295	99.7	75.3	65.4	49.5	8.8	21.4	8.8	3.4	3.4	0.3	2.7	9.2
Wyoming	60	100.0	76.7	76.7	86.7	6.7	10.0	78.3	1.7			5.0	
Other jurisdictions ³	10	100.0	20.0	30.0	50.0	20.0	10.0	10.0	10.0				30.0

⁻⁻ Quantity is zero.

CARF = Commission on Accreditation of Rehabilitation Facilities; COA = Council on Accreditation; HFAP = Healthcare Facilities Accreditation Program; NCQA = National Committee for Quality Assurance.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Percentages sum to more than 100 percent, because a facility could report more than one licensing, certification, or accreditation organization. The percent of facilities licensed, certified, or accredited and the percent not licensed, certified, or accredited by any listed organization do not sum to 100 percent, because 88 facilities did not respond to the question.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.26. Federally Qualified Health Centers providing substance use treatment, by state or jurisdiction: Number and percent, 2020

Chata an invitadiation 1		All treatment facilities	Federally Qualif	ied Health Centers
State or jurisdiction ¹		Number of facilities ¹	Number of facilities ¹	Percent of all facilities ¹
	Total	16,066	1,592	9.9
Alabama		155	29	18.7
Alaska		105	24	22.9
Arizona		447	48	10.7
Arkansas		171	21	12.3
California		1,734	127	7.3
Colorado		393	43	10.9
Connecticut		210	31	14.8
Delaware		49	3	6.1
District of Columbia		28	12	42.9
Florida		712	56	7.9
Georgia		348	38	10.9
Hawaii		161	13	8.1
Idaho		110	9	8.2
Illinois		713	112	15.7
Indiana		416	40	9.6
Iowa		185	10	5.4
Kansas		170	16	9.4
Kentucky		477	27	5.7
Louisiana		155	19	12.3
Maine		196	21	10.7
Maryland		432	41	9.5
Massachusetts		440	57	13.0
Michigan		455	46	10.1
Minnesota		401	25	6.2
Mississippi		105	14	13.3
Missouri		278	27	9.7
Montana		129	24	18.6
Nebraska		123	13	10.6

Table 6.26. Federally Qualified Health Centers providing substance use treatment, by state or jurisdiction: Number and percent, 2020 (continued)

Otata an inniadiational	All treatment facilities	Federally Qualifi	ed Health Centers
State or jurisdiction ¹	Number of facilities¹	Number of facilities ¹	Percent of all facilities ¹
Nevada	109	16	14.7
New Hampshire	109	16	14.7
New Jersey	383	25	6.5
New Mexico	162	46	28.4
New York	894	73	8.2
North Carolina	611	52	8.5
North Dakota	87	6	6.9
Ohio	619	34	5.5
Oklahoma	195	44	22.6
Oregon	247	30	12.1
Pennsylvania	604	18	3.0
Puerto Rico	101	16	15.8
Rhode Island	63	4	6.3
South Carolina	124	9	7.3
South Dakota	58	9	15.5
Tennessee	311	47	15.1
Texas	509	47	9.2
Utah	333	21	6.3
Vermont	52	6	11.5
Virginia	249	15	6.0
Washington	457	61	13.3
West Virginia	126	14	11.1
Wisconsin	295	21	7.1
Wyoming	60	15	25.0
Other jurisdictions ²	10	1	10.0

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States

Table 6.27. Clients in treatment at Federally Qualified Health Centers providing substance use treatment, by state or jurisdiction: Number and percent, March 31, 2020

State or jurisdiction1		All treatment facilities	Federally Qu	ualified Health Centers
State or jurisdiction ¹		Number of clients ¹	Number of clients ¹	Percent of clients among all facilities ¹
	Total	1,090,357	115,868	10.6
Alabama		11,838	1,176	9.9
Alaska		3,213	391	12.2
Arizona		44,825	6,524	14.6
Arkansas		4,464	909	20.4
California		70,034	5,650	8.1
Colorado		30,083	2,740	9.1
Connecticut		23,433	3,983	17.0
Delaware		12,796	302	2.4
District of Columbia		1,761	1,117	63.4
Florida		45,620	3,542	7.8
Georgia		17,642	1,745	9.9
ławaii		3,354	212	6.3
daho		3,891	74	1.9
llinois		40,978	3,318	8.1
ndiana		43,865	3,633	8.3
owa		8,013	84	1.0
Kansas		6,387	949	14.9
Kentucky		27,353	1,767	6.5
ouisiana		8,638	1,363	15.8
Maine		10,299	1,191	11.6
Maryland		35,115	2,781	7.9
Massachusetts		52,270	12,773	24.4
⁄lichigan		27,127	3,509	12.9
Minnesota		15,899	590	3.7
/lississippi		4,032	520	12.9
Missouri		12,401	1,579	12.7
Montana		4,976	943	19.0
Nebraska		3,554	530	14.9

Table 6.27. Clients in treatment at Federally Qualified Health Centers providing substance use treatment, by state or jurisdiction: Number and percent, March 31, 2020 (continued)

State or invigalistical	All treatment facilities	Federally Qualified Health Centers					
State or jurisdiction ¹	Number of clients¹	Number of clients ¹	Percent of clients among all facilities ¹				
Nevada	11,573	1,384	12.0				
New Hampshire	9,576	901	9.4				
New Jersey	26,198	2,074	7.9				
New Mexico	16,133	5,469	33.9				
New York	81,275	5,989	7.4				
North Carolina	35,874	4,274	11.9				
North Dakota	2,599	164	6.3				
Ohio	69,478	4,676	6.7				
Oklahoma	16,313	2,672	16.4				
Dregon	20,264	3,139	15.5				
Pennsylvania	45,588	1,207	2.6				
Puerto Rico	5,938	2,288	38.5				
Rhode Island	5,435	963	17.7				
South Carolina	14,152	1,335	9.4				
South Dakota	2,371	250	10.5				
ennessee	18,865	3,161	16.8				
exas	27,078	2,778	10.3				
Jtah	13,218	866	6.6				
/ermont	7,098	434	6.1				
/irginia	18,878	651	3.4				
Vashington	33,999	4,760	14.0				
West Virginia	10,898	538	4.9				
Visconsin	19,740	1,068	5.4				
Vyoming	3,802	932	24.5				
Other jurisdictions ²	153						

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.28a. Types of payments accepted by facility, by state or jurisdiction: Number, 2020

						Туре	of payment accept	ted .					Treatment at
State or jurisdiction ¹		Total²	Cash or self- payment	Private health insurance	Medicare	Medicaid	State-financed health insurance plan other than Medicaid	Federal military insurance	No payment accepted	IHS/ Tribal/ Urban funds	Other	Sliding fee scale	no charge or minimal payment for clients who cannot pay
To	otal	16,066	14,521	11,952	6,751	11,359	7,950	6,273	452	2,006	122	9,181	7,025
Alabama		155	136	98	61	107	45	59	7	3	1	86	87
Alaska		105	98	93	52	93	66	73	3	42		80	59
Arizona		447	381	296	221	334	219	172	1	187	3	208	161
Arkansas		171	151	143	80	124	109	83	4	13	1	106	107
California		1,734	1,453	1,099	431	701	447	403	68	276	21	907	703
Colorado		393	379	221	134	236	117	150	5	21	3	262	140
Connecticut		210	184	175	114	184	136	95	2	16	1	149	98
Delaware		49	47	44	32	45	23	30		1	1	36	21
District of Columbia		28	15	14	16	24	14	10		1		11	11
Florida		712	682	542	221	309	212	293	12	64	6	423	244
Georgia		348	308	198	143	191	149	131	21	13	7	165	142
Hawaii		161	88	79	19	76	53	28	70	3		33	128
Idaho		110	105	86	55	99	75	59	2	28	4	74	58
Illinois		713	687	511	276	452	341	212	8	24	6	515	360
Indiana		416	393	341	248	326	272	234	3	13	6	248	144
Iowa		185	183	170	66	175	122	91		13	1	129	80
Kansas		170	162	133	51	129	84	81	3	11	1	115	80
Kentucky		477	447	357	219	382	225	189	8	14	3	264	190
Louisiana		155	136	114	52	115	49	62	8	18		70	81
Maine		196	187	170	103	167	111	87	1	38	2	120	92
Maryland		432	391	281	197	366	169	118	5	22		192	145
Massachusetts		440	359	351	315	373	352	208	10	21		224	221
Michigan		455	427	374	300	347	266	197	4	53	2	283	201
Minnesota		401	378	363	115	285	366	141		182	1	126	83
Mississippi		105	99	68	50	63	48	55	1	6		65	58
Missouri		278	261	204	110	191	123	169	5	10	1	216	168
Montana		129	121	120	46	121	100	76	1	66		89	60
Nebraska		123	107	99	43	106	71	67	4	29	1	77	54

Table 6.28a. Types of payments accepted by facility, by state or jurisdiction: Number, 2020 (continued)

					Type	of payment accept	ted					Treatment at
State or jurisdiction¹	Total²	Cash or self- payment	Private health insurance	Medicare	Medicaid	State-financed health insurance plan other than Medicaid	Federal military insurance	No payment accepted	IHS/ Tribal/ Urban funds	Other	Sliding fee scale	no charge or minimal payment for clients who cannot pay
Nevada	109	92	77	41	89	44	47	4	26	1	59	58
New Hampshire	109	108	102	61	100	80	49		12		73	55
New Jersey	383	355	271	114	239	130	91	13	10	5	261	187
New Mexico	162	132	126	98	143	107	75	7	48	1	89	106
New York	894	841	750	494	797	602	291	8	65	5	741	435
North Carolina	611	545	415	312	421	325	269	21	29	4	286	238
North Dakota	87	81	61	35	52	52	31	4	28	3	25	31
Ohio	619	582	484	352	577	303	288	5	27	2	418	305
Oklahoma	195	156	110	78	150	88	74	13	65	1	108	137
Oregon	247	233	216	95	211	160	96		85	1	174	135
Pennsylvania	604	555	453	197	513	313	139	5	5	2	287	213
Puerto Rico	101	39	29	26	27	24	24	59	3		16	65
Rhode Island	63	53	55	28	53	49	21		4		21	14
South Carolina	124	112	90	34	90	59	39	9	4	1	47	72
South Dakota	58	51	43	17	42	29	28	1	23	1	34	38
Tennessee	311	291	229	116	216	158	121	12	12	2	184	143
Texas	509	463	330	137	290	189	158	6	41	5	261	210
Utah	333	322	288	112	199	140	192	3	68	8	154	98
Vermont	52	48	47	35	49	46	34	2	4		44	28
Virginia	249	237	210	155	198	111	145	4	8		143	83
Washington	457	408	390	138	357	289	181	5	161	2	257	186
West Virginia	126	106	93	77	112	80	73	7	8	2	54	68
Wisconsin	295	282	276	186	255	172	181	3	53	1	123	91
Wyoming	60	59	59	41	56	34	51		28	3	45	43
Other jurisdictions ³	10	5	4	2	2	2	2	5	1		4	10

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Number of facilities sums to more than the total column, because a facility could accept more than one payment option.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.28b. Types of payments accepted by facility, by state or jurisdiction: Row percent, 2020

					Тур	e of payment acce	pted					Treatment at no
State or jurisdiction ¹	Number of facilities²	Cash or self- payment	Private health insurance	Medicare	Medicaid	State-financed health insurance plan other than Medicaid	Federal military insurance	No payment accepted	IHS/ Tribal/ Urban funds	Other	Sliding fee scale	charge or minimal payment for clients who cannot pay
Total	16,066	90.4	74.4	42.0	70.7	49.5	39.0	2.8	12.5	0.8	57.1	43.7
Alabama	155	87.7	63.2	39.4	69.0	29.0	38.1	4.5	1.9	0.6	55.5	56.1
Alaska	105	93.3	88.6	49.5	88.6	62.9	69.5	2.9	40.0		76.2	56.2
Arizona	447	85.2	66.2	49.4	74.7	49.0	38.5	0.2	41.8	0.7	46.5	36.0
Arkansas	171	88.3	83.6	46.8	72.5	63.7	48.5	2.3	7.6	0.6	62.0	62.6
California	1,734	83.8	63.4	24.9	40.4	25.8	23.2	3.9	15.9	1.2	52.3	40.5
Colorado	393	96.4	56.2	34.1	60.1	29.8	38.2	1.3	5.3	0.8	66.7	35.6
Connecticut	210	87.6	83.3	54.3	87.6	64.8	45.2	1.0	7.6	0.5	71.0	46.7
Delaware	49	95.9	89.8	65.3	91.8	46.9	61.2		2.0	2.0	73.5	42.9
District of Columbia	28	53.6	50.0	57.1	85.7	50.0	35.7		3.6		39.3	39.3
Florida	712	95.8	76.1	31.0	43.4	29.8	41.2	1.7	9.0	8.0	59.4	34.3
Georgia	348	88.5	56.9	41.1	54.9	42.8	37.6	6.0	3.7	2.0	47.4	40.8
Hawaii	161	54.7	49.1	11.8	47.2	32.9	17.4	43.5	1.9		20.5	79.5
Idaho	110	95.5	78.2	50.0	90.0	68.2	53.6	1.8	25.5	3.6	67.3	52.7
Illinois	713	96.4	71.7	38.7	63.4	47.8	29.7	1.1	3.4	0.8	72.2	50.5
Indiana	416	94.5	82.0	59.6	78.4	65.4	56.3	0.7	3.1	1.4	59.6	34.6
Iowa	185	98.9	91.9	35.7	94.6	65.9	49.2		7.0	0.5	69.7	43.2
Kansas	170	95.3	78.2	30.0	75.9	49.4	47.6	1.8	6.5	0.6	67.6	47.1
Kentucky	477	93.7	74.8	45.9	80.1	47.2	39.6	1.7	2.9	0.6	55.3	39.8
Louisiana	155	87.7	73.5	33.5	74.2	31.6	40.0	5.2	11.6		45.2	52.3
Maine	196	95.4	86.7	52.6	85.2	56.6	44.4	0.5	19.4	1.0	61.2	46.9
Maryland	432	90.5	65.0	45.6	84.7	39.1	27.3	1.2	5.1		44.4	33.6
Massachusetts	440	81.6	79.8	71.6	84.8	80.0	47.3	2.3	4.8		50.9	50.2
Michigan	455	93.8	82.2	65.9	76.3	58.5	43.3	0.9	11.6	0.4	62.2	44.2
Minnesota	401	94.3	90.5	28.7	71.1	91.3	35.2		45.4	0.2	31.4	20.7
Mississippi	105	94.3	64.8	47.6	60.0	45.7	52.4	1.0	5.7		61.9	55.2
Missouri	278	93.9	73.4	39.6	68.7	44.2	60.8	1.8	3.6	0.4	77.7	60.4
Montana	129	93.8	93.0	35.7	93.8	77.5	58.9	0.8	51.2		69.0	46.5
Nebraska	123	87.0	80.5	35.0	86.2	57.7	54.5	3.3	23.6	0.8	62.6	43.9

Table 6.28b. Types of payments accepted by facility, by state or jurisdiction: Row percent, 2020 (continued)

					Тур	e of payment acce	oted					Treatment at no
State or jurisdiction ¹	Number of facilities²	Cash or self- payment	Private health insurance	Medicare	Medicaid	State-financed health insurance plan other than Medicaid	Federal military insurance	No payment accepted	IHS/ Tribal/ Urban funds	Other	Sliding fee scale	charge or minimal payment for clients who cannot pay
Nevada	109	84.4	70.6	37.6	81.7	40.4	43.1	3.7	23.9	0.9	54.1	53.2
New Hampshire	109	99.1	93.6	56.0	91.7	73.4	45.0		11.0		67.0	50.5
New Jersey	383	92.7	70.8	29.8	62.4	33.9	23.8	3.4	2.6	1.3	68.1	48.8
New Mexico	162	81.5	77.8	60.5	88.3	66.0	46.3	4.3	29.6	0.6	54.9	65.4
New York	894	94.1	83.9	55.3	89.1	67.3	32.6	0.9	7.3	0.6	82.9	48.7
North Carolina	611	89.2	67.9	51.1	68.9	53.2	44.0	3.4	4.7	0.7	46.8	39.0
North Dakota	87	93.1	70.1	40.2	59.8	59.8	35.6	4.6	32.2	3.4	28.7	35.6
Ohio	619	94.0	78.2	56.9	93.2	48.9	46.5	8.0	4.4	0.3	67.5	49.3
Oklahoma	195	80.0	56.4	40.0	76.9	45.1	37.9	6.7	33.3	0.5	55.4	70.3
Oregon	247	94.3	87.4	38.5	85.4	64.8	38.9		34.4	0.4	70.4	54.7
Pennsylvania	604	91.9	75.0	32.6	84.9	51.8	23.0	0.8	8.0	0.3	47.5	35.3
Puerto Rico	101	38.6	28.7	25.7	26.7	23.8	23.8	58.4	3.0		15.8	64.4
Rhode Island	63	84.1	87.3	44.4	84.1	77.8	33.3		6.3		33.3	22.2
South Carolina	124	90.3	72.6	27.4	72.6	47.6	31.5	7.3	3.2	0.8	37.9	58.1
South Dakota	58	87.9	74.1	29.3	72.4	50.0	48.3	1.7	39.7	1.7	58.6	65.5
Tennessee	311	93.6	73.6	37.3	69.5	50.8	38.9	3.9	3.9	0.6	59.2	46.0
Texas	509	91.0	64.8	26.9	57.0	37.1	31.0	1.2	8.1	1.0	51.3	41.3
Utah	333	96.7	86.5	33.6	59.8	42.0	57.7	0.9	20.4	2.4	46.2	29.4
Vermont	52	92.3	90.4	67.3	94.2	88.5	65.4	3.8	7.7		84.6	53.8
Virginia	249	95.2	84.3	62.2	79.5	44.6	58.2	1.6	3.2		57.4	33.3
Washington	457	89.3	85.3	30.2	78.1	63.2	39.6	1.1	35.2	0.4	56.2	40.7
West Virginia	126	84.1	73.8	61.1	88.9	63.5	57.9	5.6	6.3	1.6	42.9	54.0
Wisconsin	295	95.6	93.6	63.1	86.4	58.3	61.4	1.0	18.0	0.3	41.7	30.8
Wyoming	60	98.3	98.3	68.3	93.3	56.7	85.0		46.7	5.0	75.0	71.7
Other jurisdictions ³	10	50.0	40.0	20.0	20.0	20.0	20.0	50.0	10.0		40.0	100.0

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Percentages sum to more than 100 percent, because a facility could accept more than one payment option.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.29. Facility funding, by state or jurisdiction: Number and percent, 2020

		,	nds for substance use nt programs			,	nds for substance use nt programs
State or jurisdiction ¹	Total number of facilities	Number of facilities	Percent of all facilities within state or jurisdiction	State or jurisdiction ¹	Total number of facilities	Number of facilities	Percent of all facilities within state or jurisdiction
Total	16,066	8,262	51.4				
Alabama	155	100	64.5	Nebraska	123	88	71.5
Alaska	105	78	74.3	Nevada	109	56	51.4
Arizona	447	209	46.8	New Hampshire	109	41	37.6
Arkansas	171	96	56.1	New Jersey	383	181	47.3
California	1,734	775	44.7	New Mexico	162	100	61.7
Colorado	393	215	54.7	New York	894	484	54.1
Connecticut	210	149	71.0	North Carolina	611	228	37.3
Delaware	49	19	38.8	North Dakota	87	41	47.1
District of Columbia	28	18	64.3	Ohio	619	373	60.3
Florida	712	295	41.4	Oklahoma	195	140	71.8
Georgia	348	122	35.1	Oregon	247	136	55.1
Hawaii	161	138	85.7	Pennsylvania	604	318	52.6
Idaho	110	47	42.7	Puerto Rico	101	64	63.4
Illinois	713	380	53.3	Rhode Island	63	36	57.1
Indiana	416	229	55.0	South Carolina	124	76	61.3
Iowa	185	109	58.9	South Dakota	58	47	81.0
Kansas	170	104	61.2	Tennessee	311	202	65.0
Kentucky	477	200	41.9	Texas	509	259	50.9
Louisiana	155	83	53.5	Utah	333	112	33.6
Maine	196	96	49.0	Vermont	52	38	73.1
Maryland	432	97	22.5	Virginia	249	123	49.4
Massachusetts	440	257	58.4	Washington	457	223	48.8
Michigan	455	284	62.4	West Virginia	126	70	55.6
Minnesota	401	174	43.4	Wisconsin	295	131	44.4
Mississippi	105	69	65.7	Wyoming	60	46	76.7
Missouri Montana	278 129	212 85	76.3 65.9	Other jurisdictions ²	10	9	90.0

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.30a. Medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and other facilities, by state or jurisdiction: Number, 2020 (continued)

	All f	facilities prov assisted or	viding medic					OTP fac	cilities³					Non-O	TP facilities	3
State or jurisdiction ¹	Any MAT type²	ОТР	Bup- renor- phine	Inject- able naltrex- one	Any MAT type²	Metha- done only	Metha- done and bup- renor- phine	Metha- done, bupren- orphine, and injectable naltrexone	Methadone and injectable naltrexone	Bup- renorphine and injectable naltrexone	Bup- renor- phine only	Inject- able nal- trexone only	Any MAT type⁴	Bup- renor- phine only	Inject- able naltrex- one only	Buprenor- phine and inject- able naltrex- one
Total	8,250	1,754	7,066	6,016	1,754	303	741	545	38	100	20	7	6,496	1,170	836	4,490
Alabama	63	20	58	28	20	3	13	2		2			43	19	2	22
Alaska	42	4	35	34	4	1	3						38	4	6	28
Arizona	238	60	208	190	60	5	14	40		1			178	29	25	124
Arkansas	73	8	60	50	8	4	1	1		1	1		65	17	9	39
California	845	155	789	584	155	11	113	31					690	137	45	508
Colorado	167	28	147	127	28	3	17	8					139	20	17	102
Connecticut	159	46	143	125	46	7	9	25	2	2	1		113	17	7	89
Delaware	38	16	32	32	16		4	11		1			22	2	6	14
District of Columbia	13	4	8	9	4	3		1					9	1	2	6
Florida	402	74	346	323	74	11	28	18	1	11	3	2	328	37	42	249
Georgia	150	70	107	71	70	25	41	4					80	13	18	49
Hawaii	19	4	17	9	4	2	1	1					15	7		8
Idaho	33	4	29	26	4			4					29	7	4	18
Illinois	298	85	228	214	85	35	16	21	13				213	33	22	158
Indiana	228	20	187	187	20	7	3	10					208	31	34	143
lowa	57	8	47	46	8			8					49	11	10	28
Kansas	60	7	31	51	7	2	4	1					53	3	27	23
Kentucky	219	27	169	181	27	3	14	9		1			192	21	47	124
Louisiana	91	11	73	71	11	1	8	2					80	11	17	52
Maine	101	10	94	51	10	3	6	1					91	41	4	46
Maryland	270	89	246	168	89	14	50	22		3			181	38	10	133
Massachusetts	277	87	242	218	87	18	18	31		4	4	2	190	19	5	166
Michigan	183	43	147	137	43	8	18	16	1				140	20	27	93
Minnesota	115	18	101	72	18	1	11	4		1	1		97	30	13	54
Mississippi	53	5	43	33	5	1	3	1					48	16	9	23
Missouri	198	16	189	176	16	1	12	3					182	9	8	165
Montana	38	3	37	37	3			3					35	1	1	33
Nebraska	25	4	21	12	4	2	1			1			21	10	2	9
Nevada	51	14	48	30	14	3	3	8					37	15		22
New Hampshire	77	7	71	37	7	2	5						70	33	4	33
New Jersey	222	46	171	165	46	7	19	11	1	7		1	176	31	42	103

Table 6.30a. Medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and other facilities, by state or jurisdiction: Number, 2020 (continued)

	All fa	acilities prov assisted op	riding medic pioid therapy					OTP fac	cilities³					Non-O	TP facilities	;
State or jurisdiction ¹	Any MAT type²	ОТР	Bup- renor- phine	Inject- able naltrex- one	Any MAT type²	Metha- done only	Metha- done and bup- renor- phine	Metha- done, bupren- orphine, and injectable naltrexone	Methadone and injectable naltrexone	Bup- renorphine and injectable naltrexone	Bup- renor- phine only	Inject- able nal- trexone only	Any MAT type⁴	Bup- renor- phine only	Inject- able naltrex- one only	Buprenor- phine and inject- able naltrex- one
New Mexico	79	16	60	50	16	5	8	1			2		63	14	14	35
New York	739	184	689	549	184	29	61	66	3	20	5		555	95	18	442
North Carolina	311	76	291	182	76		47	27	1	1			235	82	19	134
North Dakota	27	4	18	24	4		2	1		1			23	1	9	13
Ohio	380	71	322	331	71	1	18	23	1	28			309	30	56	223
Oklahoma	67	19	60	37	19	4	11	4					48	15	3	30
Oregon	109	19	101	71	19	3	12	4					90	23	5	62
Pennsylvania	374	103	286	291	103	24	27	34	5	11		2	271	32	57	182
Puerto Rico	30	6	24	2	6	6							24	22		2
Rhode Island	39	22	32	30	22	4	3	14		1			17	2	3	12
South Carolina	65	22	55	38	22	3	16	3					43	8	7	28
South Dakota	12	1	10	10	1	1							11	1	1	9
Tennessee	156	10	106	124	10		9			1			146	23	50	73
Texas	237	86	196	129	86	27	32	27					151	49	14	88
Utah	186	18	167	166	18	1	8	9					168	11	18	139
Vermont	36	11	33	25	11	1	1	6			3		25	6	2	17
Virginia	158	34	135	102	34	6	23	5					124	27	17	80
Washington	190	30	170	139	30	2	20	7		1			160	29	18	113
West Virginia	84	9	66	79	9	1		7		1			75	4	17	54
Wisconsin	140	19	97	125	19	1	8	10					121	6	42	73
Wyoming	23		22	17									23	6	1	16
Other jurisdictions ⁵	3	1	2	1	1	1							2	1		11

⁻⁻ Quantity is zero.

Injectable naltrexone = extended-release injectable naltrexone; MAT = medication assisted treatment.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Any MAT type for all facilities providing medication-assisted opioid therapy includes all facilities (OTP and non-OTP) providing methadone, buprenorphine, or injectable naltrexone.

³ Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

⁴ Any MAT type for non-OTP facilities includes facilities providing buprenorphine or injectable naltrexone.

⁵ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 6.30b. Medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and other facilities, by state or jurisdiction: Column percent distribution, 2020

			viding medio					OTP	facilities ³					Non-O	TP facilities	3
State or jurisdiction ¹	Any MAT	OTP	Bup- renor- phine	Inject- able naltrex- one	Any MAT type²	Metha- done only	Metha- done and bup- renor- phine	Metha- done, bupren- orphine, and injectable naltrexone	Methadone and inject- able naltrex- one	Buprenor- phine and inject- able naltrex- one	Bup- renor- phine only	Inject- able nal- trexone only	Any MAT type⁴	Bup- renor- phine only	Inject- able naltrex- one only	Buprenor- phine and inject- able naltrex- one
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Alabama	0.8	1.1	0.8	0.5	1.1	1.0	1.8	0.4		2.0			0.7	1.6	0.2	0.5
Alaska	0.5	0.2	0.5	0.6	0.2	0.3	0.4						0.6	0.3	0.7	0.6
Arizona	2.9	3.4	2.9	3.2	3.4	1.7	1.9	7.3		1.0			2.7	2.5	3.0	2.8
Arkansas	0.9	0.5	0.8	0.8	0.5	1.3	0.1	0.2		1.0	5.0		1.0	1.5	1.1	0.9
California	10.2	8.8	11.2	9.7	8.8	3.6	15.2	5.7					10.6	11.7	5.4	11.3
Colorado	2.0	1.6	2.1	2.1	1.6	1.0	2.3	1.5					2.1	1.7	2.0	2.3
Connecticut	1.9	2.6	2.0	2.1	2.6	2.3	1.2	4.6	5.3	2.0	5.0		1.7	1.5	0.8	2.0
Delaware	0.5	0.9	0.5	0.5	0.9		0.5	2.0		1.0			0.3	0.2	0.7	0.3
District of Columbia	0.2	0.2	0.1	0.1	0.2	1.0		0.2					0.1	0.1	0.2	0.1
Florida	4.9	4.2	4.9	5.4	4.2	3.6	3.8	3.3	2.6	11.0	15.0	28.6	5.0	3.2	5.0	5.5
Georgia	1.8	4.0	1.5	1.2	4.0	8.3	5.5	0.7					1.2	1.1	2.2	1.1
Hawaii	0.2	0.2	0.2	0.1	0.2	0.7	0.1	0.2					0.2	0.6		0.2
Idaho	0.4	0.2	0.4	0.4	0.2			0.7					0.4	0.6	0.5	0.4
Illinois	3.6	4.8	3.2	3.6	4.8	11.6	2.2	3.9	34.2				3.3	2.8	2.6	3.5
Indiana	2.8	1.1	2.6	3.1	1.1	2.3	0.4	1.8					3.2	2.6	4.1	3.2
lowa	0.7	0.5	0.7	0.8	0.5			1.5					0.8	0.9	1.2	0.6
Kansas	0.7	0.4	0.4	0.8	0.4	0.7	0.5	0.2					0.8	0.3	3.2	0.5
Kentucky	2.7	1.5	2.4	3.0	1.5	1.0	1.9	1.7		1.0			3.0	1.8	5.6	2.8
Louisiana	1.1	0.6	1.0	1.2	0.6	0.3	1.1	0.4					1.2	0.9	2.0	1.2
Maine	1.2	0.6	1.3	8.0	0.6	1.0	0.8	0.2					1.4	3.5	0.5	1.0
Maryland	3.3	5.1	3.5	2.8	5.1	4.6	6.7	4.0		3.0			2.8	3.2	1.2	3.0
Massachusetts	3.4	5.0	3.4	3.6	5.0	5.9	2.4	5.7	26.3	4.0	20.0	28.6	2.9	1.6	0.6	3.7
Michigan	2.2	2.5	2.1	2.3	2.5	2.6	2.4	2.9	2.6				2.2	1.7	3.2	2.1
Minnesota	1.4	1.0	1.4	1.2	1.0	0.3	1.5	0.7		1.0	5.0		1.5	2.6	1.6	1.2
Mississippi	0.6	0.3	0.6	0.5	0.3	0.3	0.4	0.2					0.7	1.4	1.1	0.5
Missouri	2.4	0.9	2.7	2.9	0.9	0.3	1.6	0.6					2.8	0.8	1.0	3.7
Montana	0.5	0.2	0.5	0.6	0.2			0.6					0.5	0.1	0.1	0.7
Nebraska	0.3	0.2	0.3	0.2	0.2	0.7	0.1			1.0			0.3	0.9	0.2	0.2
Nevada	0.6	0.8	0.7	0.5	8.0	1.0	0.4	1.5					0.6	1.3		0.5
New Hampshire	0.9	0.4	1.0	0.6	0.4	0.7	0.7						1.1	2.8	0.5	0.7
New Jersey	2.7	2.6	2.4	2.7	2.6	2.3	2.6	2.0	2.6	7.0		14.3	2.7	2.6	5.0	2.3

Table 6.30b. Medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and other facilities, by state or jurisdiction: Column percent distribution, 2020 (continued)

		•	viding medio					OTP	facilities ³					Non-O	TP facilities	3
State or jurisdiction¹	Any MAT type²	ОТР	Bup- renor- phine	Inject- able naltrex- one	Any MAT type²	Metha- done only	Metha- done and bup- renor- phine	Metha- done, bupren- orphine, and injectable naltrexone	Methadone and inject- able naltrex- one	Buprenor- phine and inject- able naltrex- one	Bup- renor- phine only	Inject- able nal- trexone only	Any MAT type⁴	Bup- renor- phine only	Inject- able naltrex- one only	Buprenor- phine and inject- able naltrex- one
New Mexico	1.0	0.9	8.0	8.0	0.9	1.7	1.1	0.2			10.0		1.0	1.2	1.7	0.8
New York	9.0	10.5	9.8	9.1	10.5	9.6	8.2	12.1	7.9	20.0	25.0		8.5	8.1	2.2	9.8
North Carolina	3.8	4.3	4.1	3.0	4.3		6.3	5.0	2.6	1.0			3.6	7.0	2.3	3.0
North Dakota	0.3	0.2	0.3	0.4	0.2		0.3	0.2		1.0			0.4	0.1	1.1	0.3
Ohio	4.6	4.0	4.6	5.5	4.0	0.3	2.4	4.2	2.6	28.0			4.8	2.6	6.7	5.0
Oklahoma	0.8	1.1	8.0	0.6	1.1	1.3	1.5	0.7					0.7	1.3	0.4	0.7
Oregon	1.3	1.1	1.4	1.2	1.1	1.0	1.6	0.7					1.4	2.0	0.6	1.4
Pennsylvania	4.5	5.9	4.0	4.8	5.9	7.9	3.6	6.2	13.2	11.0		28.6	4.2	2.7	6.8	4.1
Puerto Rico	0.4	0.3	0.3		0.3	2.0							0.4	1.9		
Rhode Island	0.5	1.3	0.5	0.5	1.3	1.3	0.4	2.6		1.0			0.3	0.2	0.4	0.3
South Carolina	0.8	1.3	0.8	0.6	1.3	1.0	2.2	0.6					0.7	0.7	0.8	0.6
South Dakota	0.1	0.1	0.1	0.2	0.1	0.3							0.2	0.1	0.1	0.2
Tennessee	1.9	0.6	1.5	2.1	0.6		1.2			1.0			2.2	2.0	6.0	1.6
Texas	2.9	4.9	2.8	2.1	4.9	8.9	4.3	5.0					2.3	4.2	1.7	2.0
Utah	2.3	1.0	2.4	2.8	1.0	0.3	1.1	1.7					2.6	0.9	2.2	3.1
Vermont	0.4	0.6	0.5	0.4	0.6	0.3	0.1	1.1			15.0		0.4	0.5	0.2	0.4
Virginia	1.9	1.9	1.9	1.7	1.9	2.0	3.1	0.9					1.9	2.3	2.0	1.8
Washington	2.3	1.7	2.4	2.3	1.7	0.7	2.7	1.3		1.0			2.5	2.5	2.2	2.5
West Virginia	1.0	0.5	0.9	1.3	0.5	0.3		1.3		1.0			1.2	0.3	2.0	1.2
Wisconsin	1.7	1.1	1.4	2.1	1.1	0.3	1.1	1.8					1.9	0.5	5.0	1.6
Wyoming	0.3		0.3	0.3									0.4	0.5	0.1	0.4
Other jurisdictions ⁵		0.1	*		0.1	0.3								0.1		*

⁻⁻ Quantity is zero; * Less than 0.05 percent.

Injectable naltrexone = extended-release injectable naltrexone; MAT = medication assisted treatment.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Any MAT type for all facilities providing medication-assisted opioid therapy includes all facilities (OTP and non-OTP) providing methadone, buprenorphine, or injectable naltrexone.

³ Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

⁴ Any MAT type for non-OTP facilities includes facilities providing buprenorphine or injectable naltrexone.

⁵ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 6.31a. Type of care offered in facilities with opioid treatment programs (OTPs), by state or jurisdiction: Number, 2020

							Type of ca	re offered						
					Outer attack					Residential				spital
State or jurisdiction ¹					Outpatient		Methadone/	1		non-hospita	<u>)</u>		Inp	atient
State of Jurisdiction	Total ^{2,3}	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
Total	1,754	1,602	1291	517	106	734	1,570	165	129	87	100	134	96	125
Alabama	20	19	14	8	3	9	19	2	2	1	2	1	1	1
Alaska	4	4	3			2	4							
Arizona	60	59	54	24	6	24	58	1	1	1		1		1
Arkansas	8	8	8	1		2	8	1	1	1	1			
California	155	155	114	16	6	133	153	1	1	1		1		1
Colorado	28	28	26	11		6	28	2	1	1	2			
Connecticut	46	34	25	29	3	14	34	13	8	6	6	7	5	7
Delaware	16	14	14	12		3	14	2	1	1	1	1	1	1
District of Columbia	4	4	4	1	1	2	4					1	1	1
Florida	74	65	43	16	11	27	58	22	15	9	12	9	5	9
Georgia	70	70	54	6	2	35	70							
Hawaii	4	4	4	2		4	4							
Idaho	4	4	4	4		4	4							
Illinois	85	81	79	45	2	33	80	10	9	6	5	7	4	7
Indiana	20	20	12	9	1	13	20					1	1	1
Iowa	8	8	8	5		4	8							
Kansas	7	7	6			4	7							
Kentucky	27	27	22	13	1	16	26					1	1	1
Louisiana	11	11	8	2		5	10	1		1				
Maine	10	10	7	2		2	10							
Maryland	89	86	75	40	6	32	86	4	3	4	4	3	3	3
Massachusetts	87	58	40	11	6	27	53	23	18	9	16	23	17	21
Michigan	43	43	41	15	6	23	43	3	3	3	3			
Minnesota	18	16	9	4		3	16	1	1		1	1	1	1
Mississippi	5	5	4	3		4	5							
Missouri	16	16	13	2	1	8	16							
Montana	3	3	3			2	3							
Nebraska	4	4	4	1		3	4							
Nevada	14	14	13	7	2	7	12	1	1	1		2	2	2
New Hampshire	7	7	5			6	7							

Table 6.31a. Type of care offered in facilities with opioid treatment programs (OTPs), by state or jurisdiction: Number, 2020 (continued)

							Type of ca	re offered						
					Outpatient					Residential non-hospita				spital atient
State or jurisdiction ¹	Total ^{2,3}	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
New Jersey	46	41	36	38	12	22	40	6	6	4	5	2	2	2
New Mexico	16	16	14			9	16							
New York	184	135	106	34	11	35	133	24	13	9	12	36	28	29
North Carolina	76	74	54	10	6	24	73	3	3	2		5	4	5
North Dakota	4	4	4	2	2	2	4	2	2	2	2			
Ohio	71	68	64	42	7	38	68	8	7	4	5	7	2	7
Oklahoma	19	19	17	3	1	5	18					1		1
Oregon	19	19	13	5		6	19							
Pennsylvania	103	81	71	33	2	11	78	23	22	15	15	13	11	13
Puerto Rico	6	6	5			1	6							
Rhode Island	22	18	18	7	2	14	18	3	3	2	2	5	3	5
South Carolina	22	22	11	3	1	6	22	1	1		1	1	1	1
South Dakota	1	1	1			1	1							
Tennessee	10	9	9			8	9	1	1	1	1			
Texas	86	86	55	18	1	48	85	1	1	1	1	2	1	2
Utah	18	18	17	3		9	17	1		1				
Vermont	11	10	8	2	1	2	9					1	1	1
Virginia	34	33	21	5	1	8	32	3	3	1	2	1	1	1
Washington	30	30	25	15	1	13	30	1	1		1	1		1
West Virginia	9	8	8	3		8	8	1	1					
Wisconsin	19	19	17	5		7	19							
Wyoming	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other jurisdictions⁴	1	1	1		1		1							

⁻⁻ Quantity is zero; ‡ No facilities in this category.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

³ Number of facilities sum to more than the total column because a facility could provide more than one type of care.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 6.31b. Type of care offered in facilities with opioid treatment programs (OTPs), by state or jurisdiction: Row percent, 2020

							Type of care of	fered						
					Outpatient				-	Residentia on-hospita	-			spital atient
State or jurisdiction ¹	Number of facilities ^{2,3}	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
Total	1,754	91.3	73.6	29.5	6.0	41.8	89.5	9.4	7.4	5.0	5.7	7.6	5.5	7.1
Alabama	20	95.0	70.0	40.0	15.0	45.0	95.0	10.0	10.0	5.0	10.0	5.0	5.0	5.0
Alaska	4	100.0	75.0			50.0	100.0							
Arizona	60	98.3	90.0	40.0	10.0	40.0	96.7	1.7	1.7	1.7		1.7		1.7
Arkansas	8	100.0	100.0	12.5		25.0	100.0	12.5	12.5	12.5	12.5			
California	155	100.0	73.5	10.3	3.9	85.8	98.7	0.6	0.6	0.6		0.6		0.6
Colorado	28	100.0	92.9	39.3		21.4	100.0	7.1	3.6	3.6	7.1			
Connecticut	46	73.9	54.3	63.0	6.5	30.4	73.9	28.3	17.4	13.0	13.0	15.2	10.9	15.2
Delaware	16	87.5	87.5	75.0		18.8	87.5	12.5	6.3	6.3	6.3	6.3	6.3	6.3
District of Columbia	4	100.0	100.0	25.0	25.0	50.0	100.0					25.0	25.0	25.0
Florida	74	87.8	58.1	21.6	14.9	36.5	78.4	29.7	20.3	12.2	16.2	12.2	6.8	12.2
Georgia	70	100.0	77.1	8.6	2.9	50.0	100.0							
Hawaii	4	100.0	100.0	50.0		100.0	100.0							
Idaho	4	100.0	100.0	100.0		100.0	100.0							
Illinois	85	95.3	92.9	52.9	2.4	38.8	94.1	11.8	10.6	7.1	5.9	8.2	4.7	8.2
Indiana	20	100.0	60.0	45.0	5.0	65.0	100.0					5.0	5.0	5.0
Iowa	8	100.0	100.0	62.5		50.0	100.0							
Kansas	7	100.0	85.7			57.1	100.0							
Kentucky	27	100.0	81.5	48.1	3.7	59.3	96.3					3.7	3.7	3.7
Louisiana	11	100.0	72.7	18.2		45.5	90.9	9.1		9.1				
Maine	10	100.0	70.0	20.0		20.0	100.0							
Maryland	89	96.6	84.3	44.9	6.7	36.0	96.6	4.5	3.4	4.5	4.5	3.4	3.4	3.4
Massachusetts	87	66.7	46.0	12.6	6.9	31.0	60.9	26.4	20.7	10.3	18.4	26.4	19.5	24.1
Michigan	43	100.0	95.3	34.9	14.0	53.5	100.0	7.0	7.0	7.0	7.0			
Minnesota	18	88.9	50.0	22.2		16.7	88.9	5.6	5.6		5.6	5.6	5.6	5.6
Mississippi	5	100.0	80.0	60.0		80.0	100.0							
Missouri	16	100.0	81.3	12.5	6.3	50.0	100.0							
Montana	3	100.0	100.0			66.7	100.0							
Nebraska	4	100.0	100.0	25.0		75.0	100.0							
Nevada	14	100.0	92.9	50.0	14.3	50.0	85.7	7.1	7.1	7.1		14.3	14.3	14.3
New Hampshire	7	100.0	71.4			85.7	100.0							

Table 6.31b. Type of care offered in facilities with opioid treatment programs (OTPs), by state or jurisdiction: Row percent, 2020 (continued)

							Type of care of	fered						
					Outpatient					Residentia on-hospita				spital atient
State or jurisdiction ¹	Number of facilities ^{2,3}	Any out- patient	Regular	Intensive	Day treatment or partial hospitali- zation	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Any residen- tial	Short- term	Long- term	Detox	Any hospital inpatient	Treat- ment	Detox
New Jersey	46	89.1	78.3	82.6	26.1	47.8	87.0	13.0	13.0	8.7	10.9	4.3	4.3	4.3
New Mexico	16	100.0	87.5			56.3	100.0							
New York	184	73.4	57.6	18.5	6.0	19.0	72.3	13.0	7.1	4.9	6.5	19.6	15.2	15.8
North Carolina	76	97.4	71.1	13.2	7.9	31.6	96.1	3.9	3.9	2.6		6.6	5.3	6.6
North Dakota	4	100.0	100.0	50.0	50.0	50.0	100.0	50.0	50.0	50.0	50.0			
Ohio	71	95.8	90.1	59.2	9.9	53.5	95.8	11.3	9.9	5.6	7.0	9.9	2.8	9.9
Oklahoma	19	100.0	89.5	15.8	5.3	26.3	94.7					5.3		5.3
Oregon	19	100.0	68.4	26.3		31.6	100.0							
Pennsylvania	103	78.6	68.9	32.0	1.9	10.7	75.7	22.3	21.4	14.6	14.6	12.6	10.7	12.6
Puerto Rico	6	100.0	83.3			16.7	100.0							
Rhode Island	22	81.8	81.8	31.8	9.1	63.6	81.8	13.6	13.6	9.1	9.1	22.7	13.6	22.7
South Carolina	22	100.0	50.0	13.6	4.5	27.3	100.0	4.5	4.5		4.5	4.5	4.5	4.5
South Dakota	1	100.0	100.0			100.0	100.0							
Tennessee	10	90.0	90.0			80.0	90.0	10.0	10.0	10.0	10.0			
Texas	86	100.0	64.0	20.9	1.2	55.8	98.8	1.2	1.2	1.2	1.2	2.3	1.2	2.3
Utah	18	100.0	94.4	16.7		50.0	94.4	5.6		5.6				
Vermont	11	90.9	72.7	18.2	9.1	18.2	81.8					9.1	9.1	9.1
Virginia	34	97.1	61.8	14.7	2.9	23.5	94.1	8.8	8.8	2.9	5.9	2.9	2.9	2.9
Washington	30	100.0	83.3	50.0	3.3	43.3	100.0	3.3	3.3		3.3	3.3		3.3
West Virginia	9	88.9	88.9	33.3		88.9	88.9	11.1	11.1					
Wisconsin	19	100.0	89.5	26.3		36.8	100.0							
Wyoming	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other jurisdictions⁴	1	100.0	100.0		100.0		100.0							

⁻⁻ Quantity is zero; ‡ No facilities in this category.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

³ Percentages sum to more than 100 percent, because a facility could provide more than one type of care.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 6.32a. Facility licensing, certification, or accreditation of facilities with opioid treatment programs (OTPs), by state or jurisdiction: Number, 2020

					Licens	ing, certificat	ion, or accre	ditation or	ganization				
State or jurisdiction ¹	Total ^{2,3}	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commis- sion	CARF	NCQA	COA	HFAP	Other organization/ federal/state/ local agency	Not licensed, certified, or accredited
Tota	ıl 1,754	1,739	1,550	546	1,057	102	487	1,156	44	89	11	224	4
Alabama	20	20	20	18	1		8	12	1			3	
Alaska	4	4	3	1	1			4				2	
Arizona	60	60	39	26	52	1	3	53		1		7	
Arkansas	8	8	7	1	4	1	3	6				1	
California	155	154	134	14	66	3	15	101	3	42	1	14	
Colorado	28	27	25	9	7	1	6	20		1		4	
Connecticut	46	40	36	31	37	2	16	27	2			6	
Delaware	16	16	16	11	13		7	12	2	2		1	
District of Columbia	4	4	3	1	2		1	2		1		1	
Florida	74	73	71	14	58	2	25	50	2			12	
Georgia	70	70	60	11	41		13	58	2	2		10	
Hawaii	4	4	3		2			4				1	
Idaho	4	4	4	4	2			4				2	
Illinois	85	85	78	23	25	3	28	57		2	2	7	
Indiana	20	20	18	11	4	2	4	15		1	1	4	
Iowa	8	8	8	6	7			6					
Kansas	7	7	7		1	1	2	5				1	
Kentucky	27	27	26	13	10		11	20	2			6	
Louisiana	11	11	11	4	10		2	9				1	
Maine	10	10	10	6	3		2	8				2	
Maryland	89	89	84	30	70	3	19	70	3	4	1	13	
Massachusetts	87	87	78	24	77	4	32	52	4	1		5	
Michigan	43	42	39	12	18	1	10	33			1	4	
Minnesota	18	18	16	3	12	2	5	12				3	
Mississippi	5	5	3	5	1		2	5	1			1	
Missouri	16	16	13	13	5		8	2				3	
Montana	3	3						3				3	
Nebraska	4	4	2		3			3					

Table 6.32a. Facility licensing, certification, or accreditation of facilities with opioid treatment programs (OTPs), by state or jurisdiction: Number, 2020 (continued)

					Licens	ing, certificat	ion, or accre	ditation org	ganization				
State or jurisdiction ¹	Total ^{2,3}	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commis- sion	CARF	NCQA	COA	HFAP	Other organization/ federal/state/ local agency	Not licensed, certified, or accredited
Nevada	14	14	14	7	12	1	3	11				3	
New Hampshire	7	7	7		4			7				2	
New Jersey	46	45	43	13	36	2	6	35	2	1		4	1
New Mexico	16	16	12	6	12	2	3	9		4		1	
New York	184	183	179	33	114	41	123	46	3	6	2	14	
North Carolina	76	74	61	40	45	3	8	66	3	1	1	11	2
North Dakota	4	4	4	1	1		2	2				1	
Ohio	71	70	63	35	17	1	25	41		5	1	16	1
Oklahoma	19	19	14	12	2	1	1	16				3	
Oregon	19	19	17	4	5		6	13	1	1		5	
Pennsylvania	103	103	93	17	85	12	28	74	2	4		8	
Puerto Rico	6	6	6	6	5			6				1	
Rhode Island	22	22	20	15	18	4	4	18	1		1	1	
South Carolina	22	22	18	3	14		3	20	2	1		2	
South Dakota	1	1	1					1					
Tennessee	10	10	8	7	4		7	4	1			2	
Texas	86	86	67	5	69	1	26	54	2	5		12	
Utah	18	18	16	8	5		1	16	1			6	
Vermont	11	11	9	1	9	3	5	6	2				
Virginia	34	34	31	20	19	2	9	27	1			7	
Washington	30	30	29	13	29	2	3	8	1			4	
West Virginia	9	9	9	5	8			8		1		1	
Wisconsin	19	19	15	4	11	1	1	15		3		3	
Wyoming	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other jurisdictions⁴	1	1			1		1						

⁻⁻ Quantity is zero; ‡ No facilities in this category.

CARF = Commission on Accreditation of Rehabilitation Facilities; COA = Council on Accreditation; HFAP = Healthcare Facilities Accreditation Program; NCQA = National Committee for Quality Assurance.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

³ Number of facilities sums to more than the total column, because a facility could report more than one licensing, certification, or accreditation organization. The number of facilities licensed, certified, or accredited and the number not licensed, certified, or accredited by any listed organization do not sum to the total number of facilities, because one facility did not respond to the question.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.32b. Facility licensing, certification, or accreditation of facilities with opioid treatment programs (OTPs), by state or jurisdiction:

Row percent, 2020

					Licer	sing, certifica	ation, or accre	editation orga	anization				
State or jurisdiction ¹	Number of facilities ^{2,3}	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commis- sion	CARF	NCQA	COA	HFAP	Other organization/ federal/state/ local agency	Not licensed, certified, or accredited
Total	1,754	99.1	88.4	31.1	60.3	5.8	27.8	65.9	2.5	5.1	0.6	12.8	0.2
Alabama	20	100.0	100.0	90.0	5.0		40.0	60.0	5.0			15.0	
Alaska	4	100.0	75.0	25.0	25.0			100.0				50.0	
Arizona	60	100.0	65.0	43.3	86.7	1.7	5.0	88.3		1.7		11.7	
Arkansas	8	100.0	87.5	12.5	50.0	12.5	37.5	75.0				12.5	
California	155	99.4	86.5	9.0	42.6	1.9	9.7	65.2	1.9	27.1	0.6	9.0	
Colorado	28	96.4	89.3	32.1	25.0	3.6	21.4	71.4		3.6		14.3	
Connecticut	46	87.0	78.3	67.4	80.4	4.3	34.8	58.7	4.3			13.0	
Delaware	16	100.0	100.0	68.8	81.3		43.8	75.0	12.5	12.5		6.3	
District of Columbia	4	100.0	75.0	25.0	50.0		25.0	50.0		25.0		25.0	
Florida	74	98.6	95.9	18.9	78.4	2.7	33.8	67.6	2.7			16.2	
Georgia	70	100.0	85.7	15.7	58.6		18.6	82.9	2.9	2.9		14.3	
Hawaii	4	100.0	75.0		50.0			100.0				25.0	
Idaho	4	100.0	100.0	100.0	50.0			100.0				50.0	
Illinois	85	100.0	91.8	27.1	29.4	3.5	32.9	67.1		2.4	2.4	8.2	
Indiana	20	100.0	90.0	55.0	20.0	10.0	20.0	75.0		5.0	5.0	20.0	
lowa	8	100.0	100.0	75.0	87.5			75.0					
Kansas	7	100.0	100.0		14.3	14.3	28.6	71.4				14.3	
Kentucky	27	100.0	96.3	48.1	37.0		40.7	74.1	7.4			22.2	
Louisiana	11	100.0	100.0	36.4	90.9		18.2	81.8				9.1	
Maine	10	100.0	100.0	60.0	30.0		20.0	80.0				20.0	
Maryland	89	100.0	94.4	33.7	78.7	3.4	21.3	78.7	3.4	4.5	1.1	14.6	
Massachusetts	87	100.0	89.7	27.6	88.5	4.6	36.8	59.8	4.6	1.1		5.7	
Michigan	43	97.7	90.7	27.9	41.9	2.3	23.3	76.7			2.3	9.3	
Minnesota	18	100.0	88.9	16.7	66.7	11.1	27.8	66.7				16.7	
Mississippi	5	100.0	60.0	100.0	20.0		40.0	100.0	20.0			20.0	
Missouri	16	100.0	81.3	81.3	31.3		50.0	12.5				18.8	
Montana	3	100.0						100.0				100.0	
Nebraska	4	100.0	50.0		75.0			75.0					

Table 6.32b. Facility licensing, certification, or accreditation of facilities with opioid treatment programs (OTPs), by state or jurisdiction:

Row percent, 2020 (continued)

					Licer	nsing, certifica	ation, or accre	editation orga	anization				
State or jurisdiction ¹	Number of facilities ^{2,3}	Any listed agency/ organization	State substance abuse agency	State mental health department	State department of health	Hospital licensing authority	Joint Commis- sion	CARF	NCQA	COA	HFAP	Other organization/ federal/state/ local agency	Not licensed, certified, or accredited
Nevada	14	100.0	100.0	50.0	85.7	7.1	21.4	78.6				21.4	
New Hampshire	7	100.0	100.0		57.1			100.0				28.6	
New Jersey	46	97.8	93.5	28.3	78.3	4.3	13.0	76.1	4.3	2.2		8.7	2.2
New Mexico	16	100.0	75.0	37.5	75.0	12.5	18.8	56.3		25.0		6.3	
New York	184	99.5	97.3	17.9	62.0	22.3	66.8	25.0	1.6	3.3	1.1	7.6	
North Carolina	76	97.4	80.3	52.6	59.2	3.9	10.5	86.8	3.9	1.3	1.3	14.5	2.6
North Dakota	4	100.0	100.0	25.0	25.0		50.0	50.0				25.0	
Ohio	71	98.6	88.7	49.3	23.9	1.4	35.2	57.7		7.0	1.4	22.5	1.4
Oklahoma	19	100.0	73.7	63.2	10.5	5.3	5.3	84.2				15.8	
Oregon	19	100.0	89.5	21.1	26.3		31.6	68.4	5.3	5.3		26.3	
Pennsylvania	103	100.0	90.3	16.5	82.5	11.7	27.2	71.8	1.9	3.9		7.8	
Puerto Rico	6	100.0	100.0	100.0	83.3			100.0				16.7	
Rhode Island	22	100.0	90.9	68.2	81.8	18.2	18.2	81.8	4.5		4.5	4.5	
South Carolina	22	100.0	81.8	13.6	63.6		13.6	90.9	9.1	4.5		9.1	
South Dakota	1	100.0	100.0					100.0					
Tennessee	10	100.0	80.0	70.0	40.0		70.0	40.0	10.0			20.0	
Texas	86	100.0	77.9	5.8	80.2	1.2	30.2	62.8	2.3	5.8		14.0	
Utah	18	100.0	88.9	44.4	27.8		5.6	88.9	5.6			33.3	
Vermont	11	100.0	81.8	9.1	81.8	27.3	45.5	54.5	18.2				
Virginia	34	100.0	91.2	58.8	55.9	5.9	26.5	79.4	2.9			20.6	
Washington	30	100.0	96.7	43.3	96.7	6.7	10.0	26.7	3.3			13.3	
West Virginia	9	100.0	100.0	55.6	88.9			88.9		11.1		11.1	
Wisconsin	19	100.0	78.9	21.1	57.9	5.3	5.3	78.9		15.8		15.8	
Wyoming	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other jurisdictions ⁴	1	100.0			100.0		100.0						

⁻⁻ Quantity is zero; ‡ No facilities in this category.

CARF = Commission on Accreditation of Rehabilitation Facilities; COA = Council on Accreditation; HFAP = Healthcare Facilities Accreditation Program; NCQA = National Committee for Quality Assurance.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Facilities that have opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

³ Percentages sum to more than 100 percent, because a facility could report more than one licensing, certification, or accreditation organization. The percent of facilities licensed, certified, or accredited and the percent not licensed, certified, or accredited by any listed organization do not sum to 100 percent, because one facility did not respond to the question.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020.

Table 6.33. Facility smoking policy, by state or jurisdiction: Number and row percent distribution, 2020

_			Nu	mber of facilit	ies					Row percer	nt distributio	n of facilities		
_			Ту	pe of facility s	moking po	licy				Тур	e of facility	smoking policy	/	
State or jurisdiction ¹	Total ²	Not permitted to smoke anywhere outside or within any building	Permit- ted in desig- nated outdoor area(s)	Permitted anywhere outside	Permit- ted in desig- nated indoor area(s)	Permitted anywhere inside	Permitted anywhere without restriction	Total ²	Not permitted to smoke anywhere outside or within any building	Permitted in designated outdoor area(s)	Permit- ted any- where outside	Permitted in designated indoor area(s)	Permitted anywhere inside	Permitted anywhere without restriction
Total	15,980	5,750	9,140	1,046	31	3	10	100.0	36.0	57.2	6.5	0.2	*	0.1
Alabama	155	35	114	6				100.0	22.6	73.5	3.9			
Alaska	105	66	35	4				100.0	62.9	33.3	3.8			
Arizona	445	129	298	18				100.0	29.0	67.0	4.0			
Arkansas	167	47	118	2				100.0	28.1	70.7	1.2			
California	1,722	425	1,234	60	3			100.0	24.7	71.7	3.5	0.2		
Colorado	391	142	219	29	1			100.0	36.3	56.0	7.4	0.3		
Connecticut	202	95	100	6	1			100.0	47.0	49.5	3.0	0.5		
Delaware	49	15	33	1				100.0	30.6	67.3	2.0			
District of														
Columbia	28	6	17	4	1			100.0	21.4	60.7	14.3	3.6		
Florida	707	212	430	65				100.0	30.0	60.8	9.2			
Georgia	346	100	216	30				100.0	28.9	62.4	8.7			
Hawaii	161	103	51	7				100.0	64.0	31.7	4.3			
Idaho	110	16	93	1				100.0	14.5	84.5	0.9			
Illinois	712	196	424	88	2	1	1	100.0	27.5	59.6	12.4	0.3	0.1	0.1
Indiana	416	227	171	18				100.0	54.6	41.1	4.3			
lowa	185	110	59	16				100.0	59.5	31.9	8.6			
Kansas	167	50	112	5				100.0	29.9	67.1	3.0			
Kentucky	475	49	368	54	4			100.0	10.3	77.5	11.4	0.8		
Louisiana	154	41	105	8				100.0	26.6	68.2	5.2			
Maine	196	99	80	13	4			100.0	50.5	40.8	6.6	2.0		
Maryland	431	106	277	44	2		2	100.0	24.6	64.3	10.2	0.5		0.5
Massachusetts	435	177	248	10				100.0	40.7	57.0	2.3			
Michigan	453	154	246	52	1			100.0	34.0	54.3	11.5	0.2		
Minnesota	399	72	306	18	2		1	100.0	18.0	76.7	4.5	0.5		0.3
Mississippi	104	38	63	3				100.0	36.5	60.6	2.9			
Missouri	277	94	167	15			1	100.0	33.9	60.3	5.4			0.4
Montana	129	70	51	8				100.0	54.3	39.5	6.2			
Nebraska	123	48	65	10				100.0	39.0	52.8	8.1			

Table 6.33. Facility smoking policy, by state or jurisdiction: Number and row percent distribution, 2020 (continued)

				mber of facilit								on of facilities		
			Ту	pe of facility s	smoking po	licy				Тур	e of facility	smoking policy	/	
State or jurisdiction ¹	Total ²	Not permitted to smoke anywhere outside or within any building	Permit- ted in desig- nated outdoor area(s)	Permitted anywhere outside	Permit- ted in desig- nated indoor area(s)	Permitted anywhere inside	Permitted anywhere without restriction	Total ²	Not permitted to smoke anywhere outside or within any building	Permitted in designated outdoor area(s)	Permit- ted any- where outside	Permitted in designated indoor area(s)	Permitted anywhere inside	Permitted anywhere without restriction
Nevada	108	42	63	3				100.0	38.9	58.3	2.8			
New Hampshire	109	54	52	3				100.0	49.5	47.7	2.8			
New Jersey	383	77	274	31	1			100.0	20.1	71.5	8.1	0.3		
New Mexico	157	44	93	20				100.0	28.0	59.2	12.7			
New York	892	730	129	31	2			100.0	81.8	14.5	3.5	0.2		
North Carolina	603	166	357	78			2	100.0	27.5	59.2	12.9			0.3
North Dakota	87	31	48	8				100.0	35.6	55.2	9.2			
Ohio	616	162	429	24	1			100.0	26.3	69.6	3.9	0.2		
Oklahoma	194	157	31	6				100.0	80.9	16.0	3.1			
Oregon	245	140	100	5				100.0	57.1	40.8	2.0			
Pennsylvania	604	169	383	51	1			100.0	28.0	63.4	8.4	0.2		
Puerto Rico	100	39	51	9	1			100.0	39.0	51.0	9.0	1.0		
Rhode Island	63	23	36	4				100.0	36.5	57.1	6.3			
South Carolina	124	54	62	8				100.0	43.5	50.0	6.5			
South Dakota	58	23	31	4				100.0	39.7	53.4	6.9			
Tennessee	310	76	212	22				100.0	24.5	68.4	7.1			
Texas	504	211	280	12			1	100.0	41.9	55.6	2.4			0.2
Utah	333	133	178	20	1		1	100.0	39.9	53.5	6.0	0.3		0.3
Vermont	52	43	7	2				100.0	82.7	13.5	3.8			
Virginia	249	87	138	24				100.0	34.9	55.4	9.6			
Washington	455	178	254	21	1		1	100.0	39.1	55.8	4.6	0.2		0.2
West Virginia	126	36	77	13				100.0	28.6	61.1	10.3			
Wisconsin	294	118	128	44	2	2		100.0	40.1	43.5	15.0	0.7	0.7	
Wyoming Other	60	30	23	7				100.0	50.0	38.3	11.7			
jurisdictions ³	10	5	4	1				100.0	50.0	40.0	10.0			

^{- -} Quantity is zero; * Less than 0.05 percent.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Of 16,066 facilities, 86 facilities (less than 1 percent) did not respond to the question. Percentages are based on the remaining 15,980 facilities.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTE: Percentages may not sum to 100 percent because of rounding.

Table 6.34a. Clients in treatment, according to facility operation, by state or jurisdiction: Number, March 31, 2020

					F	acility opera	ation				
								Federa	al govt.		
State or jurisdiction ¹	Total	Private non-profit	Private for-profit	Local county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Total	1,090,357	504,780	485,411	39,571	19,601	30,589	26,825	2,278	502	984	10,405
Alabama	11,838	4,188	7,388	16		246	246				
Alaska	3,213	1,549	933	50		153		40	113		528
Arizona	44,825	22,426	19,444	129	3	614	588	6	20		2,209
Arkansas	4,464	1,901	1,534		287	742	742				
California	70,034	25,051	36,382	5,273	62	3,050	2,883	104	63		216
Colorado	30,083	11,041	16,981	121	780	1,160	307	828	25		
Connecticut	23,433	21,334	1,348	280	422	49		49			
Delaware	12,796	10,930	1,666			200	200				
District of Columbia	1,761	1,542	197		22						
Florida	45,620	19,022	24,011	877	257	1,453	1,430	23			
Georgia	17,642	3,138	11,140	182	2,959	223	166	30		27	
Hawaii	3,354	1,747	1,534		2	71	62	9			
Idaho	3,891	115	3,383	311		71	59	12			11
Illinois	40,978	31,109	7,679	386	455	1,349	1,349				
Indiana	43,865	18,244	23,984	1,376	52	209	180			29	
Iowa	8,013	6,625	1,104			271	271				13
Kansas	6,387	3,728	1,763	618	4	274	274				
Kentucky	27,353	8,595	18,465	2		291	251	40			
Louisiana	8,638	1,392	5,225	1,233	608	180	180				
Maine	10,299	2,797	7,372	55		16		6		10	59
Maryland	35,115	6,440	25,763	1,281	1,062	569	466	103			
Massachusetts	52,270	26,214	24,871	100	83	1,002	278		6	718	
Michigan	27,127	16,144	9,848	459							676
Minnesota	15,899	5,447	9,919	23	33	44	44				433
Mississippi	4,032	1,036	1,634	1,159	84	119	119				
Missouri	12,401	8,773	3,400			228	228				
Montana	4,976	1,396	3,052		112	9			9		407
Nebraska	3,554	2,091	958	250	14	111	64	6	41		130

Table 6.34a. Clients in treatment, according to facility operation, by state or jurisdiction: Number, March 31, 2020 (continued)

					F	acility opera	ntion				
	-							Federa	al govt.		
State or jurisdiction ¹	Total	Private non-profit	Private for-profit	Local county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Nevada	11,573	4,350	5,857		800	536	531	5			30
New Hampshire	9,576	2,657	6,919								
New Jersey	26,198	13,697	11,668	640	193						
New Mexico	16,133	9,998	4,809	65	97	200				200	964
New York	81,275	55,375	16,643	4,677	1,955	2,194	2,194				431
North Carolina	35,874	13,692	20,729	267	88	1,098	437	661			
North Dakota	2,599	747	908		859						85
Ohio	69,478	38,348	29,962	417	541	210	210				
Oklahoma	16,313	8,791	3,760	68	2,465	470	370	100			759
Oregon	20,264	11,534	6,385	1,668	28	361	281		80		288
Pennsylvania	45,588	21,186	22,249			2,153	2,153				
Puerto Rico	5,938	1,841	414		2,964	719	719				
Rhode Island	5,435	2,020	2,246			1,165	1165				4
South Carolina	14,152	4,655	5,360	2,486	1,136	515	507	8			
South Dakota	2,371	1,801	141		16	98	67		31		315
Tennessee	18,865	7,991	10,294		30	550	550				
Texas	27,078	7,254	14,723	513	929	3,605	3,605				54
Utah	13,218	4,180	6,478	2,362							198
Vermont	7,098	4,423	2,210			465	465				
Virginia	18,878	2,611	9,204	6,475	25	563	333	230			
Washington	33,999	13,336	15,367	2,686	101	463	408	18	37		2,046
West Virginia	10,898	4,339	5,068	57		1,434	1,434				
Wisconsin	19,740	4,012	12,475	2,092		897	820		77		264
Wyoming	3,802	1,847	564	917		189	189				285
Other jurisdictions ²	153	80			73						

⁻⁻ Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.34b. Clients in treatment, according to facility operation, by state or jurisdiction: Row percent distribution, March 31, 2020

						Facility op	eration				
								Federa	al govt.		
State or jurisdiction ¹	Total	Private non-profit	Private for-profit	Local county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Total	1,090,357	46.3	44.5	3.6	1.8	2.8	2.5	0.2	*	0.1	1.0
Alabama	11,838	35.4	62.4	0.1		2.1	2.1				
Alaska	3,213	48.2	29.0	1.6		4.8		1.2	3.5		16.4
Arizona	44,825	50.0	43.4	0.3	*	1.4	1.3	*			4.9
Arkansas	4,464	42.6	34.4		6.4	16.6	16.6				
California	70,034	35.8	51.9	7.5	0.1	4.4	4.1	0.1	0.1		0.3
Colorado	30,083	36.7	56.4	0.4	2.6	3.9	1.0	2.8	0.1		
Connecticut	23,433	91.0	5.8	1.2	1.8	0.2		0.2			
Delaware	12,796	85.4	13.0			1.6	1.6				
District of Columbia	1,761	87.6	11.2		1.2						
Florida	45,620	41.7	52.6	1.9	0.6	3.2	3.1	0.1			
Georgia	17,642	17.8	63.1	1.0	16.8	1.3	0.9	0.2		0.2	
Hawaii	3,354	52.1	45.7		0.1	2.1	1.8	0.3			
Idaho	3,891	3.0	86.9	8.0		1.8	1.5	0.3			0.3
Illinois	40,978	75.9	18.7	0.9	1.1	3.3	3.3				
Indiana	43,865	41.6	54.7	3.1	0.1	0.5	0.4			0.1	
lowa	8,013	82.7	13.8			3.4	3.4				0.2
Kansas	6,387	58.4	27.6	9.7	0.1	4.3	4.3				
Kentucky	27,353	31.4	67.5	*		1.1	0.9	0.1			
Louisiana	8,638	16.1	60.5	14.3	7.0	2.1	2.1				
Maine	10,299	27.2	71.6	0.5		0.2		0.1		0.1	0.6
Maryland	35,115	18.3	73.4	3.6	3.0	1.6	1.3	0.3			
Massachusetts	52,270	50.2	47.6	0.2	0.2	1.9	0.5		*	1.4	
Michigan	27,127	59.5	36.3	1.7							2.5
Minnesota	15,899	34.3	62.4	0.1	0.2	0.3	0.3				2.7
Mississippi	4,032	25.7	40.5	28.7	2.1	3.0	3.0				
Missouri	12,401	70.7	27.4			1.8	1.8				
Montana	4,976	28.1	61.3		2.3	0.2			0.2		8.2
Nebraska	3,554	58.8	27.0	7.0	0.4	3.1	1.8	0.2	1.2		3.7

Table 6.34b. Clients in treatment, according to facility operation, by state or jurisdiction: Row percent distribution, March 31, 2020 (continued)

						Facility ope	eration				
								Federa	al govt.		
State or jurisdiction ¹	Total	Private non-profit	Private for-profit	Local county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Nevada	11,573	37.6	50.6		6.9	4.6	4.6	*			0.3
New Hampshire	9,576	27.7	72.3								
New Jersey	26,198	52.3	44.5	2.4	0.7						
New Mexico	16,133	62.0	29.8	0.4	0.6	1.2				1.2	6.0
New York	81,275	68.1	20.5	5.8	2.4	2.7	2.7				0.5
North Carolina	35,874	38.2	57.8	0.7	0.2	3.1	1.2	1.8			
North Dakota	2,599	28.7	34.9		33.1						3.3
Ohio	69,478	55.2	43.1	0.6	0.8	0.3	0.3				
Oklahoma	16,313	53.9	23.0	0.4	15.1	2.9	2.3	0.6			4.7
Oregon	20,264	56.9	31.5	8.2	0.1	1.8	1.4		0.4		1.4
Pennsylvania	45,588	46.5	48.8			4.7	4.7				
Puerto Rico	5,938	31.0	7.0		49.9	12.1	12.1				
Rhode Island	5,435	37.2	41.3			21.4	21.4				0.1
South Carolina	14,152	32.9	37.9	17.6	8.0	3.6	3.6	0.1			
South Dakota	2,371	76.0	5.9		0.7	4.1	2.8		1.3		13.3
Tennessee	18,865	42.4	54.6		0.2	2.9	2.9				
Texas	27,078	26.8	54.4	1.9	3.4	13.3	13.3				0.2
Utah	13,218	31.6	49.0	17.9							1.5
Vermont	7,098	62.3	31.1			6.6	6.6				
Virginia	18,878	13.8	48.8	34.3	0.1	3.0	1.8	1.2			
Washington	33,999	39.2	45.2	7.9	0.3	1.4	1.2	0.1	0.1		6.0
West Virginia	10,898	39.8	46.5	0.5		13.2	13.2				
Wisconsin	19,740	20.3	63.2	10.6		4.5	4.2		0.4		1.3
Wyoming	3,802	48.6	14.8	24.1		5.0	5.0				7.5
Other jurisdictions ²	153	52.3			47.7						

⁻⁻ Quantity is zero; * Less than 0.05 percent.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

NOTE: Percentages may not sum to 100 percent because of rounding.

Table 6.35a. Clients in treatment, according to type of care received, by state or jurisdiction: Number, March 31, 2020

							Type of care	received						
					Outpatien	t			Reside	ential (non-	hospital)		Hospita	l inpatient
State or jurisdiction ¹	Total	Total out- patient	Regular	Intensive	Day treatment or partial hospitalization	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Total residen- tial	Short- term	Long- term	Detox	Total hospital inpatient	Treat- ment	Detox
Total	1,090,357	1,021,185	459,157	83,073	14,112	13,445	451,398	58,952	20,440	33,135	5,377	10,220	5,444	4,776
Alabama	11,838	10,985	4,694	915	77	101	5,198	796	204	547	45	57	10	47
Alaska	3,213	3,009	1,189	534	19		1,267	182	80	102		22	9	13
Arizona	44,825	42,992	23,062	3,411	533	1,359	14,627	1,348	656	627	65	485	333	152
Arkansas	4,464	4,219	2,418	178	138	16	1,469	119	31	78	10	126	100	26
California	70,034	60,658	28,745	5,883	1,237	820	23,973	8,966	2,181	5,813	972	410	174	236
Colorado	30,083	29,333	23,512	1,431	181	259	3,950	542	143	312	87	208	145	63
Connecticut	23,433	22,564	9,454	926	198	41	11,945	694	271	371	52	175	121	54
Delaware	12,796	12,700	5,978	170	10	5	6,537	80	3	61	16	16	3	13
District of Columbia	1,761	1,591	350	125			1,116	170	141	29				
Florida	45,620	40,817	15,493	1,966	1,280	450	21,628	3,868	1,512	1,674	682	935	426	509
Georgia	17,642	15,077	5,611	974	605	50	7,837	1,280	357	854	69	1,285	161	1,124
Hawaii	3,354	3,048	1,860	450	47	3	688	306	19	283	4			
Idaho	3,891	3,803	1,637	713	70	2	1,381	36	27	5	4	52	35	17
Illinois	40,978	39,557	12,883	4,542	293	49	21,790	1,203	753	350	100	218	101	117
Indiana	43,865	42,884	18,524	1,798	213	324	22,025	835	388	334	113	146	96	50
lowa	8,013	7,493	5,477	301	10	30	1,675	494	217	266	11	26	12	14
Kansas	6,387	5,904	4,116	454	10	2	1,322	460	303	118	39	23	10	13
Kentucky	27,353	25,033	10,636	1,522	146	236	12,493	2,121	753	1,092	276	199	126	73
Louisiana	8,638	7,481	2,390	1,143	24	949	2,975	881	473	390	18	276	135	141
Maine	10,299	10,116	3,176	363	7		6,570	168	13	150	5	15	10	5
Maryland	35,115	33,802	7,834	2,779	220	468	22,501	1,120	194	664	262	193	110	83
Massachusetts	52,270	48,839	16,315	940	1,415	145	30,024	2,602	602	1,728	272	829	359	470
Michigan	27,127	25,555	14,207	617	138	906	9,687	1,548	751	660	137	24	11	13
Minnesota	15,899	14,095	3,504	4,104	476	3	6,008	1,750	882	791	77	54	33	21
Mississippi	4,032	3,430	2,272	156	57		945	583	303	266	14	19		19
Missouri	12,401	11,921	3,707	2,584	402	399	4,829	472	260	180	32	8	8	
Montana	4,976	4,724	1,813	518	47	102	2,244	242	149	93		10	5	5
Nebraska	3,554	3,148	2,485	210	6	225	222	405	113	279	13	1		1
Nevada	11,573	11,262	7,858	985	33	389	1,997	258	128	82	48	53	28	25
New Hampshire	9,576	9,318	1,456	598	80	1,298	5,886	212	152	60		46	41	5

Table 6.35a. Clients in treatment, according to type of care received, by state or jurisdiction: Number, March 31, 2020 (continued)

							Type of care	received						
					Outpatient	t .			Reside	ential (non-	hospital)		Hospital	inpatient
State or jurisdiction ¹	Total	Total out- patient	Regular	Intensive	Day treatment or partial hospitalization	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Total residen- tial	Short- term	Long- term	Detox	Total hospital inpatient	Treat- ment	Detox
New Jersey	26,198	24,486	7,450	3,813	965	426	11,832	1,388	512	703	173	324	185	139
New Mexico	16,133	15,768	10,204	716	30	357	4,461	357	85	120	152	8		8
New York	81,275	75,485	38,661	2,075	1,086	231	33,432	5,001	837	3,727	437	789	672	117
North Carolina	35,874	34,579	17,821	2,772	685	100	13,201	988	306	607	75	307	163	144
North Dakota	2,599	2,426	1,100	325	131		870	173	85	83	5			
Ohio	69,478	66,853	33,713	7,090	1,085	1,635	23,330	2,181	990	1,095	96	444	246	198
Oklahoma	16,313	14,914	11,908	342	10	20	2,634	1,328	147	1,172	9	71	21	50
Oregon	20,264	19,684	8,153	2,852	120	174	8,385	474	57	362	55	106	68	38
Pennsylvania	45,588	40,764	16,136	5,303	715	128	18,482	4,350	2,398	1,528	424	474	270	204
Puerto Rico	5,938	4,625	1,609	53	51	33	2,879	1,253		1,251	2	60	53	7
Rhode Island	5,435	5,234	2,249	147	35	10	2,793	172	84	88		29	3	26
South Carolina	14,152	13,548	6,124	1,623	31	101	5,669	260	134	120	6	344	255	89
South Dakota	2,371	2,192	1,349	778		10	55	133	46	82	5	46	45	1
Tennessee	18,865	17,797	7,066	2,408	120	14	8,189	1,016	568	407	41	52	11	41
Texas	27,078	24,391	9,170	2,890	310	15	12,006	2,113	935	1,033	145	574	421	153
Utah	13,218	11,877	6,617	1,372	258	48	3,582	1,252	244	951	57	89	68	21
Vermont	7,098	7,076	2,767	277		44	3,988	20	13	3	4	2		2
Virginia	18,878	18,184	8,276	1,012	209	324	8,363	534	204	301	29	160	93	67
Washington	33,999	33,082	11,091	4,056	75	37	17,823	814	427	252	135	103	53	50
West Virginia	10,898	10,242	4,237	239		55	5,711	616	118	473	25	40	30	10
Wisconsin	19,740	19,197	8,858	660	200	1,025	8,454	323	100	223		220	125	95
Wyoming	3,802	3,285	1,863	921	24	27	450	450	91	282	77	67	60	7
Other jurisdictions ²	153	138	79	59				15		13	2			

^{- -} Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. These tables include only clients who receive or are prescribed buprenorphine through physicians, physician assistants, and nurse practitioners affiliated with a substance abuse treatment facility, they do not include clients who receive or are prescribed buprenorphine through an independent DATA 2000-waivered physician, physician assistant, and nurse practitioner.

Table 6.35b. Clients in treatment, according to type of care received, by state or jurisdiction: Row percent distribution, March 31, 2020

							Type of ca	are received						
State or jurisdiction ¹	Total	Total out- patient	Regular	Intensive	Outpatient Day treatment or partial hospitalization	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Total residen- tial	Resider Short- term	ntial (non-h Long- term	ospital) Detox	Total hospital inpatient	Hospital in	npatient Detox
Total	1,090,357	93.7	42.1	7.6	1.3	1.2	41.4	5.4	1.9	3.0	0.5	0.9	0.5	0.4
Alabama	11,838	92.8	39.7	7.7	0.7	0.9	43.9	6.7	1.7	4.6	0.4	0.5	0.1	0.4
Alaska	3,213	93.7	37.0	16.6	0.6		39.4	5.7	2.5	3.2		0.7	0.3	0.4
Arizona	44,825	95.9	51.4	7.6	1.2	3.0	32.6	3.0	1.5	1.4	0.1	1.1	0.7	0.3
Arkansas	4,464	94.5	54.2	4.0	3.1	0.4	32.9	2.7	0.7	1.7	0.2	2.8	2.2	0.6
California	70,034	86.6	41.0	8.4	1.8	1.2	34.2	12.8	3.1	8.3	1.4	0.6	0.2	0.3
Colorado	30,083	97.5	78.2	4.8	0.6	0.9	13.1	1.8	0.5	1.0	0.3	0.7	0.5	0.2
Connecticut	23,433	96.3	40.3	4.0	0.8	0.2	51.0	3.0	1.2	1.6	0.2	0.7	0.5	0.2
Delaware	12,796	99.2	46.7	1.3	0.1	*	51.1	0.6	*	0.5	0.1	0.1	*	0.1
District of Columbia	1,761	90.3	19.9	7.1			63.4	9.7	8.0	1.6				
Florida	45,620	89.5	34.0	4.3	2.8	1.0	47.4	8.5	3.3	3.7	1.5	2.0	0.9	1.1
Georgia	17,642	85.5	31.8	5.5	3.4	0.3	44.4	7.3	2.0	4.8	0.4	7.3	0.9	6.4
Hawaii	3,354	90.9	55.5	13.4	1.4	0.1	20.5	9.1	0.6	8.4	0.1			
Idaho	3,891	97.7	42.1	18.3	1.8	0.1	35.5	0.9	0.7	0.1	0.1	1.3	0.9	0.4
Illinois	40,978	96.5	31.4	11.1	0.7	0.1	53.2	2.9	1.8	0.9	0.2	0.5	0.2	0.3
Indiana	43,865	97.8	42.2	4.1	0.5	0.7	50.2	1.9	0.9	0.8	0.3	0.3	0.2	0.1
lowa	8,013	93.5	68.4	3.8	0.1	0.4	20.9	6.2	2.7	3.3	0.1	0.3	0.1	0.2
Kansas	6,387	92.4	64.4	7.1	0.2	*	20.7	7.2	4.7	1.8	0.6	0.4	0.2	0.2
Kentucky	27,353	91.5	38.9	5.6	0.5	0.9	45.7	7.8	2.8	4.0	1.0	0.7	0.5	0.3
Louisiana	8,638	86.6	27.7	13.2	0.3	11.0	34.4	10.2	5.5	4.5	0.2	3.2	1.6	1.6
Maine	10,299	98.2	30.8	3.5	0.1		63.8	1.6	0.1	1.5	*	0.1	0.1	*
Maryland	35,115	96.3	22.3	7.9	0.6	1.3	64.1	3.2	0.6	1.9	0.7	0.5	0.3	0.2
Massachusetts	52,270	93.4	31.2	1.8	2.7	0.3	57.4	5.0	1.2	3.3	0.5	1.6	0.7	0.9
Michigan	27,127	94.2	52.4	2.3	0.5	3.3	35.7	5.7	2.8	2.4	0.5	0.1	*	*
Minnesota	15,899	88.7	22.0	25.8	3.0	*	37.8	11.0	5.5	5.0	0.5	0.3	0.2	0.1
Mississippi	4,032	85.1	56.3	3.9	1.4		23.4	14.5	7.5	6.6	0.3	0.5		0.5
Missouri	12,401	96.1	29.9	20.8	3.2	3.2	38.9	3.8	2.1	1.5	0.3	0.1	0.1	
Montana	4,976	94.9	36.4	10.4	0.9	2.0	45.1	4.9	3.0	1.9		0.2	0.1	0.1
Nebraska	3,554	88.6	69.9	5.9	0.2	6.3	6.2	11.4	3.2	7.9	0.4	*		*
Nevada	11,573	97.3	67.9	8.5	0.3	3.4	17.3	2.2	1.1	0.7	0.4	0.5	0.2	0.2
New Hampshire	9,576	97.3	15.2	6.2	0.8	13.6	61.5	2.2	1.6	0.6		0.5	0.4	0.1

Table 6.35b. Clients in treatment, according to type of care received, by state or jurisdiction: Row percent distribution, March 31, 2020 (continued)

							Type of ca	are received						
					Outpatient				Resider	ntial (non-h	ospital)		Hospital ii	npatient
State or jurisdiction ¹	Total	Total out- patient	Regular	Intensive	Day treatment or partial hospitalization	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Total residen- tial	Short- term	Long- term	Detox	Total hospital inpatient	Treatment	Detox
New Jersey	26,198	93.5	28.4	14.6	3.7	1.6	45.2	5.3	2.0	2.7	0.7	1.2	0.7	0.5
New Mexico	16,133	97.7	63.2	4.4	0.2	2.2	27.7	2.2	0.5	0.7	0.9	*		*
New York	81,275	92.9	47.6	2.6	1.3	0.3	41.1	6.2	1.0	4.6	0.5	1.0	0.8	0.1
North Carolina	35,874	96.4	49.7	7.7	1.9	0.3	36.8	2.8	0.9	1.7	0.2	0.9	0.5	0.4
North Dakota	2,599	93.3	42.3	12.5	5.0		33.5	6.7	3.3	3.2	0.2			
Ohio	69,478	96.2	48.5	10.2	1.6	2.4	33.6	3.1	1.4	1.6	0.1	0.6	0.4	0.3
Oklahoma	16,313	91.4	73.0	2.1	0.1	0.1	16.1	8.1	0.9	7.2	0.1	0.4	0.1	0.3
Oregon	20,264	97.1	40.2	14.1	0.6	0.9	41.4	2.3	0.3	1.8	0.3	0.5	0.3	0.2
Pennsylvania	45,588	89.4	35.4	11.6	1.6	0.3	40.5	9.5	5.3	3.4	0.9	1.0	0.6	0.4
Puerto Rico	5,938	77.9	27.1	0.9	0.9	0.6	48.5	21.1		21.1		1.0	0.9	0.1
Rhode Island	5,435	96.3	41.4	2.7	0.6	0.2	51.4	3.2	1.5	1.6		0.5	0.1	0.5
South Carolina	14,152	95.7	43.3	11.5	0.2	0.7	40.1	1.8	0.9	8.0		2.4	1.8	0.6
South Dakota	2,371	92.5	56.9	32.8		0.4	2.3	5.6	1.9	3.5	0.2	1.9	1.9	*
Tennessee	18,865	94.3	37.5	12.8	0.6	0.1	43.4	5.4	3.0	2.2	0.2	0.3	0.1	0.2
Texas	27,078	90.1	33.9	10.7	1.1	0.1	44.3	7.8	3.5	3.8	0.5	2.1	1.6	0.6
Utah	13,218	89.9	50.1	10.4	2.0	0.4	27.1	9.5	1.8	7.2	0.4	0.7	0.5	0.2
Vermont	7,098	99.7	39.0	3.9		0.6	56.2	0.3	0.2	*	0.1	*		*
Virginia	18,878	96.3	43.8	5.4	1.1	1.7	44.3	2.8	1.1	1.6	0.2	0.8	0.5	0.4
Washington	33,999	97.3	32.6	11.9	0.2	0.1	52.4	2.4	1.3	0.7	0.4	0.3	0.2	0.1
West Virginia	10,898	94.0	38.9	2.2		0.5	52.4	5.7	1.1	4.3	0.2	0.4	0.3	0.1
Wisconsin	19,740	97.2	44.9	3.3	1.0	5.2	42.8	1.6	0.5	1.1		1.1	0.6	0.5
Wyoming	3,802	86.4	49.0	24.2	0.6	0.7	11.8	11.8	2.4	7.4	2.0	1.8	1.6	0.2
Other jurisdictions ²	153	90.2	51.6	38.6				9.8		8.5	1.3			

⁻⁻ Quantity is zero; * Less than 0.05 percent.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTES: Percentages may not sum to 100 percent because of rounding. Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 6.36. Clients in outpatient treatment at Federally Qualified Health Centers providing substance use treatment, by type of care received and state or jurisdiction: Number and row percent distribution, March 31, 2020

					Federall	y Qualified Health (Centers				
_			Num	ber of clients				R	ow percent distribution	on of clients	
State or jurisdiction ¹	Total out- patient	Regular	Intensive	Day treatment or partial hospitalization	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Regular	Intensive	Day treatment or partial hospitalization	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment
Total	111,276	51,672	8,027	833	3,210	47,534	46.4	7.2	0.7	2.9	42.7
Alabama	1,134	365	, 76		5	688	32.2	6.7		0.4	60.7
Alaska	387	350	37				90.4	9.6			
Arizona	6,501	1,049	395		1,055	4,002	16.1	6.1		16.2	61.6
Arkansas	905	813		7		85	89.8		0.8		9.4
California	5,353	2,759	574	29	25	1,966	51.5	10.7	0.5	0.5	36.7
Colorado	2,647	1,536	15		22	1,074	58.0	0.6		0.8	40.6
Connecticut	3,972	2,195	82			1,695	55.3	2.1			42.7
Delaware	302	250	39			13	82.8	13			4.3
District of Columbia	1,080	203	36			841	18.8	3.3			77.9
Florida	3,492	1,975	97	5		1,415	56.6	2.8	0.1		40.5
Georgia	1,678	550	128	32	10	958	32.8	7.6	1.9	0.6	57.1
Hawaii	172	43	94	35			25.0	54.7	20.3		
Idaho	74	56	18				75.7	24.3			
Illinois	3,200	1,336	179	4	20	1,661	41.8	5.6	0.1	0.6	51.9
Indiana	3,298	1,086	599	12	5	1,596	32.9	18.2	0.4	0.2	48.4
lowa	84	84					100.0				
Kansas	915	643	28			244	70.3	3.1			26.7
Kentucky	1,681	1,011	30			640	60.1	1.8			38.1
Louisiana	1,324	152	253		27	892	11.5	19.1		2.0	67.4
Maine	1,159	967	9			183	83.4	8.0			15.8
Maryland	2,594	457	421	35	282	1,399	17.6	16.2	1.3	10.9	53.9
Massachusetts	12,409	6,555	4	161	112	5,577	52.8		1.3	0.9	44.9
Michigan	3,321	810	69		861	1,581	24.4	2.1		25.9	47.6
Minnesota	511	256	226	7		22	50.1	44.2	1.4		4.3
Mississippi	458	434	11			13	94.8	2.4			2.8
Missouri	1,561	297	360	50	4	850	19.0	23.1	3.2	0.3	54.5
Montana	914	558	134		100	122	61.1	14.7		10.9	13.3
Nebraska	525	480	33		9	3	91.4	6.3		1.7	0.6
Nevada	1,374	665	226	3		480	48.4	16.4	0.2		34.9
New Hampshire	901	171	98			632	19.0	10.9			70.1

Table 6.36. Clients in outpatient treatment at Federally Qualified Health Centers providing substance use treatment, by type of care received and state or jurisdiction: Number and row percent distribution, March 31, 2020 (continued)

					Federal	ly Qualified Health (Centers				
			Num	ber of clients				Ro	w percent distribution	on of clients	
State or jurisdiction ¹	Total out- patient	Regular	Intensive	Day treatment or partial hospitalization	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment	Regular	Intensive	Day treatment or partial hospitalization	Detox	Methadone/ buprenorphine maintenance or naltrexone treatment
New Jersey	2,028	493	469	91	255	720	24.3	23.1	4.5	12.6	35.5
New Mexico	5,469	3,393	262	20	60	1,734	62.0	4.8	0.4	1.1	31.7
New York	5,460	2,516	208	144	97	2,495	46.1	3.8	2.6	1.8	45.7
North Carolina	4,109	2,297	411	103	20	1,278	55.9	10.0	2.5	0.5	31.1
North Dakota	138	40	13	10		75	29.0	9.4	7.2		54.3
Ohio	4,659	3,463	125	58	33	980	74.3	2.7	1.2	0.7	21.0
Oklahoma	1,835	1,339	62		10	424	73.0	3.4		0.5	23.1
Oregon	3,075	993	316		118	1,648	32.3	10.3		3.8	53.6
Pennsylvania	1,159	551	151		12	445	47.5	13.0		1.0	38.4
Puerto Rico	2,231	1,014	8		3	1,206	45.5	0.4		0.1	54.1
Rhode Island	963	270				693	28.0				72.0
South Carolina	1,335	580	50	8	60	637	43.4	3.7	0.6	4.5	47.7
South Dakota	250	217	33				86.8	13.2			
Tennessee	3,085	1,378	374		4	1,329	44.7	12.1		0.1	43.1
Texas	2,641	1,300	279	2		1,060	49.2	10.6	0.1		40.1
Utah	794	268	123	2		401	33.8	15.5	0.3		50.5
Vermont	434	69				365	15.9				84.1
Virginia	651	146	31	1		473	22.4	4.8	0.2		72.7
Washington	4,636	2,229	421		1	1,985	48.1	9.1			42.8
West Virginia	456	3				453	0.7				99.3
Wisconsin	1,056	483	59	14		500	45.7	5.6	1.3		47.3
Wyoming	886	524	361			1	59.1	40.7			0.1
Other jurisdictions ²	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

⁻⁻ Quantity is zero; ‡ No facilities in this category.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. These tables include only clients who receive or are prescribed buprenorphine through physicians, physician assistants, and nurse practitioners affiliated with a substance abuse treatment facility, they do not include clients who receive or are prescribed buprenorphine through an independent DATA 2000-waivered physician, physician assistant, and nurse practitioner.

Table 6.37. Clients in treatment, according to substance abuse problem and diagnosed co-occurring mental and substance use disorders, by state or jurisdiction:

Number and row percent distribution, March 31, 2020

				Substance abu	se problem				•	d co-occurring stance use disc	
State or jurisdiction ¹		Number of	clients			Row percent distr	ribution of clien	ts			Row percent
•	Total ²	Both alcohol and drug abuse	Drug abuse only	Alcohol abuse only	Total	Both alcohol and drug abuse	Drug abuse only	Alcohol abuse only	Total³	Number of clients	distribution of clients
Total	1,049,758	333,526	569,522	146,710	100.0	31.8	54.3	14.0	930,672	531,105	57.1
Alabama	12,121	3,322	7,850	948	100.0	27.4	64.8	7.8	10,566	4,417	41.8
Alaska	3,213	937	1,561	715	100.0	29.2	48.6	22.3	2,004	1,121	55.9
Arizona	46,097	12,755	26,130	7,211	100.0	27.7	56.7	15.6	42,075	25,181	59.8
Arkansas	4,342	1,506	2,318	518	100.0	34.7	53.4	11.9	3,649	2,470	67.7
California	69,067	22,896	34,002	12,169	100.0	33.2	49.2	17.6	59,804	29,888	50.0
Colorado	29,562	10,332	9,485	9.745	100.0	34.9	32.1	33.0	27.139	12.787	47.1
Connecticut	23,233	7,306	12,408	3,518	100.0	31.4	53.4	15.1	21,780	15,285	70.2
Delaware	12,799	3,762	7,933	1,104	100.0	29.4	62.0	8.6	12,799	4,087	31.9
District of Columbia	1,701	267	1,196	238	100.0	15.7	70.3	14.0	1,693	1,020	60.3
Florida	45,050	12,767	27,753	4,530	100.0	28.3	61.6	10.1	38,171	21,140	55.4
Georgia	17,576	4,129	11,232	2,215	100.0	23.5	63.9	12.6	13,955	7,778	55.7
Hawaii	3,354	1,080	1,884	390	100.0	32.2	56.2	11.6	2,926	1,513	51.7
Idaho	3,790	1,396	2,037	357	100.0	36.8	53.7	9.4	3,423	2,425	70.9
Illinois	33,257	9,277	18,494	5,486	100.0	27.9	55.6	16.5	28,197	13,984	49.6
Indiana	43,320	9,973	28,855	4,492	100.0	23.0	66.6	10.4	31,842	20,294	63.7
lowa	8,005	3,108	3,400	1,497	100.0	38.8	42.5	18.7	7,361	3,655	49.7
Kansas	6,354	2,521	2,748	1,085	100.0	39.7	43.2	17.1	5,579	2,467	44.2
Kentucky	26,248	8,094	15,973	2,181	100.0	30.8	60.9	8.3	21,855	12,395	56.7
Louisiana	6,712	2,127	3,610	976	100.0	31.7	53.8	14.5	6,536	3,524	53.9
Maine	10,267	1,980	7,437	850	100.0	19.3	72.4	8.3	6,567	4,323	65.8
Maryland	34,822	6,473	25,178	3,171	100.0	18.6	72.3	9.1	31,668	15,115	47.7
Massachusetts	46,194	13,168	27,688	5,337	100.0	28.5	59.9	11.6	44,302	31,367	70.8
Michigan	27,127	9,695	12,736	4,696	100.0	35.7	46.9	17.3	26,262	15,017	57.2
Minnesota	15,786	5,592	7,767	2,427	100.0	35.4	49.2	15.4	15,031	10,407	69.2
Mississippi	4,006	1,721	1,967	318	100.0	43.0	49.1	7.9	3,849	3,056	79.4
Missouri	12,156	4,472	6,399	1,285	100.0	36.8	52.6	10.6	11,747	7,525	64.1
Montana	4,967	1,644	2,748	575	100.0	33.1	55.3	11.6	3,225	2,163	67.1
Nebraska	3,554	1,504	1,370	681	100.0	42.3	38.5	19.1	3,552	2,064	58.1

Table 6.37. Clients in treatment, according to substance abuse problem and diagnosed co-occurring mental and substance use disorders, by state or jurisdiction:

Number and row percent distribution, March 31, 2020 (continued)

				Substance abu	ıse problem	1			•	d co-occurring stance use disc	
State or jurisdiction1		Number of	clients			Row percent distr	ribution of clien	ts			Row percent
	Total ²	Both alcohol and drug abuse	Drug abuse only	Alcohol abuse only	Total	Both alcohol and drug abuse	Drug abuse only	Alcohol abuse only	Total³	Number of clients	distribution of clients
Nevada	11,573	5,684	4,044	1,845	100.0	49.1	34.9	15.9	11,447	8,146	71.2
New Hampshire	9,508	3,732	4,954	822	100.0	39.3	52.1	8.6	8,252	6,198	75.1
New Jersey	25,415	8,336	14,114	2,966	100.0	32.8	55.5	11.7	24,931	12,740	51.1
New Mexico	15,070	6,121	5,914	3,035	100.0	40.6	39.2	20.1	13,230	10,095	76.3
New York	76,820	31,464	34,782	10,573	100.0	41.0	45.3	13.8	73,605	39,124	53.2
North Carolina	35,118	12,960	17,817	4,341	100.0	36.9	50.7	12.4	31,481	20,420	64.9
North Dakota	2,429	782	1,238	409	100.0	32.2	51.0	16.8	1,733	836	48.3
Ohio	63,652	22,554	32,997	8,101	100.0	35.4	51.8	12.7	55,433	33,908	61.2
Oklahoma	16,065	4,318	8,330	3,417	100.0	26.9	51.8	21.3	13,916	7,534	54.1
Oregon	20,447	6,684	9,896	3,868	100.0	32.7	48.4	18.9	18,247	8,666	47.5
Pennsylvania	44,620	14,611	24,665	5,344	100.0	32.7	55.3	12.0	42,310	24,496	57.9
Puerto Rico	5,934	1,393	4,133	408	100.0	23.5	69.7	6.9	4,905	2,665	54.3
Rhode Island	4,222	2,012	1,608	603	100.0	47.6	38.1	14.3	4,222	2,819	66.8
South Carolina	13,892	4,507	7,691	1,695	100.0	32.4	55.4	12.2	10,750	3,752	34.9
South Dakota	2,371	1,487	303	580	100.0	62.7	12.8	24.5	2,035	977	48.0
Tennessee	18,439	4,748	11,816	1,875	100.0	25.8	64.1	10.2	17,206	11,111	64.6
Texas	25,278	5,997	15,213	4,068	100.0	23.7	60.2	16.1	22,823	11,393	49.9
Utah	13,218	4,342	7,081	1,795	100.0	32.9	53.6	13.6	11,308	7,287	64.4
Vermont	7,098	1,800	4,047	1,251	100.0	25.4	57.0	17.6	6,687	4,358	65.2
Virginia	18,288	6,120	9,413	2,755	100.0	33.5	51.5	15.1	16,255	8,662	53.3
Washington	31,999	9,290	18,629	4,080	100.0	29.0	58.2	12.8	20,038	8,645	43.1
West Virginia	10,898	2,374	7,694	830	100.0	21.8	70.6	7.6	10,026	6,289	62.7
Wisconsin	18,769	6,833	9,822	2,114	100.0	36.4	52.3	11.3	18,652	12,639	67.8
Wyoming	3,802	1,505	1,124	1,173	100.0	39.6	29.6	30.9	3,470	1,816	52.3
Other jurisdictions ⁴	153	68	39	46	100.0	44.3	25.7	30.0	153	58	37.6

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Of 1,090,357 clients, 40,599 clients (4 percent) reported by the 632 facilities that did not respond to the substance abuse problem question (Question 34) were excluded.

³ Of 1,090,357 clients, 60,369 clients (6 percent) reported by the 727 facilities that did not respond to the co-occurring disorders question (Question 35) and 99,316 clients (9 percent) reported by the 908 facilities that did respond to the co-occurring disorders question, but which reported no clients with a mental health disorder, were excluded.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTE: Numbers and percentages may not sum to totals because of rounding.

Table 6.38a. Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by state or jurisdiction: Number, March 31, 2020

2/1		All	clients receiving r opioid tl		sted		OTP (clients			Non-OTP clients	s
State or jurisdiction ¹	_	Any MAT type²	Methadone	Buprenor- phine	Naltrexone	Any MAT type²	Methadone	Buprenor- phine	Naltrexone	Any MAT type³	Buprenor- phine	Naltrexone
	Total	509,008	311,531	176,152	21,325	347,223	311,531	31,864	3,828	161,785	144,288	17,497
Alabama		6,803	4,860	1,815	128	4,965	4,860	105		1,838	1,710	128
Alaska		1,031	316	670	45	320	316	4		711	666	45
Arizona		21,094	11,550	6,980	2,564	14,794	11,550	1,254	1,990	6,300	5,726	574
Arkansas		1,661	627	999	35	1,068	627	440	1	593	559	34
California		28,352	23,542	3,906	904	24,562	23,542	909	111	3,790	2,997	793
Colorado		4,909	3,594	1,084	231	3,982	3,594	357	31	927	727	200
Connecticut		13,322	11,087	1,843	392	11,694	11,087	590	17	1,628	1,253	375
Delaware		6,975	5,751	1,132	92	6,254	5,751	490	13	721	642	79
District of Columbia		1,136	920	213	3	920	920			216	213	3
Florida		22,909	17,546	4,450	913	18,460	17,546	745	169	4,449	3,705	744
Georgia		8,193	7,300	755	138	7,728	7,300	428		465	327	138
Hawaii		696	412	284		532	412	120		164	164	
Idaho		1,315	689	569	57	771	689	82		544	487	57
Illinois		24,063	19,630	3,884	549	20,403	19,630	660	113	3,660	3,224	436
Indiana		23,244	8,303	14,581	360	9,040	8,303	737		14,204	13,844	360
Iowa		1,698	1,170	487	41	1,541	1,170	348	23	157	139	18
Kansas		1,513	1,238	177	98	1,251	1,238	13		262	164	98
Kentucky		13,310	3,959	9,054	297	4,437	3,959	469	9	8,873	8,585	288
Louisiana		3,456	1,766	1,449	241	1,797	1,766	31		1,659	1,418	241
Maine		7,470	2,878	4,544	48	3,054	2,878	176		4,416	4,368	48
Maryland		23,264	16,685	6,171	408	18,326	16,685	1,598	43	4,938	4,573	365
Massachusetts		33,463	16,327	15,369	1,767	18,364	16,327	1,921	116	15,099	13,448	1,651
Michigan		11,090	8,930	1,825	335	9,571	8,930	631	10	1,519	1,194	325
Minnesota		6,283	5,259	930	94	5,627	5,259	368		656	562	94
Mississippi		1,170	557	586	27	580	557	23		590	563	27
Missouri		5,214	2,558	2,304	352	2,793	2,558	228	7	2,421	2,076	345
Montana		2,268	567	1,678	23	744	567	177		1,524	1,501	23
Nebraska		756	650	91	15	650	650			106	91	15

Table 6.38a. Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by state or jurisdiction: Number, March 31, 2020 (continued)

	All	clients receiving r		isted		OTP	clients			Non-OTP client	•
State or jurisdiction1	Any MAT	opioid th	Buprenor-		Anv MAT	011	Buprenor-		Any MAT	Buprenor-	•
	type ²	Methadone	phine	Naltrexone	type ²	Methadone	phine	Naltrexone	type ³	phine	Naltrexone
Nevada	2,470	2,116	305	49	2,193	2,116	67	10	277	238	39
New Hampshire	6,078	2,295	3,035	748	2,408	2,295	113		3,670	2,922	748
New Jersey	13,280	10,841	1,833	606	11,585	10,841	703	41	1,695	1,130	565
New Mexico	5,590	3,485	1,726	379	3,645	3,485	160		1,945	1,566	379
New York	38,240	26,299	10,183	1,758	27,455	26,299	1,055	101	10,785	9,128	1,657
North Carolina	15,247	7,814	7,209	224	9,311	7,814	1,463	34	5,936	5,746	190
North Dakota	1,006	160	840	6	288	160	124	4	718	716	2
Ohio	29,257	7,007	20,824	1,426	13,767	7,007	6,445	315	15,490	14,379	1,111
Oklahoma	3,834	2,287	1,308	239	3,135	2,287	782	66	699	526	173
Oregon	8,748	5,825	2,745	178	6,769	5,825	939	5	1,979	1,806	173
Pennsylvania	21,310	13,630	5,814	1,866	15,425	13,630	1,536	259	5,885	4,278	1,607
Puerto Rico	3,271	2,818	450	3	2,818	2,818			453	450	3
Rhode Island	2,927	1,694	859	374	2,298	1,694	320	284	629	539	90
South Carolina	6,073	3,992	1,869	212	4,390	3,992	387	11	1,683	1,482	201
South Dakota	110		58	52					110	58	52
Tennessee	8,936	3,510	5,102	324	3,927	3,510	412	5	5,009	4,690	319
Texas	13,271	11,114	1,980	177	11,862	11,114	743	5	1,409	1,237	172
Utah	4,702	2,749	1,600	353	3,068	2,749	319	0	1,634	1,281	353
Vermont	4,000	2,285	1,677	38	2,926	2,285	639	2	1,074	1,038	36
Virginia	9,070	5,046	3,642	382	5,465	5,046	417	2	3,605	3,225	380
Washington	18,086	9,832	7,968	286	10,640	9,832	795	13	7,446	7,173	273
West Virginia	6,577	2,946	3,430	201	4,251	2,946	1,300	5	2,326	2,130	196
Wisconsin	9,711	5,115	3,336	1,260	5,369	5,115	241	13	4,342	3,095	1,247
Wyoming	556		529	27					556	529	27
Other jurisdictions ⁴											

⁻⁻ Quantity is zero.

MAT = medication assisted treatment.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Includes clients receiving methadone, buprenorphine, or naltrexone.

³ Includes clients receiving buprenorphine or naltrexone.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

Table 6.38b. Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and other facilities, by state or jurisdiction:

Column percent distribution, March 31, 2020

		All	clients receiving r opioid ti		isted		OTP (clients			Non-OTP clients	S
State or jurisdiction ¹	_	Any MAT type²	Methadone	Buprenor- phine	Naltrexone	Any MAT type²	Methadone	Buprenor- phine	Naltrexone	Any MAT type³	Buprenor- phine	Naltrexone
	Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Alabama		1.3	1.6	1.0	0.6	1.4	1.6	0.3		1.1	1.2	0.7
Alaska		0.2	0.1	0.4	0.2	0.1	0.1	*		0.4	0.5	0.3
Arizona		4.1	3.7	4.0	12.0	4.3	3.7	3.9	52.0	3.9	4.0	3.3
Arkansas		0.3	0.2	0.6	0.2	0.3	0.2	1.4	*	0.4	0.4	0.2
California		5.6	7.6	2.2	4.2	7.1	7.6	2.9	2.9	2.3	2.1	4.5
Colorado		1.0	1.2	0.6	1.1	1.1	1.2	1.1	0.8	0.6	0.5	1.1
Connecticut		2.6	3.6	1.0	1.8	3.4	3.6	1.9	0.4	1.0	0.9	2.1
Delaware		1.4	1.8	0.6	0.4	1.8	1.8	1.5	0.3	0.4	0.4	0.5
District of Columbia		0.2	0.3	0.1	*	0.3	0.3			0.1	0.1	*
Florida		4.5	5.6	2.5	4.3	5.3	5.6	2.3	4.4	2.7	2.6	4.3
Georgia		1.6	2.3	0.4	0.6	2.2	2.3	1.3		0.3	0.2	0.8
Hawaii		0.1	0.1	0.2		0.2	0.1	0.4		0.1	0.1	
Idaho		0.3	0.2	0.3	0.3	0.2	0.2	0.3		0.3	0.3	0.3
Illinois		4.7	6.3	2.2	2.6	5.9	6.3	2.1	3.0	2.3	2.2	2.5
Indiana		4.6	2.7	8.3	1.7	2.6	2.7	2.3		8.8	9.6	2.1
lowa		0.3	0.4	0.3	0.2	0.4	0.4	1.1	0.6	0.1	0.1	0.1
Kansas		0.3	0.4	0.1	0.5	0.4	0.4	*		0.2	0.1	0.6
Kentucky		2.6	1.3	5.1	1.4	1.3	1.3	1.5	0.2	5.5	5.9	1.6
Louisiana		0.7	0.6	0.8	1.1	0.5	0.6	0.1		1.0	1.0	1.4
Maine		1.5	0.9	2.6	0.2	0.9	0.9	0.6		2.7	3.0	0.3
Maryland		4.6	5.4	3.5	1.9	5.3	5.4	5.0	1.1	3.1	3.2	2.1
Massachusetts		6.6	5.2	8.7	8.3	5.3	5.2	6.0	3.0	9.3	9.3	9.4
Michigan		2.2	2.9	1.0	1.6	2.8	2.9	2.0	0.3	0.9	0.8	1.9
Minnesota		1.2	1.7	0.5	0.4	1.6	1.7	1.2		0.4	0.4	0.5
Mississippi		0.2	0.2	0.3	0.1	0.2	0.2	0.1		0.4	0.4	0.2
Missouri		1.0	0.8	1.3	1.7	0.8	0.8	0.7	0.2	1.5	1.4	2.0
Montana		0.4	0.2	1.0	0.1	0.2	0.2	0.6		0.9	1.0	0.1
Nebraska		0.1	0.2	0.1	0.1	0.2	0.2			0.1	0.1	0.1
Nevada		0.5	0.7	0.2	0.2	0.6	0.7	0.2	0.3	0.2	0.2	0.2
New Hampshire		1.2	0.7	1.7	3.5	0.7	0.7	0.4		2.3	2.0	4.3

Table 6.38b. Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs) and other facilities, by state or jurisdiction:

Column percent distribution, March 31, 2020 (continued)

	All	clients receiving n		isted		OTP (clients			Non-OTP clients	s
State or jurisdiction ¹	Any MAT type²	Methadone	Buprenor- phine	Naltrexone	Any MAT type²	Methadone	Buprenor- phine	Naltrexone	Any MAT type³	Buprenor- phine	Naltrexone
New Jersey	2.6	3.5	1.0	2.8	3.3	3.5	2.2	1.1	1.0	0.8	3.2
New Mexico	1.1	1.1	1.0	1.8	1.0	1.1	0.5		1.2	1.1	2.2
New York	7.5	8.4	5.8	8.2	7.9	8.4	3.3	2.6	6.7	6.3	9.5
North Carolina	3.0	2.5	4.1	1.1	2.7	2.5	4.6	0.9	3.7	4.0	1.1
North Dakota	0.2	0.1	0.5	*	0.1	0.1	0.4		0.4	0.5	*
Ohio	5.7	2.2	11.8	6.7	4.0	2.2	20.2	8.2	9.6	10.0	6.3
Oklahoma	0.8	0.7	0.7	1.1	0.9	0.7	2.5	1.7	0.4	0.4	1.0
Oregon	1.7	1.9	1.6	0.8	1.9	1.9	2.9	0.1	1.2	1.3	1.0
Pennsylvania	4.2	4.4	3.3	8.8	4.4	4.4	4.8	6.8	3.6	3.0	9.2
Puerto Rico	0.6	0.9	0.3		0.8	0.9			0.3	0.3	
Rhode Island	0.6	0.5	0.5	1.8	0.7	0.5	1.0	7.4	0.4	0.4	0.5
South Carolina	1.2	1.3	1.1	1.0	1.3	1.3	1.2		1.0	1.0	1.1
South Dakota	*		*	0.2					0.1	*	0.3
Tennessee	1.8	1.1	2.9	1.5	1.1	1.1	1.3		3.1	3.3	1.8
Texas	2.6	3.6	1.1	0.8	3.4	3.6	2.3	0.1	0.9	0.9	1.0
Utah	0.9	0.9	0.9	1.7	0.9	0.9	1.0		1.0	0.9	2.0
Vermont	0.8	0.7	1.0	0.2	0.8	0.7	2.0	0.1	0.7	0.7	0.2
Virginia	1.8	1.6	2.1	1.8	1.6	1.6	1.3	0.1	2.2	2.2	2.2
Washington	3.6	3.2	4.5	1.3	3.1	3.2	2.5	0.3	4.6	5.0	1.6
West Virginia	1.3	0.9	1.9	0.9	1.2	0.9	4.1	0.1	1.4	1.5	1.1
Wisconsin	1.9	1.6	1.9	5.9	1.5	1.6	0.8	0.3	2.7	2.1	7.1
Wyoming	0.1		0.3	0.1					0.3	0.4	0.2
Other jurisdictions ⁴											

⁻⁻ Quantity is zero; * Less than 0.05 percent.

MAT = medication assisted treatment.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Includes clients receiving methadone, buprenorphine, or naltrexone.

³ Includes clients receiving buprenorphine or naltrexone.

⁴ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States. NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility. Percentages may not sum to 100 percent due to rounding.

Table 6.39a. Clients under the age of 18 years in treatment, according to facility operation, by state or jurisdiction: Number, March 31, 2020

						Facility oper	ration				
				Local,				Federa	l govt.		
State or jurisdiction ¹	Total	Private non-profit	Private for-profit	county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Total	39,271	24,049	11,302	1,881	666	127		10	117		1,246
Alabama	171	124	47								
Alaska	161	86	5	3		13			13		54
Arizona	2,043	1,144	376			20			20		503
Arkansas	269	226	43								
California	2,287	1,358	563	353		4			4		9
Colorado	758	445	279		32	2			2		
Connecticut	395	335	20	40							
Delaware	7	5	2								
District of Columbia	22	22									
Florida	1,965	984	981								
Georgia	376	135	155	2	84						
Hawaii	494	490	4								
Idaho	163	17	83	57							6
Illinois	856	679	166	11							
Indiana	1,992	1,752	239	1							
Iowa	438	388	49								1
Kansas	267	214	47	6							
Kentucky	473	307	166								
Louisiana	392	125	149	40	78						
Maine	207	138	69								
Maryland	416	170	216	5	25						
Massachusetts	2,028	1,713	315								
Michigan	715	381	124	35							175
Minnesota	338	199	131								8
Mississippi	31	21	7	3							
Missouri	245	235	10								
Montana	297	184	101		2						10
Nebraska	780	484	243	5	14						34

Table 6.39a. Clients under the age of 18 years in treatment, according to facility operation, by state or jurisdiction: Number, March 31, 2020 (continued)

						Facility oper	ation				
				Local,				Federa	l govt.		
State or jurisdiction ¹	Total	Private non-profit	Private for-profit	county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Nevada	2,142	291	1,849								2
New Hampshire	107	78	29								
New Jersey	814	524	247	41	2						
New Mexico	1,292	1,063	90		10						129
New York	1,363	1,002	125	134							102
North Carolina	2,183	869	1,313		1						
North Dakota	158	18	4		130						6
Ohio	3,162	2,080	1,082								
Oklahoma	981	888	42	40							11
Oregon	841	622	19	121		70			70		9
Pennsylvania	906	581	325								
Puerto Rico	30	28	2								
Rhode Island	13	13									
South Carolina	823	403	50	190	180						
South Dakota	195	102	11			2			2		80
Tennessee	1,094	914	180								
Texas	1,216	581	512	97	26						
Utah	686	110	484	87							5
Vermont	24	24									
Virginia	364	96	32	203	23	10		10			
Washington	1,209	756	68	306		6			6		73
West Virginia	175	97	78								
Wisconsin	664	450	129	71							14
Wyoming	147	61	41	30							15
Other jurisdictions ²	96	37			59						

⁻⁻ Quantity is zero.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.39b. Clients under the age of 18 years in treatment, according to facility operation, by state or jurisdiction: Row percent distribution, March 31, 2020

						Facility	operation				
				Local,				Federa	al govt.		
State or jurisdiction ¹	Total	Private non-profit	Private for-profit	county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Total	100.0	61.2	28.8	4.8	1.7	0.3		*	0.3		3.2
Alabama	100.0	72.5	27.5								
Alaska	100.0	53.4	3.1	1.9		8.1			8.1		33.5
Arizona	100.0	56.0	18.4			1.0			1.0		24.6
Arkansas	100.0	84.0	16.0								
California	100.0	59.4	24.6	15.4		0.2			0.2		0.4
Colorado	100.0	58.7	36.8		4.2	0.3			0.3		
Connecticut	100.0	84.8	5.1	10.1							
Delaware	100.0	71.4	28.6								
District of Columbia	100.0	100.0									
Florida	100.0	50.1	49.9								
Georgia	100.0	35.9	41.2	0.5	22.3						
Hawaii	100.0	99.2	0.8								
Idaho	100.0	10.4	50.9	35.0							3.7
Illinois	100.0	79.3	19.4	1.3							
Indiana	100.0	88.0	12.0	0.1							
lowa	100.0	88.6	11.2								0.2
Kansas	100.0	80.1	17.6	2.2							
Kentucky	100.0	64.9	35.1								
Louisiana	100.0	31.9	38.0	10.2	19.9						
Maine	100.0	66.7	33.3								
Maryland	100.0	40.9	51.9	1.2	6.0						
Massachusetts	100.0	84.5	15.5								
Michigan	100.0	53.3	17.3	4.9							24.5
Minnesota	100.0	58.9	38.8								2.4
Mississippi	100.0	67.7	22.6	9.7							
Missouri	100.0	95.9	4.1								
Montana	100.0	62.0	34.0		0.7						3.4
Nebraska	100.0	62.1	31.2	0.6	1.8						4.4

Table 6.39b. Clients under the age of 18 years in treatment, according to facility operation, by state or jurisdiction: Row percent distribution, March 31, 2020 (continued)

						Facility	operation				
				Local.				Federa	al govt.		
State or jurisdiction ¹	Total	Private non-profit	Private for-profit	county, or community govt.	State govt.	Total federal govt.	Dept. of Veterans Affairs	Dept. of Defense	Indian Health Service	Other	Tribal govt.
Nevada	100.0	13.6	86.3								0.1
New Hampshire	100.0	72.9	27.1								
New Jersey	100.0	64.4	30.3	5.0	0.2						
New Mexico	100.0	82.3	7.0		0.8						10.0
New York	100.0	73.5	9.2	9.8							7.5
North Carolina	100.0	39.8	60.1		*						
North Dakota	100.0	11.4	2.5		82.3						3.8
Ohio	100.0	65.8	34.2								
Oklahoma	100.0	90.5	4.3	4.1							1.1
Oregon	100.0	74.0	2.3	14.4		8.3			8.3		1.1
Pennsylvania	100.0	64.1	35.9								
Puerto Rico	100.0	93.3	6.7								
Rhode Island	100.0	100.0									
South Carolina	100.0	49.0	6.1	23.1	21.9						
South Dakota	100.0	52.3	5.6			1.0			1.0		41.0
Tennessee	100.0	83.5	16.5								
Texas	100.0	47.8	42.1	8.0	2.1						
Utah	100.0	16.0	70.6	12.7							0.7
Vermont	100.0	100.0									
Virginia	100.0	26.4	8.8	55.8	6.3	2.7		2.7			
Washington	100.0	62.5	5.6	25.3		0.5			0.5		6.0
West Virginia	100.0	55.4	44.6								
Wisconsin	100.0	67.8	19.4	10.7							2.1
Wyoming	100.0	41.5	27.9	20.4							10.2
Other jurisdictions ²	100.0	38.5			61.5						

⁻⁻ Quantity is zero; * Less than 0.05 percent.

NOTE: Percentages may not sum to 100 percent because of rounding.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.40. Clients under the age of 18 years in treatment, according to type of care received, by state or jurisdiction:

Number and row percent distribution, March 31, 2020

_	Numbe	er of clients unde	er the age of 18	3 years	Row	percent distribu the age of		ınder
State or jurisdiction ¹		Тур	e of care receiv	red		Тур	e of care recei	ved
State of jurisdiction	Total	Outpatient	Residential (non- hospital)	Hospital inpatient	Total	Outpatient	Residential (non- hospital)	Hospital inpatient
Total	39,271	35,612	3,197	462	100.0	90.7	8.1	1.2
Alabama	171	163	8		100.0	95.3	4.7	
Alaska	161	125	36		100.0	77.6	22.4	
Arizona	2,043	1,880	120	43	100.0	92.0	5.9	2.1
Arkansas	269	247		22	100.0	91.8		8.2
California	2,287	2,143	137	7	100.0	93.7	6.0	0.3
Colorado	758	737	14	7	100.0	97.2	1.8	0.9
Connecticut	395	370	25		100.0	93.7	6.3	
Delaware	7	7			100.0	100.0		
District of Columbia	22	22			100.0	100.0		
Florida	1,965	1,240	705	20	100.0	63.1	35.9	1.0
Georgia	376	262	107	7	100.0	69.7	28.5	1.9
Hawaii	494	472	22		100.0	95.5	4.5	
ldaho	163	163			100.0	100.0		
Illinois	856	788	54	14	100.0	92.1	6.3	1.6
ndiana	1,992	1,925	67		100.0	96.6	3.4	
owa	438	343	95		100.0	78.3	21.7	
Kansas	267	260	7		100.0	97.4	2.6	
Kentucky	473	380	20	73	100.0	80.3	4.2	15.4
Louisiana	392	356	36		100.0	90.8	9.2	
Maine	207	167	40		100.0	80.7	19.3	
Maryland	416	416			100.0	100.0		
Massachusetts	2,028	2,018	10		100.0	99.5	0.5	
Michigan	715	678	37		100.0	94.8	5.2	
Minnesota	338	273	65		100.0	80.8	19.2	
Mississippi	31	26		5	100.0	83.9		16.1
Missouri	245	163	74	8	100.0	66.5	30.2	3.3
Montana	297	264	33		100.0	88.9	11.1	
Nebraska	780	750	30		100.0	96.2	3.8	

Table 6.40. Clients under the age of 18 years in treatment, according to type of care received, by state or jurisdiction:

Number and row percent distribution, March 31, 2020 (continued)

_	Numbe	er of clients unde	er the age of 18	3 years	Row	percent distribu the age of		under
State or jurisdiction ¹		Тур	e of care receiv	⁄ed		Тур	e of care recei	ved
State of jurisdiction	Total	Outpatient	Residential (non- hospital)	Hospital inpatient	Total	Outpatient	Residential (non- hospital)	Hospital inpatient
Nevada	2,142	2,126		16	100.0	99.3		0.7
New Hampshire	107	85		22	100.0	79.4		20.6
New Jersey	814	793	21		100.0	97.4	2.6	
New Mexico	1,292	1,232	60		100.0	95.4	4.6	
New York	1,363	1,322	41		100.0	97.0	3.0	
North Carolina	2,183	2,145	26	12	100.0	98.3	1.2	0.5
North Dakota	158	149	9		100.0	94.3	5.7	
Ohio	3,162	3,089	73		100.0	97.7	2.3	
Oklahoma	981	880	101		100.0	89.7	10.3	
Oregon	841	730	111		100.0	86.8	13.2	
Pennsylvania	906	838	68		100.0	92.5	7.5	
Puerto Rico	30	4	26		100.0	13.3	86.7	
Rhode Island	13	13			100.0	100.0		
South Carolina	823	762	7	54	100.0	92.6	0.9	6.6
South Dakota	195	175	6	14	100.0	89.7	3.1	7.2
Tennessee	1,094	966	128		100.0	88.3	11.7	
Texas	1,216	943	191	82	100.0	77.5	15.7	6.7
Utah	686	281	381	24	100.0	41.0	55.5	3.5
Vermont	24	24			100.0	100.0		
Virginia	364	359		5	100.0	98.6		1.4
Washington	1,209	1,135	74		100.0	93.9	6.1	
West Virginia	175	89	86		100.0	50.9	49.1	
Wisconsin	664	644	7	13	100.0	97.0	1.1	2.0
Wyoming	147	98	35	14	100.0	66.7	23.8	9.5
Other jurisdictions ²	96	92	4		100.0	95.8	4.2	

⁻⁻ Quantity is zero; * Less than 0.05 percent.

NOTE: Percentages may not sum to 100 percent because of rounding.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.41. Clients in treatment aged 18 years and older, according to substance abuse problem, by state or jurisdiction: Number and clients per 100,000 population aged 18 years and older, March 31, 2020

		Clients pe	er 100,000 population	n aged 18 years	and older	Clients p	Clients per 100,000 population aged 18 years and older							
State or jurisdiction ¹			Substan	nce abuse probl	lem		Substar	nce abuse prob	lem					
		Total ²	Both alcohol and drug abuse	Drug abuse only	Alcohol abuse only	Total	Both alcohol and drug abuse	Drug abuse only	Alcohol abuse only					
	Total	1,012,226	315,929	556,676	139,622	390	122	214	54					
Alabama		11,950	3,257	7,753	940	312	85	202	25					
Alaska		3,052	894	1,489	669	552	162	270	121					
Arizona		44,054	11,927	25,299	6,829	763	207	438	118					
Arkansas		4,095	1,422	2,171	502	176	61	93	22					
California		66,998	21,889	33,296	11,813	219	72	109	39					
Colorado		28,812	9,998	9,291	9,523	632	219	204	209					
Connecticut		22,838	7,190	12,231	3,417	805	253	431	120					
Delaware		12,792	3,760	7,930	1,102	1,635	481	1,014	141					
District of Columbia		1,679	266	1,176	237	288	46	202	41					
Florida		43,150	11,706	27,138	4,306	247	67	155	25					
Georgia		17,200	3,968	11,079	2,153	209	48	135	26					
Hawaii		2,860	744	1,749	367	257	67	157	33					
Idaho		3,627	1,307	1,980	340	264	95	144	25					
Illinois		32,401	8,997	18,112	5,292	330	92	185	54					
Indiana		41,328	9,049	28,106	4,174	797	174	542	80					
lowa		7,567	2,871	3,276	1,421	310	118	134	58					
Kansas		6,088	2,388	2,652	1,048	275	108	120	47					
Kentucky		25,826	7,887	15,801	2,138	743	227	455	62					
Louisiana		6,335	2,037	3,357	942	178	57	94	26					
Maine		10,060	1,855	7,401	803	913	168	672	73					
Maryland		34,406	6,348	25,021	3,037	729	134	530	64					
Massachusetts		45,166	12,796	27,324	5,046	814	230	492	91					
Michigan		26,412	9,378	12,526	4,509	337	120	160	58					
Minnesota		15,452	5,425	7,666	2,361	355	125	176	54					
Mississippi		3,975	1,695	1,964	316	175	75	86	14					
Missouri		11,964	4,348	6,357	1,259	250	91	133	26					
Montana		4,670	1,483	2,636	551	549	174	310	65					
Nebraska		2,774	1,059	1,217	498	190	72	83	34					
Nevada		9,431	4,588	3,512	1,332	386	188	144	55					
New Hampshire		9,401	3,700	4,922	778	845	332	442	70					

Table 6.41. Clients in treatment aged 18 years and older, according to substance abuse problem, by state or jurisdiction: Number and clients per 100,000 population aged 18 years and older, March 31, 2020 (continued)

	Clients pe	er 100,000 populatior	aged 18 years	and older	Clients p	Clients per 100,000 population aged 18 years and older							
State or jurisdiction ¹	'	Substar	ice abuse probl	em		Substar	nce abuse probl	lem					
	Total²	Both alcohol and drug abuse	Drug abuse only	Alcohol abuse only	Total	Both alcohol and drug abuse	Drug abuse only	Alcohol abuse only					
New Jersey	24,606	7,907	13,892	2,807	354	114	200	40					
New Mexico	13,788	5,422	5,705	2,660	844	332	349	163					
New York	75,515	30,808	34,367	10,340	492	201	224	67					
North Carolina	32,935	11,979	16,963	3,993	397	144	205	48					
North Dakota	2,280	706	1,198	375	391	121	205	64					
Ohio	60,522	21,086	32,105	7,331	663	231	352	80					
Oklahoma	15,084	3,930	7,873	3,280	498	130	260	108					
Oregon	19,608	6,199	9,644	3,765	580	183	285	111					
Pennsylvania	43,715	14,253	24,242	5,219	430	140	239	51					
Puerto Rico	5,904	1,372	4,128	405	226	52	158	15					
Rhode Island	4,209	2,005	1,605	599	492	234	188	70					
South Carolina	13,069	4,120	7,379	1,570	319	100	180	38					
South Dakota	2,176	1,344	280	552	323	199	41	82					
Tennessee	17,345	4,261	11,387	1,697	323	79	212	32					
Texas	24,097	5,566	14,733	3,798	110	25	67	17					
Utah	12,532	3,938	6,864	1,730	540	170	296	75					
Vermont	7,074	1,792	4,037	1,245	1,387	351	791	244					
Virginia	17,924	5,942	9,301	2,681	267	88	138	40					
Washington	30,802	8,737	18,159	3,905	511	145	301	65					
West Virginia	10,723	2,325	7,585	813	751	163	531	57					
Wisconsin	18,243	6,552	9,682	2,009	399	143	212	44					
Wyoming	3,655	1,441	1,081	1,133	814	321	241	252					
Other jurisdictions ³	57	11	33	14	18	3	10	4					

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

NOTE: Number of clients may not sum to total because of rounding.

SOURCES: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020. Population: U.S. Census Bureau, Population Estimates Program, SC-EST2020-18+POP-RES: "Estimates of the Total Resident Population and Resident Population Age 18 Years and Older for the United States, Regions, States, the District of Columbia, and Puerto Rico: July 1, 2020," https://www2.census.gov/programs-surveys/popest/tables/2010-2020/national/asrh/sc-est2020-18+pop-res.xlsx; U.S. Census Bureau, International Programs, International Data Base. Last Updated: December 2020. https://www.census.gov/programs-surveys/international-programs/data/tools/international-data-base.html.

² Of the 1,090,357 total clients, 39,271 were excluded from this tabulation, because they were under the age of 18 years. Also excluded are 38,860 clients in facilities that did not respond to the question about client substance problem treated. The categories for exclusion are not mutually exclusive.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

Table 6.42. Clients receiving medication-assisted opioid therapy provided at facilities with opioid treatment programs (OTPs), by state or jurisdiction: Clients per 100,000 population, March 31, 2020

		Clients pe	r 100,000	population				Clients	per 100,000) population	
			OTP	clients					OTP	clients	
State or jurisdiction ¹	Total	Any MAT Metha- Bupren- Naltrex- otal type ² done orphine one		State or jurisdiction¹	Total	Any MAT type ²	Metha- done	Bupren- orphine	Naltrex- one		
Total	115	104	94	10	1						
Alabama	106	101	99	2		Nebraska	34	34	34		
Alaska	83	44	43	†		Nevada	71	70	67	2	†
Arizona	247	199	156	17	27	New Hampshire	176	176	168	8	
Arkansas	46	35	21	15	†	New Jersey	136	130	122	8	†
California	65	62	60	2	†	New Mexico	174	173	165	8	
Colorado	74	69	62	6	†	New York	157	142	136	5	†
Connecticut	351	329	312	17	†	North Carolina	101	88	74	14	†
Delaware	1,162	634	583	50	1	North Dakota	40	38	21	16	†
District of Columbia	129	129	129			Ohio	144	118	60	55	3
Florida	90	85	81	3	†	Oklahoma	85	79	57	20	2
Georgia	74	72	68	4		Oregon	164	160	137	22	†
Hawaii	38	38	29	9		Pennsylvania	147	121	107	12	2
Idaho	42	42	38	4		Puerto Rico	89	89	89		
Illinois	175	162	156	5	†	Rhode Island	315	217	160	30	27
Indiana	138	134	123	11		South Carolina	94	84	77	7	†
Iowa	83	49	37	11	†	South Dakota					
Kansas	43	43	42			Tennessee	58	57	51	6	†
Kentucky	102	99	88	10	†	Texas	45	40	38	3	†
Louisiana	59	39	38	†		Utah	95	94	85	10	
Maine	226	226	213	13		Vermont	469	469	367	103	†
Maryland	320	303	276	26	†	Virginia	73	64	59	5	†
Massachusetts	271	266	237	28	2	Washington	142	138	128	10	†
Michigan	102	96	90	6	†	West Virginia	239	238	165	73	†
Minnesota	101	99	93	7		Wisconsin	92	92	88	4	†
Mississippi	20	20	19	†		Wyoming	‡	‡	‡	‡	‡
Missouri	45	45	42	4	†	Other jurisdictions ³	‡	‡	‡	‡	‡
Montana	69	69	52	16							

⁻⁻ Quantity is zero; ‡ No facilities in this category; † Less than 1 per 100,000 population.

MAT = medication assisted treatment.

NOTES: Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment. Buprenorphine may be prescribed by medical practitioners who have received DATA 2000-specific training and received a waiver to prescribe the medication for treatment of opioid use disorder. Naltrexone may be prescribed by any medical practitioner with prescribing privileges. This report does not include clients who received or were prescribed buprenorphine through an independent DATA 2000-waivered medical practitioner or naltrexone through an independent practitioner not affiliated with a substance abuse treatment facility.

SOURCES: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020. Population: U.S. Census Bureau, Population Estimates Program, SC-EST2020-18+POP-RES: "Estimates of the Total Resident Population and Resident Population Age 18 Years and Older for the United States, Regions, States, the District of Columbia, and Puerto Rico: July 1, 2020," https://www2.census.gov/programs-surveys/popest/tables/2010-2020/national/asrh/sc-est2020-18+popres.xlsx; U.S. Census Bureau, International Programs, International Data Base. Last Updated: December 2020. https://www.census.gov/programs-surveys/international-programs/data/tools/international-data-base.html.

¹ Facilities operated by federal agencies are included in the states in which the facilities are located.

² Includes clients receiving methadone, buprenorphine, or naltrexone.

³ Other jurisdictions include Guam, the Federated States of Micronesia, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, and the Virgin Islands of the United States.

APPENDIX A N-SSATS BACKGROUND

Survey History

N-SSATS has evolved from national survey efforts begun in the 1970s by the National Institute on Drug Abuse (NIDA) to measure the scope and use of drug abuse treatment services in the United States. The sixth of these surveys, conducted in 1976, introduced the data elements and format that have formed the core of subsequent surveys. These include organizational focus, service orientation, services available, clients in treatment by type of care, and hospital inpatient/residential capacity. The 1976 survey, called the National Drug Abuse Treatment Utilization Survey, was repeated in 1977 and 1978.

In 1979, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) became a cosponsor of the survey, alcoholism treatment facilities were added, and the study was renamed the National Drug and Alcoholism Treatment Utilization Survey. This survey was repeated in 1980 and 1982. In 1984, a one-page version called the National Alcoholism and Drug Abuse Program Inventory was used. In 1987, the full version of the survey was reinstated and renamed the National Drug and Alcoholism Treatment Unit Survey (NDATUS). NDATUS was conducted annually from 1989 to 1993.

In 1992, with the creation of SAMHSA, responsibility for conducting the survey shifted to SAMHSA's Office of Applied Studies (now the Center for Behavioral Health Statistics and Quality). The survey was redesigned, and it was conducted annually as the Uniform Facility Data Set (UFDS) survey from 1995 to 1998. During these years, the survey was conducted by mail with telephone follow-up of non-respondents. The 1999 survey year was a transition year during which the survey was redesigned and an abbreviated telephone survey of treatment facilities was conducted. In 2000, a redesigned full mail survey was reinstated with telephone follow-up; it was renamed the National Survey of Substance Abuse Treatment Services (N-SSATS). The reference date for the annual survey had always been the end of September or beginning of October. After the 2000 survey, the reference date was changed to the end of March, and no survey was conducted during 2001.

In 2000, the use of an Internet-based questionnaire was tested; beginning in 2002, all facilities were offered the opportunity to respond via the Internet.

Since 2013, the full N-SSATS questionnaire (with client counts) has alternated with an abbreviated version of the questionnaire. The full questionnaire, fielded in odd-numbered years, collects data on programs and clients; in alternate (even-numbered) years, an abbreviated N-SSATS questionnaire collects the program information needed to update the substance abuse section of the Behavioral Health Treatment Services Locator and collects information on other facility-related topics.

N-SSATS in the Context of the Behavioral Health Services Information System (BHSIS)

N-SSATS is one of the components of SAMHSA's Behavioral Health Services Information System (BHSIS). The core of BHSIS is the Inventory of Behavioral Health Services (I-BHS), a continuously

updated, comprehensive listing of all known substance abuse treatment facilities and mental health treatment facilities. The other substance abuse component of BHSIS is the Treatment Episode Data Set (TEDS), a client-level database of admissions to and discharges from substance abuse treatment. Together, the components provide national- and state-level information on the numbers and characteristics of individuals admitted to alcohol and drug treatment programs and describe the facilities that deliver care to those individuals.

I-BHS is the list frame for N-SSATS. Facilities in I-BHS fall into two general categories and are distinguished by the relationship of the facility to its state substance abuse agency. These categories are described below.

Treatment facilities approved by state substance abuse agencies

The largest group of facilities (16,856 in 2020) includes facilities that are licensed, certified, or otherwise approved by the state substance abuse agency to provide substance abuse treatment. State BHSIS representatives maintain this segment of I-BHS by reporting new facilities, closures, and address changes to SAMHSA. Some facilities are not licensed, certified, or otherwise approved by the state agency. Some private for-profit facilities fall into this category. The approved facility group also includes programs operated by federal agencies—the Department of Veterans Affairs (VA), the Department of Defense, the Indian Health Service—and opioid treatment programs certified by SAMHSA. I-BHS records for federally operated facilities are updated annually through lists provided by these agencies.

Treatment facilities not approved by state substance abuse agencies

This group of facilities (3,070 in 2020) represents the SAMHSA effort since the mid-1990s to make I-BHS as comprehensive as possible by including treatment facilities that state substance abuse agencies, for a variety of reasons, do not fund, license, or certify. Many of these facilities are private for-profit, small group practices, or hospital-based programs. Most of them are identified through periodic screening of alternative source databases. (See *Special efforts to improve survey coverage*.) State substance abuse agencies are given the opportunity to review these facilities and to add them to the state agency-approved list, if appropriate.

Survey Coverage

The use of I-BHS as the list frame for N-SSATS imposes certain constraints related to the unit of response and the scope of facilities included. In addition, the expansion of I-BHS in recent years to provide a more complete enumeration of substance abuse treatment facilities means that year-to-year comparisons of the numbers of facilities reporting to N-SSATS must be interpreted with caution.

Unit of response

N-SSATS is designed to collect data from each physical location where treatment services are provided. Accordingly, SAMHSA requests that state substance abuse agencies use the point of delivery of service (i.e., physical location) as the defining factor for a facility. Because of the different state administrative systems, however, there are some inconsistencies in implementation. For example, in some states, multiple treatment programs (e.g., detoxification, residential, and outpatient) at the same address and under the same management have separate state licenses. These

are treated as separate by the state substance abuse agency, and are given separate I-BHS ID numbers. In other states, multiple sites are included as a single entity under a parent or administrative unit. In many of these cases, individual sites can report services data in N-SSATS, but client data are available only at a higher administrative level. Beginning in 1995, efforts have been made to identify facility networks and to eliminate duplicate reporting by networks. For most facilities, reporting levels remain consistent from year to year. However, beginning in 1998, an emphasis was placed on collecting minimum information from all physical locations, and this resulted in an increase in the number of facilities.

Special efforts to improve survey coverage

The great majority of treatment facilities in I-BHS are administratively monitored by state substance abuse agencies. Therefore, the scope of facilities included in I-BHS is affected by differences in state systems of licensure, certification, accreditation, and the disbursement of public funds. For example, some state substance abuse agencies regulate private facilities and individual practitioners while others do not. In some states, hospital-based substance abuse treatment facilities are not licensed through the state substance abuse agency.

To address these differences, SAMHSA conducted a large-scale effort during 1995 and 1996 to identify substance abuse treatment facilities that, for a variety of reasons, were not on the inventory. About 15 source lists were examined, and facilities not on the inventory were contacted to ascertain whether or not they provided substance abuse treatment. As expected, this yielded a number of hospital-based and small private facilities that were not on the inventory. (These facilities were surveyed in 1995 and 1996, but they were not included in the published results of the survey until 1997.) Analysis of the results of this effort led to similar but more targeted updates before subsequent surveys. Potential new facilities are identified using data from infoUSA (formerly the American Business Index), the annual American Hospital Association survey, and SAMHSA's National Mental Health Services Survey, the source lists that yielded the most new facilities in 1995 and 1996. Survey participants, who are asked to report all of the treatment facilities in their administrative networks, also identify additional facilities during the survey itself. All newly identified facilities are initially included as not approved by the state substance abuse agency. State substance abuse agencies are given the opportunity to review these facilities and to add them to the state agency-approved list, if appropriate.

Expansion of survey coverage to include all sites within networks at which treatment was provided yielded a net increase of about 2,600 facilities between 1997 and 1998. These additions were not necessarily new facilities, but were facilities not previously included in the survey as separate sites. Between 2010 and 2020, the number of facilities eligible for inclusion in this report varied between 13,339 and 16,066. The total number is deceptive, however. There was significant turnover as facilities closed and others opened (see Table 2.1).

Data collection

Until 1996, state substance abuse agencies distributed and collected the facility survey forms. Beginning in 1996, data collection was centralized; since that time, SAMHSA has mailed survey forms directly to and collected forms directly from the facilities and has conducted follow-up telephone interviews with the facility director or his/her designee. In 2000, SAMHSA introduced

an online trial web version of the questionnaire for a few facilities in addition to the hard copy questionnaire. The web version of the questionnaire was fully implemented in 2002. The proportion of facilities using the web survey to respond to N-SSATS has increased steadily since its full inception in 2002.

Non-response

Beginning in 1992, SAMHSA expanded efforts to obtain information from non-responding facilities. A representative sample of non-respondents was contacted and administered an abbreviated version of the survey instrument via telephone. In 1993 and later years, this effort was extended to all non-responding facilities. In 1997, a series of measures was introduced to enhance the survey response rate. These included advance notification and improved methods for updating address and contact information. Between 2004 and 2019, use of these methods and intensive telephone follow-up resulted in an annual follow-up rate (i.e., facilities in the sample either completed the survey or were determined to be closed or otherwise ineligible) of 92 to 96 percent. In 2020, the final response rate, counting eligible facilities, was 90 percent.

Exclusions

In 1997, facilities offering only DUI/DWI programs were excluded; these facilities were reinstated in 1998.

Facilities operated by the Bureau of Prisons (BOP) were excluded from the 1997 survey and subsequent surveys because SAMHSA conducted a separate survey of correctional facilities.²⁴ During that survey, it was discovered that jails, prisons, and other organizations treating incarcerated persons only were poorly enumerated on the inventory. Beginning in 1999, these facilities were identified during the survey and excluded from analyses and public use data files.

I-BHS and N-SSATS are designed to include specialty substance abuse treatment facilities rather than individuals. Solo practitioners are listed on I-BHS and surveyed in N-SSATS only if the state substance abuse agency explicitly requests that they be included.

Beginning in 2000, halfway houses that did not provide substance abuse treatment were included on the inventory and in N-SSATS so that they could be listed in the *National Directory of Drug and Alcohol Abuse Treatment Facilities* (formerly the *National Directory of Drug and Alcohol Abuse Treatment Programs*) and on the Behavioral Health Treatment Services Locator (https://findtreatment.samhsa.gov). These facilities are excluded from analyses and public use data files.

Changes in Survey Content

Table A1 shows the major content areas for the survey from 1998 to 2020. Since 1992, SAMHSA has made adjustments each year to the survey design, both to minimize non-response and to include areas of emerging interest. For example, questions on the number of clients in treatment receiving buprenorphine were added in 2004. Questions about clinical/therapeutic methods, standard practices,

SAMHSA, Office of Applied Studies. Substance Abuse Treatment in Adult and Juvenile Correctional Facilities: Findings from the Uniform Facility Data Set 1997 Survey of Correctional Facilities. Drug and Alcohol Services Information System Series: S-9. DHHS Publication No. (SMA) 00-3380. Rockville, MD, 2000.

and Access to Recovery grants were added in 2007. Questions about facility smoking policy were added in 2011; questions about outpatient facility operating capacity were modified in 2012; questions about injectable naltrexone (Vivitrol®) as a pharmacotherapy were added in 2011; questions about work activity and means to accomplish them, as well as the question asking for client counts of those prescribed extended-release injectable naltrexone (Vivitrol®), were added in 2013; and in 2017, the questions asking for client counts of those prescribed Vivitrol® were changed to request client counts of those receiving naltrexone for opioid use disorder.

There have also been changes within content areas. For example, in response to concerns about over-reporting of programs or groups for specific client types, the survey question was revised in 2003 to distinguish between those facilities that accepted specific client types and those facilities that offered specially designed programs or groups for that client type. As a result, the number and proportion of facilities offering programs or groups for each of the specified client types decreased. Surveys from 2003 and later are believed to more accurately represent the number and proportions of facilities providing programs or groups for the specified client types. In addition, over time, more categories have been added to the specific client types (e.g., persons who have experienced trauma, active duty military, and members of military families in 2012 and young adults, persons who have experienced sexual abuse, and persons who have experienced intimate partner violence, domestic violence in 2013). Because of the increase in client types, the question was split in 2013. The portion asking if specific client types were served was limited to adolescents, adult women, and adult men. In addition, programs or groups were described as "specifically tailored." In 2014, the first part of the question was revised again to collect another level of detail (i.e., the age range of males and females served, if any). The client types of adolescents, adult women, and adult men were added back to the second part of the question.

From 2013 to 2019, the full N-SSATS questionnaire (with client counts) has alternated with an abbreviated version of the questionnaire, with the abbreviated version being fielded in even years; in 2020, unlike previous even years, the full questionnaire was fielded. The reason for adding the client counts in the 2020 N-SSATS was SAMHSA's interest in measuring the effect of the COVID-19 pandemic on the provision of treatment services. The abbreviated questionnaire, first introduced in 2014, collects the facility, program, and services information that are needed to update the Behavioral Health Treatment Services Locator. It omits Section B, which includes the client counts. Other changes to the 2014 questionnaire included reinstatement of the "primary focus" question, which had been dropped from the 2013 questionnaire; in addition, the question asking if a facility operates an opioid treatment program (OTP) was revised: The informational bullets describing OTPs were reworded, and the response categories were more explicit about whether or not the facility operates an OTP, as well as whether or not methadone and/or buprenorphine are used. In 2015, the OTP question was again revised to ask facilities how they treat opioid addiction; the response categories were even more specific about how they used, or did not use, methadone, buprenorphine, or extended-release injectable naltrexone (Vivitrol®) and whether or not the facility was a federally certified OTP. In 2017, reference to Vivitrol® was deleted, and the question referred simply to naltrexone. In 2019, the question regarding services offered was revised by including three new categories (medical services, recovery support services, and education and counseling services), regrouping items from previous iterations of the survey, and adding new response options. The 2019 questionnaire also introduced new questions about the sources of medication-assisted therapy (MAT) for opioid use disorder (OUD), as well as the estimated percentages of clients receiving

these medication services. Section B of the 2019 survey was further enhanced with questions about the number of clients who received specific medications for alcohol use disorder (AUD) in each service setting. Beginning in 2019, an addendum to the questionnaire was also sent to VA facilities for purposes of collecting information about suicide prevention-related services offered.

Changes in the 2020 survey

In 2020, the question regarding the medications for OUD that clients on MAT received was removed. Additionally, the 2020 questionnaire introduced a new question to better understand if the reporting facility is a part of a larger organization with multiple sites or facilities.

Table A1. Survey contents: 1998–2020

Sun roy suportion						2004–		2007–	2009–										
Survey question	1998	1999	2000	2002	2003	2005	2006	2008	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Facility information																			
Location and contact information	Χ	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Operating entity (ownership)	Х	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Halfway house	X	X	X	X	X	X	X	X	X	X	X	X	Х	X	X	X	X	X	X
Hospital and type	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Managed care agreements or contracts	Х	X	X	X	X	X	X	X	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Hotline	X	X	X	X	X	X	X	X	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Public funding earmarked for																			
substance abuse treatment	Χ	Χ	Χ	Χ	Χ	Χ	X	Χ	Χ	X	Χ	Χ	Χ	Χ	Χ	Χ	Χ	X	X
Solo practice	X	n/a	X	Х	X	Х	Х	X	Х	Х	X	Х	Х	X	Х	X	X	X	Х
Licensure/certification of facility	n/a	X	X	Х	X	Х	X	Х	X	Х	X	Х	X	X	X	X	X	X	X
Primary focus	n/a	Х	X	Х	Х	Х	Х	Х	Х	Х	X	n/a	Х	Х	X	Х	Х	X	Х
Types of payment accepted	n/a	X	X	Х	Х	Х	Х	Х	Х	Х	X	X	Х	Х	X	Х	Х	Х	Х
Sliding fee scale	n/a	X	X	Х	Х	Х	Х	Х	Х	Х	X	Х	Х	Х	X	Х	Х	Х	Х
Website	n/a	Х	X	Х	Х	Х	Х	Х	Х	Х	X	Х	Х	Х	X	Х	n/a	n/a	n/a
Religious affiliation	n/a	n/a	n/a	Х	X	Х	Х	X	Х	Х	Х	Х	X	Х	n/a	n/a	n/a	n/a	n/a
Treatment at no charge	n/a	X	n/a	n/a	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Internet access	n/a	n/a	n/a	X	X	Х	n/a	n/a	n/a	Х	Х	Х	n/a	Х	X	Х	X	n/a	n/a
Parent/subsidiary relationship	X	n/a	X	Х	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Any payment assistance	n/a	n/a	X	Х	n/a	n/a	n/a	X	X	X	X	X	X	X	X	X	X	X	X
Staff/counselor credentials	n/a	X	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Organizational setting	X	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Revenue	X	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Work activity methods	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	X	n/a	X	n/a	X	n/a	n/a	n/a
One-day census																			
No. of clients by type of care	X	n/a	Х	X	X	Х	Х	X	Х	Х	Х	Х	n/a	Х	X	X	n/a	X	X
No. of clients receiving methadone	X	n/a	X	X	X	X	X	X	X	X	X	X	n/a	X	X	X	n/a	X	X
No. of clients receiving buprenorphine	n/a	n/a	n/a	n/a	n/a	X	X	X	X	X	X	X	n/a	X	X	X	n/a	X	X
No. of clients receiving injectable																			
naltrexone ¹	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	X	n/a	X	X	n/a	n/a	n/a	n/a
No. of clients receiving naltrexone	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	X	n/a	X	Х
No. of clients receiving LAAM	X	n/a	X	X	X	n/a	n/a	n/a	n/a	n/a	X	X	n/a	n/a	n/a	n/a	n/a	n/a	n/a
No. of beds designated for substance	,,	a	,,	,,	,,	,,, u	a				,,		,,, u	a	a		a	a	
abuse treatment	n/a	n/a	X	X	X	Х	Х	X	X	Х	X	Х	n/a	Х	n/a	X	n/a	X	X
Outpatient facility operating capacity	n/a	n/a	Х	Х	Χ	Х	Х	Χ	Х	Х	Χ	Х	n/a	Х	n/a	Χ	n/a	n/a	n/a
No. of clients under age 18 years	n/a	n/a	X	X	X	X	X	X	X	X	X	X	n/a	X	n/a	X	n/a	X	X
Client demographics	X	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Client types	X	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a

Table A1. Survey contents: 1998–2020 (continued)

						2004–		2007-	2009–										
Survey question	1998	1999	2000	2002	2003	2005	2006	2008	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Program and services information																			
Types of care provided (independent of client counts)	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	X
Special programs or groups for specific client types	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Services offered	Х	n/a	Х	Х	X	Х	Х	X	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Opioid maintenance or detoxification program	n/a	Х	X	Х	Х	X	Х	Х	Х	Х	X	Х	Х	Х	Х	Х	X	Х	Х
Languages other than English Details of languages other than English	n/a n/a	n/a n/a	X	X X	X X	X X	X	X X	X X	X X	X X	X X	X X	X	X X	X X	X X	X X	X
Opioid program type	n/a n/a	n/a n/a	X n/a	X	X	X	X X	X	X	X	X	X	X	X X	X	X	X	X	X X
Services provided in sign language	n/a	n/a	n/a	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Language provider	n/a	n/a	n/a	n/a	n/a	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Clinical/therapeutic approaches	n/a	X	X	X	X	X	X	X	X	X	X	X	Х						
Standard practices	n/a	X	X	X	X	X	n/a	X	n/a	X	X	X	Х						
Detoxification from specific substances and use of medication	n/a	Х	Х	Х	Х	Х	n/a	X	n/a	Х	Х	Х	Х						
Waiting list	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a						
Facility smoking policy	n/a	n/a	n/a	X	X	X	n/a	X	X	X	X	X	X						
Other client counts																			
Annual admissions Percent of clients by substance abuse	Х	n/a	Χ	Х	Х	Х	Х	Х	Χ	Х	Х	Х	n/a	Χ	n/a	Х	n/a	Х	Х
problem treated	Χ	n/a	X	X	X	X	X	X	X	X	X	X	n/a	X	n/a	Χ	n/a	X	Χ
Annual admissions funded by ATR	n/a	X	X	X	X	X	n/a	X	n/a	X	n/a	n/a	n/a						
Percent of clients with co-occurring substance use and mental																			
disorders	n/a	X	X	X	X	X	n/a	Х	n/a	X	n/a	X	Χ						
Percent of clients by counseling type Annual unduplicated client count	n/a X	n/a n/a	n/a n/a	n/a n/a	n/a n/a	n/a n/a	n/a n/a	X n/a	X n/a	X n/a	X n/a	X n/a	n/a n/a	X n/a	X n/a	X n/a	X n/a	n/a n/a	n/a n/a

n/a Not applicable.

NOTES: An "X" indicates the presence of a feature in the given survey years. The years 2004–2005, 2007–2008, and 2009–2010 are grouped together, because the survey features for those years that are combined were identical.

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Uniform Facility Data Set (UFDS), 1998–1999; National Survey of Substance Abuse Treatment Services (N-SSATS), 2000, 2002–2020.

ATR = Access to Recovery; LAAM = levo-alpha acetyl methadol.

¹ Injectable naltrexone = extended-release injectable naltrexone.

APPENDIX B 2020 N-SSATS QUESTIONNAIRE

This appendix contains the hard copy version of the 2020 N-SSATS questionnaire. Facilities also had the option of responding to the questionnaire on the Internet. For those facilities that had not completed the survey after extensive follow-up efforts (see Chapter 1), the questionnaire was administered by computer-assisted telephone interview (CATI).

Of the responding eligible treatment facilities included in this report, 95 percent completed the questionnaire on the Internet, 4 percent completed it by CATI, and 1 percent completed it by mail [Table 1.1 and Figure 1].

Text versions of the Internet and CATI surveys are not included here because they are computer programs that contain complex skip patterns, are difficult to read, and are extremely long in text format.

OMB No. 0930-0106

APPROVAL EXPIRES: 09/30/2020
See OMB burden statement on last page

National Survey of Substance Abuse Treatment Services (N-SSATS)

March 31, 2020

Substance Abuse and Mental Health Services Administration (SAMHSA)

U.S. Department of Health and Human Services (HHS)

PLEASE REVIEW THE FACILITY INFORMATION PRINTED ABOVE. CROSS OUT ERRORS AND ENTER CORRECT OR MISSING INFORMATION.

CHECK ONE

- Information is complete and correct, no changes needed
- All missing or incorrect information has been corrected

PLEASE READ THIS ENTIRE PAGE BEFORE COMPLETING THE QUESTIONNAIRE

<u>Would you prefer to complete this questionnaire online</u>? See the pink flyer enclosed in your survey packet for the Internet address and your unique user ID and password. You can log on and off the website as often as needed to complete the questionnaire. When you log on again, the program will take you to the next unanswered question. If you need more information, call the N-SSATS helpline at 1-888-324-8337.

INSTRUCTIONS

- Most of the questions in this survey ask about "this facility." By "this facility" we mean the specific treatment facility or program whose name and location are printed on the front cover. If you have any questions about how the term "this facility" applies to your facility, please call 1-888-324-8337.
- Please answer ONLY for the specific facility or program whose name and location are printed on the front cover, unless otherwise specified in the questionnaire.
- If the questionnaire has not been completed online, return the completed questionnaire in the envelope provided. Please keep a copy for your records.
- For additional information about this survey and definitions of some of the terms used, please visit our website at https://info.nssats.com.
- If you have any questions or need additional blank surveys, contact:

MATHEMATICA POLICY RESEARCH 1-888-324-8337 NSSATSWeb@mathematica-mpr.com

IMPORTANT INFORMATION

* <u>Asterisked questions</u>. Information from asterisked (*) questions may be published in SAMHSA's online Behavioral Health Treatment Services Locator (found at https://findtreatment.samhsa.gov), in SAMHSA's *National Directory of Drug and Alcohol Abuse Treatment Programs*, and other publicly-available listings, unless you designate otherwise in question 28, page 10 of this questionnaire.

<u>Mapping feature in online Locator</u>. Complete and accurate name and address information is needed for SAMHSA's online Behavioral Health Treatment Services Locator so it can correctly map the facility location.

Eligibility for online Locator and *Directory*. Only facilities designated as eligible by their state substance abuse office and that complete this questionnaire will be listed as substance abuse facilities in the online Locator and *Directory*. Your state N-SSATS representative can tell you if your facility is eligible to be listed in the online Locator and *Directory*. For the name and telephone number of your state representative, call the N-SSATS helpline at 1-888-324-8337.

SECTION A: FACILITY CHARACTERISTICS

Section A asks about characteristics of individual facilities and should be completed for

	this facility only, that is, the treatment facility or program at the location listed on the front cover.
*1.	Which of the following substance abuse services are offered by this facility at this location, that is, the location listed on the front cover?
	MARK "YES" OR "NO" FOR EACH
	<u>YES</u> <u>NO</u>
	1. Intake, assessment, or referral 1 \square 0 \square
	2. Detoxification 1 0 0
	3. Substance use treatment
	 Treatment for co-occurring substance use disorders <u>plus</u> <u>either</u> serious mental illness (SMI) in adults <u>and/or</u> serious emotional disturbance (SED) in children 1 □ 0 □
	5. Any other substance abuse services1 □ 0 □
1a.	To which of the following clients does this facility, at this location, offer mental health treatment services (interventions such as therapy or psychotropic medication that treat a person's mental health problem or condition, reduce symptoms, and improve behavioral functioning and outcomes)? MARK ALL THAT APPLY
	□ Substance abuse clients
	² Clients other than substance abuse clients
	3 No clients are offered mental health treatment services
2.	Is this facility a jail, prison, or other organization that provides treatment <u>exclusively</u> for incarcerated persons or juvenile detainees?
	1 ☐ Yes → SKIP TO Q.37 (PAGE 15)
	— ∘ □ No
¥ 3.	Did you answer "yes" to <u>detoxification</u> in option 2 of question 1 above?

 $_1 \ \Box \ \text{Yes} \longrightarrow \text{SKIP TO Q.3a (TOP OF NEXT COLUMN)}$

 $_{\circ}$ \square No \longrightarrow SKIP TO Q.4 (NEXT COLUMN)

*3a.	Does this facility detoxify clients from
	MARK ALL THAT APPLY
	1 ☐ Alcohol
	2 ☐ Benzodiazepines
	3 Cocaine
	4 ☐ Methamphetamines
	5 Opioids
	6 ☐ Other (Specify:)
*3b.	Does this facility <u>routinely</u> use medications during detoxification?
	1 ☐ Yes → SKIP TO Q.5 (BELOW)
	□ No — Skill To 4:3 (BEESW)
4.	Did you answer "yes" to <u>substance use treatment</u> in option 3 of question 1?
	₁ □ Yes
	□ No → SKIP TO Q.25 (PAGE 10)
5.	Is this facility a solo practice, meaning, an office with only one independent practitioner or counselor?
	₁ ☐ Yes
	₀
*6.	Is this facility a Federally Qualified Health Center (FQHC)?
*6.	
*6.	 FQHCs include: (1) all organizations that receive grants under Section 330 of the Public Health Service Act; and (2) other organizations that do not receive grants, but have met the requirements to receive grants under Section 330 according to the U.S. Department of Health and Human
*6.	 FQHCs include: (1) all organizations that receive grants under Section 330 of the Public Health Service Act; and (2) other organizations that do not receive grants, but have met the requirements to receive grants under Section 330 according to the U.S. Department of Health and Human Services. For a complete definition of a FQHC, go to:
*6.	 FQHCs include: (1) all organizations that receive grants under Section 330 of the Public Health Service Act; and (2) other organizations that do not receive grants, but have met the requirements to receive grants under Section 330 according to the U.S. Department of Health and Human Services. For a complete definition of a FQHC, go to: https://info.nssats.com
*6.	 FQHC)? FQHCs include: (1) all organizations that receive grants under Section 330 of the Public Health Service Act; and (2) other organizations that do not receive grants, but have met the requirements to receive grants under Section 330 according to the U.S. Department of Health and Human Services. For a complete definition of a FQHC, go to: https://info.nssats.com Yes
*6.	 FQHCs include: (1) all organizations that receive grants under Section 330 of the Public Health Service Act; and (2) other organizations that do not receive grants, but have met the requirements to receive grants under Section 330 according to the U.S. Department of Health and Human Services. For a complete definition of a FQHC, go to: https://info.nssats.com Yes No Don't know What is the primary focus of this facility at this location, that is, the location listed on the front cover?
	 FQHCs include: (1) all organizations that receive grants under Section 330 of the Public Health Service Act; and (2) other organizations that do not receive grants, but have met the requirements to receive grants under Section 330 according to the U.S. Department of Health and Human Services. For a complete definition of a FQHC, go to: https://info.nssats.com Yes □ No d □ Don't know What is the primary focus of this facility at this location, that is, the location listed on the front cover? MARK ONE ONLY
	 FQHCs include: (1) all organizations that receive grants under Section 330 of the Public Health Service Act; and (2) other organizations that do not receive grants, but have met the requirements to receive grants under Section 330 according to the U.S. Department of Health and Human Services. For a complete definition of a FQHC, go to: https://info.nssats.com Yes □ No □ Don't know What is the primary focus of this facility at this location, that is, the location listed on the front cover? MARK ONE ONLY □ Substance use treatment services
	 FQHCs include: (1) all organizations that receive grants under Section 330 of the Public Health Service Act; and (2) other organizations that do not receive grants, but have met the requirements to receive grants under Section 330 according to the U.S. Department of Health and Human Services. For a complete definition of a FQHC, go to: https://info.nssats.com Yes □ No d □ Don't know What is the primary focus of this facility at this location, that is, the location listed on the front cover? MARK ONE ONLY 1 □ Substance use treatment services 2 □ Mental health services
	 FQHCs include: (1) all organizations that receive grants under Section 330 of the Public Health Service Act; and (2) other organizations that do not receive grants, but have met the requirements to receive grants under Section 330 according to the U.S. Department of Health and Human Services. For a complete definition of a FQHC, go to: https://info.nssats.com Yes No Don't know What is the primary focus of this facility at this location, that is, the location listed on the front cover? MARK ONE ONLY Substance use treatment services Mental health services Mix of mental health and substance use treatment services (neither is primary)
	 FQHCs include: (1) all organizations that receive grants under Section 330 of the Public Health Service Act; and (2) other organizations that do not receive grants, but have met the requirements to receive grants under Section 330 according to the U.S. Department of Health and Human Services. For a complete definition of a FQHC, go to: https://info.nssats.com Yes No □ Don't know What is the primary focus of this facility at this location, that is, the location listed on the front cover? MARK ONE ONLY □ Substance use treatment services □ Mix of mental health and substance use

*8.	Is this facility operated by MARK ONE ONLY	*10a.	Which of the following RESIDENTIAL services are offered at this facility?
	□ A private for-profit organization □		MARK "YES" OR "NO" FOR EACH
	2 ☐ A private non-profit organization		<u>YES</u> <u>NO</u>
	SKIP TO 3 □ State government Q.9		1. Residential detoxification ₁ □ 0 □
	4 ☐ Local, county, or community government (BELOW)		(clinically managed residential detoxification or social detoxification, similar to ASAM Level III.2-D)
	₅ ☐ Tribal government		2. Residential short-term treatment ₁ □ 0 □
l —	- 6 □ Federal Government		(clinically managed high-intensity residential treatment, typically 30
. ₩ *8a.	Which Federal Government agency?		days or less, similar to ASAM Level
	MARK ONE ONLY		III.5)
	□ Department of Veterans Affairs		3. Residential long-term treatment 1 □ 0 □ (clinically managed medium- or low-
	2 Department of Defense		intensity residential treatment,
	₃ ☐ Indian Health Service		typically more than 30 days, similar to ASAM Levels III.3 and III.1)
	4 □ Other (Specify:)		,
*9.	Does this facility offer HOSPITAL INPATIENT substance abuse services at this location, that is, the location listed on the front cover?	*11.	Does this facility offer OUTPATIENT substance abuse services at this location, that is, the location listed on the front cover?
l	_ 1 □ Yes		_ 1 □ Yes
	□ No → SKIP TO Q.10 (BELOW)	$\downarrow\downarrow$	$\circ \square \text{ No} \longrightarrow \text{SKIP TO Q.12 (TOP OF NEXT PAGE)}$
↓	·	*11a.	
*9a.	Which of the following HOSPITAL INPATIENT services are offered at this facility?		offered at this facility? MARK "YES" OR "NO" FOR EACH
	MARK "YES" OR "NO" FOR EACH		YES NO
	<u>YES</u> <u>NO</u>		1. Outpatient detoxification 1 □ 0 □
	 Hospital inpatient detoxification1 □ 0 □ (medically managed or monitored inpatient detoxification, similar to 		(ambulatory detoxification, similar to ASAM Levels I-D and II-D)
	ASAM Levels IV-D and III.7-D)		Outpatient methadone/ burrengribing maintanance or
	2. Hospital inpatient treatment1 □ 0 □		buprenorphine maintenance or naltrexone treatment 1 □ 0 □
	(medically managed or monitored intensive inpatient treatment, similar		3. Outpatient day treatment
	to ASAM Levels IV and III.7)		or partial hospitalization $_1 \square$ 0 \square (20 or more hours per week, similar to
NC	OTE: ASAM is the American Society of Addiction Medicine.		ASAM Level II.5)
	r more information on ASAM please go to https://info.nssats.com. Does this facility offer RESIDENTIAL (non-hospital)		 Intensive outpatient treatment 1 □ 0 □ (9 or more hours per week, similar to ASAM Level II.1)
	substance abuse services at this location, that is, the location listed on the front cover?		5. Regular outpatient treatment 1 □ 0 □ (outpatient treatment, non-intensive,
	¹ □ Yes → SKIP TO Q.10a (TOP OF NEXT COLUMN)		similar to ASAM Level I)
	$_{\circ}$ \square No \longrightarrow SKIP TO Q.11 (NEXT COLUMN)		

. Which of the following services are offered by this	Recovery Support Services
facility at this location, that is, the location listed on	28 Mentoring/peer support
the front cover? MARK ALL THAT APPLY	Self-help groups (for example, AA, NA, SMART Recovery)
Assessment and Pre-Treatment Services	30 Assistance in locating housing for clients
□ Screening for substance abuse	31
2 Greening for mental disorders	clients
3 Comprehensive substance abuse assessment or diagnosis	32 Assistance with obtaining social services (for example, Medicaid, WIC, SSI, SSDI)
□ Comprehensive mental health assessment or diagnosis (for example, psychological or psychiatric evaluation and testing)	 □ Recovery coach □ We do not offer any of these recovery support services
₅ ☐ Screening for tobacco use	Education and Counseling Services
6 ☐ Outreach to persons in the community who may need treatment	35 ☐ HIV or AIDS education, counseling, or support
Interim services for clients when immediate admission is not possible	36 Hepatitis education, counseling, or support
 Professional interventionist/educational consultant 	37 Health education other than HIV/AIDS or Hepatitis
□ We do not offer any of these assessment and	38 Substance abuse education
pre-treatment services	39 Smoking/tobacco cessation counseling
Testing (include tests performed at this location, even if	40 🛘 Individual counseling
specimen is sent to an outside source for chemical	41 Group counseling
analysis)	42 ☐ Family counseling
10 ☐ Drug and alcohol oral fluid testing	43 ☐ Marital/couples counseling
 □ Breathalyzer or other blood alcohol testing □ Drug or alcohol urine screening 	44 Vocational training or educational support (for example, high school coursework, GED preparation, etc.)
□ Testing for Hepatitis B (HBV)	 We do not offer any of these education and counseling services
□ Testing for Hepatitis C (HCV)	
15 HIV testing	Ancillary Services
16 ☐ STD testing	46 ☐ Case management services
17 ☐ TB screening	47 Social skills development
18 ☐ Testing for metabolic syndrome	48 Child care for clients' children
19 ☐ We do not offer any of these testing services	49 Domestic violence services, including family or partner violence services, for physical, sexual, or emotional abuse
Medical Services	50 Early intervention for HIV
20 Hepatitis A (HAV) vaccination	51 ☐ Transportation assistance to treatment
21 ☐ Hepatitis B (HBV) vaccination	52 ☐ Mental health services
22 ☐ We do not offer any of these medical services	53 Acupuncture
Transitional Services	54 Residential beds for clients' children
23 Discharge planning	55 ☐ We do not offer any of these ancillary
24 ☐ Aftercare/continuing care	services
□ Nolovene and evendore advection	Other Services
	56 ☐ Treatment for gambling disorder
Outcome follow-up after discharge	57 ☐ Treatment for Internet use disorder
27 ☐ We do not offer any of these transitional services	☐ Treatment for other addiction disorder (non-substance abuse)
	⁵⁹ □ We do not offer any of these other services

*12.	(continued)
	Pharmacotherapies
	₀ □ Disulfiram <i>(Antabuse®)</i>
	naltrexone (oral)
	Naltrexone (extended-release, injectable, for example, Vivitrol®)
	□ Acamprosate <i>(Campral®)</i>
	Nicotine replacement
	Non-nicotine smoking/tobacco cessation medications (for example, bupropion, varenicline)
	Medications for psychiatric disorders
	of □ Methadone
	Buprenorphine with naloxone (for example, Suboxone®, Bunavail®, Zubsolv®, Cassipa®)
	se □ Buprenorphine without naloxone
	⁷⁰ □ Buprenorphine sub-dermal implant <i>(Probuphine®)</i>
	□ Buprenorphine (extended-release, injectable, for example, Sublocade®)
	Medications for HIV treatment (for example, antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine)
	Medications for Hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)
	r₄ □ Lofexidine
	r₅ □ Clonidine
	№ Use do not offer any of these pharmacotherapy services
*13.	Facilities may treat a range of substance use disorders. The next series of questions focuses <u>only</u> on how this facility treats <u>opioid</u> use disorder.
	How does this facility treat opioid use disorder?
	Medication assisted treatment (MAT) includes the use of methadone, buprenorphine and/or naltrexone for the treatment of opioid use disorder. For this question, MAT refers to any or all of these medications unless specified.
	MARK ALL THAT APPLY
	This facility uses methadone or buprenorphine for pain management, emergency cases, or research purposes. It is NOT a federally-certified Opioid Treatment Program (OTP). SKIP TO Q.14 → (TOP 05 DAGE 2)
	This facility treats opioid use disorder, but it does not use medication assisted treatment (MAT), nor does it accept clients using MAT to treat opioid use disorder.
	□ This facility accepts clients using MAT, but the medications originate from or are prescribed by another entity. (The medications may or may not be stored/delivered/monitored onsite.) → SKIP TO Q.13a (TOP OF NEXT PAGE)
	This facility prescribes naltrexone to treat opioid use disorder. Naltrexone use is authorized through any medical staff who have prescribing privileges.
	5 ☐ This facility prescribes buprenorphine to treat opioid use disorder. Buprenorphine use is authorized through a DATA 2000 waivered physician, physician assistant, or nurse practitioner. SKIP TO Q.13b (NEXT PAGE)
	6 ☐ This facility is a <u>federally-certified</u> Opioid Treatment Program (OTP). (Most OTPs administer/dispense methadone; some only use buprenorphine.)
	¬ □ This facility does not treat opioid use disorder. → SKIP TO Q.14 (TOP OF PAGE 6)

*13a.	For those clients using MAT, but whose medications originate from or are prescribed by another entity, the clients obtain their prescriptions from
	MARK ALL THAT APPLY
	□ A prescribing entity in our network
	2 A prescribing entity with which our facility has a business, contractual, or formal referral relationship
	3 ☐ A prescribing entity with which our facility has no formal relationship
*13b.	Does this facility serve only opioid use disorder clients?
	₁ □ Yes
	∘ □ No
*13c.	Which of the following medication services does this program provide for <u>opioid use disorder</u> ? MARK ALL THAT APPLY
	□ Maintenance services with methadone or buprenorphine
	2
	3 ☐ Detoxification from opioids of abuse with methadone or buprenorphine
	□ Detoxification from opioids of abuse with lofexidine or clonidine
	5 ☐ Relapse prevention with naltrexone
	6 ☐ Other (Specify opioid use disorder service and pharmacotherapy used:
	⁷ □ We do not offer any of these medication services for opioid use disorder

	How does this facility treat <u>alcohol use disorder</u> ?
	• These medications have been approved by the FDA to treat alcohol use disorder: naltrexone, acamprosate, and disulfiram. For this question, MAT refers to any or all of these three medications.
	MARK ALL THAT APPLY
	1 ☐ This facility treats alcohol use disorder, but it does not use medication assisted treatment (MAT) for alcohol use disorder, nor does it accept clients using MAT to treat alcohol use disorder. → SKIP TO Q.14b (BELOW)
	 This facility accepts clients using MAT for alcohol use disorder, but the medications originate from or are prescribed by another entity.
	□ This facility administers/prescribes at least one of disulfiram (Antabuse®), naltrexone, and/or acamprosate (Campral®) for alcohol use disorder. → SKIP TO Q.14b (BELOW)
	⁴ □ This facility does not treat alcohol use disorder. → SKIP TO Q.15 (BELOW)
۱.	For those clients using MAT, but whose medications originate from or are prescribed by another entity, the clients obtain their prescriptions from
	MARK ALL THAT APPLY
	□ A prescribing entity in our network
	2
	3 ☐ A prescribing entity with which our facility has no formal relationship
) .	Does this facility serve only alcohol use disorder clients?
	₁ □ Yes
	o □ No
	Which of the following clinical/therapeutic approaches listed below are used frequently at this facility?
	□ Substance abuse counseling
	2 ☐ 12-step facilitation
	₃ ☐ Brief intervention
	4 ☐ Cognitive behavioral therapy
	₅ ☐ Dialectical behavior therapy
	6 ☐ Contingency management/motivational incentives
	¬ □ Motivational interviewing
	8 ☐ Trauma-related counseling
	9 ☐ Anger management
	o □ Matrix Model
	□ Community reinforcement plus vouchers
	2 ☐ Rational emotive behavioral therapy (REBT)
	₃ ☐ Relapse prevention
	4 ☐ Telemedicine/telehealth therapy (including Internet, Web, mobile, and desktop programs)
	6 ☐ We do not use any of these clinical/therapeutic approaches

*16.	Does this facility, at this location, offer a <u>specially</u> <u>designed</u> program or group intended <u>exclusively</u> for DUI/DWI or other drunk driver offenders?	*18b. In what other languages do staff counselors provide substance use treatment at this facility?
_	- 1 □ Yes	 Do not count languages provided only by on-call interpreters.
	○ □ No → SKIP TO Q.17 (BELOW)	MARK ALL THAT APPLY
↓ *16a.	Does this facility serve only DUI/DWI clients?	American Indian or Alaska Native:
	1 □ Yes	1 □ Hopi
	₀	2 □ Lakota
	Does this facility provide substance use treatment services in sign language at this	₃ □ Navajo
*17.		₄ □ Ojibwa
	location for the deaf and hard of hearing (for	₅ □ Yupik
	example, American Sign Language, Signed English, or Cued Speech)?	6 ☐ Other American Indian or Alaska Native language
	 Mark "yes" if either a staff counselor or an on-call interpreter provides this service. 	(Specify:)
	₁ ☐ Yes	Other Languages:
	∘ □ No	⁷ □ Arabic
*18.	treatment services in a language <u>other than</u> <u>English</u> at this location?	8 Any Chinese language
		∘ □ Creole
		10 □ Farsi
	- 1 □ Yes	11 □ French
$ \downarrow$	○ □ No → SKIP TO Q.19 (TOP OF NEXT PAGE)	₁₂ □ German
18a.		13 ☐ Greek
	treatment services in a language <u>other than</u> English?	14 □ Hebrew
	MARK ONE ONLY	15 🗆 Hindi
	- 1 ☐ Staff counselor who speaks a language other	16 ☐ Hmong
	than English	17 🗆 Italian
	2 ☐ On-call interpreter (in person or by phone) brought in when needed → SKIP TO Q.19	l 18 □ Japanese
	(TOP OF NEXT	l 19 □ Korean
	PAGE) ¬ ₃ □ BOTH staff counselor and on-call interpreter	20 □ Polish
↓	3 Li BOTTI Stati Couliseioi and off-call interpreter	21 ☐ Portuguese
*18a1	. Do <u>staff counselors</u> provide substance use treatment in Spanish at this facility?	22 □ Russian
	Yes	23 □ Tagalog
	□ No → SKIP TO Q.18b (TOP OF NEXT COLUMN)	24 Vietnamese
↓	·	25 Any other language
18a2	Do <u>staff counselors</u> at this facility provide substance use treatment in any other languages?	(Specify:)
	¹ □ Yes → SKIP TO Q.18b (TOP OF NEXT COLUMN)	
	$_{0}$ \square No \longrightarrow SKIP TO Q.19 (TOP OF NEXT PAGE)	

*19.	Individuals seeking substance use treatment can vary by age, gender or other characteristics.	Which
	categories of individuals listed below are served by this facility, at this location?	

• Indicate only the highest or lowest age the facility would accept. <u>Do not indicate</u> the highest or lowest age <u>currently receiving services</u> in the facility.

TYPE OF CLIENT	MARK "YES" OR "NO" FOR EACH CATEGORY SERVED BY THIS FACILITY		EACH CATEGORY IF SERVED, WHAT IS		IF SERVED, WHAT IS THE HIGHEST AGE SERVED	
1. Female	₁□ Yes	o□ No	_ YEARS	o □ No minimum age	 YEARS	₀ □ No maximum age
2. Male	1□ Yes	o□ No	 YEARS	o □ No minimum age	 YEARS	o □ No maximum age

*19a.	Many facilities have clients in one or more of the following categories. For which client categories does this
	facility at this location offer a substance use treatment program or group specifically tailored for clients in that
	category? If this facility treats clients in any of these categories but does not have a specifically tailored
	program or group for them, do <u>not</u> mark the box for that category.

MARK ALL THAT APPLY		
₁ ☐ Adolescents		
² ☐ Young adults		
3 ☐ Adult women		

3		Adult women
4		Pregnant/postpartum women
5		Adult men
6		Seniors or older adults
7		Lesbian, gay, bisexual, transgender, or queer/questioning (LGBTQ) clients
8		Veterans
9		Active duty military
	\Box	Mombors of military families

10	, <u> </u>	Members of military families
11		Criminal justice clients (other than DUI/DWI)
12	2 🗆	Clients with co-occurring mental and substance use disorders
13	3 🗆	Clients with co-occurring pain and substance use
14	ı 🗆	Clients with HIV or AIDS
15	5 🗆	Clients who have experienced sexual abuse
16	s 🗆	Clients who have experienced intimate partner violence, domestic violence
17	, П	Clients who have experienced trauma

8	☐ Specifically tailored programs or gi	oups for any other types of clients
	(Specify:)
_	□ No specifically tailored programs of	r groups are offered

19 ☐ No specifically tailored programs or groups are offered

*20.	Does this facility use a sliding fee scale?
•	Sliding fee scales are based on income and other factors.
	- 1 □ Yes
\downarrow	○ □ No → SKIP TO Q.21 (BELOW)
20a.	Do you want the availability of a sliding fee scale published in SAMHSA's online Locator and <i>Directory</i> ?
	• The online Locator and Directory will explain that potential clients should call the facility for information on eligibility.
	₁ □ Yes
	o □ No
*21.	Does this facility offer treatment at no charge or minimal payment (for example, \$1) to clients who cannot afford to pay?
	- ₁ □ Yes
	○ □ No → SKIP TO Q.22 (BELOW)
21a.	Do you want the availability of treatment at no charge or minimal payment (for example, \$1) for eligible clients published in SAMHSA's online Locator and <i>Directory</i> ?
	• The online Locator and Directory will explain that potential clients should call the facility for information on eligibility.
	₁ □ Yes
	o □ No
*22.	Does this facility receive any funding or grants from the Federal Government, or state, county or local governments, to support its substance use treatment programs?
	 Do <u>not</u> include Medicare, Medicaid, or federal military insurance. These forms of client payments are included in Q.23.
	₁ □ Yes
	o □ No
	d □ Don't know
*23.	Which of the following types of client payments or insurance are accepted by this facility for <u>substance use treatment</u> ?
	MARK ALL THAT APPLY
	□ No payment accepted (free treatment for ALL clients)
	2 ☐ Cash or self-payment
	₃ ☐ Medicare
	₄ ☐ Medicaid
	5 ☐ State-financed health insurance plan other than Medicaid
	6 ☐ Federal military insurance (e.g., TRICARE)
	→ Private health insurance → Private health insuranc
	8 ☐ IHS/Tribal/Urban (ITU) funds
	9 Other (Specify:)
*24.	Is this facility a hospital or located in or operated by a hospital?
	1 ☐ Yes→ SKIP TO Q.24a (TOP OF NEXT PAGE)
	○ □ No → SKIP TO Q.25 (NEXT PAGE)

*24a.	What type of hospital? MARK ONE ONLY	28.	If eligible, does this facility want to be listed in SAMHSA's online Behavioral Health Treatment Services Locator and Substance Abuse
	□ General hospital (including VA hospital)		Directory? (See inside front cover for eligibility
	2 ☐ Psychiatric hospital		information.)
	Other specialty hospital, for example, alcoholism, maternity, etc.		 The Locator can be found at https://findtreatment.samhsa.gov
	(Specify:)		The Directory will be available at
*25.	Does this facility operate transitional housing, a halfway house, or a sober home for substance abuse clients at this location, that is, the location listed on the front cover? 1		https://www.samhsa.gov/data 1 □ Yes
			$_{0}$ □ No \rightarrow SKIP TO Q.29 (TOP OF NEXT PAGE)
			and/or mailing address to be listed in SAMHSA's online Behavioral Health Treatment
*26.	Which of the following statements BEST describes this facility's <u>smoking policy</u> for <u>clients</u> ?		Services Locator and Substance Abuse Directory?
	MARK ONE ONLY		MARK ALL THAT APPLY
	¹ □ Not permitted to smoke anywhere outside or		Publish the <u>street</u> address
	within any building		² □ Publish the <u>mailing</u> address
	2 ☐ Permitted in <u>designated outdoor</u> area(s)		3 ☐ Do <u>not</u> publish either address
	3 ☐ Permitted anywhere outside	28b.	To increase public awareness of behavioral
	□ Permitted in <u>designated indoor</u> area(s)		health services, SAMHSA may be sharing facility information with large commercially available Internet search engines (such as
	□ Permitted <u>anywhere inside</u>		
	□ Permitted anywhere without restriction Is this facility or program licensed, certified, or accredited to provide substance abuse services by any of the following organizations?		Google, Bing, Yahoo!, etc.), businesses (such
*27.			as any .com, .org, .edu, etc.) or individuals asking for this information for any purpose. Do you want your facility information shared?
	 Do not include personal-level credentials or general business licenses such as a food service license. 	•	Information to be shared would be: facility name, location address, telephone number, website address, and all asterisked items in the
	MARK ALL THAT APPLY		questionnaire.
	□ State substance abuse agency		₁ □ Yes
	2 State mental health department		₀
	3 ☐ State department of health		
	 4 ☐ Hospital licensing authority 5 ☐ The Joint Commission 		
	6 ☐ Commission on Accreditation of Rehabilitation Facilities (CARF)		
	 National Committee for Quality Assurance (NCQA) 		
	8 Council on Accreditation (COA)		
	Healthcare Facilities Accreditation Program (HFAP)		
	Other national organization or federal, state, or local agency		
	(Specify:)		
	We are not licensed, certified, or accredited to provide substance abuse services by any of these organizations		

29.	Is this facility part of an organization with multiple facilities or sites that provide substance use treatment? - □ Yes
	0 □ No → SKIP TO Q.30 (TOP OF NEXT PAGE)
↓ 29a.	What is the name, address, and phone number of the facility that is the parent, or master site, of the organization?
	Name:
	Address:
	Phone Number: ()
29b.	Did you answer "yes" to either <u>detoxification</u> in option 2 or <u>substance use treatment</u> in option 3 of question 1?
	1 \square Yes → SKIP TO Q.30 (TOP OF NEXT PAGE) 0 \square No → SKIP TO Q.37 (PAGE 15)

SECTION B: REPORTING CLIENT COUNTS

	REPORTING CLIENT COUNTS	31. On March 31, 2020, did any patients receive			
30.	Questions 31 through 36 ask about the number	HOSPITAL INPATIENT <u>substance abuse</u> services at this facility?			
	of clients in treatment. If possible, report clients for this facility only. However, we realize	1 ☐ Yes 1 ☐ No → SKIP TO Q.32 (NEXT PAGE)			
	that is not always possible. Please indicate	31a. On March 31, 2020, how many patients received			
	whether the clients you report will be for MARK ONE ONLY	the following HOSPITAL INPATIENT substance abuse services at this facility?			
	1 ☐ Only this facility → SKIP TO Q.31	COUNT a patient in one service only, even if the			
	(TOP OF NEXT COLUMN)	patient received both services.			
	2 ☐ This facility plus others	DO NOT count family members, friends, or other non-treatment patients.			
	□ Another facility will report this facility's client counts → SKIP TO Q.37 (PAGE 15)	ENTER A NUMBER FOR EACH (IF NONE, ENTER "0")			
30a.	How many facilities will be included in your	Hospital inpatient detoxification / cimilar to ASAM Levels IV D			
	client counts?	(similar to ASAM Levels IV-D and III.7-D, medically managed or monitored inpatient detoxification)			
	THIS FACILITY 1	Hospital inpatient treatment (similar to ASAM Levels IV			
	+ ADDITIONAL FACILITIES	and III.7, medically managed or monitored intensive inpatient treatment)			
	TOTAL FACILITIES ^a	HOSPITAL INPATIENT TOTAL BOX			
		NOTE: ASAM is the American Society of Addiction Medicine.			
	$^{\alpha}$ For Section B, please include all of these facilities in the client counts that you report	For more information on ASAM please go to https://info.nssats.com.			
	in questions 31 through 36.	31b. How many of the patients from the HOSPITAL INPATIENT TOTAL BOX were <u>under</u> the age of 183			
		ENTER A NUMBER			
30b.	To avoid double-counting clients, we need to know which facilities are included in your counts. How	(IF NONE, ENTER "0")			
	will you report this information to us?	Number under age 18			
	MARK ONE ONLY	31c. How many of the patients from the HOSPITAL			
	By listing the names and location addresses of these additional facilities in the "Additional	INPATIENT TOTAL BOX received:			
	Facilities Included in Client Counts" section on page 16 of this questionnaire or attaching a sheet	Include patients who received these drugs for			
	of paper to this questionnaire	detoxification, maintenance, or relapse prevention for opioid use disorder.			
	Please call me for a list of the additional facilities included in these counts	ENTER A NUMBER FOR EACH (IF NONE, ENTER "0")			
		Methadone dispensed at this facility for opioid use disorder			
		Buprenorphine dispensed or prescribed at this facility for opioid use disorder			
		Naltrexone administered at this facility for opioid use disorder			

HOSPITAL INPATIENT CLIENT COUNTS

31d.	How many of the patients from the HOSPITAL INPATIENT TOTAL BOX received:	32b. How many of the clients from the RESIDENTIAL TOTAL BOX were <u>under</u> the age of 18?
	 Include patients who received these medications for alcohol use disorder. 	ENTER A NUMBER (IF NONE, ENTER "0")
	ENTER A NUMBER FOR EACH (IF NONE, ENTER "0")	Number under age 18
	Disulfiram (Antabuse®) dispensed or prescribed at this facility for alcohol use disorder	32c. How many of the clients from the RESIDENTIAL TOTAL BOX received:
	2. Naltrexone dispensed or prescribed at this facility for alcohol use disorder	 Include clients who received these drugs for detoxification maintenance, or relapse prevention for <u>opioid use disorde</u> ENTER A NUMBER FOR EACH (IF NONE, ENTER "0")
	Acamprosate (Campral®) dispensed or prescribed at this facility for alcohol use disorder	Methadone dispensed at this facility for opioid use disorder
31e.	On March 31, 2020, how many hospital inpatient beds were specifically designated for substance use treatment?	Buprenorphine dispensed or prescribed at this facility for opioid use disorder
	ENTER A NUMBER (IF NONE, ENTER "0") Number of beds	Naltrexone administered at this facility for opioid use disorder
	RESIDENTIAL (NON-HOSPITAL) CLIENT COUNTS	 32d. How many of the clients from the RESIDENTIAL TOTAL BOX received: Include clients who received these medications for
32.	On March 31, 2020, did any clients receive RESIDENTIAL (non-hospital) substance abuse services at this facility?	alcohol use disorder. ENTER A NUMBER FOR EACH (IF NONE, ENTER "0") 1. Disulfiram (Antabuse®) dispensed or prescribed at this facility
3 2a.	On March 31, 2020, how many clients received the following RESIDENTIAL substance abuse services at this facility? • COUNT a client in one service only, even if the client received multiple services. • DO NOT count family members, friends, or other non-treatment clients. ENTER A NUMBER FOR EACH (IF NONE, ENTER "0") 1. Residential detoxification	for alcohol use disorder 2. Naltrexone dispensed or prescribed at this facility for alcohol use disorder 3. Acamprosate (Campral®) dispensed or prescribed at this facility for alcohol use disorder 32e. On March 31, 2020, how many residential beds were specifically designated for substance use treatment?
	(similar to ASAM Level III.2-D, clinically managed residential detoxification or social detoxification)	ENTER A NUMBER (IF NONE, ENTER "0") Number of beds
	2. Residential short-term treatment (similar to ASAM Level III.5, clinically managed high-intensity residential treatment, typically 30 days or less)	Number of beds
	3. Residential long-term treatment (similar to ASAM Levels III.3 and III.1, clinically managed medium- or low- intensity residential treatment, typically more than 30 days)	
	RESIDENTIAL TOTAL BOX	

33. During the month of March 2020, did any clients receive OUTPATIENT substance abuse services at this facility? 1 □ Yes 1 □ No → SKIP TO Q.34 (TOP OF NEXT PAGE)	ENTER A NUMBER (IF NONE, ENTER "0") Number under age 18
↑ □ Yes	Number under age 18
○ □ No → SKIP TO Q.34 (TOP OF NEXT PAGE)	
33a. As of March 31, 2020, how many active clients were receiving each of the following OUTPATIENT substance abuse services at this facility? An active client is a client who received treatment in March AND was still enrolled in treatment on March 31, 2020. • COUNT a client in one service only, even if the client received multiple services. • DO NOT count family members, friends, or other non-treatment clients. ENTER A NUMBER FOR EACH (IF NONE, ENTER "0") 1. Outpatient detoxification (similar to ASAM Levels I-D and II-D, ambulatory detoxification) 2. Outpatient methadone/ buprenorphine maintenance or naltrexone treatment (count methadone/buprenorphine/ naltrexone clients on this line only) 3. Outpatient day treatment or partial hospitalization (similar to ASAM Level II.5, 20 or more hours per week) 4. Intensive outpatient treatment (similar to ASAM Level II.1, 9 or more hours per week) 5. Regular outpatient treatment (similar to ASAM Level I, outpatient treatment, non-intensive) OUTPATIENT TOTAL BOX	33c. How many of the clients from the OUTPATIENT TOTAL BOX received: • Include clients who received these drugs for detoxification, maintenance, or relapse prevention for opioid use disorder. ENTER A NUMBER FOR EACH (IF NONE, ENTER "0") 1. Methadone dispensed at this facility for opioid use disorder 2. Buprenorphine dispensed or prescribed at this facility for opioid use disorder 3. Naltrexone administered at this facility for opioid use disorder 3. Naltrexone administered at this facility for opioid use disorder 3. Include clients from the OUTPATIENT TOTAL BOX received: • Include clients who received these medications for alcohol use disorder. ENTER A NUMBER FOR EACH (IF NONE, ENTER "0") 1. Disulfiram (Antabuse®) dispensed or prescribed at this facility for alcohol use disorder 2. Naltrexone dispensed or prescribed at this facility for alcohol use disorder 3. Acamprosate (Campral®) dispensed or prescribed at this facility for alcohol use disorder

ALL SUBSTANCE ABUSE TREATMENT SETTINGS

Including Hospital Inpatient, Residential (non-hospital) and/or Outpatient

34.	This question asks you to categorize the substance use treatment clients at this facility into three groups: clients in treatment for (1) abuse of <u>both</u> alcohol and substances other than alcohol; (2) abuse <u>only</u> of alcohol; or (3) abuse <u>only</u> of substances other than alcohol.					
	Enter the percent of clients on March 31, 2020, who were in each of these three groups: Clients in treatment for abuse of:					
	BOTH alcohol <u>and</u> substances other than alcohol%					
	2. ONLY alcohol%					
	3. ONLY substances other than alcohol%					
	TOTAL 100 %					
35.	Approximately what percent of the substance use treatment clients enrolled at this facility on March 31, 2020, had a diagnosed co-occurring mental and substance use disorder?					
	PERCENT OF CLIENTS % (IF NONE, ENTER "0")					
36.	Using the most recent 12-month period for which you have data, approximately how many substance use treatment ADMISSIONS did this facility have?					
	• OUTPATIENT CLIENTS: Count admissions into treatment, <u>not</u> individual treatment visits. Consider an admission to be the initiation of a treatment program or course of treatment. Count any re-admission as an admission.					
	• IF THIS IS A MENTAL HEALTH FACILITY: Count all admissions in which clients received substance use treatment, even if substance abuse was their secondary diagnosis.					
	NUMBER OF SUBSTANCE USE TREATMENT ADMISSIONS IN A 12-MONTH PERIOD					
37.	Who was primarily responsible for completing this form? This information will only be used if we need to contact you about your responses. It will not be published.					
	MARK ONE ONLY					
	1 □ Ms 2 □ Mr 3 □ Mrs 4 □ Dr 5 □ Other (Specify:)					
	Name:					
	Title:					
	Phone Number: () Ext					
	Fax Number: ()					
	Email Address:					
	Facility Email Address:					

ADDITIONAL FACILITIES INCLUDED IN CLIENT COUNTS

Complete this section if you reported clients for this facility plus other facilities, as indicated in Question 30. For each additional facility, please mark if that facility offers hospital inpatient, residential and/or outpatient substance abuse services at that location.

FACILITY NAME:		FACILITY NAME:		
ADDRESS:		ADDRESS:		
CITY:		CITY:		
STATE:	_ZIP:	STATE:		_ ZIP:
PHONE:		PHONE:		
FACILITY EMAIL ADDRESS:		FACILITY EMAIL ADDRESS:		
☐ HOSPITAL INPATIENT ☐ RESIDENTIAL	□ OUTPATIENT	☐ HOSPITAL INPATIENT	□ RESIDENTIAL	□ OUTPATIENT
FACILITY NAME:		FACILITY NAME:		
ADDRESS:		ADDRESS:		
CITY:		CITY:		
STATE:	_ZIP:	STATE:		_ ZIP:
PHONE:		PHONE:		
FACILITY EMAIL ADDRESS:		FACILITY EMAIL ADDRESS:		
☐ HOSPITAL INPATIENT ☐ RESIDENTIAL	□ OUTPATIENT	☐ HOSPITAL INPATIENT	☐ RESIDENTIAL	OUTPATIENT
FACILITY NAME:		FACILITY NAME:		
ADDRESS:	_	ADDRESS:		
CITY:		CITY:		
STATE:	_ZIP:	STATE:		_ ZIP:
PHONE:		PHONE:		
FACILITY EMAIL ADDRESS:		FACILITY EMAIL ADDRESS:		
☐ HOSPITAL INPATIENT ☐ RESIDENTIAL	□ OUTPATIENT	☐ HOSPITAL INPATIENT	☐ RESIDENTIAL	□ OUTPATIENT

If you require additional space, please continue on the next page.

ANY ADDITIONAL COMMENTS
PLEDGE TO RESPONDENTS: The information you provide will be protected to the fullest extent allowable under the Public Health Service Act (42 USC 290aa(p)). This law permits the public release of identifiable information about an establishment only with the consent of that establishment and limits the use of the information to the purposes for which it was supplied. With the explicit consent of treatment facilities, information provided in response to survey questions marked with an asterisk may be published in SAMHSA's online Behavioral Health Treatment Services Locator, the <i>National Directory of Drug and Alcohol Abuse Treatment Programs</i> , and other publicly-available listings. Responses to non-asterisked questions will be published with no direct link to individual treatment facilities.
Thank you for your participation. Please return this questionnaire in the envelope provided. If you no longer have the envelope, please mail this questionnaire to:
MATHEMATICA POLICY RESEARCH ATTN: RECEIPT CONTROL - Project 50345 P.O. Box 2393 Princeton, NJ 08543-2393
Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0930-0106. Public reporting burden for this collection of information is estimated to average 45 minutes per respondent, per year, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to SAMHSA Reports Clearance Officer, 5600 Fishers Lane, Room 15E57-A, Rockville, Maryland 20857.

Addendum for Substance Abuse Veterans Affairs Facilities March 31, 2020

	se answer the following questions for your Veterans Affairs facility.
۱1.	Which of the following suicide-related services are offered at this facility?
	MARK ALL THAT APPLY
	 Evidence-based suicide prevention interventions (interventions such as psychotherapies, medications, and/or public health strategies specifically aimed at decreasing rates of suicide)
	2 ☐ Suicide risk screening → SKIP TO VA3 (TOP OF PAGE 2)
	₃ ☐ Suicide risk evaluation → SKIP TO VA4 (PAGE 2)
	↓ □ We do not offer any of these suicide-related services → SKIP TO VA5 (PAGE 2)
	Evidence-based suicide prevention interventions may include psychotherapies, medications, and/or public health strategies specifically aimed at decreasing rates of suicide.
	MARK ALL THAT APPLY
	MARK ALL THAT APPLY 1 □ Cognitive Therapy for Suicide Prevention (CBT-SP)
	□ Cognitive Therapy for Suicide Prevention (CBT-SP)
	Cognitive Therapy for Suicide Prevention (CBT-SP) Cognitive Behavioral Therapy (CBT)
	 Cognitive Therapy for Suicide Prevention (CBT-SP) Cognitive Behavioral Therapy (CBT) Dialectical Behavior Therapy (DBT)
	 Cognitive Therapy for Suicide Prevention (CBT-SP) Cognitive Behavioral Therapy (CBT) Dialectical Behavior Therapy (DBT) Problem Solving Therapy (PST)
	 Cognitive Therapy for Suicide Prevention (CBT-SP) Cognitive Behavioral Therapy (CBT) Dialectical Behavior Therapy (DBT) Problem Solving Therapy (PST) Safety Planning/Crisis Response Planning
	 Cognitive Therapy for Suicide Prevention (CBT-SP) Cognitive Behavioral Therapy (CBT) Dialectical Behavior Therapy (DBT) Problem Solving Therapy (PST) Safety Planning/Crisis Response Planning Ketamine Infusions
	□ Cognitive Therapy for Suicide Prevention (CBT-SP) □ Cognitive Behavioral Therapy (CBT) □ Dialectical Behavior Therapy (DBT) □ Problem Solving Therapy (PST) □ Safety Planning/Crisis Response Planning □ Ketamine Infusions □ Lithium Treatment
	□ Cognitive Therapy for Suicide Prevention (CBT-SP) □ Cognitive Behavioral Therapy (CBT) □ Dialectical Behavior Therapy (DBT) □ Problem Solving Therapy (PST) □ Safety Planning/Crisis Response Planning □ Ketamine Infusions □ Lithium Treatment □ Clozapine Treatment
	1 □ Cognitive Therapy for Suicide Prevention (CBT-SP) 2 □ Cognitive Behavioral Therapy (CBT) 3 □ Dialectical Behavior Therapy (DBT) 4 □ Problem Solving Therapy (PST) 5 □ Safety Planning/Crisis Response Planning 6 □ Ketamine Infusions 7 □ Lithium Treatment 8 □ Clozapine Treatment 9 □ Caring Communications
	Cognitive Therapy for Suicide Prevention (CBT-SP) Cognitive Behavioral Therapy (CBT) Dialectical Behavior Therapy (DBT) Problem Solving Therapy (PST) Safety Planning/Crisis Response Planning Ketamine Infusions Lithium Treatment Clozapine Treatment Caring Communications Home Support
	cognitive Therapy for Suicide Prevention (CBT-SP) Cognitive Behavioral Therapy (CBT) Dialectical Behavior Therapy (DBT) Problem Solving Therapy (PST) Safety Planning/Crisis Response Planning Ketamine Infusions Lithium Treatment Clozapine Treatment Caring Communications Home Support World Health Organization-Brief Intervention and Contact (WHO-BIC)

VA3.	Which of the following standardized suicide screening tools are used or made available at this facility?
	MARK ALL THAT APPLY
	□ Columbia-Suicide Severity Rating Scale (C-SSRS) Screener
	2 ☐ Patient Health Questionnaire (PHQ-9) Item 9
	3 □ Other (Specify:)
	□ We do not use standardized suicide screening tools
VA4.	Which of the following standardized suicide evaluation tools are used or made available at this facility?
	MARK ALL THAT APPLY
	□ Columbia-Suicide Severity Rating Scale (C-SSRS)
	2 ☐ The Mini International Neuropsychiatric Interview (MINI)
	₃ ☐ VA Comprehensive Suicide Risk Evaluation (CSRE)
	□ Suicide Assessment Five-step Evaluation and Triage (SAFE-T)
	5
	6 ☐ We do not use standardized suicide evaluation tools
	identified as being at high risk of suicide? The HOSPITAL INPATIENT TOTAL BOX can be found at question 31a on page 12 of the survey. ENTER A NUMBER (IF NONE, ENTER "0")
VA6.	How many of the substance use residential clients that you reported in the RESIDENTIAL TOTAL BOX were identified as being at high risk of suicide?
	The RESIDENTIAL TOTAL BOX can be found at question 32a on page 13 of the survey.
	ENTER A NUMBER (IF NONE, ENTER "0")
VA7.	How many of the substance use outpatient clients that you reported in the OUTPATIENT TOTAL BOX were identified as being at high risk of suicide?
	The OUTPATIENT TOTAL BOX can be found at question 33a on page 14 of the survey.
	ENTER A NUMBER (IF NONE, ENTER "0")

APPENDIX C ITEM RESPONSE FOR 2020 N-SSATS

This appendix contains Table C1, a list of item response rates for questions from the N-SSATS 2020 questionnaire. Item non-response was minimized through careful editing and extensive follow-up.

The item response rate for the 2020 N-SSATS averaged 99 percent across 322 separate response categories.

Item non-response was 10 percent or more for only four of 322 separate response categories.

When available, client values and admissions values from up to five previous surveys were used to impute the missing counts. If historical data were not available, the average client value, stratified by state and facility operation, was used to impute the missing client counts. If a facility were unique in its state and facility operation category, values were imputed using average values for the state only. Missing client counts were imputed for each type of service (i.e., hospital inpatient detoxification, hospital inpatient treatment, residential [non-hospital] detoxification, etc.) and summed to the larger service type totals (total hospital inpatient clients, total residential [non-hospital] clients, and total outpatient clients), and finally to total clients. For 2020, 40 imputations were done involving nine facilities.

Several facilities report client counts for themselves (parent) as well as for other facilities (children) within their family of substance abuse treatment facilities. Instead of reporting only the aggregate client count, we attempted to disaggregate and redistribute or unroll the parent facilities' total client count wherever possible to reflect the number of clients served by each facility within the family of facilities. Client counts reported by a parent facility were distributed among its children facilities based on the type of facilities and types of clients indicated by the family of facilities. Therefore, numbers reported may be an actual number reported by the facility itself or they may be an unrolled estimate based on the unrolling procedures. All totals sum to the actual reported numbers. For hospital inpatient care, 33 facilities and 435 clients were unrolled. For outpatient care, 1,704 facilities and 182,051 clients were unrolled. For residential care, 406 facilities and 7,144 clients were unrolled.

Table C1. Item response rates, by question number and description: 2020

Q1-2 Facility offers detoxification 1 Q1-3 Facility offers substance use treatment 1 Q1-4 Facility offers substance use treatment 1 Q1-4 Facility offers substance use treatment for co-occurring serious mental illness (SMI)/serious emotional disturbance (SED) and substance use disorders 1 Q1-5 Facility offers any other substance use services 1 Q1-1 Facility offers mental health treatment services to clients other than substance abuse clients 1 Q1-2 Facility offers mental health treatment services 1 Q1-3 No clients offered mental health treatment services 1 Q1-3 No clients offered mental health treatment services 1 Q2 Facility is a jail, prison, or other organization that exclusively treats incarcerated persons or juvenile detainees 1 Q2 Facility offers detoxification from alcohol 1 Q3-1 Facility offers detoxification from benzodiazepines 1 Q3-2 Facility offers detoxification from benzodiazepines 2 Q3-2 Facility offers detoxification from methamphetamines 2 Q3-2 Facility offers detoxification from other substance	ponse e (%)
Q1-3 Facility offers substance use treatment 1 Q1-4 Facility offers treatment for co-occurring serious mental illness (SMI)/ serious emotional disturbance (SED) and substance use disorders 1 Q1-5 Facility offers any other substance use services 1 Q1a-1 Facility offers mental health treatment services to substance abuse clients 1 Q1a-2 Facility offers mental health treatment services to clients other than substance abuse clients 1 Q1a-3 No clients offered mental health treatment services 1 Q2 Facility is a jail, prison, or other organization that exclusively treats incarcerated persons or juvenile detainees 1 Q3a-1 Facility offers detoxification from alcohol 1 Q3a-2 Facility offers detoxification from benzodiazepines 1 Q3a-3 Facility offers detoxification from cocaine 2 Q3a-4 Facility offers detoxification from methamphetamines 2 Q3a-5 Facility offers detoxification from other substances 1 Q3b Facility offers detoxification from other substances 1 Q3b Facility offers detoxification from other substances 1 Q3a-6	0.00
Pacility offers treatment for co-occurring serious mental illness (SMI)/ serious emotional disturbance (SED) and substance use disorders 1	0.00
serious emotional disturbance (SED) and substance use disorders Q1-5 Facility offers any other substance use services Q1a-1 Facility offers mental health treatment services to substance abuse clients Q1a-2 Facility offers mental health treatment services to clients other than substance abuse clients Q1a-3 No clients offered mental health treatment services Q2 Facility is a jail, prison, or other organization that exclusively treats incarcerated persons or juvenile detainees Q3a-1 Facility offers detoxification from alcohol Q3a-2 Facility offers detoxification from benzodiazepines Q3a-3 Facility offers detoxification from cocaine Q3a-4 Facility offers detoxification from opioids Q3a-5 Facility offers detoxification from other substances Q3a-6 Facility offers detoxification from other substances Q5a-7 Facility is a solo practice Q6 Facility is a Federally Qualified Health Center (FQHC) Q7 Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership Q9 Facility offers hospital inpatient substance abuse services Q9a-1 Facility offers hospital inpatient treatment Q10 Facility offers residential (non-hospital) substance abuse services Q10a-1 Facility offers residential short-term treatment Q10a-2 Facility offers residential long-term treatment	0.00
Q1a-1 Facility offers mental health treatment services to substance abuse clients 1 Q1a-2 Facility offers mental health treatment services to clients other than substance abuse clients 1 Q1a-3 No clients offered mental health treatment services 1 Q2 Facility is a jail, prison, or other organization that exclusively treats incarcerated persons or juvenile detainees 1 Q3a-1 Facility offers detoxification from alcohol Q3a-2 Facility offers detoxification from benzodiazepines Q3a-3 Facility offers detoxification from cocaine Q3a-4 Facility offers detoxification from opioids Q3a-5 Facility offers detoxification from other substances 1 Q3b Facility offers detoxification from other substances 1 Q3b Facility is a solo practice Q6 Facility is a Federally Qualified Health Center (FQHC) Q7 Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership 1 Q8a Federal government agency operation/ownership 1 Q9a-1 Facility offers hospital inpatient substance abuse services <t< td=""><td>00.0</td></t<>	00.0
Q1a-2 Facility offers mental health treatment services to clients other than substance abuse clients 1 Q1a-3 No clients offered mental health treatment services 1 Q2 Facility is a jail, prison, or other organization that exclusively treats incarcerated persons or juvenile detainees 1 Q3a-1 Facility offers detoxification from alcohol 1 Q3a-2 Facility offers detoxification from benzodiazepines 2 Q3a-3 Facility offers detoxification from cocaine 2 Q3a-4 Facility offers detoxification from methamphetamines 4 Q3a-5 Facility offers detoxification from opioids 4 Q3a-6 Facility offers detoxification from other substances 1 Q3b Facility offers detoxification from other substances 1 Q5 Facility offers detoxification from other substances 1 Q6 Facility offers detoxification from other substances 1 Q7 Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership 1 Q8a Federal government agency operation/ownership 1	99.8
substance abuse clients Q1a-3 No clients offered mental health treatment services 1 Q2 Facility is a jail, prison, or other organization that exclusively treats incarcerated persons or juvenile detainees 1 Q3a-1 Facility offers detoxification from alcohol Q3a-2 Facility offers detoxification from benzodiazepines Q3a-3 Facility offers detoxification from cocaine Q3a-4 Facility offers detoxification from methamphetamines Q3a-5 Facility offers detoxification from opioids Q3a-6 Facility offers detoxification from other substances 1 Q3b Facility routinely uses medications during detoxification Q5 Facility is a solo practice Q6 Facility is a Federally Qualified Health Center (FQHC) Q7 Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership Q9 Facility offers hospital inpatient substance abuse services 1 Q9a-1 Facility offers hospital inpatient detoxification 1 Q9a-2 Facility offers residential (non-hospital) substance abuse services 1 Q10a-1 Facility offers residential short-term treatment 1 Q10a-2 Facility offers residential short-term treatment 1 Q10a-3 Facility offers residential long-term treatment	0.00
Pacility is a jail, prison, or other organization that exclusively treats incarcerated persons or juvenile detainees 1	00.0
incarcerated persons or juvenile detainees Q3a-1 Facility offers detoxification from alcohol Q3a-2 Facility offers detoxification from benzodiazepines Q3a-3 Facility offers detoxification from cocaine Q3a-4 Facility offers detoxification from methamphetamines Q3a-5 Facility offers detoxification from opioids Q3a-6 Facility offers detoxification from other substances Q3a-7 Facility routinely uses medications during detoxification Q5 Facility is a solo practice Q6 Facility is a Federally Qualified Health Center (FQHC) Q7 Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership Q9 Facility offers hospital inpatient substance abuse services 1 Q9a-1 Facility offers hospital inpatient detoxification Q9a-2 Facility offers hospital inpatient treatment Q10 Facility offers residential (non-hospital) substance abuse services 1 Q10a-1 Facility offers residential detoxification 1 Q10a-2 Facility offers residential short-term treatment Q10a-3 Facility offers residential long-term treatment	0.00
Q3a-2 Facility offers detoxification from benzodiazepines Q3a-3 Facility offers detoxification from cocaine Q3a-4 Facility offers detoxification from methamphetamines Q3a-5 Facility offers detoxification from opioids Q3a-6 Facility offers detoxification from other substances Q3b Facility routinely uses medications during detoxification Q5 Facility is a solo practice Q6 Facility is a Federally Qualified Health Center (FQHC) Q7 Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership Q9 Facility offers hospital inpatient substance abuse services Q9a-1 Facility offers hospital inpatient detoxification Q9a-2 Facility offers hospital inpatient treatment Q10 Facility offers residential (non-hospital) substance abuse services 1 Q10a-1 Facility offers residential detoxification 1 Q10a-2 Facility offers residential short-term treatment 1 Q10a-3 Facility offers residential long-term treatment	00.0
Q3a-3Facility offers detoxification from cocaineQ3a-4Facility offers detoxification from methamphetaminesQ3a-5Facility offers detoxification from opioidsQ3a-6Facility offers detoxification from other substances1Q3bFacility routinely uses medications during detoxificationQ5Facility is a solo practiceQ6Facility is a Federally Qualified Health Center (FQHC)Q7Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/otherQ8Facility operation/ownership1Q8aFederal government agency operation/ownership1Q9Facility offers hospital inpatient substance abuse services1Q9a-1Facility offers hospital inpatient detoxification1Q9a-2Facility offers hospital inpatient treatment1Q10Facility offers residential (non-hospital) substance abuse services1Q10a-1Facility offers residential detoxification1Q10a-2Facility offers residential short-term treatment1Q10a-3Facility offers residential long-term treatment1	99.6
Q3a-4Facility offers detoxification from methamphetaminesQ3a-5Facility offers detoxification from opioidsQ3a-6Facility offers detoxification from other substances1Q3bFacility routinely uses medications during detoxificationQ5Facility is a solo practiceQ6Facility is a Federally Qualified Health Center (FQHC)Q7Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/otherQ8Facility operation/ownership1Q8aFederal government agency operation/ownership1Q9Facility offers hospital inpatient substance abuse services1Q9a-1Facility offers hospital inpatient detoxification1Q9a-2Facility offers hospital inpatient treatment1Q10Facility offers residential (non-hospital) substance abuse services1Q10a-1Facility offers residential detoxification1Q10a-2Facility offers residential short-term treatment1Q10a-3Facility offers residential long-term treatment1	99.6
Q3a-5 Facility offers detoxification from opioids Q3a-6 Facility offers detoxification from other substances 1 Q3b Facility routinely uses medications during detoxification Q5 Facility is a solo practice Q6 Facility is a Federally Qualified Health Center (FQHC) Q7 Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership 1 Q8a Federal government agency operation/ownership 1 Q9 Facility offers hospital inpatient substance abuse services 1 Q9a-1 Facility offers hospital inpatient detoxification 1 Q9a-2 Facility offers hospital inpatient treatment 1 Q10 Facility offers residential (non-hospital) substance abuse services 1 Q10a-1 Facility offers residential detoxification 1 Q10a-2 Facility offers residential short-term treatment 1 Q10a-3 Facility offers residential long-term treatment	99.6
Q3a-6Facility offers detoxification from other substances1Q3bFacility routinely uses medications during detoxificationQ5Facility is a solo practiceQ6Facility is a Federally Qualified Health Center (FQHC)Q7Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/otherQ8Facility operation/ownership1Q8aFederal government agency operation/ownership1Q9Facility offers hospital inpatient substance abuse services1Q9a-1Facility offers hospital inpatient detoxification1Q9a-2Facility offers hospital inpatient treatment1Q10Facility offers residential (non-hospital) substance abuse services1Q10a-1Facility offers residential detoxification1Q10a-2Facility offers residential detoxification1Q10a-3Facility offers residential long-term treatment1	99.6
G3b Facility routinely uses medications during detoxification Q5 Facility is a solo practice Q6 Facility is a Federally Qualified Health Center (FQHC) Q7 Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership Q8a Federal government agency operation/ownership 1 Q9 Facility offers hospital inpatient substance abuse services 1 Q9a-1 Facility offers hospital inpatient detoxification 1 Q9a-2 Facility offers hospital inpatient treatment Q10 Facility offers residential (non-hospital) substance abuse services 1 Q10a-1 Facility offers residential detoxification 1 Q10a-2 Facility offers residential short-term treatment 1 Q10a-3 Facility offers residential long-term treatment	99.6
Q5 Facility is a solo practice Q6 Facility is a Federally Qualified Health Center (FQHC) Q7 Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership 1 Q9 Facility offers hospital inpatient substance abuse services 1 Q9a-1 Facility offers hospital inpatient detoxification 1 Q9a-2 Facility offers hospital inpatient treatment 1 Q10 Facility offers residential (non-hospital) substance abuse services 1 Q10a-1 Facility offers residential detoxification 1 Q10a-2 Facility offers residential short-term treatment 1 Q10a-3 Facility offers residential long-term treatment 1	0.00
Q6 Facility is a Federally Qualified Health Center (FQHC) Q7 Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership 1 Q8a Federal government agency operation/ownership 1 Q9 Facility offers hospital inpatient substance abuse services 1 Q9a-1 Facility offers hospital inpatient detoxification 1 Q9a-2 Facility offers hospital inpatient treatment 1 Q10 Facility offers residential (non-hospital) substance abuse services 1 Q10a-1 Facility offers residential detoxification 1 Q10a-2 Facility offers residential short-term treatment 1 Q10a-3 Facility offers residential long-term treatment 1	99.0
Q7Primary focus of facility is substance use treatment services/mental health services/mix of mental health and substance use treatment services (neither is primary)/general health care/otherQ8Facility operation/ownership1Q8aFederal government agency operation/ownership1Q9Facility offers hospital inpatient substance abuse services1Q9a-1Facility offers hospital inpatient detoxification1Q9a-2Facility offers hospital inpatient treatment1Q10Facility offers residential (non-hospital) substance abuse services1Q10a-1Facility offers residential detoxification1Q10a-2Facility offers residential short-term treatment1Q10a-3Facility offers residential long-term treatment1	99.9
services/mix of mental health and substance use treatment services (neither is primary)/general health care/other Q8 Facility operation/ownership 1 Q8a Federal government agency operation/ownership 1 Q9 Facility offers hospital inpatient substance abuse services 1 Q9a-1 Facility offers hospital inpatient detoxification 1 Q9a-2 Facility offers hospital inpatient treatment 1 Q10 Facility offers residential (non-hospital) substance abuse services 1 Q10a-1 Facility offers residential detoxification 1 Q10a-2 Facility offers residential short-term treatment 1 Q10a-3 Facility offers residential long-term treatment 1	81.5
Q8Facility operation/ownership1Q8aFederal government agency operation/ownership1Q9Facility offers hospital inpatient substance abuse services1Q9a-1Facility offers hospital inpatient detoxification1Q9a-2Facility offers hospital inpatient treatment1Q10Facility offers residential (non-hospital) substance abuse services1Q10a-1Facility offers residential detoxification1Q10a-2Facility offers residential short-term treatment1Q10a-3Facility offers residential long-term treatment1	99.9
Q9Facility offers hospital inpatient substance abuse services1Q9a-1Facility offers hospital inpatient detoxification1Q9a-2Facility offers hospital inpatient treatment1Q10Facility offers residential (non-hospital) substance abuse services1Q10a-1Facility offers residential detoxification1Q10a-2Facility offers residential short-term treatment1Q10a-3Facility offers residential long-term treatment1	0.00
Q9a-1Facility offers hospital inpatient detoxification1Q9a-2Facility offers hospital inpatient treatment1Q10Facility offers residential (non-hospital) substance abuse services1Q10a-1Facility offers residential detoxification1Q10a-2Facility offers residential short-term treatment1Q10a-3Facility offers residential long-term treatment1	0.00
Q9a-2Facility offers hospital inpatient treatment1Q10Facility offers residential (non-hospital) substance abuse services1Q10a-1Facility offers residential detoxification1Q10a-2Facility offers residential short-term treatment1Q10a-3Facility offers residential long-term treatment1	0.00
Q10Facility offers residential (non-hospital) substance abuse services1Q10a-1Facility offers residential detoxification1Q10a-2Facility offers residential short-term treatment1Q10a-3Facility offers residential long-term treatment1	0.00
Q10a-1Facility offers residential detoxification1Q10a-2Facility offers residential short-term treatment1Q10a-3Facility offers residential long-term treatment1	0.00
Q10a-2Facility offers residential short-term treatment1Q10a-3Facility offers residential long-term treatment1	0.00
Q10a-3 Facility offers residential long-term treatment 1	0.00
, ,	0.00
	0.00
Q11 Facility offers outpatient services 1	0.00
Q11a-1 Facility offers outpatient detoxification 1	0.00
Q11a-2 Facility offers outpatient methadone/buprenorphine maintenance or naltrexone treatment 1	00.0
Q11a-3 Facility offers outpatient day treatment or partial hospitalization 1	0.00
Q11a-4 Facility offers intensive outpatient treatment 1	0.00
Q11a-5 Facility offers regular outpatient treatment 1	0.00

Question number	Description	Response rate (%)
Q12-1	Facility offers screening for substance abuse	100.0
Q12-2	Facility offers screening for mental disorders	100.0
Q12-3	Facility offers comprehensive substance abuse assessment or diagnosis	100.0
Q12-4	Facility offers comprehensive mental health assessment or diagnosis (for example, psychological or psychiatric evaluation and testing)	100.0
Q12-5	Facility offers screening for tobacco use	100.0
Q12-6	Facility offers outreach to persons in the community who may need treatment	100.0
Q12-7	Facility offers interim services for clients when immediate admission is not possible	100.0
Q12-8	Facility offers professional interventionist/educational consultant	100.0
Q12-9	Facility does not offer any of these assessment and pre-treatment services	100.0
Q12-10	Facility offers drug and alcohol oral fluid testing	100.0
Q12-11	Facility offers breathalyzer or other blood alcohol testing	100.0
Q12-12	Facility offers drug or alcohol urine screening	100.0
Q12-13	Facility offers testing for hepatitis B (HBV)	100.0
Q12-14	Facility offers testing for hepatitis C (HCV)	100.0
Q12-15	Facility offers HIV testing	100.0
Q12-16	Facility offers STD testing	100.0
Q12-17	Facility offers TB screening	100.0
Q12-18	Facility offers testing for metabolic syndrome	100.0
Q12-19	Facility does not offer any of these testing services	100.0
Q12-20	Facility offers hepatitis A (HAV) vaccination	100.0
Q12-21	Facility offers hepatitis B (HBV) vaccination	100.0
Q12-22	Facility does not offer any of these medical services	100.0
Q12-23	Facility offers discharge planning	100.0
Q12-24	Facility offers aftercare/continuing care	100.0
Q12-25	Facility offers naloxone and overdose education	100.0
Q12-26	Facility offers outcome follow-up after discharge	100.0
Q12-27	Facility does not offer any of these transitional services	100.0
Q12-28	Facility offers mentoring/peer support	100.0
Q12-29	Facility offers self-help groups (for example, AA, NA, SMART Recovery)	100.0
Q12-30	Facility offers assistance in locating housing for clients	100.0
Q12-31	Facility offers employment counseling or training for clients	100.0
Q12-32	Facility offers assistance with obtaining social services (for example, Medicaid, WIC, SSI, SSDI)	100.0
Q12-33	Facility offers recovery coach	100.0
Q12-34	Facility does not offer any of these recovery support services	100.0
Q12-35	Facility offers HIV or AIDS education, counseling, or support	100.0
Q12-36	Facility offers hepatitis education, counseling, or support	100.0

Question number	Description	Response rate (%)
Q12-37	Facility offers health education other than HIV/AIDS or hepatitis	100.0
Q12-38	Facility offers substance abuse education	100.0
Q12-39	Facility offers smoking/tobacco cessation counseling	100.0
Q12-40	Facility offers individual counseling	100.0
Q12-41	Facility offers group counseling	100.0
Q12-42	Facility offers family counseling	100.0
Q12-43	Facility offers marital/couples counseling	100.0
Q12-44	Facility offers vocational training or educational support (for example, high school coursework, GED preparation, etc.)	100.0
Q12-45	Facility does not offer any of these education and counseling services	100.0
Q12-46	Facility offers case management services	100.0
Q12-47	Facility offers social skills development	100.0
Q12-48	Facility offers childcare for clients' children	100.0
Q12-49	Facility offers domestic violence—family or partner violence—services (physical, sexual, and emotional abuse)	100.0
Q12-50	Facility offers early intervention HIV	100.0
Q12-51	Facility offers transportation assistance to treatment	100.0
Q12-52	Facility offers mental health services	100.0
Q12-53	Facility offers acupuncture	100.0
Q12-54	Facility offers residential beds for clients' children	100.0
Q12-55	Facility does not offer any of these ancillary services	100.0
Q12-56	Facility offers treatment for gambling disorder	100.0
Q12-57	Facility offers treatment for Internet use disorder	100.0
Q12-58	Facility offers treatment for other addiction disorder (non-substance abuse)	100.0
Q12-59	Facility does not offer any of these other services	100.0
Q12-60	Pharmacotherapies — disulfiram (Antabuse®)	100.0
Q12-61	Pharmacotherapies — naltrexone (oral)	100.0
Q12-62	Pharmacotherapies — naltrexone (extended-release, injectable, for example, Vivitrol®)	100.0
Q12-63	Pharmacotherapies — acamprosate (Campral®)	100.0
Q12-64	Pharmacotherapies — nicotine replacement	100.0
Q12-65	Pharmacotherapies — non-nicotine smoking/tobacco cessation medications (for example, bupropion, varenicline)	100.0
Q12-66	Pharmacotherapies — medications for psychiatric disorders	100.0
Q12-67	Pharmacotherapies — methadone	100.0
Q12-68	Pharmacotherapies — buprenorphine with naloxone (for example, Suboxone®, Bunavail®, Zubsolv®, Cassipa®)	100.0
Q12-69	Pharmacotherapies — buprenorphine without naloxone	100.0
Q12-70	Pharmacotherapies — buprenorphine sub-dermal implant (Probuphine®)	100.0

Question number	Description	Response rate (%)
Q12-71	Pharmacotherapies — buprenorphine (extended-release, injectable, for example, Sublocade $^{\! \rm B}\!)$	100.0
Q12-72	Pharmacotherapies — medications for HIV treatment (for example, antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine)	100.0
Q12-73	Pharmacotherapies — medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)	100.0
Q12-74	Pharmacotherapies — lofexidine	100.0
Q12-75	Pharmacotherapies — clonidine	100.0
Q12-76	Does not offer any of these pharmacotherapy services	100.0
Q13-1	Uses methadone or buprenorphine for pain management, emergency cases, or research purposes	100.0
Q13-2	Treats opioid use disorder, but it does not use medication-assisted treatment (MAT), nor does it accept clients using MAT to treat opioid use disorder	100.0
Q13-3	Accepts clients using MAT, but the medications originate from or are prescribed by another entity	100.0
Q13-4	Administers naltrexone to treat opioid use disorder	100.0
Q13-5	Prescribes buprenorphine to treat opioid use disorder through a DATA 2000-waivered provider	100.0
Q13-6	Federally certified opioid treatment program (OTP)	100.0
Q13-7	Does not treat opioid use disorder	100.0
Q13a-1	Prescribing entity (of MAT for OUD) in network	99.9
Q13a-2	Business, contractual, or formal referral relationship with prescribing entity (of MAT for OUD)	99.9
Q13a-3	Client obtains their prescription/medication (of MAT for OUD) from an entity with no formal relationship	99.9
Q13b	Facility serves only opioid use disorder clients	99.9
Q13c-1	Provides maintenance services with methadone or buprenorphine	99.8
Q13c-2	Provides maintenance services with medically supervised withdrawal (or taper) after a period of stabilization	99.8
Q13c-3	Provides detoxification from opioids of abuse with methadone or buprenorphine	99.8
Q13c-4	Provides detoxification from opioids of abuse with lofexidine or clonidine	99.8
Q13c-5	Provides relapse prevention with naltrexone	99.8
Q13c-6	Provides other medication services	100.0
Q13c-7	Does not offer any of these medication services	99.8
Q14-1	Facility treats alcohol use disorder, but does not use medication-assisted treatment (MAT) for alcohol use disorder, nor does it accept clients using MAT to treat alcohol use disorder	99.9
Q142	Facility accepts clients using MAT for alcohol use disorder, but the medications originate from or are prescribed by another entity	99.9
Q14-3	Facility administers/prescribes at least one of disulfiram (Antabuse®), naltrexone, and/or acamprosate (Campral®) for alcohol use disorder	99.9

Question number	Description	Response rate (%)
Q14-4	Facility does not treat alcohol use disorder	99.9
Q14a-1	Prescribing entity (of MAT for AUD) in network	99.9
Q14a-2	Business, contractual, or formal referral relationship with the prescribing entity (of MAT for AUD)	99.9
Q14a-3	Client obtains their prescription/medication for AUD from an entity with no formal relationship	99.9
Q14b	Facility serves only alcohol use disorder clients	99.9
Q15-1	Substance abuse counseling used frequently	99.8
Q15-2	12-step facilitation used frequently	99.8
Q15-3	Brief intervention used frequently	99.8
Q15-4	Cognitive behavioral therapy used frequently	99.8
Q15-5	Dialectical behavior therapy used frequently	99.8
Q15-6	Contingency management/motivational incentives used frequently	99.8
Q15-7	Motivational interviewing used frequently	99.8
Q15-8	Trauma-related counseling used frequently	99.8
Q15-9	Anger management used frequently	99.8
Q15-10	Matrix Model used frequently	99.8
Q15-11	Community reinforcement plus vouchers used frequently	99.8
Q15-12	Rational emotive behavioral therapy (REBT) used frequently	99.8
Q15-13	Relapse prevention used frequently	99.8
Q15-14	Telemedicine/telehealth used frequently (including Internet, Web, mobile, and desktop programs)	99.8
Q15-15	Other treatment approach used frequently	100.0
Q15-16	None of these clinical/therapeutic approaches used frequently	99.8
Q16	Offers specially designed program or group intended exclusively for DUI/DWI or other drunk driver offenders	99.7
Q16a	Facility serves only DUI/DWI clients	99.8
Q16a	Facility serves only DUI/DWI clients	99.8
Q15-12	Rational emotive behavioral therapy (REBT) used frequently	99.9
Q15-13	Relapse prevention used frequently	99.9
Q15-14	Telemedicine/telehealth used frequently (including Internet, Web, mobile, and desktop programs)	99.9
Q15-15	Other treatment approach used frequently	100.0
Q15-16	None of these clinical/therapeutic approaches used frequently	99.9
Q16	Offers specially designed program or group intended exclusively for DUI/DWI or other drunk driver offenders	99.8
Q16a	Facility serves only DUI/DWI clients	99.8
Q17	Facility provides substance use treatment services in sign language for the deaf and hard-of-hearing	99.7
Q18	Facility provides substance use treatment services in a language other than English	99.7

Question number	Description	Response rate (%)
Q18a	Who provides substance use treatment services in a language other than English?	99.9
Q18a-1	Staff counselors provide substance use treatment in Spanish	99.8
Q18a-2	Staff counselors provide substance use treatment in any other languages	99.9
Q18b-1	Staff counselors provide substance use treatment in Hopi	99.8
Q18b-2	Staff counselors provide substance use treatment in Lakota	99.8
Q18b-3	Staff counselors provide substance use treatment in Navajo	99.8
Q18b-4	Staff counselors provide substance use treatment in Ojibwa	99.8
Q18b-5	Staff counselors provide substance use treatment in Yupik	99.8
Q18b-6	Staff counselors provide substance use treatment in other American Indian/Alaska Native language	99.8
Q18b-7	Staff counselors provide substance use treatment in Arabic	99.8
Q18b-8	Staff counselors provide substance use treatment in any Chinese language	99.8
Q18b-9	Staff counselors provide substance use treatment in Creole	99.8
Q18b-10	Staff counselors provide substance use treatment in Farsi	99.8
Q18b-11	Staff counselors provide substance use treatment in French	99.8
Q18b-12	Staff counselors provide substance use treatment in German	99.8
Q18b-13	Staff counselors provide substance use treatment in Greek	99.8
Q18b-14	Staff counselors provide substance use treatment in Hebrew	99.8
Q18b-15	Staff counselors provide substance use treatment in Hindi	99.8
Q18b-16	Staff counselors provide substance use treatment in Hmong	99.8
Q18b-17	Staff counselors provide substance use treatment in Italian	99.8
Q18b-18	Staff counselors provide substance use treatment in Japanese	99.8
Q18b-19	Staff counselors provide substance use treatment in Korean	99.8
Q18b-20	Staff counselors provide substance use treatment in Polish	99.8
Q18b-21	Staff counselors provide substance use treatment in Portuguese	99.8
Q18b-22	Staff counselors provide substance use treatment in Russian	99.8
Q18b-23	Staff counselors provide substance use treatment in Tagalog	99.8
Q18b-24	Staff counselors provide substance use treatment in Vietnamese	99.8
Q18b-25	Staff counselors provide substance use treatment in any other language	99.8
Q19-1	Females are served by this facility	99.8
Q19-1	Lowest age of females served	100.0
Q19-1	No minimum age of females served	100.0
Q19-1	Highest age of females served	100.0
Q19-1	No maximum age of females served	100.0
Q19-1	No maximum age of females served	100.0
Q19-2	Males are served by this facility	99.8
Q19-2	Lowest age of males served	100.0
Q19-2	No minimum age of males served	100.0
Q19-2	Highest age of males served	100.0

Question number	Description	Response rate (%)
Q19-2	No maximum age of males served	100.0
Q19a-1	Facility offers program or group specifically tailored for adolescents	99.7
Q19a-2	Facility offers program or group specifically tailored for young adults	99.7
Q19a-3	Facility offers program or group specifically tailored for adult women	99.7
Q19a-4	Facility offers program or group specifically tailored for pregnant/ postpartum women	99.7
Q19a-5	Facility offers program or group specifically tailored for adult men	99.7
Q19a-6	Facility offers program or group specifically tailored for seniors or older adults	99.7
Q19a-7	Facility offers program or group specifically tailored for lesbian/gay/ bisexual/transgender (LGBT) clients	99.7
Q19a-8	Facility offers program or group specifically tailored for veterans	99.7
Q19a-9	Facility offers program or group specifically tailored for active duty military	99.7
Q19a-10	Facility offers program or group specifically tailored for members of military families	99.7
Q19a-11	Facility offers program or group specifically tailored for criminal justice clients (other than DUI/DWI)	99.7
Q19a-12	Facility offers program or group specifically tailored for clients with co- occurring mental and substance use disorders	99.7
Q19a-13	Facility offers program or group specifically tailored for clients with co- occurring pain and substance use	99.7
Q19a-14	Facility offers program or group specifically tailored for clients with HIV or AIDS	99.7
Q19a-15	Facility offers program or group specifically tailored for clients who have experienced sexual abuse	99.7
Q19a-16	Facility offers program or group specifically tailored for clients who have experienced intimate partner violence, domestic violence	99.7
Q19a-17	Facility offers program or group specifically tailored for clients who have experienced trauma	99.7
Q19a-18	Facility offers program or group specifically tailored for any other types of clients	100.0
Q19a-19	No specifically tailored programs or groups are offered	99.7
Q20	Facility uses a sliding fee scale	99.5
Q20a	Availability of sliding fee scale included in online Locator/Directory	100.0
Q21	Facility offers treatment at no charge or minimal payment	99.4
Q21a	Availability of treatment at no charge or minimal payment included in online Locator/Directory	100.0
Q22	Facility receives federal, state, county, or local government funding or grants to support its substance use treatment programs	96.1
Q23-1	Facility does not accept payment (free treatment for all clients)	99.3
Q23-2	Facility accepts cash or self-payment	99.3
Q23-3	Facility accepts Medicare payments	99.3
Q23-4	Facility accepts Medicaid payments	99.3

Question number	Description	Response rate (%)
Q23-5	Facility accepts state-financed health insurance plan other than Medicaid	99.3
Q23-6	Facility accepts federal military insurance	99.3
Q23-7	Facility accepts private health insurance	99.3
Q23-8	Facility accepts Indian Health Service/Tribal/Urban (ITU funds)	99.3
Q23-9	Facility accepts other types of client payments or insurance	100.0
Q24	Facility is a hospital, is located in a hospital, or is operated by a hospital	99.5
Q24a	Type of hospital	99.9
Q25	Facility operates transitional housing, halfway house, or sober home for substance abuse clients	100.0
Q26	Facility smoking policy	99.5
Q27-1	Licensed, certified, or accredited by state substance abuse agency	99.5
Q27-2	Licensed, certified, or accredited by state mental health department	99.5
Q27-3	Licensed, certified, or accredited by state health department	99.5
Q27-4	Licensed, certified, or accredited by hospital licensing authority	99.5
Q27-5	Accredited by the Joint Commission	99.5
Q27-6	Accredited by Commission on Accreditation of Rehabilitation Facilities (CARF)	99.5
Q27-7	Accredited by National Committee for Quality Assurance (NCQA)	99.5
Q27-8	Accredited by Council on Accreditation (COA)	99.5
Q27-9	Accredited by Healthcare Facilities Accreditation Program (HFAP)	99.5
Q27-10	Licensed, certified, or accredited by another national organization or federal, state, or local agency	100.0
Q28	Facility wants to be listed in SAMHSA's online Behavioral Health Treatment Services Locator and in the National Directory of Drug and Alcohol Abuse Treatment Facilities	99.5
Q28a-1	Facility wants street address listed in the Locator/Directory	99.7
Q28a-2	Facility wants mailing address listed in the Locator/Directory	99.9
Q28a-3	Facility does not want either address listed in the Locator/Directory	99.9
Q28b	Facility wants selected information shared with Internet search engines	99.9
Q30	Client counts for only this facility, this facility plus others, none	100.0
Q30a	Total number of facilities included in reported client counts	100.0
Q31	Any patients received hospital inpatient substance abuse services on March 31, 2020	100.0
Q31a	Total number of hospital inpatient clients	100.0
Q31a-1	Number of hospital inpatient detoxification clients	100.0
Q31a-2	Number of hospital inpatient treatment clients	100.0
Q31b	Number of hospital inpatient clients under 18 years old	100.0
Q31c-1	Number of hospital inpatients who received methadone dispensed at this facility for OUD	100.0
Q31c-2	Number of hospital inpatients who received buprenorphine dispensed or prescribed at this facility for OUD	100.0

Question number	Description	Response rate (%)
Q31c-3	Number of hospital inpatients who received naltrexone administered at this facility for OUD	100.0
Q31d-1	Number of hospital inpatients who received disulfiram (Antabuse®) dispensed or prescribed at this facility for AUD	100.0
Q31d-2	Number of hospital inpatients who received naltrexone dispensed or prescribed at this facility for AUD	100.0
Q31d-3	Number of hospital inpatients who received acamprosate (Campral®) dispensed or prescribed at this facility for AUD	100.0
Q31e	Number of hospital inpatient beds specifically designated for substance use treatment	81.8
Q32	Any clients received residential (non-hospital) substance abuse services on March 31, 2020	100.0
Q32a	Total number of residential clients	100.0
Q32a-1	Number of residential detoxification clients	100.0
Q32a-2	Number of residential short-term treatment clients	100.0
Q32a-3	Number of residential long-term treatment clients	100.0
Q32b	Number of residential clients under 18 years old	100.0
Q32c-1	Number of residential clients who received methadone dispensed at this facility for OUD	100.0
Q32c-2	Number of residential clients who received buprenorphine dispensed or prescribed at this facility for OUD	100.0
Q32c-3	Number of residential clients who received naltrexone administered at this facility for OUD	100.0
Q32d-1	Number of residential clients who received disulfiram (Antabuse®) dispensed or prescribed at this facility for AUD	100.0
Q32d-2	Number of residential clients who received naltrexone dispensed or prescribed at this facility for AUD	100.0
Q32d-3	Number of residential clients who received acamprosate (Campral®) dispensed or prescribed at this facility for AUD	100.0
Q32e	Number of residential beds specifically designated for substance use treatment	94.1
Q33	Any clients received outpatient substance abuse services during March 2020	100.0
Q33a	Total number of active clients receiving outpatient substance abuse services as of March 31, 2020	100.0
Q33a-1	Number of outpatient detoxification clients	100.0
Q33a-2	Number of outpatient methadone/buprenorphine maintenance or naltrexone treatment clients	100.0
Q33a-3	Number of outpatient day treatment or partial hospitalization clients	100.0
Q33a-4	Number of intensive outpatient treatment clients	100.0
Q33a-5	Number of regular outpatient treatment clients	100.0
Q33b	Number of outpatient clients under 18 years old	100.0
Q33c-1	Number of outpatient clients who received methadone dispensed at this facility for OUD	100.0

Question number	Description	Response rate (%)
Q33c-2	Number of outpatient clients who received buprenorphine dispensed or prescribed at this facility for OUD	100.0
Q33c-3	Number of outpatient clients who received naltrexone administered at this facility for OUD	99.9
Q33d-1	Number of outpatient clients who received disulfiram (Antabuse®) dispensed or prescribed at this facility for AUD	99.9
Q33d-2	Number of outpatient clients who received naltrexone dispensed or prescribed at this facility for AUD	99.9
Q33d-3	Number of outpatient clients who received acamprosate (Campral®) dispensed or prescribed at this facility for AUD	99.9
Q34-1	Percent of clients in treatment on March 31, 2020, for treatment of abuse of both alcohol and substances other than alcohol	93.1
Q34-2	Percent of clients in treatment on March 31, 2020, for treatment of abuse only of alcohol	93.1
Q34-3	Percent of clients in treatment on March 31, 2020, for treatment of abuse only of substances other than alcohol	93.1
Q35	Estimated percent of substance use treatment clients enrolled on March 31, 2020, who had a diagnosed co-occurring mental and substance use disorder	92.0
Q36	Estimated total number of admissions for substance use treatment in the most recent 12-month period for which data is available	94.4
QVA1-1	VA facility offers evidence-based suicide prevention interventions	93.9
QVA1-2	VA facility offers suicide risk screening	93.9
QVA1-3	VA facility offers suicide risk evaluation	93.9
QVA1-4	VA facility does not offer any of these suicide prevention-related services	93.9
QVA2-1	VA facility uses cognitive therapy for suicide prevention (CBT-SP)	100.0
QVA2-2	VA facility uses cognitive behavioral therapy (CBT)	100.0
QVA2-3	VA facility uses dialectic behavioral therapy (DBT)	100.0
QVA2-4	VA facility uses problem solving therapy (PST)	100.0
QVA2-5	VA facility uses safety planning/crisis response planning	100.0
QVA2-6	VA facility uses ketamine infusions	100.0
QVA2-7	VA facility uses lithium treatment	100.0
QVA2-8	VA facility uses clozapine treatment	100.0
QVA2-9	VA facility uses caring communications	100.0
QVA2-10	VA facility uses home support	100.0
QVA2-11	VA facility uses World Health Organization—Brief Intervention and Contact (WHO-BIC)	100.0
QVA2-12	VA facility uses gate keeper training	100.0
QVA2-13	VA facility uses lethal means safety counseling	100.0
QVA2-14	VA facility uses other evidence-based suicide prevention interventions	100.0
QVA3-1	VA facility uses or makes available the Columbia–Suicide Severity Rating Scale (C–SSRS) Screener	100.0

Question number	Description	Response rate (%)
QVA3-2	VA facility uses or makes available Patient Health Questionnaire (PHQ-9) Item 9	100.0
QVA3-3	VA facility uses or makes available other standardized suicide risk screening tools	100.0
QVA4-1	VA facility uses or makes available the Columbia–Suicide Severity Rating Scale (C–SSRS)	100.0
QVA4-2	VA facility uses or makes available the Mini International Neuropsychiatric Interview (MINI)	100.0
QVA4-3	VA facility uses or makes available the VA Comprehensive Suicide Risk Evaluation (CSRE)	100.0
QVA4-4	VA facility uses or makes available the Suicide Assessment Five-Step Evaluation and Triage (SAFE-T)	100.0
QVA4-5	VA facility uses or makes available other standardized suicide risk evaluation tools	100.0
QVA4-6	VA facility does not use standardized suicide evaluation tools	100.0
QVA5	Number of VA facility's hospital inpatient clients identified as being at high risk of suicide	94.3

AA = Alcoholics Anonymous; AUD = alcohol use disorder; DUI/DWI = driving under the influence/driving while intoxicated or impaired; MAT = medication-assisted therapy; NA = Narcotics Anonymous; OUD = opioid use disorder; PTSD = post-traumatic stress disorder; TBI = traumatic brain injury; SED = serious emotional disturbance; SMART = Self-Management and Recovery Training; SMI = serious mental illness; VA = Veterans Affairs.

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS), 2020. Addendum for Substance Abuse Veterans Affairs Facilities, March 31, 2020.

APPENDIX D LIST OF CONTRIBUTORS

This report was prepared for the Center for Behavioral Health Statistics and Quality (CBHSQ), Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services (HHS), by Eagle Technologies, Inc. Data collection was performed by Mathematica Policy Research. Work was performed by Eagle and Mathematica under Contract No. HHSS283201600001C.

Contributors and reviewers at Eagle, listed alphabetically, include Anand Borse, Shanshan Hao, Parth Thakore, Doren Walker (Project Director), and John Zuwasti Curran, with additional support from Mathematica. Production of the report at SAMHSA was managed by Nichele Waller (COR). SAMHSA contributors and reviewers, listed alphabetically, include Herman Alvarado, Suparna Das, Heydy Juarez, Kasimu Muhetaer, Krishna Palipudi, and Nichele Waller.